<html lang="en"><head><!-- Shady DOM styles for custom-style --><!-- Shady DOM styles for dom-template --><!-- Shady DOM styles for dom-repeat --><!-- Shady DOM styles for array-selector --><!-- Shady DOM styles for dom-if --><!-- Shady DOM styles for state-modifier --><style scope="state-modifier">a[inherit].state-modifier {
  color: inherit;
}</style><!-- Shady DOM styles for browser-ui --><!-- Shady DOM styles for outlined-text-field --><style scope="outlined-text-field">outlined-text-field {
  display: flex;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  flex-direction: column;
}

outlined-text-field span.outlined-text-field {
  display: flex;
  flex-direction: row;
  align-items: center;
}

outlined-text-field input.outlined-text-field {
  height: 40px;
  padding: 0 33px 0 16px;
  
  border-color: #b0b3b6;
  border-width: 1px;
  border-style: solid;
  
  border-radius: 8px;
  caret-color: #3c78e0;
  color: #6a6c71;
  font-size: 14px;
  flex-grow: 1;
}

outlined-text-field[orig] input.outlined-text-field {
  border-color: #e5e5e5;
  
  border-radius: 0;
}

outlined-text-field[dense] input.outlined-text-field {
  height: 32px;
}

outlined-text-field[uppercase] input.outlined-text-field {
  text-transform: uppercase;
}

outlined-text-field:not([wizard-focused]):hover input.outlined-text-field {
  border-color: #737375;
  color: #414447;
}

outlined-text-field:not([wizard-focused]):focus-within input.outlined-text-field,outlined-text-field[wizard-focused] input.outlined-text-field {
  border-color: #3574e0;
  caret-color: #80a5f1;
}

outlined-text-field[wizard-focused] input.outlined-text-field {
  border-width: 2px;
}

outlined-text-field input.outlined-text-field::placeholder {
  color: #65686c;
}

outlined-text-field[uppercase] input.outlined-text-field::placeholder {
  text-transform: none;
}</style><!-- Shady DOM styles for mat-keyword-editor --><!-- Shady DOM styles for mat-chips-input --><!-- Shady DOM styles for mat-input-chip --><!-- Shady DOM styles for pat-dialog --><style scope="pat-dialog">pat-dialog {
  background: white;
  position: absolute;
  border-radius: 8px;
  
  box-shadow: 0 24px 38px 3px rgb(0 0 0 / 14%),
              0 9px 46px 8px rgb(0 0 0 / 12%),
              0 11px 15px -7px rgb(0 0 0 / 20%);
  z-index: 1;
  display: flex;
  flex-direction: column;
}

pat-dialog:not([open]) {
  display: none;
}</style><!-- Shady DOM styles for mat-tabs --><!-- Shady DOM styles for filter-chip --><style scope="filter-chip">filter-chip {
  align-items: center;
  background-color: #fff;
  border-color: #dadce0;
  border-radius: 8px;
  border-style: solid;
  border-width: 1px;
  color: #606368;
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 32px;
  letter-spacing: 0.2px;
  padding: 0 16px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
}

filter-chip[disabled] {
  background-color: #e8e8e8;
  border-color: #e8e8e8;
  color: #a9abad;
  cursor: auto;
}

filter-chip svg.filter-chip {
  visibility: collapse;
  font-size: 18px;
  width: 0;
  height: 18px;
}

filter-chip[selected] svg.filter-chip {
  visibility: visible;
  margin: 0 8px;
  width: 18px;
}

filter-chip[selected] svg.filter-chip path.filter-chip {
  fill: #4577d1;
}

filter-chip:not([disabled]):hover {
  background-color: #f7f8f8;
  border-color: #d7d9dc;
  color: #454649;
}

filter-chip:not([disabled]):hover:active {
  background-color: #eff0f0;
  border-color: #d2d5d8;
  color: #222326;
}

filter-chip:not([disabled]):focus {
  background-color: #e7e8e8;
  border-color: #232528;
  color: #202124;
}

filter-chip:not([disabled])[selected] {
  background-color: #e9f0fd;
  border-color: #e9f0fd;
  color: #4577d1;
  padding-left: 0;
}

filter-chip:not([disabled]):focus[selected] {
  background-color: #d5e1fb;
  border-color: #d5e1fb;
  color: #2550a0;
}

filter-chip:not([disabled]):hover[selected] {
  box-shadow: rgba(0, 0, 0, 0.2) 0px 3px 1px -2px,
    rgba(0, 0, 0, 0.14) 0px 2px 2px 0px, rgba(0, 0, 0, 0.12) 0px 1px 5px 0px;
}

filter-chip:not([disabled]):hover:active[selected] {
  background-color: #abc8f2;
  border-color: #abc8f2;
  color: #2a54a3;
}</style><!-- Shady DOM styles for figure-callout --><!-- Shady DOM styles for mat-button --><style scope="mat-button-0">.mat-button-0 {
  ;
  align-items: center;
  border-radius: 4px;
  color: hsl(217 4% 39%); 
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 36px;
  letter-spacing: 0.2px;
  padding: 0 8px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
}

.mat-button-0[filled] {
  background-color: hsl(217 73% 54%); 
  color: white;
}

.mat-button-0[filled]:hover {
  background-color: hsl(217 60% 47%);
}

.mat-button-0[filled]:focus {
  background-color: hsl(217 59% 44%);
}

.mat-button-0[filled]:active {
  background-color: hsl(217 59% 45%);
}

.mat-button-0[filled][disabled] {
  background-color: hsl(217 2% 90%); 
  color: hsl(217 1% 65%);
}</style><!-- Shady DOM styles for search-term-wizard --><style scope="search-term-wizard">search-term-wizard:not([open]) {
  display: none;
}

search-term-wizard .header.search-term-wizard {
  border-bottom: 1px solid #e5e5e5;
  padding: 24px;
  padding-bottom: 0;
}

search-term-wizard .title.search-term-wizard {
  color: #3c4043;
  font-family: Google Sans,Roboto,Arial,sans-serif;
  font-size: 22px;
  user-select: none;
  margin: 0 48px;
}

search-term-wizard #panels.search-term-wizard > *.search-term-wizard:not([selected]) {
  display: none;
}</style><!-- Shady DOM styles for outlined-textarea --><style scope="outlined-textarea">outlined-textarea {
  display: flex;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  flex-direction: row;
  
  position: relative;
}

outlined-textarea span.outlined-textarea {
  display: flex;
  flex-direction: column;
  flex-grow: 1;
  justify-content: center;
}

outlined-textarea span.right-button-container.outlined-textarea {
  position: absolute;
  right: 0;
  height: 100%;
}

outlined-textarea textarea.outlined-textarea {
  padding: 16px 16px 0 16px;
  border-color: #b0b3b6;
  border-width: 1px;
  border-style: solid;
  border-radius: 8px;
  caret-color: #3c78e0;
  color: #6a6c71;
  font-size: 14px;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  resize: none;
}

outlined-textarea[dense] textarea.outlined-textarea {
  padding: 8px;
}

outlined-textarea[has-icon] textarea.outlined-textarea {
  padding-right: 38px;
}

outlined-textarea[orig] textarea.outlined-textarea {
  border-color: #e5e5e5;
  
  border-radius: 0;
}

outlined-textarea:not([rows]) textarea.outlined-textarea {
  height: 40px;
}

outlined-textarea textarea.resizable.outlined-textarea {
  resize: vertical;
}

outlined-textarea textarea.outlined-textarea:focus,outlined-textarea[wizard-focused] textarea.outlined-textarea,outlined-textarea textarea.outlined-textarea:focus:hover {
  border-color: #3574e0 !important;
  
  outline: none !important;
}

outlined-textarea textarea.outlined-textarea:hover {
  border-color: #202124;
  color: #414447;
}

outlined-textarea.hasValue textarea.outlined-textarea {
  border-color: #888d91;
  color: #45474a;
}

outlined-textarea #helperText.outlined-textarea {
  color: #6a6c71;
  font-size: 12px;
  letter-spacing: 0.3px;
  margin-left: 17px;
  margin-top: 6px;
  user-select: none;
}

outlined-textarea:not([helper-text]) #helperText.outlined-textarea {
  display: none;
}

outlined-textarea[error] textarea.outlined-textarea {
  border-color: #cb4b3d;
  caret-color: #ca493a;
  color: #3d4043;
}

outlined-textarea textarea.outlined-textarea::placeholder {
  font-size: 14px;
  font-weight: 400;
}

outlined-textarea:not([error]):not([disabled]) textarea.outlined-textarea::placeholder {
  color: #6a6c71;
}

outlined-textarea[error] textarea.outlined-textarea::placeholder {
  color: #c84132;
}

outlined-textarea[error] #helperText.outlined-textarea {
  color: #cd5648;
}

outlined-textarea[error] textarea.outlined-textarea:focus {
  border-color: #c84031;
  border-width: 2px;
  outline: none !important;
}

outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover {
  border-color: #97231b;
}

outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover::placeholder,outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover + #helperText.outlined-textarea {
  color: #a94945;
}

outlined-textarea[disabled] textarea.outlined-textarea {
  border-color: #e9e9e9;
  color: #b5b6b8;
}

outlined-textarea[disabled] #helperText.outlined-textarea {
  color: #c4c6c7;
}

outlined-textarea[error][disabled] {
  opacity: 50%;
}

outlined-textarea[error][disabled] textarea.outlined-textarea {
  border-color: #cb4b3d;
  caret-color: #ca493a;
}

outlined-textarea[error][disabled] #helperText.outlined-textarea,outlined-textarea[error][disabled] textarea.outlined-textarea {
  color: #a94945;
}

outlined-textarea[error][disabled] textarea.outlined-textarea::placeholder {
  color: #c84132;
}</style><!-- Shady DOM styles for chemistry-search-term-wizard --><style scope="chemistry-search-term-wizard">chemistry-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
}

chemistry-search-term-wizard > span.chemistry-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

chemistry-search-term-wizard .suggestions.chemistry-search-term-wizard {
  margin-top: 4px;
}

chemistry-search-term-wizard > span.chemistry-search-term-wizard svg.chemistry-search-term-wizard {
  margin-right: 24px;
}

chemistry-search-term-wizard path.chemistry-search-term-wizard {
  fill: #5f6368;
}

chemistry-search-term-wizard .help.chemistry-search-term-wizard {
  margin-left: 12px;
  margin-right: 0;
  cursor: pointer;
}

chemistry-search-term-wizard outlined-text-field.chemistry-search-term-wizard {
  flex-grow: 1;
}

chemistry-search-term-wizard mat-button.chemistry-search-term-wizard {
  margin-left: 48px;
}

chemistry-search-term-wizard filter-chip.chemistry-search-term-wizard {
  margin-right: 4px;
}

chemistry-search-term-wizard outlined-textarea.chemistry-search-term-wizard {
  flex-grow: 1;
}

chemistry-search-term-wizard outlined-text-field[batchMode].chemistry-search-term-wizard {
  display: none;
}

chemistry-search-term-wizard outlined-textarea.chemistry-search-term-wizard:not([batchMode]) {
  display: none;
}</style><!-- Shady DOM styles for text-search-term-wizard --><style scope="text-search-term-wizard">text-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
}

text-search-term-wizard > span.text-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

text-search-term-wizard > span.text-search-term-wizard svg.text-search-term-wizard {
  margin-right: 24px;
}

text-search-term-wizard path.text-search-term-wizard {
  fill: #5f6368;
}

text-search-term-wizard outlined-text-field.text-search-term-wizard {
  flex-grow: 1;
}

text-search-term-wizard mat-button.text-search-term-wizard {
  margin-left: 48px;
}

text-search-term-wizard filter-chip.text-search-term-wizard {
  margin-right: 4px;
}</style><!-- Shady DOM styles for classification-wizard --><style scope="classification-wizard">classification-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

classification-wizard > span.classification-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

classification-wizard .suggestions.classification-wizard {
  margin-top: 4px;
}

classification-wizard > span.classification-wizard svg.classification-wizard {
  margin-right: 24px;
}

classification-wizard path.classification-wizard {
  fill: #5f6368;
}

classification-wizard outlined-text-field.classification-wizard {
  flex-grow: 1;
}

classification-wizard mat-button.classification-wizard {
  margin-left: 48px;
}

classification-wizard filter-chip.classification-wizard {
  margin-right: 4px;
}

classification-wizard .no-matches.classification-wizard {
  margin-left: 64px;
}

classification-wizard .table-container.classification-wizard {
  max-height: 300px;
  overflow: scroll;
  margin-top: 8px;
}

classification-wizard .table-container.classification-wizard::-webkit-scrollbar {
  -webkit-appearance: none;
  width: 10px;
}

classification-wizard .table-container.classification-wizard::-webkit-scrollbar-thumb {
  border-radius: 5px;
  background-color: #5f636880;
  -webkit-box-shadow: 0 0 1px rgba(255,255,255,.5);
}

classification-wizard table.classification-wizard {
  margin-left: 51px;
  max-width: 575px;
}

classification-wizard tr.classification-wizard {
  margin-top: 4px;
}

classification-wizard tr.classification-wizard suggestive-chip.classification-wizard {
  margin-right: 8px;
}

classification-wizard #spinner.classification-wizard {
  justify-content: space-around;
  margin-left: 48px;
  transform: scale(0.5);
}</style><!-- Shady DOM styles for suggestive-chip --><!-- Shady DOM styles for mat-checkbox --><!-- Shady DOM styles for measure-search-term-wizard --><style scope="measure-search-term-wizard">measure-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

measure-search-term-wizard > span.measure-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

measure-search-term-wizard .suggestions.measure-search-term-wizard {
  margin-top: 4px;
}

measure-search-term-wizard > span.measure-search-term-wizard svg.measure-search-term-wizard {
  margin-right: 24px;
}

measure-search-term-wizard path.measure-search-term-wizard {
  fill: #5f6368;
}

measure-search-term-wizard outlined-text-field.measure-search-term-wizard {
  flex-grow: 1;
}

measure-search-term-wizard mat-button.measure-search-term-wizard {
  margin-left: 48px;
}

measure-search-term-wizard filter-chip.measure-search-term-wizard {
  margin-right: 4px;
}</style><!-- Shady DOM styles for numerical-search-term-wizard --><style scope="numerical-search-term-wizard">numerical-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

numerical-search-term-wizard > span.numerical-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

numerical-search-term-wizard .suggestions.numerical-search-term-wizard {
  margin-top: 4px;
}

numerical-search-term-wizard > span.numerical-search-term-wizard svg.numerical-search-term-wizard {
  margin-right: 24px;
}

numerical-search-term-wizard path.numerical-search-term-wizard {
  fill: #5f6368;
}

numerical-search-term-wizard outlined-text-field.numerical-search-term-wizard,numerical-search-term-wizard outlined-textarea.numerical-search-term-wizard {
  flex-grow: 1;
}

numerical-search-term-wizard mat-button.numerical-search-term-wizard {
  margin-left: 48px;
}

numerical-search-term-wizard filter-chip.numerical-search-term-wizard {
  margin-right: 4px;
}

numerical-search-term-wizard #spinner.numerical-search-term-wizard {
  justify-content: space-around;
  margin-left: 48px;
  transform: scale(0.5);
}

numerical-search-term-wizard #suggestions.numerical-search-term-wizard {
  margin-left: 58px;
  display: flex;
  flex-direction: column;
  align-items: flex-start;
}

numerical-search-term-wizard .suggestion.numerical-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
}

numerical-search-term-wizard .suggestion.numerical-search-term-wizard mat-checkbox.numerical-search-term-wizard {
  margin-right: 8px;
}</style><!-- Shady DOM styles for text-button --><style scope="text-button">text-button {
  align-items: center;
  border-radius: 4px;
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 36px;
  letter-spacing: .25px;
  margin: 6px 0;
  padding: 0 8px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
  line-height: 36px;
  text-decoration: none;
  text-transform: none;
  color: #5f6368;
}

text-button:hover {
  background-color: #f8f9fa;
}

text-button:active {
  background-color: #d5e2fa;
}

text-button[selected] {
  background-color: #e8f0fe;
  color: #1967d2;
}

text-button[selected]:active {
  background-color: #d2e3fc;
}</style><!-- Shady DOM styles for mat-spinner --><!-- Shady DOM styles for requery-tile --><style scope="requery-tile">requery-tile {
  display: flex;
  justify-content: space-between;
  align-items: center;
  box-sizing: border-box;
  min-height: 40px;
  padding: 8px 12px 8px 8px;
  gap: 8px;

  border-radius: 16px;
  background: #f7f8f9;
  color: #1f1f1f;
}

requery-tile:hover {
  background: #d7d8d9;
}

requery-tile > [slot="image"] {
  flex-shrink: 0;

  border-radius: 8px;

  background: #fff;
}

.label.requery-tile {
  flex-grow: 999;

  font: 16px/20px "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
}

.search-icon.requery-tile {
  flex-shrink: 0;

  width: 24px;
  height: 24px;
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/search/default/24px.svg');
}</style><!-- Shady DOM styles for s-more-inline --><style scope="s-more-inline">s-more-inline {
  display: block;
  margin-top: 24px;
  padding: 16px;
  padding-top: 0;
  position: relative;

  line-height: 18px;
  text-overflow: ellipsis;
  white-space: nowrap;
  cursor: pointer;
}

hr.s-more-inline {
  background-color: #dadce0;
  margin-top: 18px;
  position: absolute;
  border: 0;
  height: 1px;
  left: 0;
  width: 100%;
}

.button.s-more-inline {
  display: flex;
  align-items: center;
  justify-content: center;

  position: relative; 
  margin: 0 auto;

  font: 400 14px Roboto, arial, sans-serif;
  height: 36px;
  width: 300px;
  border-radius: 18px;
  background-color: #f1f3f4;
}

.button.s-more-inline:hover {
  background-color: #d8d7dc;
}

.button.s-more-inline > [slot] {
  padding-right: 8px;
}

.expand.s-more-inline {
  display: inline-block;
  width: 20px;
  height: 20px;
}

.expand.less.s-more-inline {
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/expand_less/default/20px.svg');
}

.expand.more.s-more-inline {
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/expand_more/default/20px.svg');
}</style><!-- Shady DOM styles for workspace-ui-search --><!-- Shady DOM styles for keyword-wizard --><style scope="keyword-wizard">keyword-wizard {
  display: inline-block;
}

iron-icon.keyword-wizard {
  height: 20px;
    width: 20px;
    color: #999;
    cursor: pointer;
}

iron-icon[active].keyword-wizard {
  color: #4285f4 !important;
}

iron-icon.keyword-wizard:hover {
  color: #ccc;
}

#wizardIcon.keyword-wizard {
  padding-left: 1px;
    height: 16px;
    width: 16px;
    margin: 4px 1px 1px 1px;
}

#wizard.keyword-wizard {
  padding: 0;
    left: 0;
    top: 37px;
    position: absolute;
    background-color: white;
    z-index: 2;
    overflow: hidden;
}

.wizard-header.keyword-wizard {
  display: block;
    width: 100%;
    color: #737373;
    text-transform: uppercase;
    font-size: 13px;
    margin: 16px 0 6px 12px;
}

.filter-chips.keyword-wizard {
  margin-left: 20px;
}

.chip.keyword-wizard {
  background-color: #ebebeb;
    color: #6a6a6a;
    display: inline-block;
    font-size: 13px;
    font-family: inherit;
    border-radius: 12px;
    padding: 6px 12px;
}

.chip.keyword-wizard:hover {
  cursor: pointer;
}

.chip[selected].keyword-wizard {
  background-color: #4285f4;
    color: white;
}

.input-label.keyword-wizard {
  display: inline-block;
    font-size: 13px;
    font-family: inherit;
}

.keyword-input.keyword-wizard {
  display: inline-block;
    border-top: 0;
    border-left: 0;
    border-right: 0;
    border-bottom: 1px solid #dfe1e5;
    padding: 3px;
}

.keyword-input.keyword-wizard::placeholder {
  font-style: italic;
}

.keyword-input.keyword-wizard:hover,.keyword-input.keyword-wizard:focus {
  border-color: #4284f4;
    border-width: 1px;
    outline: none;
}

.cpc-field.keyword-wizard {
  display: inline-block;
    margin: 6px 0 0 24px;
}

#checkboxCPC.keyword-wizard:hover {
  cursor: pointer;
}

.checkbox-label.keyword-wizard {
  font-size: 13px;
    font-style: italic;
    color: #737373;
}

.chemistry-field.keyword-wizard {
  display: block;
}

#inputChem.input-batch.keyword-wizard {
  height: 150px;
    border: 1px solid #dfe1e5;
    padding: 6px;
}

#inputChem.keyword-wizard {
  resize: none;
    height: 15px;
    vertical-align: text-top;
    font-size: 13px;
    font-family: inherit;
    padding: 2px;
}

.chem-type-label.keyword-wizard {
  display: inline;
    font-size: 13px;
    margin-left: 12px;
    margin-right: 4px;
}

#chemType.keyword-wizard {
  border-top: 0;
    border-left: 0;
    border-right: 0;
    border-bottom: 1px solid #dfe1e5;
    margin: 6px;
    padding: 2px;
    outline: none;
    font-family: inherit;
    font-size: 13px;
}

.import.keyword-wizard {
  font-size: 13px;
    font-family: inherit;
}

.import-text.keyword-wizard {
  vertical-align: middle;
    display: inline-block;
}

.import-button.keyword-wizard {
  margin: 6px 0 0 24px;
}

.import-button.keyword-wizard button.keyword-wizard {
  border: 0;
    border-radius: 4px;
    padding: 6px 12px;
    font-family: inherit;
    background-color: #4284f4;
    color: white;
}

.import-button.keyword-wizard button.keyword-wizard:hover {
  cursor: pointer;
    background-color: #4284f4;
    color: white;
}

.wizard-buttons.keyword-wizard {
  float: right;
    padding: 12px;
}

.wizard-buttons.keyword-wizard button.keyword-wizard {
  border: 0;
    border-radius: 4px;
    padding: 6px 12px;
    margin: 2px;
    font-family: inherit;
    background-color: #4284f4;
    color: white;
}

.wizard-buttons.keyword-wizard button.keyword-wizard:hover {
  cursor: pointer;
}

@media screen and (max-width: 700px) {
#wizard.keyword-wizard {
  width: 275px;
}

.chip.keyword-wizard {
  margin: 4px 2px;
}

.keyword-input.keyword-wizard {
  width: 82%;
      margin: 4px 12px 12px 24px;
}

.search-within.keyword-wizard .input-label.keyword-wizard {
  display: none;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard {
  width: 225px;
      margin: 12px 0 6px 0;
}

.find-patents.keyword-wizard .input-label.keyword-wizard {
  display: none;
}

.search-by.keyword-wizard .input-label.keyword-wizard {
  width: 55px;
      margin-left: 24px;
}

.search-by.keyword-wizard .keyword-input.keyword-wizard {
  margin-top: 6px;
}

#inputChem.keyword-wizard {
  width: 82%;
      padding: 2px;
      margin: 8px 12px 12px 24px;
}

#inputChem.input-batch.keyword-wizard {
  width: 220px;
      padding: 4px;
}

#chemType.keyword-wizard {
  width: 150px;
}

.import-text.keyword-wizard {
  margin: 6px 12px 6px 24px;
      width: 220px;
}

iron-icon.help-header.keyword-wizard {
  display: none;
}

}

@media screen and (min-width: 700px) {
#wizard.keyword-wizard {
  width: 540px;
}

.chip.keyword-wizard {
  margin: 0 2px;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard {
  width: 240px;
      margin: 12px 16px 6px 6px;
}

.cpc-inputs.keyword-wizard {
  display: inline;
}

.find-patents.keyword-wizard .keyword-input.keyword-wizard {
  width: 53%;
      margin: 4px 10px;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard::placeholder,#inputAnd.keyword-wizard::placeholder,#inputExact.keyword-wizard::placeholder,#inputOr.keyword-wizard::placeholder,#inputMinus.keyword-wizard::placeholder {
  color: white;
}

.find-patents.keyword-wizard .input-label.keyword-wizard {
  width: 35%;
      margin-left: 24px;
}

.search-by.keyword-wizard .keyword-input.keyword-wizard {
  width: 42%;
      margin: 6px 4px;
}

.search-by.keyword-wizard .input-label.keyword-wizard {
  width: 55px;
      margin-left: 24px;
}

#inputChem.keyword-wizard {
  width: 290px;
      margin: 2px 12px 2px 6px;
}

#inputChem.input-batch.keyword-wizard {
  width: 280px;
      padding: 6px;
}

.import-text.keyword-wizard {
  margin: 6px 12px;
      width: 415px;
}

#chemType.keyword-wizard {
  width: 105px;
}

iron-icon.keyword-wizard:hover.help-header {
  cursor: default;
}

iron-icon.help-header.keyword-wizard {
  height: 16px;
      padding: 0 2px 2px 2px;
      color: #a3a3a3;
}

.help.keyword-wizard p.keyword-wizard {
  margin: 0 0 8px 0
}

.help.keyword-wizard .q.keyword-wizard {
  font-family: monospace;
      color: #0b8043;
      white-space: nowrap;
}

.help.keyword-wizard {
  z-index: 4;
      position: absolute;
      right: 10px;
      padding: 12px;
      border-radius: 2px;
      border: 1px solid #e0e0e0;
      box-shadow: 0 2px 2px 0 rgba(0, 0, 0, 0.2), 0 6px 10px 0 rgba(0, 0, 0, 0.3);
      background: white;
      font-size: 13px;
      line-height: 20px;
      width: 450px;
      max-height: 400px;
      overflow: auto;
}

#withinHelp.keyword-wizard {
  top: 75px;
}

#chemHelp.keyword-wizard {
  top: 0;
}

#searchBooleanHelp.keyword-wizard {
  top: 140px;
}

}</style><!-- Shady DOM styles for bottom-bar --><style scope="bottom-bar">.fixed.bottom-bar {
  display: block;
  position: fixed;
  height: 46px;
  bottom: 0;
}

.fixed[medium].bottom-bar {
  height: 280px;
}

.fixed[large].bottom-bar {
  height: 480px;
}

.shadow.bottom-bar {
  background: white;
  padding: 16px;
  border-radius: 8px 8px 0px 0px;
  box-shadow: 0px 8px 10px 1px rgba(0,0,0,.14), 0px 3px 14px 2px rgba(0,0,0,.12), 0px 5px 5px -3px rgba(0,0,0,.2);
}

.oneline.bottom-bar {
  white-space: nowrap;
  overflow: hidden;
  text-overflow: ellipsis;
  cursor: pointer;
}

.button.bottom-bar {
  cursor: pointer;
}

.buttonAlign.bottom-bar {
  margin-top: -4px;
}

.header.bottom-bar {
  height: 30px;
  font-family: 'Google Sans';
  font-size: 18px;
  padding-bottom: 8px;
}

.list.bottom-bar {
  overflow-y: auto;
  line-height: 20px;
}

.definition.bottom-bar {
  padding: 0px 0px 4px 0px;
  cursor: pointer;
}

[medium].bottom-bar .content.bottom-bar {
  height: 230px;
}

[large].bottom-bar .content.bottom-bar {
  height: 430px;
}

[medium].bottom-bar .content.bottom-bar .list.bottom-bar {
  height: 200px;
}

[large].bottom-bar .content.bottom-bar .list.bottom-bar {
  height: 400px;
}

[hidden].bottom-bar {
  display: none;
}

.label.bottom-bar {
  font-family: 'Google Sans';
  font-size: 12px;
  line-height: 16px;
  font-weight: 400;
  padding: 6px 0px 4px 0px;
  color: #1f1f1f;
}

[pad].bottom-bar {
  margin-left: 16px;
}

.layout.vertical.bottom-bar {
  display: flex;
  flex-direction: column;
}

.layout.horizontal.bottom-bar {
  display: flex;
  flex-direction: row;
}

.flex.bottom-bar {
  flex: 1;
  flex-basis: 0.000000001px;
}

.layout.start.bottom-bar {
  align-items: flex-start;
}

.layout.center.bottom-bar {
  align-items: center;
}

.layout.end.bottom-bar {
  align-items: flex-end;
}

.flex-2.bottom-bar {
  flex: 2;
}

.flex-3.bottom-bar {
  flex: 3;
}

.flex-4.bottom-bar {
  flex: 4;
}

.flex-5.bottom-bar {
  flex: 5;
}

.flex-6.bottom-bar {
  flex: 6;
}

.flex-7.bottom-bar {
  flex: 7;
}

.flex-8.bottom-bar {
  flex: 8;
}

.flex-9.bottom-bar {
  flex: 9;
}

.flex-10.bottom-bar {
  flex: 10;
}

.flex-11.bottom-bar {
  flex: 11;
}

.flex-12.bottom-bar {
  flex: 12;
}</style><!-- Shady DOM styles for landscape-link --><!-- Shady DOM styles for landscape-summary-box --><!-- Shady DOM styles for search-state --><!-- Shady DOM styles for iron-overlay-backdrop --><!-- Shady DOM styles for opaque-animation --><!-- Shady DOM styles for iron-dropdown --><!-- Shady DOM styles for iron-meta --><!-- Shady DOM styles for iron-icon --><style scope="iron-icon-0">.iron-icon-0 {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;-ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;-ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
        position: relative;

        vertical-align: middle;

        fill: currentcolor;
        stroke: none;

        width: 24px;
        height: 24px;;
}

.iron-icon-0[hidden] {
  display: none;
}</style><!-- Shady DOM styles for iron-iconset-svg --><!-- Shady DOM styles for iron-list --><!-- Shady DOM styles for paper-icon-item --><!-- Shady DOM styles for paper-item-body --><!-- Shady DOM styles for paper-item --><!-- Shady DOM styles for dropdown-menu --><!-- Shady DOM styles for chips-input --><!-- Shady DOM styles for input-chip --><!-- Shady DOM styles for keyword-editor --><!-- Shady DOM styles for paper-ripple --><!-- Shady DOM styles for paper-button --><!-- Shady DOM styles for date-editor --><!-- Shady DOM styles for metadata-editor --><!-- Shady DOM styles for restrict-editor --><!-- Shady DOM styles for overlay-tooltip --><style scope="overlay-tooltip">overlay-tooltip {
  display: none;
        color: #fff;
        background-color: #000;
        padding: 10px 12px;
        border-radius: 3px;
        font-size: 13px;
        font-weight: normal;
        line-height: normal;
        position: fixed;
        z-index: 100;
}

#arrow.overlay-tooltip {
  width: 0;
        height: 0;
        border-style: solid;
        border-width: 0 6px 8px 6px;
        border-color: transparent transparent #000 transparent;
        position: absolute;
        top: -8px;
        left: calc(50% - 6px);
}</style><!-- Shady DOM styles for query-renderer --><!-- Shady DOM styles for result-nav --><style scope="result-nav">result-nav {
  display: block;
        white-space: nowrap;
        padding: 0 30px;
        line-height: 30px;
        height: 30px;
        margin-top: 17px;
        font-weight: 500;
        font-size: 15px;
}

state-modifier.result-nav {
  color: #333;
}

state-modifier[disabled].result-nav {
  pointer-events: none;
        color: #ccc;
}</style><!-- Shady DOM styles for raw-html --><!-- Shady DOM styles for paper-material --><style scope="paper-material-0">.paper-material-0 {
  display: block;
        position: relative;
}

.paper-material-0[elevation="1"] {
  box-shadow: 0 2px 2px 0 rgba(0, 0, 0, 0.14),
                    0 1px 5px 0 rgba(0, 0, 0, 0.12),
                    0 3px 1px -2px rgba(0, 0, 0, 0.2);
}

.paper-material-0[elevation="2"] {
  box-shadow: 0 4px 5px 0 rgba(0, 0, 0, 0.14),
                    0 1px 10px 0 rgba(0, 0, 0, 0.12),
                    0 2px 4px -1px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="3"] {
  box-shadow: 0 6px 10px 0 rgba(0, 0, 0, 0.14),
                    0 1px 18px 0 rgba(0, 0, 0, 0.12),
                    0 3px 5px -1px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="4"] {
  box-shadow: 0 8px 10px 1px rgba(0, 0, 0, 0.14),
                    0 3px 14px 2px rgba(0, 0, 0, 0.12),
                    0 5px 5px -3px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="5"] {
  box-shadow: 0 16px 24px 2px rgba(0, 0, 0, 0.14),
                    0  6px 30px 5px rgba(0, 0, 0, 0.12),
                    0  8px 10px -5px rgba(0, 0, 0, 0.4);
}

.paper-material-0[animated] {
  transition: box-shadow 0.28s cubic-bezier(0.4, 0, 0.2, 1);
}

.paper-material-0 {
  ;
}</style><!-- Shady DOM styles for search-box --><style scope="search-box">.layout.horizontal.search-box,.layout.vertical.search-box {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-box {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-box {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-box {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-box {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-box {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-box,.layout.center-center.search-box {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-box,.layout.center-center.search-box {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-box {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-box {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-box {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.inputbox.search-box {
  border: 1px solid #ccc;
        padding: 0 12px;
        background: white;
}

.inputbox[focused].search-box {
  border: 1px solid #4285f4 !important;
}

.inputbox.search-box:hover {
  border: 1px solid #999;
}

#searchInput.search-box {
  font-family: inherit;
        font-size: 16px;
        padding: 8px 0;
        outline: none;
        border-right: none;
        width: 100%;
        margin-right: 0;
        border: 0;
}

#searchButton.search-box {
  cursor: pointer;
        background-color: #4285f4;
        border: none;
        color: #fff;
        vertical-align: top;
        width: 70px;
        height: 37px;
        outline: none;
}

.suggest-bg.search-box {
  display: inline-block;
        min-width: 0;
        white-space: nowrap;
}

#suggestMenu.search-box {
  position: absolute;
        margin-top: 38px;
        width: 100%;
        background: white;
        z-index: 1;
}

#suggestMenu.search-box .row.search-box {
  font-size: 13px;
        line-height: 28px;
        white-space: nowrap;
        overflow: hidden;
        text-overflow: ellipsis;
        padding: 4px 2px;
        cursor: pointer;
}

.row[selected].search-box {
  background: rgba(0, 0, 0, 0.05);
}

.suggest-icon.search-box {
  height: 20px;
        width: 20px;
        padding: 0 12px 0 6px;
        transition: transform .15s linear;
        transform: scale(1);
}

.suggest-icon[hide].search-box {
  transform: scale(0);
}

#corpora.search-box {
  padding: 6px 0;
        user-select: none;
}

#corpora.search-box iron-icon.search-box {
  height: 20px;
        width: 20px;
        color: #ccc;
        cursor: pointer;
}

#corpora.search-box iron-icon[active].search-box {
  color: #4285f4 !important;
}

#corpora.search-box iron-icon.search-box:hover {
  color: #999;
}</style><!-- Shady DOM styles for iron-media-query --><!-- Shady DOM styles for paper-header-panel --><!-- Shady DOM styles for iron-a11y-announcer --><style scope="iron-a11y-announcer">iron-a11y-announcer {
  display: inline-block;
        position: fixed;
        clip: rect(0px,0px,0px,0px);
}</style><!-- Shady DOM styles for iron-autogrow-textarea --><!-- Shady DOM styles for iron-input --><!-- Shady DOM styles for paper-input-char-counter --><!-- Shady DOM styles for paper-input-container --><!-- Shady DOM styles for paper-input-error --><!-- Shady DOM styles for paper-input --><!-- Shady DOM styles for paper-textarea --><!-- Shady DOM styles for paper-toast --><style scope="paper-toast-0">.paper-toast-0 {
  display: block;
        position: fixed;
        background-color: #323232;
        color: #f1f1f1;
        min-height: 48px;
        min-width: 288px;
        padding: 16px 24px;
        box-sizing: border-box;
        box-shadow: 0 2px 5px 0 rgba(0, 0, 0, 0.26);
        border-radius: 2px;
        margin: 12px;
        font-size: 14px;
        cursor: default;
        -webkit-transition: -webkit-transform 0.3s, opacity 0.3s;
        transition: transform 0.3s, opacity 0.3s;
        opacity: 0;
        -webkit-transform: translateY(100px);
        transform: translateY(100px);font-family: 'Roboto', 'Noto', sans-serif;
        -webkit-font-smoothing: antialiased;
}

.paper-toast-0.capsule {
  border-radius: 24px;
}

.paper-toast-0.fit-bottom {
  width: 100%;
        min-width: 0;
        border-radius: 0;
        margin: 0;
}

.paper-toast-0.paper-toast-open {
  opacity: 1;
        -webkit-transform: translateY(0px);
        transform: translateY(0px);
}</style><!-- Shady DOM styles for paper-toolbar --><!-- Shady DOM styles for search-footer --><style scope="search-footer">#footer.search-footer {
  font-size: 13px;
        margin-top: 10px;
        background: #fafafa;
        padding: 20px 10px;
        align-items: center;
        border-top: 1px solid #ebebeb;
}

#footer.search-footer .links.search-footer > *.search-footer {
  display: inline-block;
        margin: 0 12px;
}

.layout.horizontal.search-footer,.layout.vertical.search-footer {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-footer {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-footer {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-footer {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-footer {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-footer {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-footer,.layout.center-center.search-footer {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-footer,.layout.center-center.search-footer {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-footer {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-footer {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-footer {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-footer {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-footer,.layout.center-center.search-footer {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-footer {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-footer {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-footer {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-footer,.layout.center-center.search-footer {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-footer {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-footer {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-footer {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-footer {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-footer {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-footer {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-footer {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-footer {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-footer {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-footer {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-footer {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-footer {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-footer {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}</style><!-- Shady DOM styles for search-header --><style scope="search-header">search-header {
  display: block;
}

.lockup-logo.search-header,.lockup-text.search-header {
  display: inline-block;
}

.lockup-logo.search-header {
  width: 74px;
        height: 24px;
        background-image: url('https://www.gstatic.com/images/branding/googlelogo/1x/googlelogo_color_74x24dp.png');
        background-size: 74px 24px;
}

.lockup-text.search-header {
  font-family: "Product Sans", Arial, Helvetica, sans-serif;

        
        font-size: 22.1px;

        
        text-rendering: optimizeLegibility;

        
        position: relative;
        top: -6px;
        left: -5px;

        
        -webkit-font-smoothing: antialiased;
        -moz-osx-font-smoothing: grayscale;
}

.lockup-brand.search-header {
  opacity: 0.54;
}

@media (-webkit-min-device-pixel-ratio: 1.5), (min-resolution: 144dpi) {
.lockup-logo.search-header {
  background-image: url('https://www.gstatic.com/images/branding/googlelogo/2x/googlelogo_color_74x24dp.png');
}

.lockup-text.search-header {
  font-size: 21.3px;
          left: -7px;
}

}

header.search-header {
  background-color: #fafafa;
        border-bottom: 1px solid #ebebeb;
        color: #333;
        height: 60px;
        width: 100%;
        z-index: 1;
        display: block;
}

[latestStyle].search-header header.search-header {
  background-color: transparent;
}

.headerpad.search-header {
  margin-left: 16px;
}

[wide].search-header .headerpad.search-header {
  margin-left: 32px;
}

.leftheader.search-header {
  width: 322px;
}

header.search-header h1.search-header {
  display: none;
}

header.search-header h1.search-header state-modifier.search-header {
  color: #777;
        text-decoration: none;
        display: inline-block;
}

[wide].search-header header.search-header h1.search-header {
  box-sizing: border-box;
        margin: 0;
        padding: 20px 0 10px;
        font-size: 20px;
        font-weight: 400;
        white-space: nowrap;
        display: block;
}

search-box.search-header {
  height: 37px;
        padding: 0 16px;
        width: 900px;
        align-self: center;
}

.layout.horizontal.search-header,.layout.vertical.search-header {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-header {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-header {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-header {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-header {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-header {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-header,.layout.center-center.search-header {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-header,.layout.center-center.search-header {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-header {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-header {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-header {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-header {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-header,.layout.center-center.search-header {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-header {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-header {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-header {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-header,.layout.center-center.search-header {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-header {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-header {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-header {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-header {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-header {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-header {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-header {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-header {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-header {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-header {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-header {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-header {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-header {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}</style><!-- Shady DOM styles for search-ui --><style scope="search-ui-0">.search-ui-0 paper-button.search-ui {
  display: inline-block;
        text-align: center;
        font-family: inherit;
}

.search-ui-0 .layout.horizontal.search-ui,.search-ui-0 .layout.vertical.search-ui {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.search-ui-0 .layout.inline.search-ui {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.search-ui-0 .layout.horizontal.search-ui {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.search-ui-0 .layout.vertical.search-ui {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.search-ui-0 .layout.wrap.search-ui {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.search-ui-0 .layout.no-wrap.search-ui {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.search-ui-0 .layout.center.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.search-ui-0 .layout.center-justified.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.search-ui-0 .flex.search-ui {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.search-ui-0 .flex-auto.search-ui {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.search-ui-0 .flex-none.search-ui {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.search-ui-0 .layout.start.search-ui {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.search-ui-0 .layout.center.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.search-ui-0 .layout.end.search-ui {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.search-ui-0 .layout.baseline.search-ui {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.search-ui-0 .layout.start-justified.search-ui {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.search-ui-0 .layout.center-justified.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.search-ui-0 .layout.end-justified.search-ui {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.search-ui-0 .layout.around-justified.search-ui {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.search-ui-0 .layout.justified.search-ui {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.search-ui-0 .self-start.search-ui {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.search-ui-0 .self-center.search-ui {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.search-ui-0 .self-end.search-ui {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.search-ui-0 .self-stretch.search-ui {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.search-ui-0 .self-baseline.search-ui {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.search-ui-0 .layout.start-aligned.search-ui {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.search-ui-0 .layout.end-aligned.search-ui {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.search-ui-0 .layout.center-aligned.search-ui {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.search-ui-0 .layout.between-aligned.search-ui {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.search-ui-0 .layout.around-aligned.search-ui {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

.search-ui-0 {
  display: block;
        min-width: 350px;
        height: 100%;
}

.search-ui-0 #content.search-ui {
  height: 100%;
}

.search-ui-0 #leftBarOverflow.search-ui {
  padding-right: 16px;
}

.search-ui-0 [wide].search-ui #leftBarOverflow.search-ui {
  overflow: auto;
}

.search-ui-0 #leftBar.search-ui {
  box-sizing: border-box;
        color: #666;
        font-size: 13px;
        padding: 16px 0 16px 16px;
        border-bottom: 1px solid #e5e5e5;
}

.search-ui-0 [wide].search-ui #leftBar.search-ui {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;

        -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
        position: relative;
        width: 350px;
        margin-bottom: 0;
        padding-bottom: 0;
        border-bottom: none;
}

@media print {
.search-ui-0 #leftBar.search-ui {
  display: none !important;
}

}

.search-ui-0 #leftBar.search-ui h3.search-ui {
  text-transform: uppercase;
        font-size: 13px;
        font-weight: normal;
        margin-top: 6px;
        margin-bottom: 6px;
        cursor: default;
        display: inline-block;
        color: #a3a3a3;
}

.search-ui-0 #closeButton.search-ui {
  position: absolute;
        right: 0;
}

.search-ui-0 #searchTermsHeader.search-ui {
  position: relative;
}

.search-ui-0 #searchTermsQ.search-ui iron-icon.search-ui {
  height: 16px;
        padding: 0 2px 2px 2px;
        color: #a3a3a3;
}

.search-ui-0 #searchTermsHeader.search-ui:hover iron-icon.search-ui {
  color: #4285f4;
}

.search-ui-0 #closeLeftBar.search-ui {
  height: 16px;
        width: 16px;
        padding: 0 0 8px 0;
        cursor: pointer;
}

.search-ui-0 #compactQuery.search-ui iron-icon.search-ui {
  height: 20px;
}

.search-ui-0 #backToResultsButton.search-ui {
  color: #fff;
        background: #4285f4;
        margin-top: 20px;
        text-align: center;
}

.search-ui-0 #main.search-ui {
  display: block;
        min-height: calc(100vh - 127px);
}

@media print {
.search-ui-0 [wide].search-ui main.search-ui {
  margin-left: 0;
}

}</style><!-- Shady DOM styles for import-list --><!-- Shady DOM styles for iron-request --><!-- Shady DOM styles for iron-ajax --><!-- Shady DOM styles for paper-dialog --><!-- Shady DOM styles for coverage-stats --><!-- Shady DOM styles for iron-image --><!-- Shady DOM styles for iron-selector --><!-- Shady DOM styles for paper-card --><!-- Shady DOM styles for paper-checkbox --><!-- Shady DOM styles for landing-page --><!-- Shady DOM styles for remote-fetch --><!-- Shady DOM styles for paper-spinner --><style scope="paper-spinner-0">.paper-spinner-0 {
  display: inline-block;
        position: relative;
        width: 28px;
        height: 28px;
}

.paper-spinner-0 #spinnerContainer.paper-spinner {
  width: 100%;
        height: 100%;

        
        direction: ltr;
}

.paper-spinner-0 #spinnerContainer.active.paper-spinner {
  -webkit-animation: container-rotate-paper-spinner-0 1568ms linear infinite;
        animation: container-rotate-paper-spinner-0 1568ms linear infinite;
}

@-webkit-keyframes container-rotate-paper-spinner-0 {
to {
  -webkit-transform: rotate(360deg)
}

}

@keyframes container-rotate-paper-spinner-0 {
to {
  transform: rotate(360deg)
}

}

.paper-spinner-0 .spinner-layer.paper-spinner {
  position: absolute;
        width: 100%;
        height: 100%;
        opacity: 0;
        white-space: nowrap;
        color: #4285f4;
}

.paper-spinner-0 .layer-1.paper-spinner {
  color: #4285f4;
}

.paper-spinner-0 .layer-2.paper-spinner {
  color: #db4437;
}

.paper-spinner-0 .layer-3.paper-spinner {
  color: #f4b400;
}

.paper-spinner-0 .layer-4.paper-spinner {
  color: #0f9d58;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0;
        -webkit-animation-duration: 5332ms;
        -webkit-animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        -webkit-animation-iteration-count: infinite;
        animation-name: fill-unfill-rotate-paper-spinner-0;
        animation-duration: 5332ms;
        animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        animation-iteration-count: infinite;
        opacity: 1;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-1.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-1-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-1-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-2.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-2-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-2-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-3.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-3-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-3-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-4.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-4-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-4-fade-in-out-paper-spinner-0;
}

@-webkit-keyframes fill-unfill-rotate-paper-spinner-0 {
12.5% {
  -webkit-transform: rotate(135deg)
}

25% {
  -webkit-transform: rotate(270deg)
}

37.5% {
  -webkit-transform: rotate(405deg)
}

50% {
  -webkit-transform: rotate(540deg)
}

62.5% {
  -webkit-transform: rotate(675deg)
}

75% {
  -webkit-transform: rotate(810deg)
}

87.5% {
  -webkit-transform: rotate(945deg)
}

to {
  -webkit-transform: rotate(1080deg)
}

}

@keyframes fill-unfill-rotate-paper-spinner-0 {
12.5% {
  transform: rotate(135deg)
}

25% {
  transform: rotate(270deg)
}

37.5% {
  transform: rotate(405deg)
}

50% {
  transform: rotate(540deg)
}

62.5% {
  transform: rotate(675deg)
}

75% {
  transform: rotate(810deg)
}

87.5% {
  transform: rotate(945deg)
}

to {
  transform: rotate(1080deg)
}

}

@-webkit-keyframes layer-1-fade-in-out-paper-spinner-0 {
0% {
  opacity: 1
}

25% {
  opacity: 1
}

26% {
  opacity: 0
}

89% {
  opacity: 0
}

90% {
  opacity: 1
}

to {
  opacity: 1
}

}

@keyframes layer-1-fade-in-out-paper-spinner-0 {
0% {
  opacity: 1
}

25% {
  opacity: 1
}

26% {
  opacity: 0
}

89% {
  opacity: 0
}

90% {
  opacity: 1
}

to {
  opacity: 1
}

}

@-webkit-keyframes layer-2-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

15% {
  opacity: 0
}

25% {
  opacity: 1
}

50% {
  opacity: 1
}

51% {
  opacity: 0
}

to {
  opacity: 0
}

}

@keyframes layer-2-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

15% {
  opacity: 0
}

25% {
  opacity: 1
}

50% {
  opacity: 1
}

51% {
  opacity: 0
}

to {
  opacity: 0
}

}

@-webkit-keyframes layer-3-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

40% {
  opacity: 0
}

50% {
  opacity: 1
}

75% {
  opacity: 1
}

76% {
  opacity: 0
}

to {
  opacity: 0
}

}

@keyframes layer-3-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

40% {
  opacity: 0
}

50% {
  opacity: 1
}

75% {
  opacity: 1
}

76% {
  opacity: 0
}

to {
  opacity: 0
}

}

@-webkit-keyframes layer-4-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

65% {
  opacity: 0
}

75% {
  opacity: 1
}

90% {
  opacity: 1
}

to {
  opacity: 0
}

}

@keyframes layer-4-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

65% {
  opacity: 0
}

75% {
  opacity: 1
}

90% {
  opacity: 1
}

to {
  opacity: 0
}

}

.paper-spinner-0 .circle-clipper.paper-spinner {
  display: inline-block;
        position: relative;
        width: 50%;
        height: 100%;
        overflow: hidden;
}

.paper-spinner-0 .spinner-layer.paper-spinner::after {
  left: 45%;
        width: 10%;
        border-top-style: solid;
}

.paper-spinner-0 .spinner-layer.paper-spinner::after,.paper-spinner-0 .circle-clipper.paper-spinner::after {
  content: '';
        box-sizing: border-box;
        position: absolute;
        top: 0;
        border-width: 3px;
        border-radius: 50%;
}

.paper-spinner-0 .circle-clipper.paper-spinner::after {
  bottom: 0;
        width: 200%;
        border-style: solid;
        border-bottom-color: transparent !important;
}

.paper-spinner-0 .circle-clipper.left.paper-spinner::after {
  left: 0;
        border-right-color: transparent !important;
        -webkit-transform: rotate(129deg);
        transform: rotate(129deg);
}

.paper-spinner-0 .circle-clipper.right.paper-spinner::after {
  left: -100%;
        border-left-color: transparent !important;
        -webkit-transform: rotate(-129deg);
        transform: rotate(-129deg);
}

.paper-spinner-0 .active.paper-spinner .gap-patch.paper-spinner::after,.paper-spinner-0 .active.paper-spinner .circle-clipper.paper-spinner::after {
  -webkit-animation-duration: 1333ms;
        -webkit-animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        -webkit-animation-iteration-count: infinite;
        animation-duration: 1333ms;
        animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        animation-iteration-count: infinite;
}

.paper-spinner-0 .active.paper-spinner .circle-clipper.left.paper-spinner::after {
  -webkit-animation-name: left-spin-paper-spinner-0;
        animation-name: left-spin-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .circle-clipper.right.paper-spinner::after {
  -webkit-animation-name: right-spin-paper-spinner-0;
        animation-name: right-spin-paper-spinner-0;
}

@-webkit-keyframes left-spin-paper-spinner-0 {
0% {
  -webkit-transform: rotate(130deg)
}

50% {
  -webkit-transform: rotate(-5deg)
}

to {
  -webkit-transform: rotate(130deg)
}

}

@keyframes left-spin-paper-spinner-0 {
0% {
  transform: rotate(130deg)
}

50% {
  transform: rotate(-5deg)
}

to {
  transform: rotate(130deg)
}

}

@-webkit-keyframes right-spin-paper-spinner-0 {
0% {
  -webkit-transform: rotate(-130deg)
}

50% {
  -webkit-transform: rotate(5deg)
}

to {
  -webkit-transform: rotate(-130deg)
}

}

@keyframes right-spin-paper-spinner-0 {
0% {
  transform: rotate(-130deg)
}

50% {
  transform: rotate(5deg)
}

to {
  transform: rotate(-130deg)
}

}

.paper-spinner-0 #spinnerContainer.cooldown.paper-spinner {
  -webkit-animation: container-rotate-paper-spinner-0 1568ms linear infinite, fade-out-paper-spinner-0 400ms cubic-bezier(0.4, 0.0, 0.2, 1);
        animation: container-rotate-paper-spinner-0 1568ms linear infinite, fade-out-paper-spinner-0 400ms cubic-bezier(0.4, 0.0, 0.2, 1);
}

@-webkit-keyframes fade-out-paper-spinner-0 {
0% {
  opacity: 1
}

to {
  opacity: 0
}

}

@keyframes fade-out-paper-spinner-0 {
0% {
  opacity: 1
}

to {
  opacity: 0
}

}</style><!-- Shady DOM styles for paper-spinner-lite --><!-- Shady DOM styles for concept-card --><!-- Shady DOM styles for concept-mention --><style scope="concept-mention">.block.concept-mention {
  display: block;
}

[hidden].concept-mention {
  display: none !important;
}

.invisible.concept-mention {
  visibility: hidden !important;
}

.relative.concept-mention {
  position: relative;
}

.fit.concept-mention {
  position: absolute;
        top: 0;
        right: 0;
        bottom: 0;
        left: 0;
}

body.fullbleed.concept-mention {
  margin: 0;
        height: 100vh;
}

.scroll.concept-mention {
  -webkit-overflow-scrolling: touch;
        overflow: auto;
}

.fixed-bottom.concept-mention,.fixed-left.concept-mention,.fixed-right.concept-mention,.fixed-top.concept-mention {
  position: fixed;
}

.fixed-top.concept-mention {
  top: 0;
        left: 0;
        right: 0;
}

.fixed-right.concept-mention {
  top: 0;
        right: 0;
        bottom: 0;
}

.fixed-bottom.concept-mention {
  right: 0;
        bottom: 0;
        left: 0;
}

.fixed-left.concept-mention {
  top: 0;
        bottom: 0;
        left: 0;
}

#target.concept-mention:hover {
  background-color: #e8f0fe;
}

#target[noicon].concept-mention {
  padding: 1px;
}

#target.concept-mention:hover[noicon] {
  border: 1px solid #e8f0fe;
        padding: 0;
}

#target.concept-mention {
  display: inline-block;
}

.inline-icon.concept-mention {
  cursor: pointer;
        height: 12px;
        width: 12px;
        padding-left: 4px;
        color: #5e6368;
}

concept-card.concept-mention {
  z-index: 1;
        position: absolute;
}</style><!-- Shady DOM styles for fterm-concept-card --><!-- Shady DOM styles for fterm-concept-mention --><!-- Shady DOM styles for paper-fab --><!-- Shady DOM styles for paper-icon-button --><!-- Shady DOM styles for paper-icon-button-light --><!-- Shady DOM styles for classification-tree --><style scope="classification-tree">.layout.horizontal.classification-tree,.layout.vertical.classification-tree {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.classification-tree {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.classification-tree {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.classification-tree {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.classification-tree {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.classification-tree {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.classification-tree,.layout.center-center.classification-tree {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.classification-tree,.layout.center-center.classification-tree {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.classification-tree {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.classification-tree {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.classification-tree {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

classification-tree {
  display: block;
        line-height: 20px;
}

.wrap.classification-tree {
  padding: 6px 12px;
}

.wrap.classification-tree:hover {
  background: #fafafa;
}

.description.classification-tree {
  padding-left: 4px;
}

iron-icon.classification-tree {
  color: #eaeaea;
}

.code[first].classification-tree {
  font-weight: 500;
}

.code[additional].classification-tree {
  font-style: italic;
}</style><!-- Shady DOM styles for classification-viewer --><style scope="classification-viewer">.table.classification-viewer {
  border: 1px solid #eaeaea;
        display: block;
}

.more.classification-viewer {
  padding: 6px 12px;
        cursor: pointer;
        font-style: italic;
        color: #aaa;
}

.more.classification-viewer:hover {
  background: #fafafa;
}

.chip.classification-viewer {
  display: inline-block;
        padding: 4px 6px;
        border-radius: 2px;
}

.chip[additional].classification-viewer {
  font-style: italic;
}</style><!-- Shady DOM styles for image-carousel --><!-- Shady DOM styles for image-viewer --><!-- Shady DOM styles for patent-result --><style scope="patent-result">#wrapper.patent-result {
  padding: 20px;
        max-width: 1050px;
        outline: 0;
}

.scroll-target.patent-result:before {
  display: block;
        content: '';
        visibility: hidden;
}

h1.patent-result {
  font-weight: 500;
        font-size: 20px;
        margin: 0 0 20px 0;
}

h3.patent-result {
  font-size: 15px;
        font-weight: 500;
        margin: 28px 0 18px 0;
}

dl.patent-result {
  line-height: 1.5;
        font-size: 0;
}

dt.patent-result,dd.patent-result {
  display: inline;
        font-size: 13px;
        margin: 0;
}

dt.patent-result {
  font-weight: 500;
        color: #000;
}

dt.patent-result::after {
  content: ': ';
}

dd.patent-result {
  color: #aaa;
}

dd.patent-result ~ dd.patent-result::before {
  content: ', ';
}

dt.patent-result + dd.patent-result::before {
  content: '';
}

dd.patent-result ~ dt.patent-result::before {
  display: block;
        content: '';
        margin-top: 8px;
}

dd.patent-result core-icon.patent-result {
  width: 14px;
        height: 14px;
        vertical-align: top;
        color: inherit;
}

.table.patent-result {
  display: table;
        border-collapse: collapse;
        border-spacing: 0;
        border: 1px solid #eaeaea;
        width: 100%;
        box-sizing: border-box;
}

.tr.patent-result {
  display: table-row;
        border-bottom: 1px solid #eaeaea;
}

.th.patent-result,.td.patent-result {
  display: table-cell;
        padding: 10px 12px;
}

.thead.patent-result {
  display: table-header-group;
}

.tbody.patent-result {
  display: table-row-group;
}

.th.patent-result {
  text-align: left;
        white-space: nowrap;
        background-color: #fafafa;
        color: #757575;
}

.td.patent-result {
  vertical-align: top;
}

.td.patent-result > p.patent-result {
  margin-top: 0;
}

.nowrap.patent-result {
  white-space: nowrap;
}

.knowledge-card.patent-result {
  border: 1px solid #e5e5e5;
        border-radius: 2px;
}

.knowledge-card.patent-result > header.patent-result {
  -webkit-font-smoothing: antialiased;
        -moz-osx-font-smoothing: grayscale;
        background: #4285f4;
        color: #fff;
        padding: 20px 12px;
}

.knowledge-card.patent-result > header.patent-result state-modifier.patent-result,.knowledge-card.patent-result > header.patent-result a.patent-result {
  color: inherit;
        margin: 0 12px 0 0;
        display: inline-block;
}

.knowledge-card.patent-result > header.patent-result h2.patent-result,.knowledge-card.patent-result > header.patent-result .tagline.patent-result {
  margin: 0;
        font-weight: normal;
        padding-top: 4px;
}

.knowledge-card.patent-result > header.patent-result h2.patent-result {
  font-size: 20px;
}

.knowledge-card.patent-result .knowledge-card-action-bar.patent-result {
  background: #3367d6;
        padding: 10px 12px;
        margin: 20px -12px -20px;
}

.knowledge-card.patent-result .knowledge-card-action-bar.patent-result core-icon.patent-result {
  margin-right: 12px;
        width: 24px;
        height: 24px;
}

.knowledge-card.patent-result dl.patent-result {
  padding: 16px 12px;
}

.knowledge-card.patent-result hr.patent-result {
  border: none;
        height: 1px;
        background: #e5e5e5;
        margin: 0;
}

.main-link.patent-result {
  margin: 14px;
        font-weight: 500;
}

.footer.patent-result h3.patent-result state-modifier.patent-result,.footer.patent-result h3.patent-result a.patent-result {
  float: right;
        font-weight: 400;
        font-size: 13px;
        line-height: 24px;
}

.footer.patent-result dl.patent-result {
  margin-left: 30px;
}

.footer.patent-result > ul.patent-result > li.patent-result {
  margin-bottom: 8px;
}

h3.patent-result .righthead.patent-result {
  color: #aaa;
        font-weight: 400;
        font-size: 13px;
        cursor: help;
}

.tooltip-hint.patent-result {
  border-bottom: 1px dotted #ccc;
}

[marginRight].patent-result {
  margin-right: 60px;
}

.flex-width.patent-result {
  min-width: 0;
        word-break: break-word;
}

.responsive-table.patent-result {
  width: 100%;
        overflow-x: auto;
        overflow-y: hidden;
}

.layout.horizontal.patent-result,.layout.vertical.patent-result {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.patent-result {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.patent-result {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.patent-result {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.patent-result {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.patent-result {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.patent-result,.layout.center-center.patent-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.patent-result,.layout.center-center.patent-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.patent-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.patent-result {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.patent-result {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.patent-result {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.patent-result,.layout.center-center.patent-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.patent-result {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.patent-result {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.patent-result {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.patent-result,.layout.center-center.patent-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.patent-result {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.patent-result {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.patent-result {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.patent-result {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.patent-result {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.patent-result {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.patent-result {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.patent-result {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.patent-result {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.patent-result {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.patent-result {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.patent-result {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.patent-result {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

.flex.patent-result,.flex-1.patent-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-2.patent-result {
  -ms-flex: 2;
        -webkit-flex: 2;
        flex: 2;
}

.flex-3.patent-result {
  -ms-flex: 3;
        -webkit-flex: 3;
        flex: 3;
}

.flex-4.patent-result {
  -ms-flex: 4;
        -webkit-flex: 4;
        flex: 4;
}

.flex-5.patent-result {
  -ms-flex: 5;
        -webkit-flex: 5;
        flex: 5;
}

.flex-6.patent-result {
  -ms-flex: 6;
        -webkit-flex: 6;
        flex: 6;
}

.flex-7.patent-result {
  -ms-flex: 7;
        -webkit-flex: 7;
        flex: 7;
}

.flex-8.patent-result {
  -ms-flex: 8;
        -webkit-flex: 8;
        flex: 8;
}

.flex-9.patent-result {
  -ms-flex: 9;
        -webkit-flex: 9;
        flex: 9;
}

.flex-10.patent-result {
  -ms-flex: 10;
        -webkit-flex: 10;
        flex: 10;
}

.flex-11.patent-result {
  -ms-flex: 11;
        -webkit-flex: 11;
        flex: 11;
}

.flex-12.patent-result {
  -ms-flex: 12;
        -webkit-flex: 12;
        flex: 12;
}

@media print {
#text.patent-result {
  flex-direction: column-reverse !important;
}

}

patent-result-ref-list.patent-result {
  width: 100%;
}

patent-result-ref-list.patent-result + patent-result-ref-list.patent-result {
  margin-left: 10px;
}

[narrow].patent-result {
  flex-direction: column-reverse !important;
}

.famheader.patent-result {
  text-align: left;
        white-space: nowrap;
        background-color: #fafafa;
        color: #757575;
}

.collapse.patent-result {
  color: #616161;
        font-size: 13px;
        cursor: pointer;
}

#imageDrag.patent-result {
  position: fixed;
        cursor: col-resize;
}

#imageDrag.patent-result div.patent-result {
  width: 4px;
        height: 100%;
        margin: 0 4px;
        background: #eee;
}

#imageDrag.patent-result:hover {
  background: #eee;
}

#imageDrag.patent-result:hover div.patent-result {
  background: #ccc;
}

.imageWrapper.patent-result {
  position: fixed;
        top: 60px;
        background: white;
        margin-left: 12px;
}

#notices.patent-result {
  padding: 20px;
}

#figures.patent-result {
  background: #efefef;
}

.headerButton.patent-result {
  color: #3c80f6;
        cursor: pointer;
        display: inline-block;
        padding: 0 14px;
        line-height: 27px;
}

.headerButton.patent-result iron-icon.patent-result {
  width: 16px;
        height: 16px;
}

.tr.conceptDomain.patent-result {
  display: table-row;
}

.responsive-grid.patent-result {
  display: grid;
        gap: 8px;
        grid-template-columns: none;
}</style><!-- Shady DOM styles for family-viewer --><!-- Shady DOM styles for app-row --><!-- Shady DOM styles for application-timeline --><style scope="application-timeline">.layout.horizontal.application-timeline,.layout.vertical.application-timeline {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.application-timeline {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.application-timeline {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.application-timeline {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.application-timeline {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.application-timeline {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.application-timeline,.layout.center-center.application-timeline {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.application-timeline,.layout.center-center.application-timeline {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.application-timeline {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.application-timeline {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.application-timeline {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.wrap.application-timeline {
  padding: 16px 12px;
}

.event.application-timeline {
  padding: 3px 0;
}

[date].application-timeline {
  color: #5f6368;
        font-size: 13px;
        padding: 3px 0;
        width: 70px;
        line-height: 16px;
}

[critical].application-timeline [date].application-timeline {
  color: #202124;
        font-weight: 500;
        line-height: 18px;
}

.line.application-timeline {
  margin: 9px 6px;
        border-radius: 4px;
        background: #dadce0;
        width: 4px;
        height: 4px;
}

.dot.application-timeline {
  margin: 3px 0;
        border-radius: 4px;
        background: #dadce0;
        width: 4px;
        height: 4px;
        display: inline-block;
}

[critical].application-timeline .line.application-timeline {
  background: #4285f4;
}

[current].application-timeline .line.application-timeline {
  background: #81c995;
}

[current][critical].application-timeline .line.application-timeline {
  background: #81c995;
}

.title.application-timeline {
  font-size: 13px;
        padding: 3px 0;
        line-height: 16px;
}

.title-text.application-timeline {
  color: #5f6368;
}

.description-item.application-timeline {
  font-size: 12px;
        padding: 6px 0;
        max-width: 300px;
}

#legal.application-timeline {
  height: 14px;
        width: 14px;
        padding: 0 3px 1px 3px;
        vertical-align: text-bottom;
}

#icon.application-timeline {
  height: 12px;
        width: 12px;
        padding: 0 3px 3px 3px;
        vertical-align: text-bottom;
}

.unknown.application-timeline {
  font-style: italic;
}

.not_active.application-timeline {
  text-decoration: line-through;
}

.active.application-timeline {
  font-weight: 500;
}

#cc[this].application-timeline {
  color: #202124 !important;
        text-decoration: underline;
}

#cc[this].not_active.application-timeline {
  text-decoration: line-through underline;
}

hr.application-timeline {
  border: none;
        height: 1px;
        background: #e5e5e5;
        margin: 10px 0 16px 0;
}

.header.application-timeline {
  font-size: 13px;
        line-height: 20px;
        font-weight: 500;
        color: #202124;
        padding-bottom: 8px;
}

.block.application-timeline {
  padding: 0 6px 0 0;
}

.year.application-timeline {
  color: #5f6368;
        font-size: 13px;
        font-weight: 500;
        padding: 3px 1px;
        width: 70px;
}

.expand.application-timeline {
  cursor: pointer;
        padding: 6px 0 3px 0;
}</style><!-- Shady DOM styles for patent-text --><style scope="patent-text">.layout.horizontal.patent-text,.layout.vertical.patent-text {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.patent-text {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.patent-text {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.patent-text {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.patent-text {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.patent-text {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.patent-text,.layout.center-center.patent-text {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.patent-text,.layout.center-center.patent-text {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.patent-text {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.patent-text {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.patent-text {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.patent-text {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.patent-text,.layout.center-center.patent-text {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.patent-text {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.patent-text {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.patent-text {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.patent-text,.layout.center-center.patent-text {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.patent-text {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.patent-text {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.patent-text {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.patent-text {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.patent-text {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.patent-text {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.patent-text {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.patent-text {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.patent-text {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.patent-text {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.patent-text {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.patent-text {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.patent-text {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

patent-text {
  display: block;
}

#text.patent-text {
  line-height: 20px;
        min-width: 0;
}

#margin.patent-text {
  width: 16px;
}

#createHighlight.patent-text {
  position: relative;
        width: 16px;
        height: 16px;
        cursor: pointer;
}

.notranslate.patent-text > .google-src-text.patent-text {
  display: none;
}

.notranslate.patent-text:hover,mark.patent-text {
  background-color: #fbfcae;
}

.description-paragraph.patent-text {
  margin-block-start: 1em;
        margin-block-end: 1em;
}

.claim-text.patent-text {
  margin: 14px 0 0 20px;
}

.claim-dependent.patent-text {
  margin-left: 40px;
        color: #888;
}

[hide-claims].patent-text .claim-dependent.patent-text .claim-text.patent-text {
  height: 0;
        width: 0;
        visibility: hidden;
}

[hide-claims].patent-text .claim-dependent.patent-text .claim.patent-text:after {
  content: "…"
}

.patent-full-image.patent-text {
  max-width: 100%;
        height: auto;
}

.small-patent-image.patent-text {
  display: inline;
}

ul.patent-text {
  padding: 0 0 0 50px;
}

li.patent-text {
  list-style-type: none;
        position: relative;
}

ol.claims.patent-text li.patent-text {
  list-style-type: decimal;
        font-weight: bold;
}

ol.claims.patent-text li.patent-text > *.patent-text {
  font-weight: normal;
}

li.patent-text > para-num.patent-text {
  position: absolute;
        left: -45px;
        color: #888;
}

mark.patent-text {
  background: #fff59d;
}

mark.searchText.patent-text {
  background: #80deea;
}

.searchTextHeader.patent-text {
  font-weight: 500;
}

pre.patent-text {
  white-space: pre-wrap;
}

heading.patent-text {
  display: block;
        font-weight: 500;
        font-size: 13px;
}

#comment.patent-text {
  width: 16px;
        height: 16px;
}

[has-search][no-results].patent-text {
  display: none;
}

.highlight.patent-text {
  background-color: #fef7e0;
}</style><!-- Shady DOM styles for para-num --><!-- Shady DOM styles for result-container --><style scope="result-container">paper-spinner.result-container {
  position: absolute;
        
        top: calc(50%  + 56px - 16px);
        left: calc(50% + 175px - 16px);
}</style><!-- Shady DOM styles for scholar-result --><!-- Shady DOM styles for search-result --><style scope="search-result">.layout.horizontal.search-result,.layout.vertical.search-result {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-result {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-result {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-result {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-result {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-result {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-result,.layout.center-center.search-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-result,.layout.center-center.search-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-result {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-result {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-result {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-result,.layout.center-center.search-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-result {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-result {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-result {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-result,.layout.center-center.search-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-result {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-result {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-result {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-result {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-result {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-result {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-result {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-result {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-result {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-result {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-result {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-result {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-result {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

search-result {
  display: block;
        font-size: 13px;
}

#mainContainer.search-result {
  min-height: calc(100vh - 127px);
        color: #333;
}

#compactQuery.search-result {
  padding: 18px 20px 10px 20px;
        cursor: pointer;
}

#compactQuery.search-result > span.search-result {
  padding: 0 14px 0 0;
}

#compactQuery.search-result iron-icon.search-result {
  padding-right: 6px;
        height: 16px;
        width: 16px;
}</style><!-- Shady DOM styles for webdoc-result --><!-- Shady DOM styles for iron-pages --><!-- Shady DOM styles for paper-tab --><!-- Shady DOM styles for paper-tabs --><!-- Shady DOM styles for debug-info --><!-- Shady DOM styles for search-paging --><!-- Shady DOM styles for search-result-item --><!-- Shady DOM styles for search-result-image --><!-- Shady DOM styles for search-result-entities --><!-- Shady DOM styles for search-result-measures --><!-- Shady DOM styles for search-results --><!-- Shady DOM styles for summary-box --><!-- Shady DOM styles for timeline-page --><!-- Shady DOM styles for iron-localstorage --><!-- Shady DOM styles for search-app --><style scope="search-app">search-app {
  display: block;
        height: 100%;
}

#toast.search-app {
  min-height: 64px;
        min-width: 742px;
}</style><style>body {transition: opacity ease-in 0.2s; } 
body[unresolved] {opacity: 0; display: block; overflow: hidden; position: relative; } 
</style>
    <title>ES2887903T3 - 
  Compositions comprising bacterial strains
 
      - Google Patents</title>

    <meta name="viewport" content="width=device-width, initial-scale=1">
    <meta charset="UTF-8">
    <meta name="referrer" content="origin-when-crossorigin">
    <link rel="canonical" href="https://patents.google.com/patent/ES2887903T3/en">
    <meta name="description" content="
   
    A composition comprising a bacterial strain of the genus Bariatricus, for use in therapy.
   
 
   ">
    <meta name="DC.type" content="patent">
    <meta name="DC.title" content="
  Compositions comprising bacterial strains
 
     ">
    <meta name="DC.date" content="2019-06-25" scheme="dateSubmitted">
    <meta name="DC.description" content="
   
    A composition comprising a bacterial strain of the genus Bariatricus, for use in therapy.
   
 
   ">
    <meta name="citation_patent_application_number" content="ES:19755806T">
    <meta name="citation_pdf_url" content="https://patentimages.storage.googleapis.com/4c/dd/af/b5c42a31881c76/ES2887903T3.pdf">
    <meta name="citation_patent_number" content="ES:2887903:T3">
    <meta name="DC.date" content="2021-12-28" scheme="issue">
    <meta name="DC.contributor" content="Samantha Yuille" scheme="inventor">
    <meta name="DC.contributor" content="Nicole Reichardt" scheme="inventor">
    <meta name="DC.contributor" content="Sarah Reid" scheme="inventor">
    <meta name="DC.contributor" content="Suaad Ahmed" scheme="inventor">
    <meta name="DC.contributor" content="Helene Savignac" scheme="inventor">
    <meta name="DC.contributor" content="Imke Elisabeth MULDER" scheme="inventor">
    <meta name="DC.contributor" content="Anna Ettorre" scheme="inventor">
    <meta name="DC.contributor" content="4D Pharma Research Ltd" scheme="assignee">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:400,400italic,500,500italic,700">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Product+Sans">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Google+Sans:wght@400;500;700">

    <style>
      body { transition: none; }
    </style>

    <script src="https://apis.google.com/_/scs/abc-static/_/js/k=gapi.lb.en.IKZeRvoAYNY.O/m=client/rt=j/sv=1/d=1/ed=1/am=AAAQ/rs=AHpOoo-SMWTzMRJrTty6iE5dL_aWGYOnuw/cb=gapi.loaded_0?le=scs" async=""></script><script>
      window.version = 'patent-search.search_20240531_RC00';

      function sendFeedback() {
        userfeedback.api.startFeedback({
          'productId': '713680',
          'bucket': 'patent-search-web',
          'productVersion': window.version,
        });
      }

      window.experiments = {};
      window.experiments.patentCountries = "ae,ag,al,am,ao,ap,ar,at,au,aw,az,ba,bb,bd,be,bf,bg,bh,bj,bn,bo,br,bw,bx,by,bz,ca,cf,cg,ch,ci,cl,cm,cn,co,cr,cs,cu,cy,cz,dd,de,dj,dk,dm,do,dz,ea,ec,ee,eg,em,ep,es,fi,fr,ga,gb,gc,gd,ge,gh,gm,gn,gq,gr,gt,gw,hk,hn,hr,hu,ib,id,ie,il,in,ir,is,it,jo,jp,ke,kg,kh,km,kn,kp,kr,kw,kz,la,lc,li,lk,lr,ls,lt,lu,lv,ly,ma,mc,md,me,mg,mk,ml,mn,mo,mr,mt,mw,mx,my,mz,na,ne,ng,ni,nl,no,nz,oa,om,pa,pe,pg,ph,pl,pt,py,qa,ro,rs,ru,rw,sa,sc,sd,se,sg,si,sk,sl,sm,sn,st,su,sv,sy,sz,td,tg,th,tj,tm,tn,tr,tt,tw,tz,ua,ug,us,uy,uz,vc,ve,vn,wo,yu,za,zm,zw";
      
      
      window.experiments.keywordWizard = true;
      
      
      
      window.experiments.definitions = true;

      window.Polymer = {
        dom: 'shady',
        lazyRegister: true,
      };
    </script>

    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/webcomponentsjs/webcomponents-lite.min.js"></script>
    <style>[hidden]:not([style-scope]):not(.style-scope) {
  display: none !important;
}

</style><style></style><style></style><style></style><style></style><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:400,300,300italic,400italic,500,500italic,700,700italic"><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto+Mono:400,700"><style></style><style></style><style>
  html, body {
    min-width: 100%;
    width: 100%;
    min-height: 100%;
    height: 100%;
  }

  body {
    background-color: #fff;
    font-family: 'Roboto', sans-serif;
    color: #333;
    margin: 0;
    padding: 0;
    /*
     * Turn off https://github.com/WICG/ScrollAnchoring/blob/master/explainer.md
     * https://memegen.googleplex.com/5230756293246976
     */
    overflow-anchor: none;
  }

  body h1, body h2, body h3 {
    -webkit-font-smoothing: antialiased;
    -moz-osx-font-smoothing: grayscale;
  }

  body a:link {
    color: #3c80f6;
    text-decoration: none;
  }

  body a:visited {
    color: #3c80f6;
  }

  body a[open-result]:visited {
    color: #7e57c2;
  }

  /* For Firefox */
  a:link {
    color: #3c80f6;
    text-decoration: none;
  }

  a:visited {
    color: #3c80f6;
  }

  a[open-result]:visited {
    color: #7e57c2;
  }

  ::selection , body ::selection {
    background-color: #c6dafc;
    color: #333;
  }
</style><link rel="import" href="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/search-app-vulcanized.html">
  <style>[hidden] { display: none !important; }</style><script type="text/javascript" charset="UTF-8" src="https://apis.google.com/js/client.js" gapi_processed="true"></script></head>
  <body>
    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/search-app-vulcanized.js"></script><span style="font-size: 13px; white-space: pre-wrap; display: inline-block; position: absolute; left: -99999px; top: -99999px; max-width: 217px;"></span><span style="font-size: 13px; white-space: pre-wrap; display: inline-block; position: absolute; left: -99999px; top: -99999px; max-width: 217px;"></span>
    <search-app>
    
    <remote-fetch class="style-scope search-app"></remote-fetch>
    <search-state class="style-scope search-app"></search-state>
    <browser-ui class="style-scope search-app"></browser-ui>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    
      <search-result id="result" class="style-scope search-app">
    
    
    <search-ui mode="result" class="style-scope search-result x-scope search-ui-0">
    
    
    
    <div id="content" class="style-scope search-ui" wide="">
      <search-header show-search="" class="style-scope search-ui">
    
    
    <div class="style-scope search-header" wide="">
      <header class="style-scope search-header">
        <div class="layout horizontal headerpad style-scope search-header">
          <div class="layout horizontal leftheader style-scope search-header">
            <h1 class="style-scope search-header">
              <state-modifier inherit="" act="{&quot;type&quot;: &quot;HOME&quot;}" class="style-scope search-header"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                <div class="lockup style-scope search-header">
                  <span class="lockup-logo style-scope search-header"></span>
                  <span class="lockup-text style-scope search-header">
                    <span class="lockup-brand style-scope search-header">&nbsp;Patents</span>
                  </span>
                </div>
              </a></state-modifier>
            </h1>
          </div>
          
            <search-box class="style-scope search-header">
    
    <div class="layout horizontal style-scope search-box" style="position: relative;">
      <div class="inputbox flex layout horizontal style-scope search-box">
        <div class="suggest-bg flex style-scope search-box">
          <input name="q" id="searchInput" data-proto="SEARCH_INPUT" autocomplete="off" class="style-scope search-box">
        </div>
        <div id="corpora" class="style-scope search-box">
          <iron-icon icon="icons:lightbulb-outline" id="patentIcon" class="style-scope search-box x-scope iron-icon-0" active=""><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M9 21c0 .55.45 1 1 1h4c.55 0 1-.45 1-1v-1H9v1zm3-19C8.14 2 5 5.14 5 9c0 2.38 1.19 4.47 3 5.74V17c0 .55.45 1 1 1h6c.55 0 1-.45 1-1v-2.26c1.81-1.27 3-3.36 3-5.74 0-3.86-3.14-7-7-7zm2.85 11.1l-.85.6V16h-4v-2.3l-.85-.6C7.8 12.16 7 10.63 7 9c0-2.76 2.24-5 5-5s5 2.24 5 5c0 1.63-.8 3.16-2.15 4.1z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
          <overlay-tooltip positioning-target="#patentIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Include patents
    </div>
  </overlay-tooltip>
          <iron-icon icon="social:school" id="nplIcon" class="style-scope search-box x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M5 13.18v4L12 21l7-3.82v-4L12 17l-7-3.82zM12 3L1 9l11 6 9-4.91V17h2V9L12 3z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
          <overlay-tooltip positioning-target="#nplIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Include non-patent literature
    </div>
  </overlay-tooltip>
          <keyword-wizard id="wizardIcon" class="style-scope search-box">


<div id="wizardContainer" class="style-scope keyword-wizard">
  <iron-icon icon="image:tune" id="wizardIcon" class="style-scope keyword-wizard x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M3 17v2h6v-2H3zM3 5v2h10V5H3zm10 16v-2h8v-2h-8v-2h-2v6h2zM7 9v2H3v2h4v2h2V9H7zm14 4v-2H11v2h10zm-6-4h2V7h4V5h-4V3h-2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
  <paper-material elevation="2" id="wizard" class="style-scope keyword-wizard x-scope paper-material-0" hidden="">
    
    

    
    
    <div class="search-within style-scope keyword-wizard">
      <span class="wizard-header style-scope keyword-wizard">
        Search within
        <iron-icon icon="icons:help-outline" class="help-header style-scope keyword-wizard x-scope iron-icon-0" id="within"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </span>
      
      <div class="help style-scope keyword-wizard" id="withinHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Search within the title, abstract, claims, or full patent document</b>: You can
          restrict your search to a specific field using field names.</p>
        <p class="style-scope keyword-wizard">Use <span class="q style-scope keyword-wizard">TI=</span> to search in the title, <span class="q style-scope keyword-wizard">AB=</span> for the
          abstract, <span class="q style-scope keyword-wizard">CL=</span> for the claims, or <span class="q style-scope keyword-wizard">TAC=</span> for
          all three. For example, <span class="q style-scope keyword-wizard">TI=(safety belt)</span>.
        </p>
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Search by Cooperative Patent Classifications (CPCs)</b>: These are commonly used to
          represent ideas in place of keywords, and can also be entered in a search term box. If
          you're searching for<span class="q style-scope keyword-wizard">seat belts</span>, you could also search for
          <span class="q style-scope keyword-wizard">B60R22/00</span> to retrieve documents that mention safety belts or body
          harnesses. <span class="q style-scope keyword-wizard">CPC=B60R22</span> will match documents with exactly this CPC,
          <span class="q style-scope keyword-wizard">CPC=B60R22/low</span> matches documents with this CPC or a child
          classification of this CPC.
        </p>
          <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      <div class="filter-chips style-scope keyword-wizard">
        <span class="chip style-scope keyword-wizard" id="title" selected="">Title</span>
        <span class="chip style-scope keyword-wizard" id="abstract" selected="">Abstract</span>
        <span class="chip style-scope keyword-wizard" id="claims" selected="">Claims</span>
        <span class="chip style-scope keyword-wizard" id="fullDoc" selected="">Full Document</span>
      </div>
      
      <div class="cpc-field style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputCPC" class="style-scope keyword-wizard">or CPC</label></span>
        <div class="cpc-inputs style-scope keyword-wizard">
          <input class="keyword-input style-scope keyword-wizard" id="inputCPC" placeholder="Or search with CPC">
          <input type="checkbox" id="childCPC" checked="" class="style-scope keyword-wizard">
          <label class="checkbox-label style-scope keyword-wizard" for="childCPC">
            Include child classifications
          </label>
        </div>
      </div>
    </div>
    
    <div class="find-patents style-scope keyword-wizard">
      <span class="wizard-header style-scope keyword-wizard">
        Find patents
        <iron-icon class="help-header style-scope keyword-wizard x-scope iron-icon-0" icon="icons:help-outline" id="searchBoolean"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </span>
      
      <div class="help style-scope keyword-wizard" id="searchBooleanHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Keywords and boolean syntax (USPTO or EPO format)</b>:
          <span class="q style-scope keyword-wizard">seat belt</span> searches these two words, or their plurals and close
          synonyms. <span class="q style-scope keyword-wizard">"seat belt"</span> searches this exact phrase, in order.
          <span class="q style-scope keyword-wizard">-seat -belt</span> searches for documents not containing either word.
        </p>
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">For searches using boolean logic</b>, the default operator is
          <span class="q style-scope keyword-wizard">AND</span> with left associativity. <i class="style-scope keyword-wizard">Note:</i> this means
          <span class="q style-scope keyword-wizard">safety OR seat belt</span> is searched as <span class="q style-scope keyword-wizard">(safety OR seat)
          AND belt</span>. Each word automatically includes plurals and close synonyms. Adjacent
          words that are implicitly ANDed together, such as <span class="q style-scope keyword-wizard">(safety belt)</span>,
          are treated as a phrase when generating synonyms.
        </p>
        <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputAnd" class="style-scope keyword-wizard">with ALL of the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputAnd" placeholder="with ALL of the words">
      </div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputExact" class="style-scope keyword-wizard">with the EXACT PHRASE</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputExact" placeholder="with the EXACT PHRASE"></div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputOr" class="style-scope keyword-wizard">with AT LEAST ONE of the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputOr" placeholder="with AT LEAST ONE of the words"></div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputMinus" class="style-scope keyword-wizard">WITHOUT the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputMinus" placeholder="WITHOUT the words"></div>
    </div>
    <div class="search-by style-scope keyword-wizard">
      <div class="wizard-header style-scope keyword-wizard">
          Search by
          <iron-icon icon="icons:help-outline" class="help-header style-scope keyword-wizard x-scope iron-icon-0" id="chem"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </div>
      
      <div class="help style-scope keyword-wizard" id="chemHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Chemistry searches</b> match terms (trade names, IUPAC names, etc.
          extracted from the entire document, and processed from .MOL files.)
        </p>
        <p class="style-scope keyword-wizard">Substructure (use <span class="q style-scope keyword-wizard">SSS=</span>) and similarity (use
          <span class="q style-scope keyword-wizard">~</span>) searches are limited to one per search at the top-level
          <span class="q style-scope keyword-wizard">AND</span> condition. Exact searches can be used multiple times throughout
          the search query.
        </p>
        <p class="style-scope keyword-wizard">Searching by SMILES or InChi key requires no special syntax. To search by SMARTS, use
          <span class="q style-scope keyword-wizard">SMARTS=</span>.
        </p>
        <p class="style-scope keyword-wizard">To search for multiple molecules, select "Batch" in the "Type" menu. Enter multiple
          molecules separated by whitespace or by comma.
        </p>
        <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      
      <div class="chemistry-field style-scope keyword-wizard">
          <span class="input-label style-scope keyword-wizard"><label for="inputChem" class="style-scope keyword-wizard">Chemistry</label></span>
          <span class="chem-type-label style-scope keyword-wizard"><label for="chemType" hidden="" class="style-scope keyword-wizard">Type</label></span>
          <select id="chemType" class="style-scope keyword-wizard">
            <option value="identical" class="style-scope keyword-wizard">Identical</option>
            <option value="substructure" class="style-scope keyword-wizard">Substructure</option>
            <option value="smarts" class="style-scope keyword-wizard">SMARTS</option>
            <option value="similarity" class="style-scope keyword-wizard">Similarity</option>
            <option value="batch" class="style-scope keyword-wizard">Batch</option>
          </select>
          <textarea class="keyword-input style-scope keyword-wizard" id="inputChem" placeholder="Trade name, SMILES, InChiKey"></textarea>
      </div>
      <div class="import style-scope keyword-wizard">
        <div class="wizard-header style-scope keyword-wizard">
          Patent numbers
        </div>
        <span class="import-button style-scope keyword-wizard">
          <a href="https://patents.google.com/import" class="style-scope keyword-wizard"><button class="style-scope keyword-wizard">Import</button></a>
        </span>
        <p class="import-text style-scope keyword-wizard">
          Search specific patents by importing a CSV or list of patent publication or application numbers.
        </p>
      </div>
    </div>
    
    <div class="wizard-buttons style-scope keyword-wizard">
      <button type="reset" class="style-scope keyword-wizard">Close</button>
      <button type="button" autofocus="" class="style-scope keyword-wizard">Add</button>
    </div>
  
  </paper-material>
</div>
</keyword-wizard>
          <overlay-tooltip positioning-target="#wizardIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Display advanced search options
    </div>
  </overlay-tooltip>
        </div>
      </div>
      <paper-material id="suggestMenu" class="style-scope search-box x-scope paper-material-0" elevation="1" hidden="">
    
    

    
        <template is="dom-repeat" class="style-scope search-box"></template>
        <div class="row style-scope search-box" hidden="">
          <iron-icon class="suggest-icon style-scope search-box x-scope iron-icon-0" icon="error"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 2C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm1 15h-2v-2h2v2zm0-4h-2V7h2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Sorry, we couldn't find this patent number.
        </div>
        <div class="row style-scope search-box" hidden="">
          <iron-icon class="suggest-icon style-scope search-box x-scope iron-icon-0" icon="error"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 2C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm1 15h-2v-2h2v2zm0-4h-2V7h2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> 
        </div>
      
  </paper-material>
      <button id="searchButton" class="style-scope search-box"><iron-icon class="style-scope search-box x-scope iron-icon-0" icon="search"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M15.5 14h-.79l-.28-.27C15.41 12.59 16 11.11 16 9.5 16 5.91 13.09 3 9.5 3S3 5.91 3 9.5 5.91 16 9.5 16c1.61 0 3.09-.59 4.23-1.57l.27.28v.79l5 4.99L20.49 19l-4.99-5zm-6 0C7.01 14 5 11.99 5 9.5S7.01 5 9.5 5 14 7.01 14 9.5 11.99 14 9.5 14z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></button>
    </div>
  </search-box>
          <template is="dom-if" class="style-scope search-header"></template>
          <div class="flex style-scope search-header"></div>
          
            <div id="header-container" class="style-scope search-header">
              <result-nav class="style-scope search-header">
    
    <div class="style-scope result-nav" hidden="">
      <state-modifier id="current" act="{&quot;type&quot;: &quot;BACK_TO_RESULTS&quot;}" inherit="" class="style-scope result-nav"><a id="link" href="#" class="style-scope state-modifier" inherit=""><span class="style-scope result-nav"></span> of
      <template is="dom-if" class="style-scope result-nav"></template>
      0<template is="dom-if" class="style-scope result-nav"></template></a></state-modifier>
      <state-modifier id="prevResult" inherit="" act="{&quot;type&quot;: &quot;NAV_RESULT&quot;, &quot;result&quot;: &quot;$id&quot;, &quot;page&quot;: $page}" class="style-scope result-nav" disabled=""><a id="link" href="#" class="style-scope state-modifier" inherit="">
        <iron-icon icon="chevron-left" class="style-scope result-nav x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M15.41 7.41L14 6l-6 6 6 6 1.41-1.41L10.83 12z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </a></state-modifier><state-modifier id="nextResult" inherit="" act="{&quot;type&quot;: &quot;NAV_RESULT&quot;, &quot;result&quot;: &quot;$id&quot;, &quot;page&quot;: $page}" class="style-scope result-nav" disabled=""><a id="link" href="#" class="style-scope state-modifier" inherit="">
        <iron-icon icon="chevron-right" class="style-scope result-nav x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M10 6L8.59 7.41 13.17 12l-4.58 4.59L10 18l6-6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </a></state-modifier>
      <overlay-tooltip positioning-target="#prevResult" direction="bottom" arrow="" class="style-scope result-nav" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip"></div>
    <div class="style-scope overlay-tooltip">
      Previous result
    </div>
  </overlay-tooltip>
      <overlay-tooltip positioning-target="#nextResult" direction="bottom" arrow="" class="style-scope result-nav" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip"></div>
    <div class="style-scope overlay-tooltip">
      Next result
    </div>
  </overlay-tooltip>
    </div>
  </result-nav>
            </div>
          <template is="dom-if" class="style-scope search-header"></template>
        </div>
      </header>
    </div>
  </search-header>

      <div class="layout horizontal style-scope search-ui">
        <template is="dom-if" class="style-scope search-ui"></template>

        <div id="main" class="style-scope search-ui">
          <search-term-wizard class="style-scope search-ui"><pat-dialog open="" class="style-scope search-term-wizard">
  <span class="header style-scope search-term-wizard">
    <span class="title style-scope search-term-wizard">Search tools</span>
    <span id="language" class="style-scope search-term-wizard">
      <text-button id="textButton" selected="" class="style-scope search-term-wizard">Text
</text-button>
      <text-button id="classificationButton" class="style-scope search-term-wizard">Classification
</text-button>
      <text-button id="chemistryButton" class="style-scope search-term-wizard">Chemistry
</text-button>
      <text-button id="measureButton" class="style-scope search-term-wizard">Measure
</text-button>
      <text-button id="numbersButton" class="style-scope search-term-wizard">Numbers
</text-button>
    </span>
  </span>
  <span id="panels" class="style-scope search-term-wizard">
    <text-search-term-wizard id="textPanel" class="style-scope search-term-wizard" selected=""><span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Type a concept you want to search for here" class="style-scope text-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Type a concept you want to search for here">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M8 18.025h8v-2.1H8Zm0-4h8v-2.1H8ZM6.075 22.2q-.95 0-1.612-.662-.663-.663-.663-1.613V4.075q0-.95.663-1.613.662-.662 1.612-.662h8L20.2 7.925v12q0 .95-.662 1.613-.663.662-1.613.662Zm6.85-13.125v-5h-6.85v15.85h11.85V9.075Zm-6.85-5v5-5 15.85-15.85Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <filter-chip id="fullDocuments" selected="" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Full documents</filter-chip>
  <filter-chip id="title" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Title</filter-chip>
  <filter-chip id="abstract" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Abstract</filter-chip>
  <filter-chip id="claims" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Claims</filter-chip>
</span>
<span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M16 16.925q2.05 0 3.488-1.437Q20.925 14.05 20.925 12t-1.437-3.488Q18.05 7.075 16 7.075q-.625 0-1.2.15t-1.075.425q.7.925 1.087 2.025.388 1.1.388 2.325t-.388 2.325q-.387 1.1-1.087 2.025.5.275 1.075.425.575.15 1.2.15Zm-4-2.075q.45-.575.688-1.313.237-.737.237-1.537 0-.8-.237-1.538Q12.45 9.725 12 9.15q-.45.575-.688 1.312-.237.738-.237 1.538t.237 1.537q.238.738.688 1.313Zm-4 2.075q.625 0 1.2-.15t1.075-.425q-.7-.925-1.087-2.025Q8.8 13.225 8.8 12t.388-2.325q.387-1.1 1.087-2.025-.5-.275-1.075-.425-.575-.15-1.2-.15-2.05 0-3.487 1.437Q3.075 9.95 3.075 12t1.438 3.488Q5.95 16.925 8 16.925ZM8 19.2q-3 0-5.1-2.1Q.8 15 .8 12q0-3 2.1-5.1Q5 4.8 8 4.8q1.125 0 2.137.312 1.013.313 1.863.913.85-.6 1.863-.913Q14.875 4.8 16 4.8q3 0 5.1 2.1Q23.2 9 23.2 12q0 3-2.1 5.1-2.1 2.1-5.1 2.1-1.125 0-2.137-.313-1.013-.312-1.863-.912-.85.6-1.863.912Q9.125 19.2 8 19.2Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <filter-chip id="all" selected="" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
All</filter-chip>
  <filter-chip id="any" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Any</filter-chip>
  <filter-chip id="exact" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact</filter-chip>
  <filter-chip id="not" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Not</filter-chip>
</span>
<span class="style-scope text-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope text-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope text-search-term-wizard">Add AND condition</span></mat-button></span></text-search-term-wizard>
    <classification-wizard id="classificationPanel" class="style-scope search-term-wizard"><span class="style-scope classification-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope classification-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope classification-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Enter a CPC here" uppercase="" class="style-scope classification-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Enter a CPC here">
  
</span>
</outlined-text-field>
</span>
<template is="dom-if" class="style-scope classification-wizard"></template>
<template is="dom-if" class="style-scope classification-wizard"></template>
<template is="dom-if" class="style-scope classification-wizard"></template>
<span class="style-scope classification-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope classification-wizard">
    <path d="M16 16.925q2.05 0 3.488-1.437Q20.925 14.05 20.925 12t-1.437-3.488Q18.05 7.075 16 7.075q-.625 0-1.2.15t-1.075.425q.7.925 1.087 2.025.388 1.1.388 2.325t-.388 2.325q-.387 1.1-1.087 2.025.5.275 1.075.425.575.15 1.2.15Zm-4-2.075q.45-.575.688-1.313.237-.737.237-1.537 0-.8-.237-1.538Q12.45 9.725 12 9.15q-.45.575-.688 1.312-.237.738-.237 1.538t.237 1.537q.238.738.688 1.313Zm-4 2.075q.625 0 1.2-.15t1.075-.425q-.7-.925-1.087-2.025Q8.8 13.225 8.8 12t.388-2.325q.387-1.1 1.087-2.025-.5-.275-1.075-.425-.575-.15-1.2-.15-2.05 0-3.487 1.437Q3.075 9.95 3.075 12t1.438 3.488Q5.95 16.925 8 16.925ZM8 19.2q-3 0-5.1-2.1Q.8 15 .8 12q0-3 2.1-5.1Q5 4.8 8 4.8q1.125 0 2.137.312 1.013.313 1.863.913.85-.6 1.863-.913Q14.875 4.8 16 4.8q3 0 5.1 2.1Q23.2 9 23.2 12q0 3-2.1 5.1-2.1 2.1-5.1 2.1-1.125 0-2.137-.313-1.013-.312-1.863-.912-.85.6-1.863.912Q9.125 19.2 8 19.2Z" class="style-scope classification-wizard"></path>
  </svg>
  <filter-chip id="notExact" class="style-scope classification-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>

    These CPCs and their children
  </filter-chip>
  <filter-chip selected="" id="exact" class="style-scope classification-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>

    These exact CPCs
  </filter-chip>
</span>
<span class="style-scope classification-wizard">
  <mat-button id="button" filled="" class="style-scope classification-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope classification-wizard">Add AND condition</span></mat-button>
</span></classification-wizard>
    <chemistry-search-term-wizard id="chemistryPanel" class="style-scope search-term-wizard"><span class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Trade name, SMILES, InChI Key" class="style-scope chemistry-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Trade name, SMILES, InChI Key">
  
</span>
</outlined-text-field>
  <outlined-textarea id="textArea" placeholder="Enter multiple SMILES or InChI Keys, one per line" rows="4" class="style-scope chemistry-search-term-wizard"><span class="style-scope outlined-textarea">
  <textarea id="textarea" autocomplete="off" autocorrect="off" spellcheck="false" tabindex="0" aria-disabled="false" wrap="soft" class="style-scope outlined-textarea" rows="4" placeholder="Enter multiple SMILES or InChI Keys, one per line">  </textarea>
  <div id="helperText" class="style-scope outlined-textarea"> </div>
</span>
<span class="right-button-container style-scope outlined-textarea">
  
</span>
</outlined-textarea>
  <a href="https://support.google.com/faqs/answer/7049475#zippy=%2Csearching-by-chemistry" target="_blank" class="style-scope chemistry-search-term-wizard">
    <svg class="help style-scope chemistry-search-term-wizard" xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49">
      <path d="M11.95 18q.525 0 .888-.363.362-.362.362-.887t-.362-.887q-.363-.363-.888-.363t-.888.363q-.362.362-.362.887t.362.887q.363.363.888.363Zm-.9-3.85h1.85q0-.825.188-1.3.187-.475 1.062-1.3.65-.65 1.025-1.238.375-.587.375-1.412 0-1.4-1.025-2.15T12.1 6q-1.425 0-2.312.75-.888.75-1.238 1.8l1.65.65q.125-.45.563-.975Q11.2 7.7 12.1 7.7q.8 0 1.2.437.4.438.4.963 0 .5-.3.937-.3.438-.75.813-1.1.975-1.35 1.475-.25.5-.25 1.825ZM12 22q-2.075 0-3.9-.788-1.825-.787-3.175-2.137-1.35-1.35-2.137-3.175Q2 14.075 2 12t.788-3.9q.787-1.825 2.137-3.175 1.35-1.35 3.175-2.138Q9.925 2 12 2t3.9.787q1.825.788 3.175 2.138 1.35 1.35 2.137 3.175Q22 9.925 22 12t-.788 3.9q-.787 1.825-2.137 3.175-1.35 1.35-3.175 2.137Q14.075 22 12 22Zm0-2q3.35 0 5.675-2.325Q20 15.35 20 12q0-3.35-2.325-5.675Q15.35 4 12 4 8.65 4 6.325 6.325 4 8.65 4 12q0 3.35 2.325 5.675Q8.65 20 12 20Zm0-8Z" class="style-scope chemistry-search-term-wizard"></path>
    </svg>
  </a>
</span>
<span id="chemQuantifiers" class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M5 21.2q-1.4 0-2-1.25-.6-1.25.3-2.325l5.5-6.7V5.15h-.825q-.475 0-.8-.338Q6.85 4.475 6.85 4q0-.475.325-.813.325-.337.8-.337h8.05q.475 0 .8.337.325.338.325.813 0 .475-.325.812-.325.338-.8.338H15.2v5.775l5.5 6.7q.9 1.075.3 2.325-.6 1.25-2 1.25Zm2.15-3.275h9.7l-3.275-3.85h-3.15Zm-2 1h13.7l-5.925-7.2V5.15h-1.85v6.575Zm6.85-6.9Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <filter-chip id="exact" selected="" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact</filter-chip>
  <filter-chip id="exactBatch" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact Batch</filter-chip>
  <filter-chip id="similar" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Similar</filter-chip>
  <filter-chip id="substructure" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Substructure</filter-chip>
  <filter-chip id="smarts" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Substructure (SMARTS)</filter-chip>
</span>
<span id="location" class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M8 18.025h8v-2.1H8Zm0-4h8v-2.1H8ZM6.075 22.2q-.95 0-1.612-.662-.663-.663-.663-1.613V4.075q0-.95.663-1.613.662-.662 1.612-.662h8L20.2 7.925v12q0 .95-.662 1.613-.663.662-1.613.662Zm6.85-13.125v-5h-6.85v15.85h11.85V9.075Zm-6.85-5v5-5 15.85-15.85Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <filter-chip id="fullDocuments" selected="" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Full documents</filter-chip>
  <filter-chip id="claims" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Claims only</filter-chip>
</span>
<span class="style-scope chemistry-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope chemistry-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope chemistry-search-term-wizard">Add AND condition</span></mat-button>
</span>
</chemistry-search-term-wizard>
    <measure-search-term-wizard id="measurePanel" class="style-scope search-term-wizard"><span class="style-scope measure-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope measure-search-term-wizard">
    <path d="M4.1 18.15q-.95 0-1.612-.663-.663-.662-.663-1.612v-7.75q0-.95.663-1.613Q3.15 5.85 4.1 5.85h15.8q.95 0 1.613.662.662.663.662 1.613v7.75q0 .95-.662 1.612-.663.663-1.613.663Zm0-2.275h15.8v-7.75H17V12h-2V8.125h-2V12h-2V8.125H9V12H7V8.125H4.1v7.75ZM7 12h2Zm4 0h2Zm4 0h2Zm-3 0Z" class="style-scope measure-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="measureExpression" placeholder="1.5 mm, 20 ft, 400-500 fahrenheit, 800 MHz, 0.01-100 mol" class="style-scope measure-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="1.5 mm, 20 ft, 400-500 fahrenheit, 800 MHz, 0.01-100 mol">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope measure-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope measure-search-term-wizard">
    <path d="M3.875 20.15V8.85h4.25v11.3Zm6 0V3.85h4.25v16.3Zm6 0v-7.3h4.25v7.3Z" class="style-scope measure-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="context" placeholder="activity, wavelength, embossing depth, absorption" class="style-scope measure-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="activity, wavelength, embossing depth, absorption">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope measure-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope measure-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope measure-search-term-wizard">Add AND condition</span></mat-button>
</span>
</measure-search-term-wizard>
    <numerical-search-term-wizard id="numericalPanel" class="style-scope search-term-wizard"><span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-textarea id="batch" placeholder="Enter multiple Patent Application and Publication Numbers, one per line" rows="4" class="style-scope numerical-search-term-wizard"><span class="style-scope outlined-textarea">
  <textarea id="textarea" autocomplete="off" autocorrect="off" spellcheck="false" tabindex="0" aria-disabled="false" wrap="soft" class="style-scope outlined-textarea" rows="4" placeholder="Enter multiple Patent Application and Publication Numbers, one per line">  </textarea>
  <div id="helperText" class="style-scope outlined-textarea"> </div>
</span>
<span class="right-button-container style-scope outlined-textarea">
  
</span>
</outlined-textarea>
</span>
<template is="dom-if" class="style-scope numerical-search-term-wizard"></template>
<template is="dom-if" class="style-scope numerical-search-term-wizard"></template>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="m10.825 23.45-1.6-1.625L10.9 20.15H8q-.35.9-1.162 1.488-.813.587-1.838.587-1.35 0-2.287-.937-.938-.938-.938-2.288 0-1.025.588-1.837Q2.95 16.35 3.85 16V8q-.9-.35-1.487-1.163Q1.775 6.025 1.775 5q0-1.35.938-2.288Q3.65 1.775 5 1.775q1.025 0 1.838.587Q7.65 2.95 8 3.85h2.9L9.225 2.175l1.6-1.625L15.275 5l-4.45 4.45-1.6-1.625L10.9 6.15H8q-.25.65-.725 1.125T6.15 8v8q.65.25 1.125.725T8 17.85h2.9l-1.675-1.675 1.6-1.625 4.45 4.45ZM19 22.225q-1.35 0-2.287-.937-.938-.938-.938-2.288 0-1.05.588-1.863.587-.812 1.487-1.137V8q-.9-.325-1.487-1.137-.588-.813-.588-1.863 0-1.35.938-2.288.937-.937 2.287-.937 1.35 0 2.288.937.937.938.937 2.288 0 1.05-.587 1.863Q21.05 7.675 20.15 8v8q.9.35 1.488 1.163.587.812.587 1.837 0 1.35-.937 2.288-.938.937-2.288.937ZM5 19.95q.4 0 .675-.275T5.95 19q0-.4-.275-.675T5 18.05q-.4 0-.675.275T4.05 19q0 .4.275.675T5 19.95Zm14 0q.4 0 .675-.275T19.95 19q0-.4-.275-.675T19 18.05q-.4 0-.675.275T18.05 19q0 .4.275.675t.675.275Zm-14-14q.4 0 .675-.275T5.95 5q0-.4-.275-.675T5 4.05q-.4 0-.675.275T4.05 5q0 .4.275.675T5 5.95Zm14 0q.4 0 .675-.275T19.95 5q0-.4-.275-.675T19 4.05q-.4 0-.675.275T18.05 5q0 .4.275.675T19 5.95ZM5 19Zm14 0ZM5 5Zm14 0Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <filter-chip id="applicationNumbers" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Application Numbers</filter-chip>
  <filter-chip id="publicationNumbers" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Publication Numbers</filter-chip>
  <filter-chip id="either" selected="" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Either</filter-chip>
</span>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M12 22.2q-2.1 0-3.962-.8-1.863-.8-3.25-2.175Q3.4 17.85 2.6 15.988 1.8 14.125 1.8 12t.8-3.988q.8-1.862 2.188-3.237Q6.175 3.4 8.038 2.6 9.9 1.8 12 1.8q2.125 0 3.988.8 1.862.8 3.237 2.175Q20.6 6.15 21.4 8.012q.8 1.863.8 3.988t-.8 3.988q-.8 1.862-2.175 3.237Q17.85 20.6 15.988 21.4q-1.863.8-3.988.8Zm-1-2.325v-1.95q-.8 0-1.387-.575-.588-.575-.588-1.4v-.975L4.275 10.2q-.075.45-.137.9-.063.45-.063.9 0 3 1.975 5.25T11 19.875Zm6.85-2.525q.5-.55.888-1.175.387-.625.65-1.313.262-.687.4-1.412.137-.725.137-1.45 0-2.425-1.338-4.438-1.337-2.012-3.612-2.887v.375q0 .825-.587 1.4-.588.575-1.388.575h-2v2q0 .4-.287.687-.288.288-.688.288h-2v2h5.95q.425 0 .713.287.287.288.287.688v2.975h1q.65 0 1.163.387.512.388.712 1.013Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="countryFilter" placeholder="Restrict search to these countries" class="style-scope numerical-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Restrict search to these countries">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M2.85 18.225V15.95h6.3v2.275Zm0-5.075v-2.3h12.3v2.3Zm0-5.1V5.775h18.3V8.05Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="countryOrder" placeholder="Prefer results from these countries in this order" class="style-scope numerical-search-term-wizard" value="US, EP, WO, JP, CN"><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Prefer results from these countries in this order">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope numerical-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope numerical-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope numerical-search-term-wizard">Add AND condition</span></mat-button>
</span>
</numerical-search-term-wizard>
  </span>

</pat-dialog>
</search-term-wizard>
          
      <div content="" class="style-scope search-result">
        <div id="mainContainer" class="vertical layout style-scope search-result">
          <template is="dom-if" class="style-scope search-result"></template>
          <result-container class="style-scope search-result">
    

    <paper-spinner class="style-scope result-container x-scope paper-spinner-0" aria-hidden="true" hidden=""><div id="spinnerContainer" class="  style-scope paper-spinner"><div class="spinner-layer layer-1 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-2 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-3 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-4 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div></div></paper-spinner>
    
      <patent-result class="style-scope result-container">
    
    
    <div class="layout horizontal style-scope patent-result">
      <div style="width: 1200px; height: auto; overflow: auto;" class="style-scope patent-result">
        <div id="wrapper" tabindex="0" class="style-scope patent-result">
          <result-tags class="style-scope patent-result"></result-tags>
          <h1 id="title" class="scroll-target style-scope patent-result">
            
  Compositions comprising bacterial strains
 
     </h1>
          <div class="horizontal layout style-scope patent-result">
            
            <div class="flex-3 style-scope patent-result" style="margin-top:-20px;overflow:hidden;" marginright="">
              <section id="abstract" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Abstract</div>
                  <div class="righthead style-scope patent-result">translated from Spanish</div>
                </h3>
                <patent-text name="abstract" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><abstract mxw-id="PA496215632" lang="EN" source="national office" load-source="google" class="style-scope patent-text">
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Una composición que comprende una cepa bacteriana del género Bariatricus, para uso en terapia.</span>A composition comprising a bacterial strain of the genus Bariatricus, for use in therapy.</span>
  </p>
</abstract>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              <section id="classifications" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Classifications</div>
                  <div id="machineClassifiedWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">machine-classified</div>
                  <div id="machineClassifiedCPCWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">cpc-machine-classified</div>
                  <div id="machineClassifiedFtermWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">fterm-machine-classified</div>
                  <div class="style-scope patent-result" hidden="">&nbsp;</div>
                  <div id="familyClassifiedFtermWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">fterm-family-classified</div>
                </h3>
                <overlay-tooltip positioning-target="#machineClassifiedWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#machineClassifiedCPCWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The CPC classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#familyClassifiedFtermWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The F-term classifications are assigned based on a patent family member containing these classification codes.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#machineClassifiedFtermWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The F-term classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <classification-viewer class="style-scope patent-result">
    
    <div class="table style-scope classification-viewer">
      
        <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K35/00"><a id="link" href="#" class="style-scope state-modifier">A61K35/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations containing materials or reaction products thereof with undetermined constitution</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K35/66"><a id="link" href="#" class="style-scope state-modifier">A61K35/66</a></state-modifier>
                  <span class="description style-scope classification-tree">Microorganisms or materials therefrom</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" first="true" data-cpc="A61K35/74"><a id="link" href="#" class="style-scope state-modifier">A61K35/74</a></state-modifier>
                  <span class="description style-scope classification-tree">Bacteria</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
      <template is="dom-repeat" class="style-scope classification-viewer"></template>
      
      <div class="style-scope classification-viewer">
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K35/00"><a id="link" href="#" class="style-scope state-modifier">A61K35/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations containing materials or reaction products thereof with undetermined constitution</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K35/66"><a id="link" href="#" class="style-scope state-modifier">A61K35/66</a></state-modifier>
                  <span class="description style-scope classification-tree">Microorganisms or materials therefrom</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K35/74"><a id="link" href="#" class="style-scope state-modifier">A61K35/74</a></state-modifier>
                  <span class="description style-scope classification-tree">Bacteria</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K35/741"><a id="link" href="#" class="style-scope state-modifier">A61K35/741</a></state-modifier>
                  <span class="description style-scope classification-tree">Probiotics</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K9/00"><a id="link" href="#" class="style-scope state-modifier">A61K9/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by special physical form</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K9/14"><a id="link" href="#" class="style-scope state-modifier">A61K9/14</a></state-modifier>
                  <span class="description style-scope classification-tree">Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K9/19"><a id="link" href="#" class="style-scope state-modifier">A61K9/19</a></state-modifier>
                  <span class="description style-scope classification-tree">Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P1/00"><a id="link" href="#" class="style-scope state-modifier">A61P1/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for disorders of the alimentary tract or the digestive system</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P25/00"><a id="link" href="#" class="style-scope state-modifier">A61P25/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for disorders of the nervous system</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P29/00"><a id="link" href="#" class="style-scope state-modifier">A61P29/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P35/00"><a id="link" href="#" class="style-scope state-modifier">A61P35/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Antineoplastic agents</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P43/00"><a id="link" href="#" class="style-scope state-modifier">A61P43/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12"><a id="link" href="#" class="style-scope state-modifier">C12</a></state-modifier>
                  <span class="description style-scope classification-tree">BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12N"><a id="link" href="#" class="style-scope state-modifier">C12N</a></state-modifier>
                  <span class="description style-scope classification-tree">MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12N1/00"><a id="link" href="#" class="style-scope state-modifier">C12N1/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12N1/20"><a id="link" href="#" class="style-scope state-modifier">C12N1/20</a></state-modifier>
                  <span class="description style-scope classification-tree">Bacteria; Culture media therefor</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12"><a id="link" href="#" class="style-scope state-modifier">C12</a></state-modifier>
                  <span class="description style-scope classification-tree">BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12R"><a id="link" href="#" class="style-scope state-modifier">C12R</a></state-modifier>
                  <span class="description style-scope classification-tree">INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12R2001/00"><a id="link" href="#" class="style-scope state-modifier">C12R2001/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Microorganisms ; Processes using microorganisms</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="C12R2001/01"><a id="link" href="#" class="style-scope state-modifier">C12R2001/01</a></state-modifier>
                  <span class="description style-scope classification-tree">Bacteria or Actinomycetales ; using bacteria or Actinomycetales</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        <template is="dom-repeat" class="style-scope classification-viewer"></template>
        <div class="more style-scope classification-viewer" style="" hidden="">View 9 more classifications</div>
        <div class="more style-scope classification-viewer">Hide more classifications</div>
      </div>
      <template is="dom-if" class="style-scope classification-viewer"></template>
    </div>
  </classification-viewer>
              </section>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              
                <section class="style-scope patent-result">
                  <h3 class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result">Landscapes</div>
                  </h3>
                  <div class="responsive-grid style-scope patent-result">
                    
                      <landscape-link class="style-scope patent-result"><state-modifier act="{&quot;type&quot;:&quot;QUERY_SET_TERM&quot;,&quot;term&quot;:&quot;$term&quot;,&quot;origin&quot;:&quot;LANDSCAPE_LINK&quot;}" class="style-scope landscape-link" data-term="Health &amp; Medical Sciences"><a id="link" href="#" class="style-scope state-modifier">
  <requery-tile class="area style-scope landscape-link">
<span class="label style-scope requery-tile">
    Health &amp; Medical Sciences
  </span>
<span class="search-icon style-scope requery-tile"></span>
</requery-tile>
</a></state-modifier>
</landscape-link>
                    
                      <landscape-link class="style-scope patent-result"><state-modifier act="{&quot;type&quot;:&quot;QUERY_SET_TERM&quot;,&quot;term&quot;:&quot;$term&quot;,&quot;origin&quot;:&quot;LANDSCAPE_LINK&quot;}" class="style-scope landscape-link" data-term="Life Sciences &amp; Earth Sciences"><a id="link" href="#" class="style-scope state-modifier">
  <requery-tile class="area style-scope landscape-link">
<span class="label style-scope requery-tile">
    Life Sciences &amp; Earth Sciences
  </span>
<span class="search-icon style-scope requery-tile"></span>
</requery-tile>
</a></state-modifier>
</landscape-link>
                    <template is="dom-repeat" class="style-scope patent-result"></template>
                  </div>
                  <s-more-inline class="style-scope patent-result"><hr aria-hidden="true" class="style-scope s-more-inline">

<div class="button style-scope s-more-inline">
  <span slot="expand_text" class="style-scope patent-result">Show more</span>
  <span class="expand more style-scope s-more-inline"></span>
</div>
<div class="button style-scope s-more-inline" hidden="">
  <span slot="collapse_text" class="style-scope patent-result">Show less</span>
  <span class="expand less style-scope s-more-inline"></span>
</div>
</s-more-inline>
                </section>
              <template is="dom-if" class="style-scope patent-result"></template>
            </div>
            <div class="flex-2 style-scope patent-result">
              <section class="knowledge-card style-scope patent-result">
                <header class="style-scope patent-result">
                  <h2 id="pubnum" class="style-scope patent-result">ES2887903T3</h2>
                  <p class="tagline style-scope patent-result">Spain</p>
                  <overlay-tooltip positioning-target="#pubnum" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                    <div style="max-width: 300px;" class="style-scope patent-result">Translation of granted European patent ( former B3)</div>
                  
    </div>
  </overlay-tooltip>

                  <div class="knowledge-card-action-bar style-scope patent-result">
                    <a target="_blank" class="style-scope patent-result" href="https://patentimages.storage.googleapis.com/4c/dd/af/b5c42a31881c76/ES2887903T3.pdf"><iron-icon icon="description" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Download PDF</a>
                    <state-modifier inherit="" act="{&quot;type&quot;: &quot;QUERY_FIND_PRIOR_ART&quot;, &quot;keywords&quot;: $keywords, &quot;before&quot;: &quot;$before&quot;}" class="style-scope patent-result" data-keywords="[&quot;compositions&quot;,&quot;disease&quot;,&quot;certain embodiments&quot;,&quot;treatment&quot;,&quot;composition&quot;]" data-before="20180625"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                      <iron-icon icon="find-in-page" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 19.59V8l-6-6H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c.45 0 .85-.15 1.19-.4l-4.43-4.43c-.8.52-1.74.83-2.76.83-2.76 0-5-2.24-5-5s2.24-5 5-5 5 2.24 5 5c0 1.02-.31 1.96-.83 2.75L20 19.59zM9 13c0 1.66 1.34 3 3 3s3-1.34 3-3-1.34-3-3-3-3 1.34-3 3z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Find Prior Art
                    </a></state-modifier>
                    <state-modifier inherit="" act="{&quot;type&quot;: &quot;QUERY_SIMILAR_DOCUMENTS&quot;, &quot;id&quot;: &quot;$id&quot;}" class="style-scope patent-result" data-id="patent/ES2887903T3"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                      <iron-icon icon="editor:functions" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M18 4H6v2l6.5 6L6 18v2h12v-3h-7l5-5-5-5h7z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Similar
                    </a></state-modifier>
                  </div>
                </header>

                <dl class="important-people style-scope patent-result">
                  
                    <dt class="style-scope patent-result">Other languages</dt>
                    <dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ES2887903T3/es"><a id="link" href="#" class="style-scope state-modifier">Spanish</a></state-modifier></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>
                  
                  <dt class="style-scope patent-result">Inventor</dt>
                  <dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Samantha Yuille"><a id="link" href="#" class="style-scope state-modifier">Samantha Yuille</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Nicole Reichardt"><a id="link" href="#" class="style-scope state-modifier">Nicole Reichardt</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Sarah Reid"><a id="link" href="#" class="style-scope state-modifier">Sarah Reid</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Suaad Ahmed"><a id="link" href="#" class="style-scope state-modifier">Suaad Ahmed</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Helene Savignac"><a id="link" href="#" class="style-scope state-modifier">Helene Savignac</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Imke Elisabeth MULDER"><a id="link" href="#" class="style-scope state-modifier">Imke Elisabeth MULDER</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Anna Ettorre"><a id="link" href="#" class="style-scope state-modifier">Anna Ettorre</a></state-modifier></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>

                  
                  <dt class="style-scope patent-result">
                    <span class="tooltip-hint style-scope patent-result" id="assigneeWarning">Current Assignee</span>
                    <overlay-tooltip positioning-target="#assigneeWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                      The listed assignees may be inaccurate.<br class="style-scope patent-result">
                      Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.
                    
    </div>
  </overlay-tooltip>
                  </dt>
                  <dd class="style-scope patent-result">
                    
    4D Pharma Research Ltd
  
                  </dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>
                </dl>

                <hr class="style-scope patent-result">

                <application-timeline class="style-scope patent-result">
    
    
    <div class="wrap style-scope application-timeline">
      <div class="header style-scope application-timeline">Worldwide applications</div>
      <div class="event style-scope application-timeline">
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2019</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/AU2019294284B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">AU</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: AU2019294284A</div>
                <div class="style-scope application-timeline">Filing date: 2019-06-25</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/RS61972B1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">RS</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: RS20210731A</div>
                <div class="style-scope application-timeline">Filing date: 2019-06-25</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/JP6987259B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">JP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: JP2020540266A</div>
                <div class="style-scope application-timeline">Filing date: 2019-06-25</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/MA51185B1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">MA</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: MA51185A</div>
                <div class="style-scope application-timeline">Filing date: 2019-06-25</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/LT3723777T/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">LT</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: LTEP19755806.7T</div>
                <div class="style-scope application-timeline">Filing date: 2019-06-25</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/DK3723777T3/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">DK</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: DK19755806.7T</div>
                <div class="style-scope application-timeline">Filing date: 2019-06-25</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/WO2020002370A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">WO</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: PCT/EP2019/066905</div>
                <div class="style-scope application-timeline">Filing date: 2019-06-25</div>
                <div class="style-scope application-timeline">Legal status: Search and Examination</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/SI3723777T1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">SI</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: SI201930063T</div>
                <div class="style-scope application-timeline">Filing date: 2019-06-25</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/TW202019446A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">TW</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: TW108122216A</div>
                <div class="style-scope application-timeline">Filing date: 2019-06-25</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/EP3723777B1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">EP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: EP19755806.7A</div>
                <div class="style-scope application-timeline">Filing date: 2019-06-25</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/SG11202012221YA/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">SG</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: SG11202012221YA</div>
                <div class="style-scope application-timeline">Filing date: 2019-06-25</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/HUE054904T2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">HU</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: HUE19755806A</div>
                <div class="style-scope application-timeline">Filing date: 2019-06-25</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CA3103161C/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">CA</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CA3103161A</div>
                <div class="style-scope application-timeline">Filing date: 2019-06-25</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/MD3723777T2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">MD</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: MDE20201083T</div>
                <div class="style-scope application-timeline">Filing date: 2019-06-25</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/EP3922256A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">EP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: EP21165418.1A</div>
                <div class="style-scope application-timeline">Filing date: 2019-06-25</div>
                <div class="style-scope application-timeline">Legal status: Pending</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/PL3723777T3/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">PL</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: PL19755806T</div>
                <div class="style-scope application-timeline">Filing date: 2019-06-25</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CN112912090A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">CN</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CN201980051210.4A</div>
                <div class="style-scope application-timeline">Filing date: 2019-06-25</div>
                <div class="style-scope application-timeline">Legal status: Pending</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/KR102383535B1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">KR</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: KR1020217002203A</div>
                <div class="style-scope application-timeline">Filing date: 2019-06-25</div>
                <div class="style-scope application-timeline">Legal status: IP Right Grant</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/ES2887903T3/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline" this="">ES</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: ES19755806T</div>
                <div class="style-scope application-timeline">Filing date: 2019-06-25</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2020</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US20210085728A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">US</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: US17/062,239</div>
                <div class="style-scope application-timeline">Filing date: 2020-10-02</div>
                <div class="style-scope application-timeline">Legal status: Abandoned</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/IL279724B/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">IL</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: IL279724A</div>
                <div class="style-scope application-timeline">Filing date: 2020-12-23</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2021</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/HRP20210772T1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">HR</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: HRP20210772TT</div>
                <div class="style-scope application-timeline">Filing date: 2021-05-13</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CY1124623T1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">CY</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CY20211100528T</div>
                <div class="style-scope application-timeline">Filing date: 2021-06-14</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/AU2021204337A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">AU</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: AU2021204337A</div>
                <div class="style-scope application-timeline">Filing date: 2021-06-25</div>
                <div class="style-scope application-timeline">Legal status: Pending</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/JP2022033856A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">JP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: JP2021194935A</div>
                <div class="style-scope application-timeline">Filing date: 2021-11-30</div>
                <div class="style-scope application-timeline">Legal status: Pending</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2022</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US20230134714A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">US</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: US17/820,252</div>
                <div class="style-scope application-timeline">Filing date: 2022-08-17</div>
                <div class="style-scope application-timeline">Legal status: Abandoned</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        <template is="dom-repeat" class="style-scope application-timeline"></template>
      </div>
      <hr class="style-scope application-timeline">
      <div class="header style-scope application-timeline">Application ES19755806T events <iron-icon id="legal" icon="icons:help-outline" class="style-scope application-timeline x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        <overlay-tooltip positioning-target="#legal" direction="right" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
          <div style="max-width: 300px;" class="style-scope application-timeline">
            A timeline of key events for this patent application, including priority claims, publications, legal status, reassignments, and litigation.<br class="style-scope application-timeline"><br class="style-scope application-timeline">
            Google has not performed a legal analysis and makes no representation as to the accuracy or completeness of the events listed.
          </div>
        
    </div>
  </overlay-tooltip>
      </div>
      <div class="event layout horizontal style-scope application-timeline"><div date="" class="external-priority style-scope application-timeline">2018-09-12</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/GB201814836D0/en"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Priority claimed from GBGB1814836.1A</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline"><div date="" class="external-priority style-scope application-timeline">2019-04-09</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/GB201905000D0/en"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Priority claimed from GBGB1905000.4A</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="filed style-scope application-timeline">2019-06-25</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_ASSIGNEE&quot;, &quot;assignee&quot;: &quot;$assignee&quot;}" class="style-scope application-timeline" data-assignee="4D Pharma Research Ltd"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Application filed by 4D Pharma Research Ltd</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="granted style-scope application-timeline">2021-12-28</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><span class="title-text style-scope application-timeline">Application granted</span><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="publication style-scope application-timeline">2021-12-28</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/ES2887903T3/en"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Publication of ES2887903T3</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" current="" critical=""><div date="" class="legal-status style-scope application-timeline">Status</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><span class="title-text style-scope application-timeline">Active</span><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="legal-status style-scope application-timeline">2039-06-25</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><span class="title-text style-scope application-timeline">Anticipated expiration</span><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><template is="dom-repeat" strip-whitespace="" class="style-scope application-timeline"></template>
      <template is="dom-if" class="style-scope application-timeline"></template>
    </div>
  </application-timeline>
                <hr class="style-scope patent-result">

                <dl class="links style-scope patent-result">
                  <dt class="style-scope patent-result">Info</dt>

                  
                  <dd class="style-scope patent-result"><a href="#patentCitations" class="style-scope patent-result">Patent citations (6)</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#similarDocuments" class="style-scope patent-result">Similar documents</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#relatedApplications" class="style-scope patent-result">Priority and Related Applications</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  <dt class="style-scope patent-result">External links</dt>

                  <dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://worldwide.espacenet.com/publicationDetails/biblio?CC=ES&amp;NR=2887903T3&amp;KC=T3&amp;FT=D">Espacenet</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://globaldossier.uspto.gov/#/result/publication/ES/2887903/1">Global Dossier</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://patents.stackexchange.com/questions/tagged/ES2887903T3">Discuss</a></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                </dl>
              </section>
            </div>
          </div>

          <div id="text" class="horizontal layout style-scope patent-result">
            <div class="flex flex-width style-scope patent-result" marginright="">
              <section id="description" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Description</div>
                  <div class="righthead style-scope patent-result">translated from Spanish</div>
                </h3>
                <patent-text name="description" id="descriptionText" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><description mxw-id="PDES321083816" lang="EN" load-source="google" class="style-scope patent-text">
  
  <p class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DESCRIPCIÓN</span>DESCRIPTION</span>
    </b>
  </p>
  <p id="p0001" num="0001" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Composiciones que comprenden cepas bacterianas</span>Compositions comprising bacterial strains</span>
  </p>
  <p id="p0002" num="0002" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">CAMPO TÉCNICO</span>TECHNICAL FIELD</span>
    </b>
  </p>
  <p id="p0003" num="0003" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Esta invención pertenece al campo de las composiciones que comprenden cepas bacterianas aisladas del tracto digestivo de mamíferos y al uso de tales composiciones en el tratamiento de enfermedades, como se define en las reivindicaciones.</span>This invention pertains to the field of compositions comprising bacterial strains isolated from the digestive tract of mammals and the use of such compositions in the treatment of diseases, as defined in the claims.</span>
  </p>
  <p id="p0004" num="0004" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ANTECEDENTES DE LA INVENCIÓN</span>BACKGROUND OF THE INVENTION</span>
    </b>
  </p>
  <p id="p0005" num="0005" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se cree que el intestino humano es estéril en el útero, pero está expuesto a una gran variedad de microbios maternos y ambientales inmediatamente después del nacimiento. A partir de entonces, se produce un período dinámico de colonización y sucesión microbiana, que está influenciado por factores como el modo de administración, el medio ambiente, la dieta y el genotipo del huésped, todos los cuales afectan a la composición de la microbiota intestinal, particularmente durante los primeros años de vida. Posteriormente, la microbiota se estabiliza y se vuelve adulta [1]. La microbiota intestinal humana contiene más de 500-1000 filotipos diferentes que pertenecen esencialmente a dos divisiones bacterianas principales, Bacteroidetes y Firmicutes [2]. Las relaciones simbióticas exitosas que surgen de la colonización bacteriana del intestino humano han producido una amplia variedad de funciones metabólicas, estructurales, protectoras y otras funciones beneficiosas. Las actividades metabólicas mejoradas del intestino colonizado aseguran que los componentes de la dieta que de otro modo no serían digeribles se degraden con la liberación de subproductos que proporcionan una importante fuente de nutrientes para el huésped. De manera similar, la importancia inmunológica de la microbiota intestinal está bien reconocida y se ejemplifica en animales libres de gérmenes que tienen un sistema inmunológico deteriorado que se reconstituye funcionalmente después de la introducción de bacterias comensales [3-5].</span>The human intestine is believed to be sterile in utero, but is exposed to a wide variety of maternal and environmental microbes immediately after birth. Thereafter, a dynamic period of colonization and microbial succession ensues, which is influenced by factors such as mode of administration, environment, diet, and host genotype, all of which affect the composition of the gut microbiota. , particularly during the first years of life. Subsequently, the microbiota stabilizes and becomes adult [1]. The human gut microbiota contains more than 500-1000 different phylotypes essentially belonging to two main bacterial divisions, Bacteroidetes and Firmicutes [2]. Successful symbiotic relationships arising from bacterial colonization of the human gut have produced a wide variety of metabolic, structural, protective, and other beneficial functions. The enhanced metabolic activities of the colonized gut ensure that otherwise indigestible components of the diet are degraded with the release of by-products that provide an important source of nutrients for the host. Similarly, the immunological importance of the gut microbiota is well recognized and is exemplified in germ-free animals that have an impaired immune system that is functionally reconstituted after the introduction of commensal bacteria [3-5].</span>
  </p>
  <p id="p0006" num="0006" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se han documentado cambios drásticos en la composición de la microbiota en trastornos gastrointestinales como la enfermedad inflamatoria intestinal (IBD). Por ejemplo, los niveles de la <i class="style-scope patent-text">bacteria Clostridium </i>grupo XIVa se reducen en pacientes con IBD mientras que el número de <i class="style-scope patent-text">E. coli </i>aumenta, lo que sugiere un desplazamiento en el equilibrio de simbiontes y patobiontes dentro del intestino [6-9]. Curiosamente, esta disbiosis microbiana también se asocia con desequilibrios en las poblaciones de células efectoras T.</span>Drastic changes in the composition of the microbiota have been documented in gastrointestinal disorders such as inflammatory bowel disease (IBD). For example, levels of <i class="style-scope patent-text">Clostridium</i> group XIVa bacteria are reduced in IBD patients while <i class="style-scope patent-text">E. coli</i> numbers are increased, suggesting a shift in the balance of symbionts and pathobionts within the gut [6-9]. Interestingly, this microbial dysbiosis is also associated with imbalances in effector T cell populations.</span>
  </p>
  <p id="p0007" num="0007" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En reconocimiento del posible efecto positivo que pueden tener ciertas cepas bacterianas en el intestino del animal, se han propuesto varias cepas para su uso en el tratamiento de diversas enfermedades (ver, por ejemplo, [10-13]). Además, se han propuesto ciertas cepas, incluidas principalmente cepas de <i class="style-scope patent-text">Lactobacillus </i>y <i class="style-scope patent-text">Bifidobacterium, </i>para su uso en el tratamiento de diversas enfermedades inflamatorias y autoinmunes que no están directamente relacionadas con los intestinos (ver [14] y [15] para consulta). Sin embargo, la relación entre diferentes enfermedades y diferentes cepas bacterianas, y los efectos precisos de cepas bacterianas particulares en el intestino y a nivel sistémico y en cualquier tipo particular de enfermedad, están pobremente caracterizados.</span>In recognition of the possible positive effect that certain bacterial strains may have on the animal intestine, several strains have been proposed for use in the treatment of various diseases (see, eg, [10-13]). In addition, certain strains, including mainly <i class="style-scope patent-text">Lactobacillus</i> and <i class="style-scope patent-text">Bifidobacterium</i> strains, have been proposed for use in the treatment of various inflammatory and autoimmune diseases that are not directly related to the intestines (see [14] and [15] for reference). However, the relationship between different diseases and different bacterial strains, and the precise effects of particular bacterial strains at the gut and systemic level and on any particular type of disease, are poorly characterized.</span>
  </p>
  <p id="p0008" num="0008" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Existe un requisito en la técnica de nuevos métodos de tratamiento de enfermedades. También existe la necesidad de caracterizar los efectos potenciales de las bacterias intestinales para poder desarrollar nuevas terapias que utilicen bacterias intestinales.</span>There is a requirement in the art for new methods of treating diseases. There is also a need to characterize the potential effects of gut bacteria so that new therapies using gut bacteria can be developed.</span>
  </p>
  <p id="p0009" num="0009" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El documento WO2017/160711 describe la modulación del microbioma intestinal para tratar trastornos mentales o enfermedades del sistema nervioso central.</span>WO2017/160711 describes the modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system.</span>
  </p>
  <p id="p0010" num="0010" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Bessis et al. (2016, New Microbe and New Infect 12: 54-55) describe <i class="style-scope patent-text">Bariatricus massiliensis </i>como una nueva especie bacteriana de la microbiota intestinal humana.</span>Besis et al. (2016, New Microbe and New Infect 12: 54-55) describe <i class="style-scope patent-text">Bariatricus massiliensis</i> as a new bacterial species of the human gut microbiota.</span>
  </p>
  <p id="p0011" num="0011" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">COMPENDIO DE LA INVENCIÓN</span>SUMMARY OF THE INVENTION</span>
    </b>
  </p>
  <p id="p0012" num="0012" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los inventores han desarrollado nuevas composiciones que comprenden una cepa bacteriana del género Bariatricus que puede usarse en terapia. En particular, los inventores han desarrollado nuevas composiciones que comprenden una cepa del género <i class="style-scope patent-text">Bariatricus </i>para uso en el tratamiento y prevención de enfermedades o afecciones mediadas por una actividad elevada de histona desacetilasa (HDAC). Los inventores han identificado que las cepas bacterianas del género <i class="style-scope patent-text">Bariatricus </i>pueden ser eficaces para reducir la actividad de la histona desacetilasa. Se ha demostrado que la actividad de la histona desacetilasa media los síntomas patológicos en una variedad de enfermedades y afecciones que incluyen, entre otras, enfermedades y afecciones autoinmunes o inflamatorias que incluyen, entre otras, la enfermedad de injerto contra huésped (GVHD), enfermedades inflamatorias del intestino, tales como la enfermedad de Crohn, enfermedades neurodegenerativas, como la enfermedad de Parkinson, lesiones cerebrales, como los accidentes cerebrovasculares, y una variedad de cánceres. Como tales, las composiciones de la invención pueden tener beneficios pleiotrópicos en el tratamiento o prevención de múltiples enfermedades mediadas al menos en parte por la actividad de HDAC. En algunas realizaciones, las composiciones de la invención son para uso en el tratamiento de la prevención de enfermedades mediadas por una actividad de HDAC aumentada. 
</span>The inventors have developed new compositions comprising a bacterial strain of the Bariatricus genus that can be used in therapy. In particular, the inventors have developed novel compositions comprising a <i class="style-scope patent-text">Bariatricus</i> genus strain for use in treating and preventing diseases or conditions mediated by elevated histone deacetylase (HDAC) activity. The inventors have identified that bacterial strains of the <i class="style-scope patent-text">Bariatricus</i> genus can be effective in reducing histone deacetylase activity. Histone deacetylase activity has been shown to mediate pathologic symptoms in a variety of diseases and conditions including but not limited to autoimmune or inflammatory diseases and conditions including but not limited to graft versus host disease (GVHD), inflammatory bowel diseases, such as Crohn's disease, neurodegenerative diseases, such as Parkinson's disease, brain injuries, such as strokes, and a variety of cancers. As such, the compositions of the invention may have pleiotropic benefits in the treatment or prevention of multiple diseases mediated at least in part by HDAC activity. In some embodiments, the compositions of the invention are for use in treating or preventing diseases mediated by increased HDAC activity. </span>
  </p>
  <p id="p0013" num="0013" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Como se describe en los ejemplos, la administración oral de composiciones que comprenden <i class="style-scope patent-text">Bariatricus </i>puede reducir la actividad de la histona desacetilasa en modelos de enfermedad. Además, como se describe en los ejemplos, la administración oral de composiciones que comprenden <i class="style-scope patent-text">Bariatricus </i>puede reducir la hiperactividad en modelos de enfermedad en ratones. En determinadas realizaciones, las composiciones de la invención pueden usarse en el tratamiento o prevención de una enfermedad o afección asociada con la hiperactividad. Las composiciones pueden usarse en el tratamiento o prevención de la hiperactividad. Las composiciones pueden usarse en el tratamiento o prevención de la hiperactividad asociada con trastornos del comportamiento, tal como el trastorno por déficit de atención e hiperactividad. Por tanto, los inventores han identificado composiciones efectivas en la prevención o tratamiento de enfermedades mediadas por la actividad de HDAC y composiciones efectivas en el tratamiento o prevención de trastornos del comportamiento. Los trastornos del comportamiento adecuados para el tratamiento con composiciones de la invención pueden o no estar mediados en parte por la actividad de HDAC. </span>As described in the examples, oral administration of compositions comprising <i class="style-scope patent-text">Bariatricus</i> can reduce histone deacetylase activity in disease models. Furthermore, as described in the examples, oral administration of compositions comprising <i class="style-scope patent-text">Bariatricus</i> can reduce hyperactivity in mouse models of disease. In certain embodiments, the compositions of the invention can be used in the treatment or prevention of a disease or condition associated with hyperactivity. The compositions can be used in the treatment or prevention of hyperactivity. The compositions can be used in the treatment or prevention of hyperactivity associated with behavioral disorders, such as attention deficit hyperactivity disorder. Thus, the inventors have identified compositions effective in the prevention or treatment of diseases mediated by HDAC activity and compositions effective in the treatment or prevention of behavioral disorders. Behavioral disorders suitable for treatment with compositions of the invention may or may not be mediated in part by HDAC activity.</span>
  </p>
  <p id="p0014" num="0014" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En una primera realización, la invención proporciona una composición que comprende una cepa bacteriana del género <i class="style-scope patent-text">Bariatricus</i>, para uso en terapia.</span>In a first embodiment, the invention provides a composition comprising a bacterial strain of the <i class="style-scope patent-text">Bariatricus</i> genus, for use in therapy.</span>
  </p>
  <p id="p0016" num="0016" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones particulares, la invención proporciona una composición que comprende una cepa bacteriana del género <i class="style-scope patent-text">Bariatricus</i>, para su uso en el tratamiento y prevención de enfermedades mediadas por una actividad de HDAC elevada. Los inventores han identificado que el tratamiento con cepas bacterianas de este género puede reducir la actividad de HDAC, lo que puede proporcionar beneficios clínicos en el tratamiento de enfermedades mediadas por la actividad de HDAc . En algunas realizaciones, se ha encontrado que las composiciones de la invención son particularmente beneficiosas en la reducción de la actividad de HDAC de Clase I. Las HDAC de clase I se expresan de manera ubicua y con mayor frecuencia residen en el núcleo. Las HDAC de clase I desacetilan los residuos de lisina de histona para restaurar la carga positiva de la histona, lo que aumenta la unión electrostática entre las histonas y el ADN. Por tanto, la actividad de HDAC aumenta la compactación de la cromatina provocando una regulación a la baja de la expresión de genes en la secuencia de ADN subyacente. Las HDAC también tienen efectos reguladores adicionales al modificar los objetivos de proteínas que no son histonas. La inhibición de la acetilación de dianas proteicas que no son histonas puede ser beneficiosa en el tratamiento o prevención de otros aspectos de la enfermedad que no están directamente relacionados con el control de la expresión génica mediante la expansión de la cromatina. Por tanto, en determinadas realizaciones, las composiciones de la invención se pueden utilizar para regular la expresión del gen diana.</span>In particular embodiments, the invention provides a composition comprising a bacterial strain of the <i class="style-scope patent-text">Bariatricus</i> genus, for use in the treatment and prevention of diseases mediated by elevated HDAC activity. The inventors have identified that treatment with bacterial strains of this genus can reduce HDAC activity, which may provide clinical benefits in the treatment of diseases mediated by HDAc activity. In some embodiments, compositions of the invention have been found to be particularly beneficial in reducing Class I HDAC activity. Class I HDACs are ubiquitously expressed and most often reside in the nucleus. Class I HDACs deacetylate histone lysine residues to restore the positive charge of the histone, thereby increasing electrostatic binding between histones and DNA. Thus, HDAC activity increases chromatin compaction by causing downregulation of gene expression in the underlying DNA sequence. HDACs also have additional regulatory effects by modifying non-histone protein targets. Inhibition of non-histone protein acetylation may be beneficial in the treatment or prevention of other aspects of the disease that are not directly related to the control of gene expression by chromatin expansion. Thus, in certain embodiments, the compositions of the invention can be used to regulate expression of the target gene.</span>
  </p>
  <p id="p0018" num="0018" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones particulares, la invención proporciona una composición que comprende una cepa bacteriana del género <i class="style-scope patent-text">Bariatricus, </i>para uso en un método de tratamiento o prevención de una enfermedad o afección seleccionada del grupo que consiste en: una enfermedad neurodegenerativa, como la enfermedad de Alzheimer, la enfermedad de Huntington o Enfermedad de Parkinson; lesión cerebral, como accidente cerebrovascular; trastornos del comportamiento o psiquiátricos, tales como trastorno por déficit de atención e hiperactividad, trastorno obsesivo compulsivo, trastorno de ansiedad, trastorno bipolar o trastorno por estrés postraumático; una enfermedad inflamatoria o autoinmune, como asma, artritis, psoriasis, esclerosis múltiple, diabetes, rechazo de aloinjertos, enfermedad de injerto contra huésped o una enfermedad inflamatoria del intestino, como la enfermedad de Crohn; o cáncer, como cáncer de próstata, cáncer colorrectal, cáncer de mama, cáncer de pulmón, cáncer de hígado o cáncer gástrico. El efecto mostrado para las cepas bacterianas del género <i class="style-scope patent-text">Bariatricus </i>sobre la actividad de HDAC puede proporcionar beneficios terapéuticos para enfermedades y afecciones mediadas por la actividad de HDAC aberrante, como las enumeradas anteriormente. En determinadas realizaciones, las composiciones de la invención pueden proporcionar beneficios terapéuticos en el tratamiento de enfermedades o afecciones con una expresión de HDAC aumentada. En determinadas realizaciones, las composiciones de la invención pueden proporcionar beneficios terapéuticos en el tratamiento de enfermedades o afecciones con una actividad de HDAC aumentada. Además, los inventores han identificado que el tratamiento con una cepa bacteriana del género <i class="style-scope patent-text">Bariatricus </i>puede reducir la activación de moléculas proinflamatorias, tales como IL-6, por LPS. La inflamación crónica inducida por IL-6 puede conducir finalmente a la muerte celular. Por tanto, las cepas bacterianas de la invención pueden ser particularmente útiles en el tratamiento o prevención de trastornos inflamatorios o autoinmunitarios. En algunas realizaciones, las cepas bacterianas son útiles en el tratamiento de trastornos inflamatorios o autoinmunitarios caracterizados por la activación mejorada de IL-6. Además, los inventores han identificado que el tratamiento con una cepa bacteriana del género <i class="style-scope patent-text">Bariatricus </i>puede aumentar la activación de MAP2 (proteína 2 asociada a microtúbulos). MAP2 es un gen asociado con la diferenciación neuronal de MAP2 y se cree que es esencial para la formación de microtúbulos en neuritogénesis, por lo que las composiciones de la invención pueden ser particularmente útiles para tratar enfermedades neurodegenerativas o lesiones cerebrales. En algunas realizaciones, las composiciones de la invención son para uso en el tratamiento de enfermedades neurodegenerativas activando o aumentando los niveles de MAP2. Además, los inventores han identificado que el tratamiento con una cepa bacteriana del género <i class="style-scope patent-text">Bariatricus </i>puede alterar la expresión de IDO1 en el intestino. La expresión de IDO1 en el colon se asocia con la mejora de la enfermedad en un modelo de colitis en ratón. Por tanto, las cepas bacterianas de la invención pueden ser particularmente útiles en el tratamiento o prevención de enfermedades inflamatorias del intestino. Además, los inventores han identificado que el tratamiento con una cepa bacteriana del género <i class="style-scope patent-text">Bariatricus </i>puede alterar la expresión de varios genes en el cerebro, p. ej., aumentar la expresión de BDNF en el hipocampo y la corteza prefrontal. El BDNF es esencial para la plasticidad sináptica del adulto y la formación de recuerdos y se observa una disminución en los niveles de BDNF en pacientes con Alzheimer y Huntington. Por lo tanto, las cepas bacterianas de 
la invención pueden ser particularmente útiles en el tratamiento o prevención de enfermedades neurodegenerativas, p. ej., la enfermedad de Alzheimer y Huntington.</span>In particular embodiments, the invention provides a composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Bariatricus,</i> for use in a method of treating or preventing a disease or condition selected from the group consisting of: a neurodegenerative disease, such as Alzheimer's disease, Huntington's disease or Parkinson's disease; brain injury, such as stroke; behavioral or psychiatric disorders, such as attention deficit hyperactivity disorder, obsessive-compulsive disorder, anxiety disorder, bipolar disorder, or post-traumatic stress disorder; an inflammatory or autoimmune disease, such as asthma, arthritis, psoriasis, multiple sclerosis, diabetes, allograft rejection, graft-versus-host disease, or an inflammatory bowel disease, such as Crohn's disease; or cancer, such as prostate cancer, colorectal cancer, breast cancer, lung cancer, liver cancer, or gastric cancer. The effect shown for bacterial strains of the genus <i class="style-scope patent-text">Bariatricus</i> on HDAC activity may provide therapeutic benefits for diseases and conditions mediated by aberrant HDAC activity, such as those listed above. In certain embodiments, the compositions of the invention may provide therapeutic benefits in the treatment of diseases or conditions with increased HDAC expression. In certain embodiments, the compositions of the invention may provide therapeutic benefits in the treatment of diseases or conditions with increased HDAC activity. Furthermore, the inventors have identified that treatment with a bacterial strain of the <i class="style-scope patent-text">Bariatricus</i> genus can reduce the activation of proinflammatory molecules, such as IL-6, by LPS. IL-6 induced chronic inflammation can ultimately lead to cell death. Thus, the bacterial strains of the invention may be particularly useful in the treatment or prevention of inflammatory or autoimmune disorders. In some embodiments, the bacterial strains are useful in the treatment of inflammatory or autoimmune disorders characterized by enhanced activation of IL-6. Furthermore, the inventors have identified that treatment with a bacterial strain of the genus <i class="style-scope patent-text">Bariatricus</i> can increase the activation of MAP2 (microtubule-associated protein 2). MAP2 is a gene associated with MAP2 neuronal differentiation and is believed to be essential for microtubule formation in neuritogenesis, thus compositions of the invention may be particularly useful for treating neurodegenerative diseases or brain injuries. In some embodiments, the compositions of the invention are for use in treating neurodegenerative diseases by activating or increasing levels of MAP2. Furthermore, the inventors have identified that treatment with a bacterial strain of the genus <i class="style-scope patent-text">Bariatricus</i> can alter the expression of IDO1 in the intestine. IDO1 expression in the colon is associated with disease improvement in a mouse model of colitis. Therefore, the bacterial strains of the invention may be particularly useful in the treatment or prevention of inflammatory bowel diseases. Furthermore, the inventors have identified that treatment with a bacterial strain of the <i class="style-scope patent-text">Bariatricus</i> genus can alter the expression of several genes in the brain, e.g. eg, increasing BDNF expression in the hippocampus and prefrontal cortex. BDNF is essential for adult synaptic plasticity and memory formation and decreased levels of BDNF are observed in Alzheimer's and Huntington's patients. Therefore, the bacterial strains of  the invention may be particularly useful in the treatment or prevention of neurodegenerative diseases, e.g. eg, Alzheimer's and Huntington's disease.</span>
  </p>
  <p id="p0020" num="0020" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En algunas realizaciones, las cepas bacterianas del género <i class="style-scope patent-text">Bariatricus </i>pueden proporcionar beneficios terapéuticos en el tratamiento de trastornos del comportamiento seleccionados de la lista que consiste en: trastorno por déficit de atención e hiperactividad, trastorno negativista desafiante y trastorno de la conducta. Los inventores han identificado que el tratamiento con <i class="style-scope patent-text">cepas de Bariatricus </i>reduce la hiperactividad en ratones, que es un síntoma de trastornos del comportamiento como el ADHD. Por tanto, las cepas de la invención pueden ser útiles en el tratamiento o prevención de trastornos del comportamiento, en particular en el tratamiento o prevención de trastornos del comportamiento asociados con hiperactividad, como el ADHD. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento o prevención de la hiperactividad en un sujeto. En determinadas realizaciones, la invención proporciona una composición que comprende una cepa bacteriana de la especie <i class="style-scope patent-text">Bariatricus massiliensis </i>para uso en el tratamiento o prevención de trastornos del comportamiento. En determinadas realizaciones, la invención proporciona una composición que comprende una cepa bacteriana de la especie <i class="style-scope patent-text">Bariatricus massiliensis </i>para uso en el tratamiento o prevención de ADHD.</span>In some embodiments, bacterial strains of the <i class="style-scope patent-text">Bariatricus</i> genus may provide therapeutic benefits in the treatment of behavioral disorders selected from the list consisting of: attention deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder. The inventors have identified that treatment with <i class="style-scope patent-text">Bariatricus strains</i> reduces hyperactivity in mice, which is a symptom of behavioral disorders such as ADHD. Thus, the strains of the invention may be useful in the treatment or prevention of behavioral disorders, in particular in the treatment or prevention of behavioral disorders associated with hyperactivity, such as ADHD. In certain embodiments, the compositions of the invention are for use in treating or preventing hyperactivity in a subject. In certain embodiments, the invention provides a composition comprising a bacterial strain of the species <i class="style-scope patent-text">Bariatricus massiliensis</i> for use in the treatment or prevention of behavioral disorders. In certain embodiments, the invention provides a composition comprising a bacterial strain of the species <i class="style-scope patent-text">Bariatricus massiliensis</i> for use in the treatment or prevention of ADHD.</span>
  </p>
  <p id="p0022" num="0022" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En algunas realizaciones, las cepas bacterianas del género <i class="style-scope patent-text">Bariatricus </i>pueden proporcionar beneficios terapéuticos en el tratamiento o la prevención de la GVHD. Los inventores han identificado que el tratamiento con <i class="style-scope patent-text">cepas de Bariatricus </i>aumenta la supervivencia de GVHD en ratones. Por tanto, las cepas de la invención pueden ser útiles en el tratamiento o la prevención de la GVHD. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento o la prevención de la GVHD mediada al menos en parte por la actividad de HDAC. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento o prevención de GVHD en un sujeto.</span>In some embodiments, bacterial strains of the <i class="style-scope patent-text">Bariatricus</i> genus may provide therapeutic benefits in the treatment or prevention of GVHD. The inventors have identified that treatment with <i class="style-scope patent-text">Bariatricus strains</i> increases GVHD survival in mice. Therefore, the strains of the invention may be useful in the treatment or prevention of GVHD. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of GVHD mediated at least in part by HDAC activity. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of GVHD in a subject.</span>
  </p>
  <p id="p0024" num="0024" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En algunas realizaciones, la invención proporciona una composición que comprende una cepa bacteriana del género <i class="style-scope patent-text">Bariatricus, </i>para uso en un método de tratamiento o prevención de una enfermedad neurodegenerativa mediada por una actividad HDAC elevada. En algunas realizaciones, las composiciones de la invención pueden ser útiles en el tratamiento o prevención de síntomas de enfermedades neurodegenerativas mediadas por la actividad de HDAC. Los inventores han identificado que las cepas de la invención inhiben la actividad de HDAC. La acetilación y desacetilación de la histona es un regulador epigenético importante de la expresión génica. El desequilibrio de acetilación de histona se ha implicado en la patogénesis de enfermedades neurodegenerativas, tal como enfermedad de Alzheimer, enfermedad de Huntington y enfermedad de Parkinson. En algunas realizaciones, las cepas de la invención son para uso en el tratamiento o prevención de enfermedades neurodegenerativas asociadas a la edad. En algunas realizaciones, las composiciones de la invención son para uso en el tratamiento o la prevención de enfermedades neurodegenerativas de aparición con la edad, tales como la enfermedad de Parkinson de aparición con la edad o la enfermedad de Alzheimer de aparición con la edad. En determinadas realizaciones, la invención proporciona una composición que comprende una cepa bacteriana de la especie <i class="style-scope patent-text">Bariatricus massiliensis </i>para uso en el tratamiento o prevención de enfermedades neurodegenerativas. En realizaciones preferidas, la invención proporciona una composición que comprende una cepa bacteriana de la especie <i class="style-scope patent-text">Bariatricus massiliensis </i>para su uso en el tratamiento o prevención de la enfermedad de Alzheimer, la enfermedad de Huntington o la enfermedad de Parkinson.</span>In some embodiments, the invention provides a composition comprising a bacterial strain of the <i class="style-scope patent-text">Bariatricus</i> genus, for use in a method of treating or preventing a neurodegenerative disease mediated by elevated HDAC activity. In some embodiments, the compositions of the invention may be useful in treating or preventing symptoms of neurodegenerative diseases mediated by HDAC activity. The inventors have identified that the strains of the invention inhibit HDAC activity. Histone acetylation and deacetylation is an important epigenetic regulator of gene expression. Histone acetylation imbalance has been implicated in the pathogenesis of neurodegenerative diseases, such as Alzheimer's disease, Huntington's disease, and Parkinson's disease. In some embodiments, the strains of the invention are for use in the treatment or prevention of neurodegenerative diseases associated with age. In some embodiments, the compositions of the invention are for use in treating or preventing age-onset neurodegenerative diseases, such as age-onset Parkinson's disease or age-onset Alzheimer's disease. In certain embodiments, the invention provides a composition comprising a bacterial strain of the species <i class="style-scope patent-text">Bariatricus massiliensis</i> for use in the treatment or prevention of neurodegenerative diseases. In preferred embodiments, the invention provides a composition comprising a bacterial strain of the species <i class="style-scope patent-text">Bariatricus massiliensis</i> for use in the treatment or prevention of Alzheimer's disease, Huntington's disease or Parkinson's disease.</span>
  </p>
  <p id="p0026" num="0026" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En algunas realizaciones, la invención proporciona una composición que comprende una cepa bacteriana del género <i class="style-scope patent-text">Bariatricus, </i>para uso en un método de tratamiento o prevención de una enfermedad inflamatoria del intestino mediada por una actividad de HDAC elevada. Se ha demostrado que la inhibición de la actividad de HDAC suprime la producción de ciOCDinas proinflamatorias en el tracto gastrointestinal. Por tanto, las composiciones de la invención pueden ser útiles en el tratamiento de enfermedades inflamatorias. En particular, las composiciones de la invención pueden ser útiles en el tratamiento o la prevención de afecciones asociadas con un aumento de la patogénesis de ciOCDinas proinflamatorias del colon. En algunas realizaciones, las composiciones de la invención son para uso en el tratamiento o prevención de la enfermedad inflamatoria intestinal. En algunas realizaciones, las composiciones de la invención son para uso en el tratamiento o la prevención de la colitis ulcerosa. En algunas realizaciones, las composiciones de la invención son para uso en el tratamiento o prevención de la enfermedad de Crohn. En determinadas realizaciones, la invención proporciona una composición que comprende una cepa bacteriana de la especie <i class="style-scope patent-text">Bariatricus massiliensis </i>para uso en el tratamiento o prevención de enfermedades inflamatorias. En determinadas realizaciones, la invención proporciona una composición que comprende una cepa bacteriana de la especie <i class="style-scope patent-text">Bariatricus massiliensis </i>para uso en el tratamiento o prevención de colitis.</span>In some embodiments, the invention provides a composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Bariatricus,</i> for use in a method of treating or preventing inflammatory bowel disease mediated by elevated HDAC activity. Inhibition of HDAC activity has been shown to suppress the production of proinflammatory cyOCDins in the gastrointestinal tract. Therefore, the compositions of the invention may be useful in the treatment of inflammatory diseases. In particular, the compositions of the invention may be useful in the treatment or prevention of conditions associated with increased pathogenesis of proinflammatory colonic cyOCDins. In some embodiments, the compositions of the invention are for use in the treatment or prevention of inflammatory bowel disease. In some embodiments, the compositions of the invention are for use in the treatment or prevention of ulcerative colitis. In some embodiments, the compositions of the invention are for use in the treatment or prevention of Crohn's disease. In certain embodiments, the invention provides a composition comprising a bacterial strain of the species <i class="style-scope patent-text">Bariatricus massiliensis</i> for use in the treatment or prevention of inflammatory diseases. In certain embodiments, the invention provides a composition comprising a bacterial strain of the species <i class="style-scope patent-text">Bariatricus massiliensis</i> for use in the treatment or prevention of colitis.</span>
  </p>
  <p id="p0028" num="0028" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones de la invención, las composiciones son para uso en el tratamiento de lesiones cerebrales. La actividad neuroprotectora de las composiciones de la invención y su capacidad para reducir los niveles de actividad de la histona desacetilasa (HDAC) puede hacerlas útiles para el tratamiento de lesiones cerebrales. En realizaciones preferidas, las composiciones de la invención son para uso en el tratamiento de un accidente cerebrovascular, como el tratamiento de una lesión cerebral resultante de un accidente cerebrovascular. En determinadas realizaciones, la invención proporciona una composición que comprende una cepa bacteriana de la especie <i class="style-scope patent-text">Bariatricus massiliensis </i>para uso en el tratamiento o prevención de una lesión cerebral, en particular un accidente cerebrovascular. 
</span>In certain embodiments of the invention, the compositions are for use in treating brain injuries. The neuroprotective activity of the compositions of the invention and their ability to reduce levels of histone deacetylase (HDAC) activity may make them useful for the treatment of brain injuries. In preferred embodiments, the compositions of the invention are for use in the treatment of stroke, such as the treatment of brain injury resulting from stroke. In certain embodiments, the invention provides a composition comprising a bacterial strain of the species <i class="style-scope patent-text">Bariatricus massiliensis</i> for use in treating or preventing brain injury, in particular stroke. </span>
  </p>
  <p id="p0029" num="0029" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En algunas realizaciones, las composiciones de la invención son para uso en el tratamiento o prevención de cáncer. La desregulación de las vías de acetilación en el cáncer se ha relacionado con la supervivencia de las células cancerosas y la evasión inmunitaria del tumor. Por ejemplo, la desacetilación de p53 mediada por HDAC reduce la estabilidad y la vida media de p53. La p53 acetilada se une y regula la expresión de genes reguladores del ciclo celular y proapoptóticos con mayor eficacia, reduciendo el crecimiento de células cancerosas y promoviendo la apoptosis. Por tanto, la desacetilación de p53 puede inhibir la apoptosis en las células cancerosas, aumentando la supervivencia de las células cancerosas. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento o la prevención de cánceres. En algunas realizaciones, las composiciones de la invención son para uso en el tratamiento de cánceres con p53 no mutado. En algunas realizaciones, las composiciones de la invención se utilizan en un método para aumentar la apoptosis en células cancerosas. En algunas realizaciones, las composiciones de la invención son para uso en un método para disminuir la evasión inmunitaria tumoral. En algunas realizaciones, las composiciones de la invención son para uso en el tratamiento o prevención de cánceres con actividad HDAC aumentada. En algunas realizaciones, las composiciones son para uso como medicamentos proapoptóticos, por ejemplo, para uso en el tratamiento o la prevención de cánceres. En determinadas realizaciones, la invención proporciona una composición que comprende una cepa bacteriana de la especie <i class="style-scope patent-text">Bariatricus massiliensis </i>para uso en el tratamiento o prevención de cáncer.</span>In some embodiments, the compositions of the invention are for use in the treatment or prevention of cancer. Dysregulation of acetylation pathways in cancer has been linked to cancer cell survival and tumor immune evasion. For example, HDAC-mediated deacetylation of p53 reduces the stability and half-life of p53. Acetylated p53 binds and regulates the expression of cell cycle regulatory and proapoptotic genes more effectively, reducing cancer cell growth and promoting apoptosis. Therefore, p53 deacetylation can inhibit apoptosis in cancer cells, increasing cancer cell survival. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of cancers. In some embodiments, the compositions of the invention are for use in treating non-mutated p53 cancers. In some embodiments, the compositions of the invention are used in a method of increasing apoptosis in cancer cells. In some embodiments, the compositions of the invention are for use in a method of decreasing tumor immune evasion. In some embodiments, the compositions of the invention are for use in treating or preventing cancers with increased HDAC activity. In some embodiments, the compositions are for use as proapoptotic medicaments, eg, for use in the treatment or prevention of cancers. In certain embodiments, the invention provides a composition comprising a bacterial strain of the species <i class="style-scope patent-text">Bariatricus massiliensis</i> for use in the treatment or prevention of cancer.</span>
  </p>
  <p id="p0031" num="0031" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas adicionales, la invención proporciona una composición que comprende una cepa bacteriana del género <i class="style-scope patent-text">Bariatricus</i>, para su uso en un método de tratamiento o prevención del cáncer, tal como cáncer de mama, pulmón o hígado. En determinadas realizaciones, la composición es para uso en un método para reducir el tamaño del tumor o prevenir el crecimiento del tumor en el tratamiento del cáncer. En determinadas realizaciones, la invención proporciona una composición que comprende una cepa bacteriana de la especie <i class="style-scope patent-text">Bariatricus massiliensis </i>para uso en el tratamiento de cáncer.</span>In further preferred embodiments, the invention provides a composition comprising a bacterial strain of the <i class="style-scope patent-text">Bariatricus</i> genus, for use in a method of treating or preventing cancer, such as breast, lung or liver cancer. In certain embodiments, the composition is for use in a method of reducing tumor size or preventing tumor growth in the treatment of cancer. In certain embodiments, the invention provides a composition comprising a bacterial strain of the species <i class="style-scope patent-text">Bariatricus massiliensis</i> for use in treating cancer.</span>
  </p>
  <p id="p0033" num="0033" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las composiciones de la invención son para uso en un método para reducir la actividad histona desacetilasa en el tratamiento o prevención de una enfermedad o afección mediada por una actividad histona desacetilasa elevada.</span>In certain embodiments, the compositions of the invention are for use in a method of reducing histone deacetylase activity in the treatment or prevention of a disease or condition mediated by elevated histone deacetylase activity.</span>
  </p>
  <p id="p0035" num="0035" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, la composición es para uso en un paciente con una actividad de histona desacetilasa elevada. En determinadas realizaciones, la composición es para uso en un paciente con actividad HDAC de clase I elevada. El efecto sobre la actividad de la histona desacetilasa mostrado para las <i class="style-scope patent-text">cepas de Bariatricus </i>puede ser particularmente beneficioso para estos pacientes.</span>In certain embodiments, the composition is for use in a patient with elevated histone deacetylase activity. In certain embodiments, the composition is for use in a patient with elevated class I HDAC activity. The effect on histone deacetylase activity shown for <i class="style-scope patent-text">Bariatricus strains</i> may be particularly beneficial for these patients.</span>
  </p>
  <p id="p0037" num="0037" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La cepa bacteriana en la composición es de <i class="style-scope patent-text">Bariatricus. </i>En determinadas realizaciones de la invención, la cepa bacteriana en la composición es de <i class="style-scope patent-text">Bariatricus massiliensis. </i>También se pueden usar cepas estrechamente relacionadas, como cepas bacterianas que tienen una secuencia del gen de ARNr 16s que es al menos 95%, 96%, 97%, 98%, 99%, 99,5% o 99,9% idéntico a SEQ ID NO:1 o SEQ ID NO:2. Preferiblemente, la cepa bacteriana para uso en la invención tiene la secuencia del gen de ARNr 16s representada por SEQ ID NO: 1. Preferiblemente, la cepa bacteriana para uso en la invención tiene la secuencia del gen de ARNr 16s representada por SEQ ID NO: 2. </span>The bacterial strain in the composition is <i class="style-scope patent-text">Bariatricus.</i> In certain embodiments of the invention, the bacterial strain in the composition is <i class="style-scope patent-text">Bariatricus massiliensis.</i> Closely related strains can also be used, such as bacterial strains that have a 16s rRNA gene sequence that is at least 95%, 96%, 97%, 98%, 99%, 99.5%, or 99.9% identical to SEQ ID NO:1 or SEQ ID NO:2. Preferably, the bacterial strain for use in the invention has the 16s rRNA gene sequence represented by SEQ ID NO: 1. Preferably, the bacterial strain for use in the invention has the 16s rRNA gene sequence represented by SEQ ID NO: 1. two.</span>
  </p>
  <p id="p0038" num="0038" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, la composición de la invención es para administración oral. La administración oral de las cepas de la invención puede ser efectiva para tratar enfermedades y afecciones mediadas por la actividad de HDAC. En determinadas realizaciones, la administración oral de las cepas de la invención puede ser efectiva para tratar enfermedades y afecciones mediadas por una actividad de HDAC de clase I elevada. Además, la administración oral es conveniente para pacientes y médicos y permite el suministro a y/o colonización parcial o total del intestino.</span>In certain embodiments, the composition of the invention is for oral administration. Oral administration of the strains of the invention may be effective in treating diseases and conditions mediated by HDAC activity. In certain embodiments, oral administration of the strains of the invention may be effective in treating diseases and conditions mediated by elevated class I HDAC activity. Furthermore, oral administration is convenient for patients and physicians and allows delivery to and/or partial or total colonization of the intestine.</span>
  </p>
  <p id="p0040" num="0040" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, la composición de la invención se formula utilizando uno o más excipientes o portadores farmacéuticamente aceptables.</span>In certain embodiments, the composition of the invention is formulated using one or more pharmaceutically acceptable excipients or carriers.</span>
  </p>
  <p id="p0042" num="0042" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, la composición de la invención comprende una cepa bacteriana que ha sido liofilizada. La liofilización es una técnica efectiva y conveniente para preparar composiciones estables que permiten el suministro de bacterias.</span>In certain embodiments, the composition of the invention comprises a bacterial strain that has been lyophilized. Lyophilization is an effective and convenient technique for preparing stable compositions that allow delivery of bacteria.</span>
  </p>
  <p id="p0044" num="0044" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, la invención proporciona un producto alimenticio que comprende la composición descrita anteriormente.</span>In certain embodiments, the invention provides a food product comprising the composition described above.</span>
  </p>
  <p id="p0046" num="0046" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Además, se describe un método para tratar o prevenir una enfermedad o afección mediada por la actividad de HDAC, que comprende administrar una composición que comprende una cepa bacteriana del género <i class="style-scope patent-text">Bariatricus. </i> </span>Furthermore, a method of treating or preventing a disease or condition mediated by HDAC activity is described, comprising administering a composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Bariatricus.</i> </span>
  </p>
  <p id="p0047" num="0047" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Al desarrollar la invención anterior, los inventores han identificado y caracterizado cepas bacterianas que son particularmente útiles para terapia. Se ha demostrado que las cepas de <i class="style-scope patent-text">Bariatricus massiliensis </i>de la invención son efectivas para tratar las enfermedades descritas en el presente documento, tales como accidente cerebrovascular, ADHD y GVHD. Por tanto, en otro aspecto, la invención proporciona una célula de la <i class="style-scope patent-text">cepa Bariatricus massiliensis </i>depositada con el número de acceso NCIMB 43042. La invención también proporciona composiciones que comprenden tales células o cultivos biológicamente puros de tales células. La invención también proporciona una célula de la cepa de <i class="style-scope patent-text">Bariatricus massiliensis </i>depositada con el número de acceso NCIMB 43042 para su uso en terapia, en particular para las enfermedades descritas en este documento. Se describe una célula de la cepa 
<i class="style-scope patent-text">Bariatricus massiliensis </i>depositada con el número de acceso NCIMB 43171. También se describen composiciones que comprenden tales células o cultivos biológicamente puros de dichas células. La invención también proporciona una célula de la cepa de <i class="style-scope patent-text">Bariatricus massiliensis </i>depositada con el número de acceso NCIMB 43171 para uso en terapia, en particular para las enfermedades descritas en este documento.</span>In developing the above invention, the inventors have identified and characterized bacterial strains that are particularly useful for therapy. <i class="style-scope patent-text">The Bariatricus massiliensis</i> strains of the invention have been shown to be effective in treating the diseases described herein, such as stroke, ADHD and GVHD. Thus, in another aspect, the invention provides a cell of the <i class="style-scope patent-text">strain Bariatricus massiliensis</i> deposited under accession number NCIMB 43042. The invention also provides compositions comprising such cells or biologically pure cultures of such cells. The invention also provides a cell of the <i class="style-scope patent-text">Bariatricus massiliensis</i> strain deposited under accession number NCIMB 43042 for use in therapy, in particular for the diseases described herein. A cell of the strain is described  <i class="style-scope patent-text">Bariatricus massiliensis</i> deposited under accession number NCIMB 43171. Also disclosed are compositions comprising such cells or biologically pure cultures of such cells. The invention also provides a cell of the <i class="style-scope patent-text">Bariatricus massiliensis</i> strain deposited under accession number NCIMB 43171 for use in therapy, in particular for the diseases described herein.</span>
  </p>
  <p id="p0049" num="0049" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">BREVE DESCRIPCIÓN DE LOS DIBUJOS</span>BRIEF DESCRIPTION OF THE DRAWINGS</span>
    </b>
  </p>
  <p id="p0051" num="0051" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 1 </b>Actividad de histona desacetilasa de célula completa (Figura 1A), Actividad de histona desacetilasa de lisado celular (Figura 1B)</span> <b class="style-scope patent-text">Figure 1</b> Whole cell histone deacetylase activity (Figure 1A), Cell lysate histone deacetylase activity (Figure 1B)</span>
  </p>
  <p id="p0053" num="0053" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 2 </b>Niveles de producción de metabolitos en la cepa 43042 de <i class="style-scope patent-text">Bariatricus massiliensis</i> </span> <b class="style-scope patent-text">Figure 2</b> Levels of metabolite production in <i class="style-scope patent-text">Bariatricus massiliensis strain 43042</i> </span>
  </p>
  <p id="p0055" num="0055" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 3 </b>Inhibición de HDAC de Clase I (Figura 3A); inhibición de HDAC1 (Figura 3B); inhibición de HDAC2 (Figura 3C); inhibición de HDAC3 (Figura 3D)</span> <b class="style-scope patent-text">Figure 3</b> Class I HDAC inhibition (Figure 3A); HDAC1 inhibition (Figure 3B); HDAC2 inhibition (Figure 3C); HDAC3 inhibition (Figure 3D)</span>
  </p>
  <p id="p0057" num="0057" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 4 </b>La cepa 43042 reduce la hiperactividad en ratones</span> <b class="style-scope patent-text">Figure 4</b> Strain 43042 Reduces Hyperactivity in Mice</span>
  </p>
  <p id="p0059" num="0059" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 5 </b>Datos de peso corporal de GVHD en modelos de ratones a los que se administró la cepa 43171 de <i class="style-scope patent-text">Bariatricus massiliensis. </i>Los animales se pesaron diariamente durante el estudio. El asterisco indica importancia en comparación con el Grupo 1; la almohadilla indica importancia en comparación con el Grupo 2; y el punto indica importancia en comparación con el Grupo 3; a menos que se indique lo contrario. *p&lt;0,05, **p&lt;0,01, ***p&lt;0,005, ****p&lt;0,001. Los datos se presentan como media ± SEM. n=8-12 por grupo.</span> <b class="style-scope patent-text">Figure 5</b> GVHD body weight data in mouse models administered <i class="style-scope patent-text">Bariatricus massiliensis strain 43171.</i> The animals were weighed daily during the study. The asterisk indicates importance compared to Group 1; the hash indicates importance compared to Group 2; and the dot indicates importance compared to Group 3; unless otherwise stated. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.005, ****p&lt;0.001. Data are presented as mean ± SEM. n=8-12 per group.</span>
  </p>
  <p id="p0061" num="0061" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 6 </b>Datos de peso corporal de GVHD en modelos de ratones a los que se administró la cepa 43171 de <i class="style-scope patent-text">Bariatricus massiliensis. </i>Los animales se pesaron diariamente durante el estudio y se muestra el porcentaje de cambio de peso corporal con respecto al Día -14. El asterisco indica importancia en comparación con el Grupo 1; la almohadilla indica importancia en comparación con el Grupo 2; y el punto indica importancia en comparación con el Grupo 3; a menos que se indique lo contrario. *p&lt;0,05, **p&lt;0,01, ***p&lt;0,005, ****p&lt;0,001. Los datos se presentan como media ± SEM. n=8-12 por grupo.</span> <b class="style-scope patent-text">Figure 6</b> GVHD body weight data in mouse models administered <i class="style-scope patent-text">Bariatricus massiliensis strain 43171.</i> Animals were weighed daily during the study and the percent change in body weight from Day -14 is shown. The asterisk indicates importance compared to Group 1; the hash indicates importance compared to Group 2; and the dot indicates importance compared to Group 3; unless otherwise stated. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.005, ****p&lt;0.001. Data are presented as mean ± SEM. n=8-12 per group.</span>
  </p>
  <p id="p0063" num="0063" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 7 </b>Datos de peso corporal de GVHD en modelos de ratones a los que se administró la cepa 43171 de <i class="style-scope patent-text">Bariatricus massiliensis. </i>Los animales se pesaron diariamente durante el estudio y se muestra el porcentaje de cambio de peso corporal con respecto al Día 0. El asterisco indica importancia en comparación con el Grupo 1; la almohadilla indica importancia en comparación con el Grupo 2; y el punto indica importancia en comparación con el Grupo 3; a menos que se indique lo contrario. *p&lt;0,05, **p&lt;0,01, ***p&lt;0,005, ****p&lt;0,001. Los datos se presentan como media ± SEM. n=8-12 por grupo.</span> <b class="style-scope patent-text">Figure 7</b> GVHD body weight data in mouse models administered <i class="style-scope patent-text">Bariatricus massiliensis strain 43171.</i> Animals were weighed daily during the study and percentage change in body weight from Day 0 is shown. Asterisk indicates significance compared to Group 1; the hash indicates importance compared to Group 2; and the dot indicates importance compared to Group 3; unless otherwise stated. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.005, ****p&lt;0.001. Data are presented as mean ± SEM. n=8-12 per group.</span>
  </p>
  <p id="p0065" num="0065" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 8 </b>Datos de peso corporal de GVHD en modelos de ratones a los que se les administró la cepa 43171 de <i class="style-scope patent-text">Bariatricus massiliensis, </i>teniendo en cuenta para el grupo anfitrión, el peso corporal con el que murió un animal se llevó adelante durante el estudio para los animales encontrados muertos o sacrificados para todos los grupos excepto el Grupo 2. El asterisco indica importancia en comparación con el Grupo 1; la almohadilla indica importancia en comparación con el Grupo 2; y el punto indica importancia en comparación con el Grupo 3; a menos que se indique lo contrario. *p&lt;0,05, **p&lt;0,01, ***p&lt;0,005, ****p&lt;0,001. Los datos se presentan como media ± SEM. n=8-12 por grupo.</span> <b class="style-scope patent-text">Figure 8</b> GVHD body weight data in mouse models administered <i class="style-scope patent-text">Bariatricus massiliensis</i> strain 43171, taking into account for the host group, the body weight at which an animal died was carried forward during the study for the animals found dead or euthanized for all groups except Group 2. Asterisk indicates importance compared to Group 1; the hash indicates importance compared to Group 2; and the dot indicates importance compared to Group 3; unless otherwise stated. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.005, ****p&lt;0.001. Data are presented as mean ± SEM. n=8-12 per group.</span>
  </p>
  <p id="p0067" num="0067" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 9 </b>Datos de peso corporal de GVHD en modelos de ratones a los que se les administró tacrolimus (FK506) ***: p&lt;0,005.</span> <b class="style-scope patent-text">Figure 9</b> Body weight data of GVHD in mouse models administered tacrolimus (FK506)***: p&lt;0.005.</span>
  </p>
  <p id="p0069" num="0069" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 10 </b>Supervivencia animal en modelos de ratones a los que se administró la cepa 43171 de <i class="style-scope patent-text">Bariatricus massiliensis</i> </span> <b class="style-scope patent-text">Figure 10</b> Animal survival in mouse models administered <i class="style-scope patent-text">Bariatricus massiliensis strain 43171</i> </span>
  </p>
  <p id="p0071" num="0071" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 11 </b>Supervivencia animal en modelos de ratones a los que se les administró tacrolimus (FK506)</span> <b class="style-scope patent-text">Figure 11</b> Animal survival in mouse models administered tacrolimus (FK506)</span>
  </p>
  <p id="p0073" num="0073" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 12 </b>Puntuaciones clínicas de GVHD en modelos de ratones a los que se administró la cepa 43171 de <i class="style-scope patent-text">Bariatricus massiliensis. </i>A los animales se les asignó una puntuación clínica de GVHD diariamente desde los Días 0 a 30. El área bajo la curva (AUC) se calculó usando la regla de transformación trapezoidal y se muestra en el recuadro de la figura. El asterisco indica importancia en comparación con el Grupo 1; la almohadilla indica importancia en comparación con el Grupo 2; y el punto indica importancia en comparación con el Grupo 3; a menos que se indique lo contrario. *p&lt;0,05, **p&lt;0,01, ***p&lt;0,005, ****p&lt;0,001. Los datos se presentan como media ± SEM. n=8-12 por grupo.</span> <b class="style-scope patent-text">Figure 12</b> Clinical GVHD scores in mouse models administered <i class="style-scope patent-text">Bariatricus massiliensis strain 43171.</i> Animals were assigned a clinical GVHD score daily from Days 0 to 30. The area under the curve (AUC) was calculated using the trapezoidal transformation rule and is shown in the inset of the figure. The asterisk indicates importance compared to Group 1; the hash indicates importance compared to Group 2; and the dot indicates importance compared to Group 3; unless otherwise stated. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.005, ****p&lt;0.001. Data are presented as mean ± SEM. n=8-12 per group.</span>
  </p>
  <p id="p0075" num="0075" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 13 </b>Puntuaciones clínicas de GVHD en modelos de ratones a los que se administró la cepa 43171 de <i class="style-scope patent-text">Bariatricus massiliensis. </i>A los animales se les asignó una puntuación clínica de GVHD diariamente desde los Días 0 a 30. Para tener en cuenta la deserción del grupo, la puntuación de GVHD con la que murió un animal se trasladó durante el estudio para los animales encontrados muertos o sacrificados para todos los grupos excepto el Grupo 2. El área bajo la curva (AUC) se calculó utilizando la regla de transformación trapezoidal y se muestra en la figura insertada. El asterisco indica importancia en comparación con el Grupo 1; la almohadilla indica importancia en comparación con el Grupo 2; y el punto indica importancia en comparación con el Grupo 3; a menos que se indique 
lo contrario. *p&lt;0,05, **p&lt;0,01, ***p&lt;0,005, ****p&lt;0,001. Los datos se presentan como media ± SEM. n=8-12 por grupo.</span> <b class="style-scope patent-text">Figure 13</b> Clinical GVHD scores in mouse models administered <i class="style-scope patent-text">Bariatricus massiliensis strain 43171.</i> Animals were assigned a clinical GVHD score daily from Days 0 to 30. To account for group dropout, the GVHD score at which an animal died was carried over during the study for animals found dead or euthanized. for all groups except Group 2. The area under the curve (AUC) was calculated using the trapezoidal transformation rule and is shown in the inset figure. The asterisk indicates importance compared to Group 1; the hash indicates importance compared to Group 2; and the dot indicates importance compared to Group 3; unless noted  otherwise. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.005, ****p&lt;0.001. Data are presented as mean ± SEM. n=8-12 per group.</span>
  </p>
  <p id="p0077" num="0077" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 14 </b>(A) postura, (B) actividad, (C) textura del pelaje, (D) integridad de la piel y (E) pérdida de peso utilizada en puntuaciones compuestas de GVHD en modelos de ratones a los que se administró la cepa 43171 de <i class="style-scope patent-text">Bariatricus massiliensis.</i> </span> <b class="style-scope patent-text">Figure 14</b> (A) posture, (B) activity, (C) coat texture, (D) skin integrity, and (E) weight loss used in composite scores of GVHD in strain-administered mouse models 43171 of <i class="style-scope patent-text">Bariatricus massiliensis.</i> </span>
  </p>
  <p id="p0079" num="0079" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 15 </b>Puntuaciones clínicas de GVHD en modelos de ratones a los que se les administró tacrolimus (FK506) </span> <b class="style-scope patent-text">Figure 15</b> Clinical GVHD scores in mouse models administered tacrolimus (FK506)</span>
  </p>
  <p id="p0080" num="0080" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 16 </b>Puntuaciones de gravedad de la colitis en modelos de ratones a los que se administró la cepa 43171 de <i class="style-scope patent-text">Bariatricus massiliensis. </i>Los animales se sometieron a una videoendoscopia el Día 29 para evaluar la inflamación del colon. El asterisco indica importancia en comparación con el Grupo 1; la almohadilla indica importancia en comparación con el Grupo 2; y el punto indica importancia en comparación con el Grupo 3; a menos que se indique lo contrario. *p&lt;0,05, **p&lt;0,01, ***p&lt;0,005, ****p&lt;0,001. Los datos se presentan como media ± Se M. n=8-12 por grupo.</span> <b class="style-scope patent-text">Figure 16</b> Colitis severity scores in mouse models administered <i class="style-scope patent-text">Bariatricus massiliensis strain 43171.</i> Animals underwent video endoscopy on Day 29 to assess colonic inflammation. The asterisk indicates importance compared to Group 1; the hash indicates importance compared to Group 2; and the dot indicates importance compared to Group 3; unless otherwise stated. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.005, ****p&lt;0.001. Data are presented as mean ± Se M. n=8-12 per group.</span>
  </p>
  <p id="p0082" num="0082" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 17 </b>Imágenes de endoscopia de colon representativas.</span> <b class="style-scope patent-text">Figure 17</b> Representative colon endoscopy images.</span>
  </p>
  <p id="p0084" num="0084" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 18 </b>Niveles plasmáticos de citrulina en ratones a los que se les administró la cepa 43171 de <i class="style-scope patent-text">Bariatricus massiliensis. </i>Se recogió sangre antes de la eutanasia de todos los animales supervivientes y se procesó para obtener plasma; la citrulina plasmática se evaluó por duplicado mediante ELISA. El plasma se diluyó 1:10 para analizar. El asterisco indica importancia en comparación con el Grupo 1; la almohadilla indica importancia en comparación con el Grupo 2; y el punto indica importancia en comparación con el Grupo 3; a menos que se indique lo contrario. *p&lt;0,05, **p&lt;0,01, ***p&lt;0,005, ****p&lt;0,001. Los datos se presentan como media ± S<sup class="style-scope patent-text">e </sup>M. n=8-12 por grupo.</span> <b class="style-scope patent-text">Figure 18</b> Plasma citrulline levels in mice administered <i class="style-scope patent-text">Bariatricus massiliensis strain 43171.</i> Blood was collected prior to euthanasia from all surviving animals and processed to obtain plasma; Plasma citrulline was evaluated in duplicate by ELISA. Plasma was diluted 1:10 for analysis. The asterisk indicates importance compared to Group 1; the hash indicates importance compared to Group 2; and the dot indicates importance compared to Group 3; unless otherwise stated. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.005, ****p&lt;0.001. Data are presented as mean ± S <sup class="style-scope patent-text">and</sup> M. n=8-12 per group.</span>
  </p>
  <p id="p0086" num="0086" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 19 </b>Niveles de secreción de IL-6.</span> <b class="style-scope patent-text">Figure 19</b> IL-6 secretion levels.</span>
  </p>
  <p id="p0088" num="0088" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 20 </b>Activación de MAP2.</span> <b class="style-scope patent-text">Figure 20</b> Activation of MAP2.</span>
  </p>
  <p id="p0090" num="0090" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 21 </b>Expresión de IDOl en el íleon (A) y el colon (B) de ratones a los que se les administró <i class="style-scope patent-text">Bariatricus. </i>*p&lt;0,05.</span> <b class="style-scope patent-text">Figure 21</b> Expression of IDOl in the ileum (A) and colon (B) of mice administered <i class="style-scope patent-text">Bariatricus.</i> *p&lt;0.05.</span>
  </p>
  <p id="p0092" num="0092" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 22 </b>Expresión del receptor de glucocorticoides (A), receptor de mineralocorticoides (B), BDNF (C), Grin 2B (D), CRH (E), CFR1 (F), CD11b (G) y GABA A2 (H) en el hipocampo de ratones a los que se les administró <i class="style-scope patent-text">Bariatricus. </i>*p&lt;0,05.</span> <b class="style-scope patent-text">Figure 22</b> Expression of glucocorticoid receptor (A), mineralocorticoid receptor (B), BDNF (C), Grin 2B (D), CRH (E), CFR1 (F), CD11b (G), and GABA A2 (H) in the hippocampus of mice administered <i class="style-scope patent-text">Bariatricus.</i> *p&lt;0.05.</span>
  </p>
  <p id="p0094" num="0094" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 23 </b>Expresión de receptor de oxicodina (A), receptor de glucocorticoide (B), receptor de mineralocorticoide (C), Grin 2A (D) y Grin 2B (E) en la amígdala de ratones a los que se les administró <i class="style-scope patent-text">Bariatricus. </i>*p&lt;0,05.</span> <b class="style-scope patent-text">Figure 23</b> Expression of oxycodin receptor (A), glucocorticoid receptor (B), mineralocorticoid receptor (C), Grin 2A (D), and Grin 2B (E) in the amygdala of mice administered <i class="style-scope patent-text">Bariatricus.</i> *p&lt;0.05.</span>
  </p>
  <p id="p0096" num="0096" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 24 </b>Expresión de BDNF (A), CRFR1 (B) y receptor de mineralocorticoides (C) en la corteza prefrontal de ratones a los que se les administró <i class="style-scope patent-text">Bariatricus. </i>*p&lt;0,05, **p&lt;0,01.</span> <b class="style-scope patent-text">Figure 24</b> Expression of BDNF (A), CRFR1 (B) and mineralocorticoid receptor (C) in the prefrontal cortex of mice administered <i class="style-scope patent-text">Bariatricus.</i> *p&lt;0.05, **p&lt;0.01.</span>
  </p>
  <p id="p0098" num="0098" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DESCRIPCIÓN DE LA INVENCIÓN</span>DESCRIPTION OF THE INVENTION</span>
    </b>
  </p>
  <p id="p0100" num="0100" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cepas bacterianas</span>bacterial strains</span>
      </i>
    </b>
  </p>
  <p id="p0102" num="0102" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las composiciones de la invención comprenden una cepa bacteriana del género <b class="style-scope patent-text">Bariatricus</b>, como se define en las reivindicaciones. Los ejemplos demuestran que las bacterias de este género son útiles para tratar o prevenir enfermedades y afecciones mediadas por la actividad de HDAC. Las cepas bacterianas preferidas son de la especie <i class="style-scope patent-text">Bariatricus massiliensis.</i> </span>The compositions of the invention comprise a bacterial strain of the genus <b class="style-scope patent-text">Bariatricus</b> , as defined in the claims. The examples demonstrate that bacteria of this genus are useful for treating or preventing diseases and conditions mediated by HDAC activity. Preferred bacterial strains are of the species <i class="style-scope patent-text">Bariatricus massiliensis.</i> </span>
  </p>
  <p id="p0104" num="0104" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Un ejemplo de una cepa de <i class="style-scope patent-text">Bariatricus </i>para uso en la invención es una cepa de la especie <i class="style-scope patent-text">Bariatricus massiliensis. </i>Los <i class="style-scope patent-text">Bariatricus </i>son anaerobios obligados en forma de bastoncillo con reacción grampositiva (Bessis et al 2016 New Microbe y New Infect 12: 54-55). <i class="style-scope patent-text">Bariatricus massiliensis </i>puede aislarse del intestino humano. Las secuencias del gen de ARNr 16S de las <i class="style-scope patent-text">cepas de Bariatricus massiliensis </i>utilizadas en los ejemplos se describen en el presente documento como SEQ ID NO:1 y SEQ ID NO:2. <i class="style-scope patent-text">Una cepa de Bariatricus massiliensis </i>ilustrativa adicional se describe en Bessis et al (2016 New Microbe y New Infect 12: 54-55).</span>An example of a strain of <i class="style-scope patent-text">Bariatricus</i> for use in the invention is a strain of the species <i class="style-scope patent-text">Bariatricus massiliensis.</i> <i class="style-scope patent-text">Bariatricus</i> are Gram-positive rod-shaped obligate anaerobes (Bessis et al 2016 New Microbe and New Infect 12: 54-55). <i class="style-scope patent-text">Bariatricus massiliensis</i> can be isolated from the human intestine. The 16S rRNA gene sequences of the <i class="style-scope patent-text">Bariatricus massiliensis strains</i> used in the examples are described herein as SEQ ID NO:1 and SEQ ID NO:2. <i class="style-scope patent-text">A further illustrative Bariatricus massiliensis strain</i> is described in Bessis et al (2016 New Microbe and New Infect 12:54-55).</span>
  </p>
  <p id="p0106" num="0106" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La bacteria <i class="style-scope patent-text">Bariatricus massiliensis </i>depositada con el número de acceso NCIMB 43042 se ensayó en los Ejemplos y se denomina en el presente documento cepa 43042. Una secuencia del gen de ARNr 16s para la cepa 43042 que se ensayó se proporciona en la SEQ ID NO:1. La cepa 43042 fue depositada en la autoridad de depósito internacional NCIMB, Ltd. (Ferguson Building, Aberdeen, AB21 9YA, Escocia) por 4D Pharma Research Limited (Life Sciences Innovation Building, Aberdeen, AB25 2ZS, Escocia) el 18/05/2018 como <i class="style-scope patent-text">"Bariatricus massiliensis" </i>y se le asignó el número de acceso NCIMB 43042. La bacteria <i class="style-scope patent-text">Bariatricus massiliensis </i>depositada con el número de acceso NCIMB 43171 se ensayó en los Ejemplos y se denomina en el presente documento cepa 43171. Una secuencia del gen de ARNr 16S para la cepa 43171 que se ensayó se proporciona en la SEQ ID NO:2. La cepa 43171 se depositó en la autoridad de depósito internacional NCIMB, Ltd. (Ferguson Building, Craibstone Estate, Bucksburn, Aberdeen, AB21 9YA Scotland) por 4D Pharma Research Limited (Life Sciences Innovation Building, Cornhill Road, Aberdeen, AB25 2ZS, Escocia) el 20/08/2018 como <i class="style-scope patent-text">"Bariatricus massiliensis" </i>y se le asignó el número de acceso NCIMB 43171 
También se espera que las cepas bacterianas estrechamente relacionadas con las cepas ensayadas en los Ejemplos sean eficaces para tratar o prevenir enfermedades y afecciones mediadas por la actividad de HDAC. En determinadas realizaciones, la cepa bacteriana para uso en la invención tiene una secuencia del gen de ARNr 16s que es al menos 95%, 96%, 97%, 98%, 99%, 99,5% o 99,9% idéntico a SEQ ID NO:1. Preferiblemente, la cepa bacteriana para uso en la invención tiene la secuencia del gen de ARNr 16s representada por SEQ ID NO:1. En determinadas realizaciones, la cepa bacteriana para uso en la invención tiene una secuencia del gen de ARNr 16s que es al menos 95%, 96%, 97%, 98%, 99%, 99,5% o 99,9% idéntico a SEQ ID NO:2. Preferiblemente, la cepa bacteriana para uso en la invención tiene la secuencia del gen de ARNr 16s representada por SEQ ID NO:2.</span>The bacterium <i class="style-scope patent-text">Bariatricus massiliensis</i> deposited under NCIMB accession number 43042 was tested in the Examples and is referred to herein as strain 43042. A 16s rRNA gene sequence for strain 43042 that was tested is provided in SEQ ID NO:1 . Strain 43042 was deposited with the International Depository Authority NCIMB, Ltd. (Ferguson Building, Aberdeen, AB21 9YA, Scotland) by 4D Pharma Research Limited (Life Sciences Innovation Building, Aberdeen, AB25 2ZS, Scotland) on 05/18/2018 as <i class="style-scope patent-text">"Bariatricus massiliensis"</i> and assigned NCIMB accession number 43042. The bacterium <i class="style-scope patent-text">Bariatricus massiliensis</i> deposited under NCIMB accession number 43171 was tested in the Examples and is referred to herein as strain 43171. A 16S rRNA gene sequence for strain 43171 that was tested is given in SEQ ID NO:2. Strain 43171 was deposited with the International Depository Authority NCIMB, Ltd. (Ferguson Building, Craibstone Estate, Bucksburn, Aberdeen, AB21 9YA Scotland) by 4D Pharma Research Limited (Life Sciences Innovation Building, Cornhill Road, Aberdeen, AB25 2ZS, Scotland). ) on 08/20/2018 as <i class="style-scope patent-text">"Bariatricus massiliensis"</i> and assigned NCIMB accession number 43171  Bacterial strains closely related to the strains tested in the Examples are also expected to be effective in treating or preventing diseases and conditions mediated by HDAC activity. In certain embodiments, the bacterial strain for use in the invention has a 16s rRNA gene sequence that is at least 95%, 96%, 97%, 98%, 99%, 99.5%, or 99.9% identical to SEQ ID NO:1. Preferably, the bacterial strain for use in the invention has the 16s rRNA gene sequence represented by SEQ ID NO:1. In certain embodiments, the bacterial strain for use in the invention has a 16s rRNA gene sequence that is at least 95%, 96%, 97%, 98%, 99%, 99.5%, or 99.9% identical to SEQ ID NO:2. Preferably, the bacterial strain for use in the invention has the 16s rRNA gene sequence represented by SEQ ID NO:2.</span>
  </p>
  <p id="p0108" num="0108" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">También se espera que las cepas bacterianas que son biotipos de la bacteria depositada con el número de acceso NCIMB 43042 o NCIMB 43171 sean efectivas para tratar o prevenir enfermedades y afecciones mediadas por la actividad de HDAC. Un biotipo es una cepa estrechamente relacionada que tiene las mismas o muy similares características fisiológicas y bioquímicas.</span>Bacterial strains that are biotypes of the bacterium deposited under accession number NCIMB 43042 or NCIMB 43171 are also expected to be effective in treating or preventing diseases and conditions mediated by HDAC activity. A biotype is a closely related strain that has the same or very similar physiological and biochemical characteristics.</span>
  </p>
  <p id="p0110" num="0110" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las cepas que son biotipos de una bacteria depositada con el número de acceso NCIMB 43042 o NCIMB 43171 y que son adecuadas para su en la invención pueden identificarse secuenciando otras secuencias de nucleótidos para una bacteria depositada con el número de acceso NCIMB 43042 o NCIMB 43171. Por ejemplo, se puede secuenciar sustancialmente todo el genoma y una cepa de biotipo para uso en la invención puede tener al menos 95%, 96%, 97%, 98%, 99%, 99,5% o 99,9% de identidad de secuencia en al menos 80% de todo su genoma (p. ej., en al menos 85%, 90%, 95% o 99%, o en todo su genoma). Otras secuencias adecuadas para uso en la identificación de cepas de biotipo pueden incluir hsp60 o secuencias repetitivas como BOX, ERIC, (GTG)s o REP [16]. Las cepas de biotipo pueden tener secuencias con al menos 95%, 96%, 97%, 98%, 99%, 99,5% o 99,9% de identidad de secuencia con la secuencia correspondiente de una bacteria depositada con el número de acceso NCIMB 43042 o NCIMB 43171.</span>Strains that are biotypes of a bacterium deposited under accession number NCIMB 43042 or NCIMB 43171 and that are suitable for use in the invention can be identified by sequencing other nucleotide sequences for a bacterium deposited under accession number NCIMB 43042 or NCIMB 43171. For example, substantially the entire genome can be sequenced, and a biotype strain for use in the invention can have at least 95%, 96%, 97%, 98%, 99%, 99.5%, or 99.9% identity. of sequence in at least 80% of its entire genome (eg, in at least 85%, 90%, 95%, or 99%, or in its entire genome). Other sequences suitable for use in identifying biotype strains may include hsp60 or repetitive sequences such as BOX, ERIC, (GTG)s or REP [16]. Biotype strains may have sequences with at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% sequence identity with the corresponding sequence of a deposited bacterium with the number of access NCIMB 43042 or NCIMB 43171.</span>
  </p>
  <p id="p0112" num="0112" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Alternativamente, las cepas que son biotipos de una bacteria depositada con el número de acceso NCIMB 43042 o NCIMB 43171 y que son adecuadas para uso en la invención pueden identificarse utilizando el número de acceso NCIMB 43042 o NCIMB 43171 y análisis de fragmentos de restricción y/o análisis de PCR, por ejemplo utilizando polimorfismo de longitud de fragmento amplificado fluorescente (FAFLP) y huella digital repetitiva de elementos de ADN (rep)-PCR, o perfilado de proteínas, o secuenciación parcial de ADNr 16S o 23S. En realizaciones preferidas, tales técnicas pueden usarse para identificar otras cepas de <i class="style-scope patent-text">Bariatricus.</i> </span>Alternatively, strains that are biotypes of a bacterium deposited under accession number NCIMB 43042 or NCIMB 43171 and that are suitable for use in the invention may be identified using accession number NCIMB 43042 or NCIMB 43171 and restriction fragment analysis and/or or PCR analysis, for example using fluorescent amplified fragment length polymorphism (FAFLP) and repetitive fingerprinting of DNA elements (rep)-PCR, or protein profiling, or partial 16S or 23S rDNA sequencing. In preferred embodiments, such techniques can be used to identify other strains of <i class="style-scope patent-text">Bariatricus.</i> </span>
  </p>
  <p id="p0114" num="0114" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las cepas que son biotipos de una bacteria depositada con el número de acceso NCIMB 43042 o NCIMB 43171 y que son adecuadas para uso en la invención son cepas que proporcionan el mismo patrón que una bacteria depositada con el número de acceso NCIMB 43042 o NCIMB 43171 cuando se analiza mediante análisis de restricción de ADN ribosómico amplificado (ARDRA), por ejemplo, cuando se utiliza la enzima de restricción Sau3AI (para métodos ilustrativos y guía, véase, por ejemplo, [17]. Alternativamente, las cepas de biotipo se identifican como cepas que tienen los mismos patrones de fermentación de carbohidratos que una bacteria depositada con el número de acceso NCIMB 43042 o NCIMB 43171.</span>In certain embodiments, strains that are biotypes of a bacterium deposited under accession number NCIMB 43042 or NCIMB 43171 and that are suitable for use in the invention are strains that provide the same pattern as a bacterium deposited under accession number NCIMB 43042. or NCIMB 43171 when analyzed by amplified ribosomal DNA restriction analysis (ARDRA), for example, when using the restriction enzyme Sau3AI (for illustrative methods and guidance, see, eg, [17]. Alternatively, strains of biotype are identified as strains that have the same carbohydrate fermentation patterns as a bacterium deposited under accession number NCIMB 43042 or NCIMB 43171.</span>
  </p>
  <p id="p0116" num="0116" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Otras cepas de <i class="style-scope patent-text">Bariatricus </i>que son útiles en las composiciones y usos de la invención, tales como biotipos de una bacteria depositada con el número de acceso NCIMB 43042 o NCIMB 43171, pueden identificarse usando cualquier método o estrategia apropiados, incluidos los ensayos descritos en los ejemplos. Por ejemplo, las cepas para uso en la invención pueden identificarse administrando las bacterias al ensayo de actividad de HDAC y evaluando la inhibición de la actividad de HDAC. Las cepas bacterianas con actividad inhibidora de HDAC comparable a NCIMB 43042 son adecuadas para uso en la invención. En particular, las cepas bacterianas que tienen patrones de crecimiento similares, tipo metabólico y/o antígenos de superficie a una bacteria depositada con el número de acceso NCIMB 43042 pueden ser útiles en la invención. Una cepa útil tendrá una actividad inhibidora de HDAC comparable y/o efectos comparables sobre la reducción de hiperactividad en los ensayos usados en los Ejemplos a la cepa NCIMB 43042, que puede identificarse usando los protocolos de cultivo y administración descritos en los Ejemplos. En otros casos, las cepas para uso en la invención pueden identificarse administrando las bacterias a los modelos de GVHD descritos en los Ejemplos y evaluando la eficacia en el tratamiento de GVHD. Las cepas bacterianas con actividad comparable a NCIMB 43171 con respecto al tratamiento de GVHD en las condiciones establecidas en los Ejemplos son adecuadas para uso en la invención.</span>Other strains of <i class="style-scope patent-text">Bariatricus</i> that are useful in the compositions and uses of the invention, such as biotypes of a bacterium deposited under accession number NCIMB 43042 or NCIMB 43171, may be identified using any appropriate method or strategy, including the assays described in the examples. . For example, strains for use in the invention can be identified by administering the bacteria to the HDAC activity assay and evaluating the inhibition of HDAC activity. Bacterial strains with HDAC inhibitory activity comparable to NCIMB 43042 are suitable for use in the invention. In particular, bacterial strains that have similar growth patterns, metabolic type, and/or surface antigens to a bacterium deposited under accession number NCIMB 43042 may be useful in the invention. A useful strain will have comparable HDAC inhibitory activity and/or comparable effects on hyperactivity reduction in the assays used in the Examples to strain NCIMB 43042, which can be identified using the culture and administration protocols described in the Examples. In other cases, strains for use in the invention can be identified by administering the bacteria to the GVHD models described in the Examples and evaluating efficacy in treating GVHD. Bacterial strains with activity comparable to NCIMB 43171 with respect to treatment of GVHD under the conditions set forth in the Examples are suitable for use in the invention.</span>
  </p>
  <p id="p0118" num="0118" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Una cepa particularmente preferida de la invención es la cepa de <i class="style-scope patent-text">Bariatricus massiliensis </i>depositada con el número de acceso NCIMB 43042. Esta es la cepa 43042 ilustrativa ensayada en los ejemplos y que se ha demostrado que es efectiva para reducir la actividad de HDAC y reducir la hiperactividad. Por tanto, la invención proporciona una célula, tal como una célula aislada, de la cepa de <i class="style-scope patent-text">Bariatricus massiliensis </i>depositada con el número de acceso NCIMB 43042. La invención también proporciona una composición que comprende una célula de la cepa <i class="style-scope patent-text">Bariatricus massiliensis </i>depositada con el número de acceso NCIM<sup class="style-scope patent-text">b </sup>43042. La invención también proporciona un cultivo biológicamente puro de la cepa de <i class="style-scope patent-text">Bariatricus massiliensis </i>depositado con el número de acceso NCIMB 43042. La invención también proporciona una célula de la cepa de <i class="style-scope patent-text">Bariatricus massiliensis </i>depositada con el número de acceso NCIMB 43042 para uso en terapia, en particular para las enfermedades descritas en este documento.</span>A particularly preferred strain of the invention is the <i class="style-scope patent-text">Bariatricus massiliensis</i> strain deposited under NCIMB accession number 43042. This is the illustrative strain 43042 tested in the examples and shown to be effective in reducing HDAC activity and reducing hyperactivity. . Thus, the invention provides a cell, such as an isolated cell, from the <i class="style-scope patent-text">Bariatricus massiliensis</i> strain deposited under accession number NCIMB 43042. The invention also provides a composition comprising a cell from the <i class="style-scope patent-text">Bariatricus massiliensis</i> strain deposited under accession number NCIMB 43042. NCIM accession <sup class="style-scope patent-text">b</sup> 43042. The invention also provides a biologically pure culture of the <i class="style-scope patent-text">Bariatricus massiliensis</i> strain deposited under NCIMB accession number 43042. The invention also provides a cell of the <i class="style-scope patent-text">Bariatricus massiliensis</i> strain deposited under NCIMB accession number 43042 for use in therapy, in particular for the diseases described in this document.</span>
  </p>
  <p id="p0120" num="0120" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Un derivado de la cepa depositada con el número de acceso NCIMB 43042 puede ser una cepa hija (progenie) o una cepa cultivada (subclonada) de la original. Un derivado de una cepa de la invención puede modificarse, por 
ejemplo, a nivel genético, sin eliminar la actividad biológica. En particular, una cepa derivada de la invención es terapéuticamente activa. Una cepa derivada tendrá una actividad inhibidora de HDAC comparable a la cepa NCIMB 43042 original. En particular, una cepa derivada provocará efectos comparables sobre la actividad inhibidora de HDAC o los modelos de hiperactividad mostrados en los Ejemplos, que pueden identificarse usando los protocolos de cultivo y administración descritos en los Ejemplos. Un derivado de la cepa NCIMB 43042 será generalmente un biotipo de la cepa NCIMB 43042.</span>A derivative of the strain deposited under NCIMB accession number 43042 may be a daughter strain (progeny) or a cultured strain (subcloned) of the parent. A derivative of a strain of the invention may be modified, for  example, at the genetic level, without eliminating biological activity. In particular, a strain derived from the invention is therapeutically active. A derivative strain will have HDAC inhibitory activity comparable to the parent NCIMB 43042 strain. In particular, a derived strain will elicit comparable effects on the HDAC inhibitory activity or hyperactivity patterns shown in the Examples, which can be identified using the culture and administration protocols described in the Examples. A derivative of the NCIMB 43042 strain will generally be a biotype of the NCIMB 43042 strain.</span>
  </p>
  <p id="p0121" num="0121" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Otra cepa particularmente preferida de la invención es la cepa de <i class="style-scope patent-text">Bariatricus massiliensis </i>depositada con el número de acceso NCIMB 43171. Se muestra que la cepa ilustrativa 43171 ensayada en los ejemplos es efectiva en el tratamiento de la GVHD. Se describe una célula, tal como una célula aislada, de la cepa 43171 de <i class="style-scope patent-text">Bariatricus massiliensis, </i>o un derivado de la misma. También se describe una composición que comprende una célula de la cepa 43171 de <i class="style-scope patent-text">Bariatricus massiliensis, </i>o un derivado de la misma. También se describe un cultivo biológicamente puro de la cepa 43171 de <i class="style-scope patent-text">Bariatricus massiliensis. </i>La invención también proporciona una célula de la cepa 43171 de <i class="style-scope patent-text">Bariatricus massiliensis </i>para uso en terapia, en particular para las enfermedades descritas en este documento. Un derivado de la cepa depositada con el número de acceso NCIMB 43171 puede ser una cepa hija (progenie) o una cepa cultivada (subclonada) de la original. Un derivado de una cepa de la invención puede modificarse, por ejemplo, a nivel genético, sin eliminar la actividad biológica. En particular, una cepa derivada de la invención es terapéuticamente activa. Una cepa derivada tendrá una actividad comparable a la cepa NCIMB 43171 original con respecto al tratamiento de GVHD en las condiciones establecidas en los Ejemplos. Un derivado de la cepa NCIMB 43171 será generalmente un biotipo de la cepa NCIMB 43171.</span>Another particularly preferred strain of the invention is the <i class="style-scope patent-text">Bariatricus massiliensis</i> strain deposited under NCIMB accession number 43171. Illustrative strain 43171 tested in the examples is shown to be effective in treating GVHD. A cell, such as an isolated cell, of <i class="style-scope patent-text">Bariatricus massiliensis</i> strain 43171, or a derivative thereof, is disclosed. Also disclosed is a composition comprising a <i class="style-scope patent-text">Bariatricus massiliensis</i> strain 43171 cell, or a derivative thereof. A biologically pure culture of <i class="style-scope patent-text">Bariatricus massiliensis strain 43171 is also described.</i> The invention also provides a <i class="style-scope patent-text">Bariatricus massiliensis</i> strain 43171 cell for use in therapy, in particular for the diseases described herein. A derivative of the strain deposited under NCIMB accession number 43171 may be a daughter strain (progeny) or a cultured strain (subcloned) of the parent. A derivative of a strain of the invention can be modified, for example, at the genetic level, without eliminating biological activity. In particular, a strain derived from the invention is therapeutically active. A derivative strain will have comparable activity to the parent NCIMB 43171 strain with respect to treatment of GVHD under the conditions set forth in the Examples. A derivative of the NCIMB 43171 strain will generally be a biotype of the NCIMB 43171 strain.</span>
  </p>
  <p id="p0122" num="0122" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, las cepas bacterianas en las composiciones de la invención son viables y capaces de colonizar parcial o totalmente el intestino.</span>In preferred embodiments, the bacterial strains in the compositions of the invention are viable and capable of partially or totally colonizing the intestine.</span>
  </p>
  <p id="p0123" num="0123" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Usos terapéuticos</span>therapeutic uses</span>
      </i>
    </b>
  </p>
  <p id="p0124" num="0124" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Como se demuestra en los ejemplos, las composiciones bacterianas de la invención son efectivas para reducir la actividad de HDAC. En particular, el tratamiento con composiciones de la invención logra una reducción en la actividad de HDAC de Clase 1. En particular, el tratamiento con composiciones de la invención logra una reducción en la actividad de HDAC2. Las composiciones de la invención también muestran mejoras clínicas en modelos animales de hiperactividad. Por lo tanto, las composiciones de la invención pueden ser útiles para tratar o prevenir enfermedades o afecciones mediadas por la actividad de HDAC. Una afección puede ser un síntoma de una enfermedad. En particular, las composiciones de la invención pueden ser útiles para reducir o prevenir enfermedades o afecciones mediadas por niveles elevados de actividad de HDAC. Por lo tanto, las composiciones de la invención pueden ser útiles para tratar o prevenir enfermedades o afecciones mediadas por niveles elevados de actividad de HDAC de Clase I. Por lo tanto, las composiciones de la invención pueden ser útiles para tratar o prevenir enfermedades o afecciones mediadas por niveles elevados de actividad de HDAC2.</span>As demonstrated in the examples, the bacterial compositions of the invention are effective in reducing HDAC activity. In particular, treatment with compositions of the invention achieves a reduction in Class 1 HDAC activity. In particular, treatment with compositions of the invention achieves a reduction in HDAC2 activity. The compositions of the invention also show clinical improvements in animal models of hyperactivity. Therefore, the compositions of the invention may be useful for treating or preventing diseases or conditions mediated by HDAC activity. A condition can be a symptom of a disease. In particular, the compositions of the invention may be useful for reducing or preventing diseases or conditions mediated by elevated levels of HDAC activity. Therefore, the compositions of the invention may be useful in treating or preventing diseases or conditions mediated by elevated levels of Class I HDAC activity. Thus, the compositions of the invention may be useful in treating or preventing diseases or conditions. mediated by elevated levels of HDAC2 activity.</span>
  </p>
  <p id="p0125" num="0125" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las histonas desacetilasas son una clase de enzimas que eliminan los grupos acetilo de las proteínas objetivo. La diana de HDAC más abundante son las histonas, pero se sabe que las HDAC desacetilan residuos de lisina de dianas proteicas que no son histonas para regular temporalmente la actividad de la proteína. Como tal, las HDAC a veces se denominan lisina desacetilasas. Actualmente hay 13 HDAC conocidas que se clasifican en cuatro clases principales: clase I (HDAC 1, 2, 3 y 8), clase IIa (HDAC 4, 5, 7 y 9) y clase IIb (HDAC 6 y 10), clase III (sirt1-sirt7) y clase IV (HDAC 11) [7]. Cada clase tiene generalmente un patrón de expresión tisular y una localización subcelular diferente.</span>Histone deacetylases are a class of enzymes that remove acetyl groups from target proteins. The most abundant HDAC target is histones, but HDACs are known to deacetylate lysine residues from non-histone protein targets to temporarily regulate protein activity. As such, HDACs are sometimes referred to as lysine deacetylases. There are currently 13 known HDACs that fall into four main classes: Class I (HDACs 1, 2, 3, and 8), Class IIa (HDACs 4, 5, 7, and 9), and Class IIb (HDACs 6 and 10), Class III (sirt1-sirt7) and class IV (HDAC 11) [7]. Each class generally has a different tissue expression pattern and subcellular localization.</span>
  </p>
  <p id="p0126" num="0126" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La acetilación/desacetilación de proteínas se utiliza generalmente como un mecanismo de control postraduccional de la actividad de las proteínas. La acetilación/desacetilación de histona es un mecanismo bien establecido de regulación transcripcional. La regulación genética está causada por la escisión mediada por histona desacetilasa de un grupo acetilo de un s-N-acetilo de un aminoácido lisina en una cola de histona. La eliminación del grupo acetilo restaura la carga positiva a la cola de la histona, lo que conduce a una unión más favorable a la estructura principal del ADN del fosfodiéster con carga negativa. La unión mejorada conduce a una compactación cromosómica más estrecha y una reducción general de la expresión génica en el sitio de desacetilación de histonas.</span>Protein acetylation/deacetylation is generally used as a mechanism for post-translational control of protein activity. Histone acetylation/deacetylation is a well-established mechanism of transcriptional regulation. Gene regulation is caused by histone deacetylase-mediated cleavage of an acetyl group from an s-N-acetyl of an amino acid lysine on a histone tail. Removal of the acetyl group restores the positive charge to the histone tail, leading to more favorable binding to the negatively charged phosphodiester DNA backbone. The enhanced binding leads to tighter chromosomal compaction and an overall reduction in gene expression at the histone deacetylation site.</span>
  </p>
  <p id="p0127" num="0127" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La actividad de la histona desacetilasa se ha relacionado con una amplia gama de enfermedades y afecciones. La inhibición de la actividad de la histona desacetilasa se puede utilizar para aliviar o mejorar estas enfermedades o afecciones. Los paninhibidores de las histonas desacetilasas pueden ser útiles en el tratamiento o la prevención de enfermedades mediadas por HDAC. Los inhibidores de HDA<sup class="style-scope patent-text">c </sup>específicos de isoformas pueden ser útiles en el tratamiento o prevención de enfermedades mediadas por la actividad de isoformas de HDAC específicas.</span>Histone deacetylase activity has been linked to a wide range of diseases and conditions. Inhibition of histone deacetylase activity can be used to alleviate or ameliorate these diseases or conditions. Pan-inhibitors of histone deacetylases may be useful in the treatment or prevention of HDAC-mediated diseases. Isoform-specific HDA <sup class="style-scope patent-text">c</sup> inhibitors may be useful in the treatment or prevention of diseases mediated by the activity of specific HDAC isoforms.</span>
  </p>
  <p id="p0128" num="0128" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La inhibición de la actividad de HDAC es una modalidad de tratamiento establecida y varios inhibidores de HDAC son medicamentos aprobados, que incluyen: Vorinostat (CTCL), Romidepsin (CTCL), Chidamide (PTCL), Panobinostat (mieloma múltiple), Belinostat (linfoma de células T) y muchos están en ensayos clínicos, que incluyen: Panobinostat (CTCL), ácido valproico (cáncer de cuello uterino y cáncer de ovario, atrofia muscular espinal), Mocetinostat (linfoma folicular, linfoma de Hodgkin y leucemia mieloide aguda), Abexinostat (sarcoma), Entinostat (linfoma de Hodgkin, cáncer de pulmón y cáncer de mama), SB939 (cáncer de próstata recurrente o metastásico), 
Resminostat (linfoma de Hodgkin), Givinostat (leucemias y mielomas refractarios), HBI-800 (tumores sólidos avanzados que incluyen melanoma, carcinoma de células renales (RCC) y no Cáncer de pulmón de células pequeñas (NSCLC)), Kevetrina (cáncer de ovario), CUDC-101, AR-42 (mieloma múltiple en recaída o resistente al tratamiento, leucemia linfocítica crónica o linfoma), CHR-2845, CHR-3996, 4SC-202 (indicaciones hematológicas avanzadas), CG200745 (tumores sólidos), ACY-1215 (mieloma múltiple), ME-344 (tumores sólidos refractarios), sulforafano y Tricostatina (antiinflamatorio).</span>Inhibition of HDAC activity is an established treatment modality, and several HDAC inhibitors are approved medications, including: Vorinostat (CTCL), Romidepsin (CTCL), Chidamide (PTCL), Panobinostat (multiple myeloma), Belinostat (steroid lymphoma), T cells) and many are in clinical trials, including: Panobinostat (CTCL), Valproic Acid (cervical and ovarian cancer, spinal muscular atrophy), Mocetinostat (follicular lymphoma, Hodgkin's lymphoma, and acute myeloid leukemia), Abexinostat (sarcoma), Entinostat (Hodgkin's lymphoma, lung cancer, and breast cancer), SB939 (recurrent or metastatic prostate cancer),  Resminostat (Hodgkin's lymphoma), Givinostat (refractory leukemias and myelomas), HBI-800 (advanced solid tumors including melanoma, renal cell carcinoma (RCC) and non-small cell lung cancer (NSCLC)), Kevetrin (cancer of ovary), CUDC-101, AR-42 (relapsed or refractory multiple myeloma, chronic lymphocytic leukemia or lymphoma), CHR-2845, CHR-3996, 4SC-202 (advanced hematologic indications), CG200745 (solid tumors), ACY-1215 (multiple myeloma), ME-344 (refractory solid tumors), sulforaphane and Trichostatin (anti-inflammatory).</span>
  </p>
  <p id="p0130" num="0130" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplos de enfermedades o afecciones mediadas por la actividad de HDAC incluyen enfermedades neurodegenerativas, como la enfermedad de Alzheimer, la enfermedad de Huntington o la enfermedad de Parkinson, lesión cerebral, como accidente cerebrovascular, trastornos del comportamiento, como el trastorno por déficit de atención e hiperactividad, enfermedades inflamatorias del intestino, como la enfermedad de Crohn, cáncer, como cáncer de próstata, cáncer colorrectal, cáncer de mama, cáncer de pulmón, cáncer de hígado o cáncer gástrico. En determinadas realizaciones, las composiciones de la invención se utilizan para tratar o prevenir una de estas enfermedades o afecciones. En determinadas realizaciones, las composiciones de la invención se usan para tratar o prevenir una de estas enfermedades o afecciones mediadas por una actividad HDAC elevada. En determinadas realizaciones, las composiciones de la invención se usan para tratar o prevenir una de estas enfermedades o afecciones mediadas por una actividad elevada HDAC de clase I. En determinadas realizaciones, las composiciones de la invención se usan para tratar o prevenir una de estas enfermedades o afecciones mediadas por una actividad HDAC2 elevada.</span>Examples of diseases or conditions mediated by HDAC activity include neurodegenerative diseases, such as Alzheimer's disease, Huntington's disease, or Parkinson's disease, brain injury, such as stroke, behavioral disorders, such as attention deficit disorder, and hyperactivity, inflammatory bowel diseases, such as Crohn's disease, cancer, such as prostate cancer, colorectal cancer, breast cancer, lung cancer, liver cancer, or gastric cancer. In certain embodiments, the compositions of the invention are used to treat or prevent one of these diseases or conditions. In certain embodiments, the compositions of the invention are used to treat or prevent one of these diseases or conditions mediated by elevated HDAC activity. In certain embodiments, the compositions of the invention are used to treat or prevent one of these diseases or conditions mediated by elevated class I HDAC activity. In certain embodiments, the compositions of the invention are used to treat or prevent one of these diseases or conditions mediated by elevated HDAC2 activity.</span>
  </p>
  <p id="p0132" num="0132" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las composiciones de la invención son para uso en terapia. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento o prevención de una enfermedad o afección mediada por una actividad de HDAC elevada. En determinadas realizaciones, las composiciones de la invención son para uso en un método para reducir la actividad de HDAC en el tratamiento o prevención de una enfermedad o afección mediada por una actividad HDAC elevada. En algunas realizaciones, las composiciones de la invención son para uso en el tratamiento o prevención de una enfermedad o afección mediada por una actividad HDAC de Clase I elevada. En determinadas realizaciones, las composiciones de la invención son para uso en un método para inhibir la actividad de HDAC de Clase I. En determinadas realizaciones, las composiciones de la invención son para uso en un método para inhibir selectivamente la actividad de HDAC de Clase I en el tratamiento o prevención de una enfermedad o afección mediada por una actividad HDAC de Clase I elevada. Los inventores han identificado que determinadas composiciones de la invención inhiben selectivamente las HDAC de Clase I. Como se usa en el presente documento, "selectivo" se refiere a composiciones que tienen el mayor efecto inhibidor sobre las HDAC de Clase I, por ejemplo, en comparación con su efecto inhibidor de las HDAC de otras clases. La inhibición selectiva de las HDAC es ventajosa para el tratamiento de enfermedades que requieren la administración a largo plazo de un agente terapéutico, por ejemplo, cuando una enfermedad o afección necesita ser tratada a lo largo de la vida de un paciente. En determinadas realizaciones, las composiciones de la invención que son inhibidores selectivos de HDAC de Clase I son para uso en el tratamiento paliativo o la prevención de una enfermedad o afección mediada por una actividad de HDAC de Clase I elevada. Los inhibidores selectivos son ventajosos sobre los paninhibidores conocidos en la técnica al reducir los efectos secundarios asociados con la inhibición no deseada de otras clases de HDAC. En determinadas modalidades, los compuestos de la presente invención son inhibidores selectivos de HDAC2. En determinadas realizaciones, las composiciones de la invención son para uso en un método para reducir selectivamente la actividad de HDAC2. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento o prevención de una enfermedad mediada por una actividad de HDAC2 elevada.</span>In certain embodiments, the compositions of the invention are for use in therapy. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of a disease or condition mediated by elevated HDAC activity. In certain embodiments, the compositions of the invention are for use in a method of reducing HDAC activity in the treatment or prevention of a disease or condition mediated by elevated HDAC activity. In some embodiments, the compositions of the invention are for use in treating or preventing a disease or condition mediated by elevated Class I HDAC activity. In certain embodiments, compositions of the invention are for use in a method of inhibiting HDAC Class I activity. In certain embodiments, compositions of the invention are for use in a method of selectively inhibiting HDAC Class I activity. in the treatment or prevention of a disease or condition mediated by elevated Class I HDAC activity. The inventors have identified that certain compositions of the invention selectively inhibit Class I HDACs. As used herein, "selective" refers to compositions that have the greatest inhibitory effect on Class I HDACs, for example, in comparison with its inhibitory effect on HDACs of other classes. Selective inhibition of HDACs is advantageous for the treatment of diseases that require long-term administration of a therapeutic agent, for example, when a disease or condition needs to be treated throughout a patient's lifetime. In certain embodiments, compositions of the invention that are selective Class I HDAC inhibitors are for use in the palliative treatment or prevention of a disease or condition mediated by elevated Class I HDAC activity. Selective inhibitors are advantageous over art-known pan-inhibitors in reducing the side effects associated with undesired inhibition of other classes of HDACs. In certain embodiments, the compounds of the present invention are selective inhibitors of HDAC2. In certain embodiments, the compositions of the invention are for use in a method of selectively reducing HDAC2 activity. In certain embodiments, the compositions of the invention are for use in treating or preventing a disease mediated by elevated HDAC2 activity.</span>
  </p>
  <p id="p0134" num="0134" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Lesión cerebral</span>Brain injury</span>
      </i>
    </b>
  </p>
  <p id="p0136" num="0136" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los ejemplos demuestran que las composiciones de la invención son neuroprotectoras y tienen actividad inhibidora de HDAC. HDAC2 es una diana crucial para la recuperación funcional de un accidente cerebrovascular [18] y la inhibición de HDAC puede prevenir la lesión de la sustancia blanca [19], por tanto, las composiciones de la invención pueden ser útiles en el tratamiento de lesiones cerebrales.</span>The examples demonstrate that the compositions of the invention are neuroprotective and have HDAC inhibitory activity. HDAC2 is a crucial target for functional recovery from stroke [18] and inhibition of HDAC can prevent white matter injury [19], therefore, the compositions of the invention may be useful in the treatment of brain injuries .</span>
  </p>
  <p id="p0138" num="0138" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento de lesiones cerebrales. En algunas realizaciones, la lesión cerebral es una lesión cerebral traumática. En algunas realizaciones, la lesión cerebral es una lesión cerebral adquirida. En algunas realizaciones, las composiciones de la invención son para uso en el tratamiento de lesiones cerebrales resultantes de traumatismos. En algunas realizaciones, las composiciones de la invención son para uso en el tratamiento de lesiones cerebrales resultantes de un tumor. En algunas realizaciones, las composiciones de la invención son para uso en el tratamiento de lesiones cerebrales resultantes de un accidente cerebrovascular. En algunas realizaciones, las composiciones de la invención son para uso en el tratamiento de lesiones cerebrales resultantes de una hemorragia cerebral. En algunas realizaciones, las composiciones de la invención son para uso en el tratamiento de lesiones cerebrales resultantes de encefalitis. En algunas realizaciones, las composiciones de la invención son para uso en el tratamiento de lesiones cerebrales resultantes de hipoxia cerebral. En algunas realizaciones, las composiciones de la invención son para uso en el tratamiento de lesiones cerebrales resultantes de anoxia cerebral.</span>In certain embodiments, the compositions of the invention are for use in the treatment of brain injuries. In some embodiments, the brain injury is a traumatic brain injury. In some embodiments, the brain injury is an acquired brain injury. In some embodiments, the compositions of the invention are for use in treating brain injuries resulting from trauma. In some embodiments, the compositions of the invention are for use in treating brain lesions resulting from a tumor. In some embodiments, the compositions of the invention are for use in treating brain injury resulting from stroke. In some embodiments, the compositions of the invention are for use in treating brain injury resulting from cerebral hemorrhage. In some embodiments, the compositions of the invention are for use in treating brain injury resulting from encephalitis. In some embodiments, the compositions of the invention are for use in treating brain injury resulting from cerebral hypoxia. In some embodiments, the compositions of the invention are for use in treating brain injury resulting from cerebral anoxia.</span>
  </p>
  <p id="p0140" num="0140" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, las composiciones de la invención son para uso en el tratamiento de accidentes cerebrovasculares. Los efectos que se muestran en los ejemplos son particularmente relevantes para el tratamiento 
del accidente cerebrovascular. El accidente cerebrovascular ocurre cuando se interrumpe el flujo de sangre a al menos una parte del cerebro. Sin un suministro adecuado de sangre para proporcionar oxígeno y nutrientes al tejido cerebral y eliminar los productos de desecho del tejido cerebral, las células cerebrales comienzan a morir rápidamente. Los síntomas del accidente cerebrovascular dependen de la región del cerebro afectada por el flujo sanguíneo inadecuado. Los síntomas incluyen parálisis, entumecimiento o debilidad de los músculos, pérdida del equilibrio, mareos, dolores de cabeza repentinos intensos, dificultades en el habla, pérdida de la memoria, pérdida de la capacidad de razonamiento, confusión repentina, deterioro de la visión, coma o incluso la muerte. Un fallo cerebrovascular también se conoce como ataque cerebral o accidente cerebrovascular (CVA). Los síntomas del accidente cerebrovascular pueden ser breves si se restablece el flujo sanguíneo adecuado en un período corto de tiempo. Sin embargo, si el flujo sanguíneo inadecuado continúa durante un período de tiempo significativo, los síntomas pueden ser permanentes.</span>In preferred embodiments, the compositions of the invention are for use in the treatment of stroke. The effects shown in the examples are particularly relevant to the treatment  of cerebrovascular accident. Stroke occurs when blood flow to at least part of the brain is interrupted. Without an adequate supply of blood to provide oxygen and nutrients to brain tissue and remove waste products from brain tissue, brain cells begin to die rapidly. Stroke symptoms depend on the region of the brain affected by inadequate blood flow. Symptoms include paralysis, muscle numbness or weakness, loss of balance, dizziness, sudden severe headaches, slurred speech, memory loss, loss of reasoning ability, sudden confusion, impaired vision, coma or even death. Cerebrovascular failure is also known as a stroke or cerebrovascular accident (CVA). Stroke symptoms may be brief if adequate blood flow is restored within a short period of time. However, if the inadequate blood flow continues for a significant period of time, the symptoms may be permanent.</span>
  </p>
  <p id="p0142" num="0142" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En algunas realizaciones, el accidente cerebrovascular es isquemia cerebral. La isquemia cerebral se produce cuando hay un flujo sanguíneo insuficiente a los tejidos del cerebro para satisfacer la demanda metabólica. En algunas realizaciones, la isquemia cerebral es una isquemia cerebral focal, es decir, confinada a una región específica del cerebro. En algunas realizaciones, la isquemia cerebral es una isquemia cerebral global, es decir, que abarca un área amplia del tejido cerebral. La isquemia cerebral focal ocurre comúnmente cuando un vaso cerebral se bloquea, ya sea parcial o completamente, reduciendo el flujo de sangre a una región específica del cerebro. En algunas realizaciones, la isquemia cerebral focal es un accidente cerebrovascular isquémico. En algunas realizaciones, el accidente cerebrovascular isquémico es trombótico, es decir, causado por un trombo o coágulo de sangre, que se desarrolla en un vaso cerebral y restringe o bloquea el flujo sanguíneo. En algunas realizaciones, el accidente cerebrovascular isquémico es un accidente cerebrovascular trombótico. En algunas realizaciones, el accidente cerebrovascular isquémico es embólico, es decir, causado por un émbolo o una masa no adherida que viaja a través del torrente sanguíneo y restringe o bloquea el flujo sanguíneo en un sitio distante de su punto de origen. En algunas realizaciones, el accidente cerebrovascular isquémico es un accidente cerebrovascular embólico. La isquemia cerebral global ocurre comúnmente cuando el flujo sanguíneo al cerebro en su conjunto se bloquea o se reduce. En algunas realizaciones, la isquemia cerebral global está causada por hipoperfusión, es decir, debido a un choque. En algunas realizaciones, la isquemia cerebral global es el resultado de un paro cardíaco.</span>In some embodiments, the stroke is cerebral ischemia. Cerebral ischemia occurs when there is insufficient blood flow to brain tissues to meet metabolic demand. In some embodiments, the cerebral ischemia is focal cerebral ischemia, that is, confined to a specific region of the brain. In some embodiments, the cerebral ischemia is global cerebral ischemia, that is, encompassing a wide area of brain tissue. Focal cerebral ischemia commonly occurs when a brain vessel becomes blocked, either partially or completely, reducing blood flow to a specific region of the brain. In some embodiments, the focal cerebral ischemia is an ischemic stroke. In some embodiments, the ischemic stroke is thrombotic, that is, caused by a thrombus, or blood clot, developing in a cerebral vessel and restricting or blocking blood flow. In some embodiments, the ischemic stroke is a thrombotic stroke. In some embodiments, the ischemic stroke is embolic, that is, caused by an embolus or non-adherent mass traveling through the bloodstream and restricting or blocking blood flow at a site distant from its point of origin. In some embodiments, the ischemic stroke is an embolic stroke. Global cerebral ischemia commonly occurs when blood flow to the brain as a whole is blocked or reduced. In some embodiments, global cerebral ischemia is caused by hypoperfusion, ie, due to shock. In some embodiments, the global cerebral ischemia is the result of cardiac arrest.</span>
  </p>
  <p id="p0144" num="0144" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En algunas realizaciones, el sujeto diagnosticado con lesión cerebral ha sufrido isquemia cerebral. En algunas realizaciones, el sujeto diagnosticado con lesión cerebral ha sufrido isquemia cerebral focal. En algunas realizaciones, el sujeto diagnosticado con lesión cerebral ha sufrido un accidente cerebrovascular isquémico. En algunas realizaciones, el sujeto diagnosticado con lesión cerebral ha sufrido un accidente cerebrovascular trombótico. En algunas realizaciones, el sujeto diagnosticado con lesión cerebral ha sufrido un accidente cerebrovascular embólico. En algunas realizaciones, el sujeto diagnosticado con lesión cerebral ha sufrido isquemia cerebral global. En algunas realizaciones, el sujeto diagnosticado con lesión cerebral ha sufrido hipoperfusión. En algunas realizaciones, el sujeto diagnosticado con lesión cerebral ha sufrido un paro cardíaco.</span>In some embodiments, the subject diagnosed with brain injury has suffered from cerebral ischemia. In some embodiments, the subject diagnosed with brain injury has suffered from focal cerebral ischemia. In some embodiments, the subject diagnosed with brain injury has suffered an ischemic stroke. In some embodiments, the subject diagnosed with brain injury has suffered a thrombotic stroke. In some embodiments, the subject diagnosed with brain injury has suffered an embolic stroke. In some embodiments, the subject diagnosed with brain injury has suffered from global cerebral ischemia. In some embodiments, the subject diagnosed with brain injury has suffered from hypoperfusion. In some embodiments, the subject diagnosed with brain injury has suffered a cardiac arrest.</span>
  </p>
  <p id="p0146" num="0146" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En algunas realizaciones, las composiciones de la invención son para uso en el tratamiento de la isquemia cerebral. En algunas realizaciones, las composiciones de la invención son para uso en el tratamiento de la isquemia cerebral. En algunas realizaciones, las composiciones de la invención son para uso en el tratamiento del accidente cerebrovascular isquémico. En algunas realizaciones, las composiciones de la invención son para uso en el tratamiento del accidente cerebrovascular trombótico. En algunas realizaciones, las composiciones de la invención son para uso en el tratamiento del accidente cerebrovascular. En algunas realizaciones, las composiciones de la invención son para uso en el tratamiento de la isquemia cerebral. En algunas realizaciones, se proporcionan las composiciones de la invención para uso en el tratamiento de la hipoperfusión.</span>In some embodiments, the compositions of the invention are for use in the treatment of cerebral ischemia. In some embodiments, the compositions of the invention are for use in the treatment of cerebral ischemia. In some embodiments, the compositions of the invention are for use in the treatment of ischemic stroke. In some embodiments, the compositions of the invention are for use in the treatment of thrombotic stroke. In some embodiments, the compositions of the invention are for use in the treatment of stroke. In some embodiments, the compositions of the invention are for use in the treatment of cerebral ischemia. In some embodiments, compositions of the invention are provided for use in treating hypoperfusion.</span>
  </p>
  <p id="p0148" num="0148" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En algunas realizaciones, el accidente cerebrovascular es un accidente cerebrovascular hemorrágico. El accidente cerebrovascular hemorrágico es causado por una hemorragia en o alrededor del cerebro, lo que provoca hinchazón, presión y daño a las células y tejidos del cerebro. El accidente cerebrovascular hemorrágico es comúnmente el resultado de un vaso sanguíneo debilitado que se rompe y sangra en el cerebro circundante. En algunas realizaciones, el accidente cerebrovascular hemorrágico es una hemorragia intracerebral, es decir, causada por hemorragia dentro del propio tejido cerebral. En algunas realizaciones, la hemorragia intracerebral es causada por una hemorragia intraparenquimatosa. En algunas realizaciones, la hemorragia intracerebral es causada por una hemorragia intraventricular. En algunas realizaciones, el accidente cerebrovascular hemorrágico es una hemorragia subaracnoidea, es decir, una hemorragia que se produce fuera del tejido cerebral pero todavía dentro del cráneo. En algunas realizaciones, el accidente cerebrovascular hemorrágico es el resultado de una angiopatía amiloide cerebral. En algunas realizaciones, el accidente cerebrovascular hemorrágico es el resultado de un aneurisma cerebral. En algunas realizaciones, el accidente cerebrovascular hemorrágico es el resultado de una malformación arteriovenosa cerebral (AVM).</span>In some embodiments, the stroke is a hemorrhagic stroke. Hemorrhagic stroke is caused by bleeding in or around the brain, causing swelling, pressure, and damage to brain cells and tissues. Hemorrhagic stroke is commonly the result of a weakened blood vessel that ruptures and bleeds into the surrounding brain. In some embodiments, the hemorrhagic stroke is an intracerebral hemorrhage, ie, caused by hemorrhage within the brain tissue itself. In some embodiments, the intracerebral hemorrhage is caused by intraparenchymal hemorrhage. In some embodiments, the intracerebral hemorrhage is caused by an intraventricular hemorrhage. In some embodiments, the hemorrhagic stroke is a subarachnoid hemorrhage, ie, a hemorrhage that occurs outside of brain tissue but still within the skull. In some embodiments, the hemorrhagic stroke is the result of cerebral amyloid angiopathy. In some embodiments, the hemorrhagic stroke is the result of a brain aneurysm. In some embodiments, the hemorrhagic stroke is the result of a cerebral arteriovenous malformation (AVM).</span>
  </p>
  <p id="p0150" num="0150" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En algunas realizaciones, el sujeto diagnosticado con lesión cerebral ha sufrido un accidente cerebrovascular hemorrágico. En algunas realizaciones, el sujeto diagnosticado con lesión cerebral ha sufrido una hemorragia intracerebral. En algunas realizaciones, el sujeto diagnosticado con lesión cerebral ha sufrido una hemorragia intraparenquimal. En algunas realizaciones, el sujeto diagnosticado con lesión cerebral ha sufrido una hemorragia intraventricular. En algunas realizaciones, el sujeto diagnosticado con lesión cerebral ha sufrido una hemorragia subaracnoide. En algunas realizaciones, el sujeto diagnosticado con lesión cerebral ha sufrido angiopatía amiloide 
cerebral. En algunas realizaciones, el sujeto diagnosticado con lesión cerebral ha sufrido un aneurisma cerebral. En algunas realizaciones, el sujeto diagnosticado con lesión cerebral ha sufrido AVM cerebral.</span>In some embodiments, the subject diagnosed with brain injury has suffered a hemorrhagic stroke. In some embodiments, the subject diagnosed with brain injury has suffered an intracerebral hemorrhage. In some embodiments, the subject diagnosed with brain injury has suffered an intraparenchymal hemorrhage. In some embodiments, the subject diagnosed with brain injury has suffered an intraventricular hemorrhage. In some embodiments, the subject diagnosed with brain injury has suffered a subarachnoid hemorrhage. In some embodiments, the subject diagnosed with brain injury has suffered from amyloid angiopathy.  cerebral. In some embodiments, the subject diagnosed with brain injury has suffered a brain aneurysm. In some embodiments, the subject diagnosed with brain injury has suffered cerebral AVM.</span>
  </p>
  <p id="p0152" num="0152" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En algunas realizaciones, las composiciones de la invención son para uso en el tratamiento del accidente cerebrovascular hemorrágico. En algunas realizaciones, las composiciones de la invención son para uso en el tratamiento de una hemorragia intracerebral. En algunas realizaciones, las composiciones de la invención son para uso en el tratamiento de una hemorragia intraparenquimal. En algunas realizaciones, las composiciones de la invención son para uso en el tratamiento de una hemorragia intraventricular. En algunas realizaciones, las composiciones de la invención son para uso en el tratamiento de una hemorragia subaracnoide. En algunas realizaciones, las composiciones de la invención son para uso en el tratamiento de una angiopatía amiloide cerebral. En algunas realizaciones, las composiciones de la invención son para uso en el tratamiento de un aneurisma cerebral. En algunas realizaciones, las composiciones de la invención son para uso en el tratamiento de AVM cerebral.</span>In some embodiments, the compositions of the invention are for use in the treatment of hemorrhagic stroke. In some embodiments, the compositions of the invention are for use in treating intracerebral hemorrhage. In some embodiments, the compositions of the invention are for use in treating intraparenchymal hemorrhage. In some embodiments, the compositions of the invention are for use in the treatment of intraventricular hemorrhage. In some embodiments, the compositions of the invention are for use in the treatment of subarachnoid hemorrhage. In some embodiments, the compositions of the invention are for use in treating cerebral amyloid angiopathy. In some embodiments, the compositions of the invention are for use in treating a brain aneurysm. In some embodiments, the compositions of the invention are for use in treating cerebral AVM.</span>
  </p>
  <p id="p0154" num="0154" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La restauración del flujo sanguíneo adecuado al cerebro después de un período de interrupción, aunque es eficaz para aliviar los síntomas asociados con el accidente cerebrovascular, paradójicamente puede resultar en más daño al tejido cerebral. Durante el período de interrupción, el tejido afectado sufre de falta de oxígeno y nutrientes, y la restauración repentina del flujo sanguíneo puede resultar en inflamación y daño oxidativo a través de la inducción de estrés oxidativo. Esto se conoce como lesión por reperfusión y está bien documentado no solo después de un accidente cerebrovascular, sino también después de un ataque cardíaco u otro daño tisular cuando el suministro de sangre vuelve al tejido después de un período de isquemia o falta de oxígeno. En algunas realizaciones, el sujeto diagnosticado con lesión cerebral ha sufrido una lesión por reperfusión como resultado de un accidente cerebrovascular. En algunas realizaciones, las composiciones de la invención son para uso en el tratamiento de la lesión por reperfusión como resultado de un accidente cerebrovascular.</span>Restoring adequate blood flow to the brain after a period of interruption, while effective in relieving symptoms associated with stroke, can paradoxically result in further damage to brain tissue. During the interruption period, the affected tissue suffers from a lack of oxygen and nutrients, and the sudden restoration of blood flow can result in inflammation and oxidative damage through the induction of oxidative stress. This is known as reperfusion injury and is well documented not only after stroke, but also after heart attack or other tissue damage when the blood supply returns to the tissue after a period of ischemia or lack of oxygen. In some embodiments, the subject diagnosed with brain injury has suffered a reperfusion injury as a result of a stroke. In some embodiments, the compositions of the invention are for use in treating reperfusion injury as a result of stroke.</span>
  </p>
  <p id="p0156" num="0156" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Un ataque isquémico transitorio (TIA), a menudo denominado mini accidente cerebrovascular, es una señal de advertencia reconocida de un accidente cerebrovascular más grave. Los sujetos que han sufrido uno o más TIA tienen, por tanto, un mayor riesgo de sufrir un accidente cerebrovascular. En algunas realizaciones, el sujeto diagnosticado con lesión cerebral ha sufrido un TIA. En algunas realizaciones, se proporcionan las composiciones de la presente invención para uso en el tratamiento de un TIA. En algunas realizaciones, las composiciones de la invención son para uso en el tratamiento de una lesión cerebral en un sujeto que ha sufrido un TIA.</span>A transient ischemic attack (TIA), often referred to as a mini-stroke, is a recognized warning sign of a more serious stroke. Subjects who have suffered one or more TIAs are therefore at increased risk of stroke. In some embodiments, the subject diagnosed with brain injury has suffered a TIA. In some embodiments, the compositions of the present invention are provided for use in treating a TIA. In some embodiments, the compositions of the invention are for use in treating brain injury in a subject who has suffered a TIA.</span>
  </p>
  <p id="p0158" num="0158" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Presión arterial alta, colesterol alto en sangre, antecedentes familiares de accidente cerebrovascular, enfermedad cardíaca, diabetes, aneurismas cerebrales, malformaciones arteriovenosas, enfermedad de células falciformes, vasculitis, trastornos hemorrágicos, uso de antiinflamatorios no esteroideos (NSAID), fumar tabaco, el consumo de grandes cantidades de alcohol, el consumo de drogas ilegales, la obesidad, la falta de actividad física y una dieta poco saludable se consideran factores de riesgo de accidente cerebrovascular. En particular, se ha demostrado de manera concluyente que la disminución de la presión arterial previene los accidentes cerebrovasculares isquémicos y hemorrágicos [20, 21]. En algunas realizaciones, las composiciones de la invención son para uso en el tratamiento de una lesión cerebral en un sujeto que tiene al menos un factor de riesgo de accidente cerebrovascular. En algunas realizaciones, el sujeto tiene dos factores de riesgo de accidente cerebrovascular. En algunas realizaciones, el sujeto tiene tres factores de riesgo de accidente cerebrovascular. En algunas realizaciones, el sujeto tiene cuatro factores de riesgo de accidente cerebrovascular. En algunas realizaciones, el sujeto tiene más de cuatro factores de riesgo de accidente cerebrovascular. En algunas realizaciones, el sujeto tiene presión arterial alta. En algunas realizaciones, el sujeto tiene colesterol en sangre alto. En algunas realizaciones, el sujeto tiene antecedentes familiares de accidente cerebrovascular. En algunas realizaciones, el sujeto también presenta enfermedad cardíaca. En algunas realizaciones, el sujeto padece diabetes. En algunas realizaciones, el sujeto tiene un aneurisma cerebral. En algunas realizaciones, el sujeto tiene malformaciones arteriovenosas. En algunas realizaciones, el sujeto tiene vasculitis. En algunas realizaciones, el sujeto tiene anemia de células falciformes. En algunas realizaciones, el sujeto tiene un trastorno hemorrágico. En algunas realizaciones, el sujeto tiene un historial de uso de fármacos antiinflamatorios no esteroideos (NSAID). En algunas realizaciones, el sujeto fuma tabaco. En algunas realizaciones, el sujeto bebe grandes cantidades de alcohol. En algunas realizaciones, el sujeto usa drogas ilegales. En algunas realizaciones, el sujeto es obeso. En algunas realizaciones, el sujeto tiene sobrepeso. En algunas realizaciones, el sujeto carece de actividad física. En algunas realizaciones, el sujeto tiene una dieta poco saludable.</span>High blood pressure, high blood cholesterol, family history of stroke, heart disease, diabetes, brain aneurysms, arteriovenous malformations, sickle cell disease, vasculitis, bleeding disorders, use of nonsteroidal anti-inflammatory drugs (NSAIDs), tobacco smoking, use of Heavy drinking, illegal drug use, obesity, lack of physical activity, and an unhealthy diet are considered risk factors for stroke. In particular, lowering blood pressure has been conclusively shown to prevent ischemic and hemorrhagic strokes [20, 21]. In some embodiments, the compositions of the invention are for use in treating brain injury in a subject having at least one risk factor for stroke. In some embodiments, the subject has two risk factors for stroke. In some embodiments, the subject has three risk factors for stroke. In some embodiments, the subject has four risk factors for stroke. In some embodiments, the subject has more than four risk factors for stroke. In some embodiments, the subject has high blood pressure. In some embodiments, the subject has high blood cholesterol. In some embodiments, the subject has a family history of stroke. In some embodiments, the subject also has heart disease. In some embodiments, the subject has diabetes. In some embodiments, the subject has a brain aneurysm. In some embodiments, the subject has arteriovenous malformations. In some embodiments, the subject has vasculitis. In some embodiments, the subject has sickle cell anemia. In some embodiments, the subject has a bleeding disorder. In some embodiments, the subject has a history of nonsteroidal anti-inflammatory drug (NSAID) use. In some embodiments, the subject smokes tobacco. In some embodiments, the subject drinks large amounts of alcohol. In some embodiments, the subject uses illegal drugs. In some embodiments, the subject is obese. In some embodiments, the subject is overweight. In some embodiments, the subject lacks physical activity. In some embodiments, the subject has an unhealthy diet.</span>
  </p>
  <p id="p0160" num="0160" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los ejemplos indican que las composiciones de la invención pueden ser útiles para tratar lesiones cerebrales y ayudar a la recuperación cuando se administran antes de que ocurra la lesión. Por lo tanto, las composiciones de la invención pueden ser particularmente útiles para tratar lesiones cerebrales cuando se administran a sujetos con riesgo de lesión cerebral, como accidente cerebrovascular.</span>The examples indicate that the compositions of the invention may be useful in treating brain injuries and aiding recovery when administered before the injury occurs. Therefore, the compositions of the invention may be particularly useful for treating brain injury when administered to subjects at risk of brain injury, such as stroke.</span>
  </p>
  <p id="p0162" num="0162" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las composiciones de la invención son para uso en la reducción del daño causado por una posible lesión cerebral, preferiblemente un accidente cerebrovascular. Las composiciones pueden reducir el daño causado cuando se administran antes de que se produzca la posible lesión cerebral, en particular cuando se administran a un paciente identificado como con riesgo de lesión cerebral.</span>In certain embodiments, the compositions of the invention are for use in reducing damage caused by possible brain injury, preferably stroke. The compositions may reduce the damage caused when administered before possible brain injury occurs, particularly when administered to a patient identified as being at risk for brain injury.</span>
  </p>
  <p id="p0164" num="0164" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los ejemplos indican que las composiciones de la invención pueden ser útiles para tratar lesiones cerebrales y ayudar a la recuperación cuando se administran después de que ocurra la lesión. Por lo tanto, las composiciones de 
la invención pueden ser particularmente útiles para tratar lesiones cerebrales cuando se administran a sujetos después de una lesión cerebral, como accidente cerebrovascular.</span>The examples indicate that the compositions of the invention may be useful for treating brain injuries and aiding recovery when administered after the injury has occurred. Therefore, the compositions of  the invention may be particularly useful for treating brain injuries when administered to subjects following brain injury, such as stroke.</span>
  </p>
  <p id="p0166" num="0166" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En algunas realizaciones, las composiciones de la invención tratan la lesión cerebral reduciendo el daño motor. En algunas realizaciones, las composiciones de la invención tratan la lesión cerebral mejorando la función motora. En algunas realizaciones, las composiciones de la invención tratan la lesión cerebral mejorando la resistencia del músculo. En algunas realizaciones, las composiciones de la invención tratan la lesión cerebral mejorando la memoria. En algunas realizaciones, las composiciones de la invención tratan la lesión cerebral mejorando el reconocimiento social. En algunas realizaciones, las composiciones de la invención tratan la lesión cerebral mejorando la función neurológica.</span>In some embodiments, the compositions of the invention treat brain injury by reducing motor damage. In some embodiments, the compositions of the invention treat brain injury by improving motor function. In some embodiments, the compositions of the invention treat brain injury by improving muscle endurance. In some embodiments, the compositions of the invention treat brain injury by improving memory. In some embodiments, the compositions of the invention treat brain injury by improving social recognition. In some embodiments, the compositions of the invention treat brain injury by improving neurological function.</span>
  </p>
  <p id="p0168" num="0168" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El tratamiento de la lesión cerebral puede referirse, por ejemplo, al alivio de la gravedad de los síntomas. El tratamiento de la lesión cerebral también puede referirse a la reducción de las deficiencias neurológicas que siguen a un accidente cerebrovascular. Las composiciones de la invención para su uso en el tratamiento de un accidente cerebrovascular se pueden proporcionar al sujeto antes del inicio del accidente cerebrovascular, por ejemplo, en un paciente identificado como con riesgo de accidente cerebrovascular. Las composiciones de la invención para uso en el tratamiento de un accidente cerebrovascular se pueden proporcionar después de que ha ocurrido un accidente cerebrovascular, por ejemplo, durante la recuperación. Las composiciones de la invención para uso en el tratamiento de un accidente cerebrovascular se pueden proporcionar durante la fase aguda de recuperación (es decir, hasta una semana después del accidente cerebrovascular). Las composiciones de la invención para uso en el tratamiento de un accidente cerebrovascular se pueden proporcionar durante la fase subaguda de recuperación (es decir, de una semana hasta tres meses después del accidente cerebrovascular). Las composiciones de la invención para uso en el tratamiento de un accidente cerebrovascular se pueden proporcionar durante la fase crónica de recuperación (desde tres meses después del accidente cerebrovascular).</span>Treatment of brain injury may refer, for example, to alleviating the severity of symptoms. Treatment of brain injury can also refer to the reduction of neurological deficits that follow a stroke. Compositions of the invention for use in the treatment of stroke may be provided to the subject prior to the onset of stroke, for example, in a patient identified as being at risk for stroke. Compositions of the invention for use in treating stroke may be provided after a stroke has occurred, for example during recovery. Compositions of the invention for use in the treatment of stroke can be provided during the acute phase of recovery (ie, up to one week after the stroke). Compositions of the invention for use in treating stroke may be provided during the subacute phase of recovery (ie, one week to three months after stroke). Compositions of the invention for use in the treatment of stroke can be provided during the chronic phase of recovery (from three months after the stroke).</span>
  </p>
  <p id="p0170" num="0170" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las composiciones de la invención son para uso en combinación con un agente activo secundario. En determinadas realizaciones, las composiciones de la invención son para uso en combinación con aspirina o activador de plasminógeno tisular (tPA). Otros agentes secundarios incluyen otros antiagregantes plaquetarios (como clopidogrel), anticoagulantes (como heparinas, warfarina, apixabán, dabigatrán, edoxabán o rivaroxabán), antihipertensivos (como diuréticos, inhibidores de la ACE, bloqueantes de los canales del calcio, betabloqueantes o alfabloqueantes) o estatinas. Las composiciones de la invención pueden mejorar la respuesta del paciente al agente activo secundario.</span>In certain embodiments, the compositions of the invention are for use in combination with a secondary active agent. In certain embodiments, the compositions of the invention are for use in combination with aspirin or tissue plasminogen activator (tPA). Other secondary agents include other antiplatelet agents (such as clopidogrel), anticoagulants (such as heparins, warfarin, apixaban, dabigatran, edoxaban, or rivaroxaban), antihypertensives (such as diuretics, ACE inhibitors, calcium channel blockers, beta-blockers, or alpha-blockers), or statins. The compositions of the invention may improve the patient's response to the secondary active agent.</span>
  </p>
  <p id="p0172" num="0172" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las composiciones de la invención reducen el efecto de la isquemia en los tejidos. En determinadas realizaciones, las composiciones de la invención reducen la cantidad de daño a los tejidos causado por la isquemia. En determinadas realizaciones, los tejidos dañados por isquemia son los tejidos cerebrales. En determinadas realizaciones, las composiciones de la invención reducen la necrosis o el número de células necróticas. En determinadas realizaciones, las composiciones de la invención reducen la apoptosis o el número de células apoptóticas. En determinadas realizaciones, las composiciones de la invención reducen el número de células necróticas y células apoptóticas. En determinadas realizaciones, las composiciones de la invención previenen la muerte celular por necrosis y/o apoptosis. En determinadas realizaciones, las composiciones de la invención previenen la muerte celular por necrosis y/o apoptosis causada por isquemia. En determinadas realizaciones, las composiciones de la invención mejoran la recuperación del tejido dañado por isquemia. En determinadas realizaciones, las composiciones de la invención mejoran la velocidad de aclaramiento de las células necróticas y/o células apoptóticas. En determinadas realizaciones, las composiciones de la invención mejoran la eficacia de aclaramiento de las células necróticas y/o células apoptóticas. En determinadas realizaciones, las composiciones de la invención mejoran la sustitución y/o regeneración de células dentro de los tejidos. En determinadas realizaciones, las composiciones de la invención mejoran la sustitución y/o regeneración de células dentro de los tejidos dañados por isquemia. En determinadas realizaciones, las composiciones de la invención mejoran la histología global del tejido (por ejemplo, tras una biopsia).</span>In certain embodiments, the compositions of the invention reduce the effect of ischemia on tissues. In certain embodiments, the compositions of the invention reduce the amount of tissue damage caused by ischemia. In certain embodiments, the tissues damaged by ischemia are brain tissues. In certain embodiments, the compositions of the invention reduce necrosis or the number of necrotic cells. In certain embodiments, the compositions of the invention reduce apoptosis or the number of apoptotic cells. In certain embodiments, the compositions of the invention reduce the number of necrotic cells and apoptotic cells. In certain embodiments, the compositions of the invention prevent cell death by necrosis and/or apoptosis. In certain embodiments, the compositions of the invention prevent cell death by necrosis and/or apoptosis caused by ischemia. In certain embodiments, the compositions of the invention enhance the recovery of tissue damaged by ischemia. In certain embodiments, the compositions of the invention improve the rate of clearance of necrotic cells and/or apoptotic cells. In certain embodiments, the compositions of the invention improve the clearance efficiency of necrotic cells and/or apoptotic cells. In certain embodiments, the compositions of the invention enhance the replacement and/or regeneration of cells within tissues. In certain embodiments, the compositions of the invention enhance cell replacement and/or regeneration within ischemia-damaged tissues. In certain embodiments, the compositions of the invention improve the overall histology of the tissue (eg, after biopsy).</span>
  </p>
  <p id="p0174" num="0174" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los ejemplos demuestran que las composiciones de la invención activan la activación de MAP2 (proteína 2 asociada a microtúbulos). MAP2 es un gen asociado con la diferenciación neuronal de MAP2 y se cree que es esencial para la formación de microtúbulos en neuritogénesis, por lo que las composiciones de la invención pueden ser particularmente útiles para tratar lesiones cerebrales. En algunas realizaciones, las composiciones de la invención son para uso en el tratamiento de lesiones cerebrales activando o aumentando los niveles de MAP2. Además, como MAP2 promueve el crecimiento de neuritas, que desempeñan un papel importante en la redistribución de neuronas dañadas y la sinaptogénesis, la expresión de MAP2 podría ir más allá de ser un marcador de diferenciación neuronal e indicar un "recableado neuronal" asociado con el resultado terapéutico de la enfermedad neuropatológica [22]. </span>The examples demonstrate that the compositions of the invention promote the activation of MAP2 (microtubule-associated protein 2). MAP2 is a gene associated with MAP2 neuronal differentiation and is believed to be essential for microtubule formation in neuritogenesis, thus compositions of the invention may be particularly useful for treating brain injury. In some embodiments, the compositions of the invention are for use in treating brain injury by activating or increasing levels of MAP2. Furthermore, as MAP2 promotes the growth of neurites, which play an important role in the redistribution of damaged neurons and synaptogenesis, the expression of MAP2 could go beyond being a marker of neuronal differentiation and indicate "neuronal rewiring" associated with the therapeutic outcome of neuropathological disease [22].</span>
  </p>
  <p id="p0175" num="0175" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Trastornos inflamatorios y autoinmunitarios</span>Inflammatory and autoimmune disorders</span>
      </i>
    </b>
  </p>
  <p id="p0177" num="0177" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los ejemplos demuestran que las composiciones de la invención tienen actividad inhibidora de HDAC. La actividad de HDAC es fundamental para la patología de muchos trastornos inflamatorios y autoinmunitarios, y los inhibidores de HDAC han demostrado eficacia en el tratamiento de muchos trastornos inflamatorios y autoinmunes, como se analiza a continuación en relación con afecciones específicas (ver también [23]). Por tanto, las composiciones de la 
invención pueden ser útiles para tratar trastornos inflamatorios y autoinmunitarios, en particular trastornos inflamatorios y autoinmunitarios mediados por una actividad elevada de histona desacetilasa (HDAC).</span>The examples demonstrate that the compositions of the invention have HDAC inhibitory activity. HDAC activity is central to the pathology of many inflammatory and autoimmune disorders, and HDAC inhibitors have demonstrated efficacy in the treatment of many inflammatory and autoimmune disorders, as discussed below in relation to specific conditions (see also [23]). ). Therefore, the compositions of the  invention may be useful for treating inflammatory and autoimmune disorders, in particular inflammatory and autoimmune disorders mediated by elevated histone deacetylase (HDAC) activity.</span>
  </p>
  <p id="p0178" num="0178" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las composiciones de la invención son para uso en un método para tratar o prevenir un trastorno inflamatorio o autoinmunitario. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento o prevención de una enfermedad inflamatoria o autoinmune, en donde dicho tratamiento o prevención se logra reduciendo o previniendo la activación de HDAC. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento de un paciente con una enfermedad inflamatoria o autoinmune, en donde el paciente tiene niveles o actividad elevados de HDAC. En determinadas realizaciones, el paciente puede haber sido diagnosticado con una enfermedad o afección inflamatoria o autoinmune crónica, o la composición de la invención puede ser para uso en la prevención de una enfermedad o afección inflamatoria o autoinmune que se convierte en una enfermedad o afección inflamatoria o autoinmune crónica. En determinadas realizaciones, la enfermedad o afección puede no responder al tratamiento con inhibidores de TNF-a.</span>In certain embodiments, the compositions of the invention are for use in a method of treating or preventing an inflammatory or autoimmune disorder. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of an inflammatory or autoimmune disease, wherein said treatment or prevention is achieved by reducing or preventing HDAC activation. In certain embodiments, the compositions of the invention are for use in treating a patient with an inflammatory or autoimmune disease, where the patient has elevated HDAC levels or activity. In certain embodiments, the patient may have been diagnosed with a chronic inflammatory or autoimmune disease or condition, or the composition of the invention may be for use in preventing an inflammatory or autoimmune disease or condition from developing into an inflammatory disease or condition. or chronic autoimmune. In certain embodiments, the disease or condition may not respond to treatment with TNF-α inhibitors.</span>
  </p>
  <p id="p0179" num="0179" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La HDAC puede estar asociada con enfermedades autoinmunes e inflamatorias crónicas, por lo que las composiciones de la invención pueden ser particularmente útiles para tratar o prevenir enfermedades o afecciones crónicas enumeradas anteriormente. En determinadas realizaciones, las composiciones son para uso en pacientes con enfermedades crónicas. En determinadas realizaciones, las composiciones son para uso en la prevención del desarrollo de enfermedades crónicas.</span>HDAC may be associated with autoimmune and chronic inflammatory diseases, thus the compositions of the invention may be particularly useful for treating or preventing chronic diseases or conditions listed above. In certain embodiments, the compositions are for use in patients with chronic diseases. In certain embodiments, the compositions are for use in preventing the development of chronic diseases.</span>
  </p>
  <p id="p0180" num="0180" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las composiciones de la invención pueden ser útiles para tratar enfermedades y afecciones mediadas por HDAC y para abordar la activación de HDAC, por lo que las composiciones de la invención pueden ser particularmente útiles para tratar o prevenir enfermedades crónicas, tratar o prevenir enfermedades en pacientes que no han respondido a otras terapias (como el tratamiento con inhibidores de TNF-a), y/o tratar o prevenir el daño tisular y los síntomas asociados con HDAC.</span>The compositions of the invention may be useful in treating diseases and conditions mediated by HDACs and in addressing HDAC activation, thus the compositions of the invention may be particularly useful in treating or preventing chronic diseases, treating or preventing diseases in patients who have not responded to other therapies (such as treatment with TNF-a inhibitors), and/or treat or prevent the tissue damage and symptoms associated with HDAC.</span>
  </p>
  <p id="p0181" num="0181" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los ejemplos demuestran que las composiciones de la invención reducen la producción y secreción de IL-6, lo que puede ser particularmente útil para tratar trastornos inflamatorios y autoinmunitarios. En determinadas realizaciones, las composiciones de la invención son para uso en la reducción la inflamación en el tratamiento de enfermedades. En determinadas realizaciones, las composiciones de la invención reducen la producción y secreción de IL-6. En determinadas realizaciones, las composiciones de la invención disminuyen la activación del promotor NF<sup class="style-scope patent-text">k</sup>B. En determinadas realizaciones, las composiciones de la invención pueden modular la activación de la producción de IL-6 por el potente lipopolisacárido de endotoxina proinflamatorio (LPS).</span>The examples demonstrate that the compositions of the invention reduce the production and secretion of IL-6, which may be particularly useful in treating inflammatory and autoimmune disorders. In certain embodiments, the compositions of the invention are for use in reducing inflammation in the treatment of disease. In certain embodiments, the compositions of the invention reduce the production and secretion of IL-6. In certain embodiments, compositions of the invention decrease activation of the NF <sup class="style-scope patent-text">k</sup> B promoter. In certain embodiments, compositions of the invention can modulate activation of IL-6 production by the potent proinflammatory endotoxin lipopolysaccharide (LPS).</span>
  </p>
  <p id="p0182" num="0182" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- Enfermedad intestinal inflamatoria</span>- Inflammatory bowel disease</span>
    </b>
  </p>
  <p id="p0183" num="0183" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los ejemplos demuestran que las composiciones de la invención tienen actividad inhibidora de HDAC, por lo que pueden ser útiles en el tratamiento de la enfermedad inflamatoria intestinal. La sobreexpresión de diferentes isoformas de HDAC se ha implicado en una variedad de patologías de enfermedades, incluida la colitis. Además, el ácido valproico se ha asociado con la inhibición de HDAC de clase I y la mejora de la colitis en un modelo murino de colitis por DSS [24]. Este estudio sugirió un papel para los inhibidores de HDAC clase I en la supresión de IFN-<sup class="style-scope patent-text">y</sup>, IL-10, IL-1p y TNF-a, asignando funcionalidad a la inhibición de HDAC y eficacia en la colitis. Por tanto, los ejemplos indican que las composiciones de la invención pueden ser útiles para tratar enfermedades inflamatorias del intestino. En determinadas realizaciones, las composiciones de la invención se utilizan para tratar o prevenir la enfermedad inflamatoria intestinal. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento o prevención de la enfermedad inflamatoria intestinal, en donde dicho tratamiento o prevención se logra reduciendo o previniendo la activación de HDAC. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento de un paciente con una enfermedad inflamatoria intestinal, en donde el paciente tiene niveles o actividad elevada de HDAC.</span>The examples demonstrate that the compositions of the invention have HDAC inhibitory activity, thus they may be useful in the treatment of inflammatory bowel disease. Overexpression of different HDAC isoforms has been implicated in a variety of disease pathologies, including colitis. Furthermore, valproic acid has been associated with class I HDAC inhibition and colitis improvement in a mouse model of DSS colitis [24]. This study suggested a role for HDAC class I inhibitors in suppressing IFN <sup class="style-scope patent-text">and</sup> IL-10, IL-1p and TNF-a, assigning functionality to HDAC inhibition and efficacy in colitis. Thus, the examples indicate that the compositions of the invention may be useful for treating inflammatory bowel diseases. In certain embodiments, the compositions of the invention are used to treat or prevent inflammatory bowel disease. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of inflammatory bowel disease, wherein said treatment or prevention is achieved by reducing or preventing HDAC activation. In certain embodiments, the compositions of the invention are for use in treating a patient with inflammatory bowel disease, where the patient has elevated HDAC levels or activity.</span>
  </p>
  <p id="p0184" num="0184" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La enfermedad inflamatoria intestinal (IBD) es una enfermedad compleja que puede ser causada por múltiples factores ambientales y genéticos. Los factores que contribuyen a la aparición de la IBD incluyen la dieta, la microbiota, la permeabilidad intestinal y la susceptibilidad genética a una respuesta inflamatoria aumentada a la infección intestinal. Los síntomas de la enfermedad inflamatoria intestinal incluyen dolor abdominal, vómitos, diarrea, sangrado rectal, calambres internos graves/espasmos musculares en la región pélvica, pérdida de peso y anemia. En determinadas realizaciones, las composiciones son para uso en la reducción de uno o más síntomas asociados con la IBD. En determinadas realizaciones, las composiciones de la invención son para uso en la prevención de uno o más síntomas de IBD.</span>Inflammatory bowel disease (IBD) is a complex disease that can be caused by multiple environmental and genetic factors. Factors that contribute to the development of IBD include diet, microbiota, intestinal permeability, and genetic susceptibility to an increased inflammatory response to intestinal infection. Symptoms of IBD include abdominal pain, vomiting, diarrhea, rectal bleeding, severe internal cramps/muscle spasms in the pelvic region, weight loss, and anemia. In certain embodiments, the compositions are for use in reducing one or more symptoms associated with IBD. In certain embodiments, the compositions of the invention are for use in preventing one or more symptoms of IBD.</span>
  </p>
  <p id="p0185" num="0185" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La IBD puede acompañar a otras enfermedades o afecciones, como artritis, pioderma gangrenoso, colangitis esclerosante primaria, síndrome de enfermedad no tiroidea, trombosis venosa profunda, bronquiolitis obliterante con neumonía organizada. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento o la prevención de una o más enfermedades o afecciones que acompañan a la IBD.</span>IBD may accompany other diseases or conditions, including arthritis, pyoderma gangrenosum, primary sclerosing cholangitis, nonthyroidal illness syndrome, deep vein thrombosis, bronchiolitis obliterans with organizing pneumonia. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of one or more diseases or conditions that accompany IBD.</span>
  </p>
  <p id="p0186" num="0186" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La enfermedad inflamatoria intestinal generalmente se diagnostica mediante biopsia o colonoscopia. Las mediciones de calprotectina fecal son útiles para el diagnóstico preliminar de la IBD. Otras pruebas de laboratorio para el diagnóstico de IBD incluyen, hemograma completo, velocidad de sedimentación de eritrocitos, panel metabólico 
completo, prueba de sangre oculta en heces o prueba de proteína C reactiva. Normalmente se utilizará una combinación de pruebas de laboratorio y biopsia/colonoscopia para confirmar el diagnóstico de IBD. En determinadas realizaciones, las composiciones de la invención son para uso en un sujeto diagnosticado con IBD. En determinadas realizaciones, la enfermedad inflamatoria intestinal es la enfermedad de Crohn. Los estudios han mostrado que varias HDAC se regulan positivamente en la muscosa inflamatoria de los pacientes con enfermedad de Crohn. Por tanto, la inhibición de la actividad de HDAC puede ser útil en el tratamiento de la enfermedad de Crohn. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento o prevención de la enfermedad de Crohn.</span>Inflammatory bowel disease is usually diagnosed by biopsy or colonoscopy. Fecal calprotectin measurements are useful for the preliminary diagnosis of IBD. Other laboratory tests for the diagnosis of IBD include, complete blood count, erythrocyte sedimentation rate, metabolic panel  complete, fecal occult blood test, or C-reactive protein test. A combination of laboratory tests and biopsy/colonoscopy will normally be used to confirm the diagnosis of IBD. In certain embodiments, the compositions of the invention are for use in a subject diagnosed with IBD. In certain embodiments, the inflammatory bowel disease is Crohn's disease. Studies have shown that several HDACs are upregulated in the inflammatory muscosa of Crohn's disease patients. Therefore, inhibition of HDAC activity may be useful in the treatment of Crohn's disease. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of Crohn's disease.</span>
  </p>
  <p id="p0187" num="0187" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La enfermedad de Crohn es una enfermedad compleja con una variedad de causas probables, incluidos los factores de riesgo genéticos, la dieta, otros factores del estilo de vida, como el tabaquismo y el consumo de alcohol, y la composición del microbioma. La enfermedad de Crohn puede manifestarse en cualquier parte del tracto gastrointestinal.</span>Crohn's disease is a complex disease with a variety of probable causes, including genetic risk factors, diet, other lifestyle factors such as smoking and alcohol consumption, and the composition of the microbiome. Crohn's disease can manifest in any part of the gastrointestinal tract.</span>
  </p>
  <p id="p0188" num="0188" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los síntomas gastrointestinales de la enfermedad de Crohn varían de leves a graves e incluyen dolor abdominal, diarrea, sangre fecal, ileítis, aumento de los movimientos intestinales, aumento de la flatulencia, estenosis intestinal, vómitos y malestar perianal. Las composiciones de la invención pueden ser para uso en el tratamiento de la prevención de uno o más síntomas gastrointestinales de la enfermedad de Crohn.</span>Gastrointestinal symptoms of Crohn's disease range from mild to severe and include abdominal pain, diarrhea, fecal blood, ileitis, increased bowel movements, increased flatulence, intestinal stricture, vomiting, and perianal discomfort. The compositions of the invention may be for use in the treatment of prevention of one or more gastrointestinal symptoms of Crohn's disease.</span>
  </p>
  <p id="p0189" num="0189" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los síntomas sistémicos de la enfermedad de Crohn incluyen defectos de crecimiento, como la incapacidad de mantener el crecimiento durante la pubertad, disminución del apetito, fiebre y pérdida de peso. Las características extra-intestinales de la enfermedad de Crohn incluyen uveítis, fotofobia, epiescleritis, cálculos biliares, espondiloartropatía seronegativa, artritis, entesitis, eritema nudoso, pioderma gangrenoso, trombosis venosa profunda, embolia pulmonar, anemia hemolítica autoinmune, dedos hipocráticos y osteoporosis. Las características extra-intestinales son afecciones adicionales asociadas con la enfermedad de Crohn que se manifiestan fuera del tracto GI. Los sujetos con enfermedad de Crohn también exhiben una mayor susceptibilidad a complicaciones neurológicas como convulsiones, accidentes cerebrovasculares, miopatía, neuropatía periférica, dolor de cabeza y depresión. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento o prevención de uno o más síntomas sistémicos de la enfermedad de Crohn. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento o prevención de una o más características extra­ intestinales de la enfermedad de Crohn.</span>Systemic symptoms of Crohn's disease include growth defects, such as failure to maintain growth during puberty, decreased appetite, fever, and weight loss. Extra-intestinal features of Crohn's disease include uveitis, photophobia, episcleritis, gallstones, seronegative spondyloarthropathy, arthritis, enthesitis, erythema nodosum, pyoderma gangrenosum, deep vein thrombosis, pulmonary embolism, autoimmune hemolytic anemia, hippocratic fingers, and osteoporosis. Extra-intestinal features are additional conditions associated with Crohn's disease that manifest outside the GI tract. Individuals with Crohn's disease also exhibit increased susceptibility to neurological complications such as seizures, stroke, myopathy, peripheral neuropathy, headache, and depression. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of one or more systemic symptoms of Crohn's disease. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of one or more extraintestinal features of Crohn's disease.</span>
  </p>
  <p id="p0190" num="0190" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El diagnóstico de la enfermedad de Crohn suele implicar la realización de múltiples pruebas y procedimientos quirúrgicos, como la gastroscopia y/o colonoscopia y biopsia, típicamente del íleon, pruebas radiológicas, hemogramas completos, pruebas de proteína C reactiva y velocidades de sedimentación de eritrocitos. En determinadas realizaciones, las composiciones de la invención son para uso en sujetos diagnosticados con la enfermedad de Crohn. En algunas realizaciones, las composiciones de la invención son para uso en el tratamiento de un sujeto que ha sido diagnosticado con enfermedad de Crohn.</span>The diagnosis of Crohn's disease usually involves multiple tests and surgical procedures, such as gastroscopy and/or colonoscopy and biopsy, typically of the ileum, radiological tests, complete blood counts, C-reactive protein tests, and erythrocyte sedimentation rates. In certain embodiments, the compositions of the invention are for use in subjects diagnosed with Crohn's disease. In some embodiments, the compositions of the invention are for use in treating a subject who has been diagnosed with Crohn's disease.</span>
  </p>
  <p id="p0191" num="0191" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La enfermedad de Crohn se clasifica según la extensión de la región del tracto GI afectada [25]. Una enfermedad tanto del íleon como del colon se clasifica como enfermedad de Crohn ileocólica. En algunas realizaciones, las composiciones son para uso en el tratamiento o prevención de la enfermedad de Crohn ileocólica. En algunas realizaciones, las composiciones son para uso en un sujeto diagnosticado con enfermedad de Crohn ileocólica/ileítis de Crohn se clasifica si sólo está afectado el íleon. La colitis de Crohn se clasifica si solo se ve afectado el colon. En determinadas realizaciones, las composiciones son para uso en el tratamiento o la prevención de la ileítis de Crohn. En algunas realizaciones, las composiciones son para uso en un sujeto diagnosticado con ileítis de Crohn. En determinadas realizaciones, las composiciones son para uso en el tratamiento o la prevención de la colitis de Crohn. En algunas realizaciones, las composiciones son para uso en un sujeto diagnosticado con colitis de Crohn.</span>Crohn's disease is classified according to the extent of the affected region of the GI tract [25]. A disease of both the ileum and the colon is classified as ileocolic Crohn's disease. In some embodiments, the compositions are for use in the treatment or prevention of ileocolic Crohn's disease. In some embodiments, the compositions are for use in a subject diagnosed with ileocolic Crohn's disease/Crohn's ileitis is classified if only the ileum is affected. Crohn's colitis is classified if only the colon is affected. In certain embodiments, the compositions are for use in the treatment or prevention of Crohn's ileitis. In some embodiments, the compositions are for use in a subject diagnosed with Crohn's ileitis. In certain embodiments, the compositions are for use in the treatment or prevention of Crohn's colitis. In some embodiments, the compositions are for use in a subject diagnosed with Crohn's colitis.</span>
  </p>
  <p id="p0192" num="0192" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La enfermedad de Crohn se puede tratar con varios agentes terapéuticos, como corticosteroides, como prednisona, agentes inmunosupresores, como azatioprina, o biológicos, como infliximab, adalimumab y golimumab, vedolizumab y etrolizumab. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento o la prevención de la enfermedad de Crohn en combinación con un agente terapéutico adicional. En determinadas realizaciones, el agente terapéutico adicional es para uso en el tratamiento o la prevención de la enfermedad de Crohn.</span>Crohn's disease can be treated with various therapeutic agents, including corticosteroids such as prednisone, immunosuppressive agents such as azathioprine, or biologics such as infliximab, adalimumab and golimumab, vedolizumab and etrolizumab. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of Crohn's disease in combination with an additional therapeutic agent. In certain embodiments, the additional therapeutic agent is for use in the treatment or prevention of Crohn's disease.</span>
  </p>
  <p id="p0193" num="0193" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los ejemplos demuestran que las composiciones de la invención reducen la expresión modular de IDO1 en el intestino, lo que puede ser particularmente útil para tratar enfermedades inflamatorias del intestino. En determinadas realizaciones, las composiciones de la invención aumentan la expresión de IDO1.</span>The examples demonstrate that the compositions of the invention reduce the modulatory expression of IDO1 in the intestine, which may be particularly useful for treating inflammatory bowel diseases. In certain embodiments, the compositions of the invention increase the expression of IDO1.</span>
  </p>
  <p id="p0194" num="0194" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- Esclerosis múltiple</span>- Multiple sclerosis</span>
    </b>
  </p>
  <p id="p0195" num="0195" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La esclerosis múltiple (MS) es un trastorno inflamatorio autoinmune del sistema nervioso central. La MS puede modelarse en animales mediante la inducción de encefalomielitis autoinmune experimental (EAE). Se ha demostrado que los inhibidores de HDAC reducen los síntomas clínicos e inhiben el progreso de la enfermedad en ratones con EAE adoptiva (Dasgupta et al., 2003, J Immunol, 170 (7), 3874-3882). También se ha demostrado que la inyección de un inhibidor de HDAc reduce significativamente el deterioro neurológico y la discapacidad en ratones 
con un modelo experimental de MS crónica (Camelo et al., 2005, J Neuroimmunol, 164 (1-2), 10-21). Se ha sugerido que la inhibición de la actividad de HDAC es una terapia prometedora para la MS (Gray et al., 2006, Epigenetics, 1:2, 67-75). Por tanto, las composiciones de la invención pueden ser útiles para tratar o prevenir la esclerosis múltiple en un sujeto.</span>Multiple sclerosis (MS) is an inflammatory autoimmune disorder of the central nervous system. MS can be modeled in animals by the induction of experimental autoimmune encephalomyelitis (EAE). HDAC inhibitors have been shown to reduce clinical symptoms and inhibit disease progress in mice with adoptive EAE (Dasgupta et al., 2003, J Immunol, 170(7), 3874-3882). Injection of an HDAc inhibitor has also been shown to significantly reduce neurological impairment and disability in mice.  with an experimental model of chronic MS (Camelo et al., 2005, J Neuroimmunol, 164 (1-2), 10-21). Inhibition of HDAC activity has been suggested as a promising therapy for MS (Gray et al., 2006, Epigenetics, 1:2, 67-75). Thus, the compositions of the invention may be useful for treating or preventing multiple sclerosis in a subject.</span>
  </p>
  <p id="p0196" num="0196" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento o prevención de la esclerosis múltiple, en donde dicho tratamiento o prevención se logra reduciendo o previniendo la activación de HDAC. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento de un paciente con esclerosis múltiple, en donde el paciente tiene niveles o actividad elevada de HDAC.</span>In certain embodiments, the compositions of the invention are for use in the treatment or prevention of multiple sclerosis, wherein said treatment or prevention is achieved by reducing or preventing HDAC activation. In certain embodiments, the compositions of the invention are for use in treating a patient with multiple sclerosis, where the patient has elevated HDAC levels or activity.</span>
  </p>
  <p id="p0197" num="0197" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, las composiciones de la invención son para uso en el tratamiento o prevención de la esclerosis múltiple. Las composiciones de la invención pueden lograr la inhibición de HDAC y, por tanto, pueden ser útiles en el tratamiento o la prevención de la esclerosis múltiple. La esclerosis múltiple es un trastorno inflamatorio asociado con daño a las vainas de mielina de las neuronas, particularmente en el cerebro y la columna vertebral. La esclerosis múltiple es una enfermedad crónica, progresivamente incapacitante y que evoluciona en episodios.</span>In preferred embodiments, the compositions of the invention are for use in the treatment or prevention of multiple sclerosis. Compositions of the invention may achieve HDAC inhibition and thus may be useful in the treatment or prevention of multiple sclerosis. Multiple sclerosis is an inflammatory disorder associated with damage to the myelin sheaths of neurons, particularly in the brain and spinal cord. Multiple sclerosis is a chronic, progressively disabling disease that evolves in episodes.</span>
  </p>
  <p id="p0198" num="0198" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, el tratamiento con las composiciones de la invención da como resultado una reducción en la incidencia de la enfermedad o en la gravedad de la enfermedad. En determinadas realizaciones, las composiciones de la invención son para uso en la reducción de la incidencia o la gravedad de la enfermedad. En determinadas realizaciones, el tratamiento con las composiciones de la invención evita una disminución de la función motora o da como resultado una función motora mejorada. En determinadas realizaciones, las composiciones de la invención son para uso en la prevención de una disminución de la función motora o para uso en la mejora de la función motora. En determinadas realizaciones, el tratamiento con las composiciones de la invención previene el desarrollo de parálisis. En determinadas realizaciones, las composiciones de la invención son para uso en la prevención de la parálisis en el tratamiento de la esclerosis múltiple.</span>In certain embodiments, treatment with the compositions of the invention results in a reduction in the incidence of the disease or in the severity of the disease. In certain embodiments, the compositions of the invention are for use in reducing the incidence or severity of disease. In certain embodiments, treatment with the compositions of the invention prevents a decrease in motor function or results in improved motor function. In certain embodiments, the compositions of the invention are for use in preventing decreased motor function or for use in improving motor function. In certain embodiments, treatment with the compositions of the invention prevents the development of paralysis. In certain embodiments, the compositions of the invention are for use in the prevention of paralysis in the treatment of multiple sclerosis.</span>
  </p>
  <p id="p0199" num="0199" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las composiciones de la invención pueden ser útiles para modular el sistema inmunológico de un paciente, por lo que en ciertas realizaciones las composiciones de la invención son para uso en la prevención de la esclerosis múltiple en un paciente que ha sido identificado como en riesgo de esclerosis múltiple o que ha sido diagnosticado con esclerosis múltiple en etapa temprana o esclerosis múltiple "remitente-recidivante". Las composiciones de la invención pueden ser útiles para prevenir el desarrollo de esclerosis.</span>The compositions of the invention may be useful for modulating the immune system of a patient, thus in certain embodiments the compositions of the invention are for use in preventing multiple sclerosis in a patient who has been identified as being at risk for multiple sclerosis. multiple sclerosis or who has been diagnosed with early-stage multiple sclerosis or "relapsing-remitting" multiple sclerosis. The compositions of the invention may be useful in preventing the development of sclerosis.</span>
  </p>
  <p id="p0200" num="0200" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las composiciones de la invención pueden ser útiles para tratar o aliviar la esclerosis múltiple. Las composiciones de la invención pueden ser particularmente útiles para reducir los síntomas asociados con la esclerosis múltiple. El tratamiento o la prevención de la esclerosis múltiple puede referirse, por ejemplo, a un alivio de la gravedad de los síntomas o una reducción de la frecuencia de las exacerbaciones o del rango de desencadenantes que son un problema para el paciente.</span>The compositions of the invention may be useful for treating or alleviating multiple sclerosis. The compositions of the invention may be particularly useful in reducing symptoms associated with multiple sclerosis. Treatment or prevention of multiple sclerosis may refer, for example, to alleviating the severity of symptoms or reducing the frequency of exacerbations or the range of triggers that are a problem for the patient.</span>
  </p>
  <p id="p0201" num="0201" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- Artritis</span>- Arthritis</span>
    </b>
  </p>
  <p id="p0202" num="0202" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La artritis es una enfermedad caracterizada por una inflamación crónica de las articulaciones. La artritis reumatoide es un trastorno autoinmune crónico que generalmente produce articulaciones inflamadas y dolorosas. Se ha propuesto la inhibición de HDAC para tratar la artritis reumatoide mediante una variedad de mecanismos, que incluyen influir en la producción de ciOCDinas, inhibir la diferenciación de células T, suprimir la proliferación de fibroblastos sinoviales y reducir la pérdida ósea al influir en los osteoclastos y osteoblastos (Vojinov et al., 2011, Mol Med, 17 (5-6) 397-403). Se ha demostrado que la inhibición de HDAC tiene un fuerte efecto antiinflamatorio en varios modelos animales de artritis (Joosten et al., 2011, Mol Med, 17 (5-6), 391-396). Por tanto, las composiciones de la invención pueden ser útiles para tratar o prevenir la artritis en un sujeto.</span>Arthritis is a disease characterized by chronic inflammation of the joints. Rheumatoid arthritis is a chronic autoimmune disorder that typically results in swollen and painful joints. Inhibition of HDAC has been proposed to treat rheumatoid arthritis through a variety of mechanisms, including influencing cyOCDin production, inhibiting T-cell differentiation, suppressing synovial fibroblast proliferation, and reducing bone loss by influencing osteoclasts. and osteoblasts (Vojinov et al., 2011, Mol Med, 17(5-6) 397-403). HDAC inhibition has been shown to have a strong anti-inflammatory effect in various animal models of arthritis (Joosten et al., 2011, Mol Med, 17(5-6), 391-396). Thus, the compositions of the invention may be useful for treating or preventing arthritis in a subject.</span>
  </p>
  <p id="p0203" num="0203" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, las composiciones de la invención se utilizan para tratar o prevenir la artritis reumatoide (RA). En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento o prevención de la artritis reumatoide, en donde dicho tratamiento o prevención se logra reduciendo o previniendo la activación de HDAC. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento de un paciente con artritis reumatoide, en donde el paciente tiene niveles o actividad de HDAC elevada.</span>In preferred embodiments, the compositions of the invention are used to treat or prevent rheumatoid arthritis (RA). In certain embodiments, the compositions of the invention are for use in the treatment or prevention of rheumatoid arthritis, wherein said treatment or prevention is achieved by reducing or preventing HDAC activation. In certain embodiments, the compositions of the invention are for use in treating a patient with rheumatoid arthritis, where the patient has elevated HDAC levels or activity.</span>
  </p>
  <p id="p0204" num="0204" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, el tratamiento con las composiciones de la invención da como resultado una reducción de la inflamación de las articulaciones. En determinadas realizaciones, las composiciones de la invención son para uso en pacientes con articulaciones inflamadas o pacientes identificados con riesgo de tener articulaciones inflamadas. En determinadas realizaciones, las composiciones de la invención son para uso en un método para reducir la inflamación de las articulaciones en la RA.</span>In certain embodiments, treatment with the compositions of the invention results in a reduction in joint inflammation. In certain embodiments, the compositions of the invention are for use in patients with swollen joints or patients identified as being at risk of having swollen joints. In certain embodiments, the compositions of the invention are for use in a method of reducing joint inflammation in RA.</span>
  </p>
  <p id="p0205" num="0205" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, el tratamiento con las composiciones de la invención da como resultado una reducción del daño del cartílago o del hueso. En determinadas realizaciones, las composiciones de la invención son para uso en la reducción o prevención del daño del cartílago o del hueso en el tratamiento de la RA. En determinadas realizaciones, las composiciones son para uso en el tratamiento de pacientes con RA grave que tienen riesgo de daño en el cartílago o los huesos. 
</span>In certain embodiments, treatment with the compositions of the invention results in a reduction in cartilage or bone damage. In certain embodiments, the compositions of the invention are for use in reducing or preventing cartilage or bone damage in the treatment of RA. In certain embodiments, the compositions are for use in treating patients with severe RA who are at risk of cartilage or bone damage. </span>
  </p>
  <p id="p0206" num="0206" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las composiciones de la invención son para uso en la prevención de la parálisis en la erosión ósea o daño del cartílago en el tratamiento de RA. En determinadas realizaciones, las composiciones son para uso en el tratamiento de pacientes que presentan erosión ósea o daño del cartílago o pacientes identificados con riesgo de erosión ósea o daño del cartílago.</span>In certain embodiments, the compositions of the invention are for use in preventing paralysis in bone erosion or cartilage damage in the treatment of RA. In certain embodiments, the compositions are for use in treating patients exhibiting bone erosion or cartilage damage or patients identified as being at risk for bone erosion or cartilage damage.</span>
  </p>
  <p id="p0207" num="0207" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las composiciones de la invención pueden ser útiles para modular el sistema inmunológico de un paciente, por lo que en ciertas realizaciones las composiciones de la invención son para uso en la prevención de la RA en un paciente que ha sido identificado como en riesgo de padecer RA, o que ha sido diagnosticado con RA en etapa temprana. Las composiciones de la invención pueden ser útiles para prevenir el desarrollo de RA.</span>The compositions of the invention may be useful for modulating the immune system of a patient, so in certain embodiments the compositions of the invention are for use in preventing RA in a patient who has been identified as being at risk for RA. , or who has been diagnosed with early-stage RA. The compositions of the invention may be useful in preventing the development of RA.</span>
  </p>
  <p id="p0208" num="0208" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las composiciones de la invención pueden ser útiles para manejar o aliviar la RA. Las composiciones de la invención pueden ser particularmente útiles para reducir los síntomas asociados con la inflamación de las articulaciones o la destrucción de los huesos. El tratamiento o la prevención de la RA puede referirse, por ejemplo, a un alivio de la gravedad de los síntomas o una reducción de la frecuencia de las exacerbaciones o del rango de desencadenantes que son un problema para el paciente.</span>The compositions of the invention may be useful for managing or alleviating RA. The compositions of the invention may be particularly useful in reducing symptoms associated with joint inflammation or bone destruction. Treatment or prevention of AR may refer, for example, to alleviating the severity of symptoms or reducing the frequency of exacerbations or the range of triggers that are a problem for the patient.</span>
  </p>
  <p id="p0209" num="0209" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- Asma</span>- Asthma</span>
    </b>
  </p>
  <p id="p0210" num="0210" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El asma es una enfermedad respiratoria inflamatoria crónica. Se ha demostrado que los inhibidores de HDAC tienen efectos antiinflamatorios que alivian la inflamación de las vías respiratorias, la remodelación de las vías respiratorias y la hipersensibilidad de las vías respiratorias en un modelo de ratón con asma crónica (Ren et al., 2016, Inflamm Res, 65, 995-1008). Por tanto, las composiciones de la invención pueden ser útiles para tratar o prevenir el asma en un sujeto.</span>Asthma is a chronic inflammatory respiratory disease. HDAC inhibitors have been shown to have anti-inflammatory effects that alleviate airway inflammation, airway remodeling, and airway hyperresponsiveness in a mouse model of chronic asthma (Ren et al., 2016, Inflamm Res, 65, 995-1008). Thus, the compositions of the invention may be useful for treating or preventing asthma in a subject.</span>
  </p>
  <p id="p0211" num="0211" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, las composiciones de la invención son para uso para tratar o prevenir el asma. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento o prevención del asma, en donde dicho tratamiento o prevención se logra reduciendo o previniendo la activación de HDAC. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento de un paciente con asma reumatoide, en donde el paciente tiene niveles o actividad de HDAC elevada.</span>In preferred embodiments, the compositions of the invention are for use in treating or preventing asthma. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of asthma, wherein said treatment or prevention is achieved by reducing or preventing HDAC activation. In certain embodiments, the compositions of the invention are for use in treating a patient with rheumatoid asthma, where the patient has elevated HDAC levels or activity.</span>
  </p>
  <p id="p0212" num="0212" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, el asma es asma eosinofílica o alérgica. El asma eosinofílica y alérgica se caracteriza por un mayor número de eosinófilos en la sangre periférica y en las secreciones de las vías respiratorias y se asocia patológicamente con el engrosamiento de la zona de la membrana basal y farmacológicamente por la respuesta a los corticosteroides [26]. Las composiciones que reducen o inhiben el reclutamiento o activación de eosinófilos pueden ser útiles para tratar o prevenir el asma eosinofílica y alérgica. El asma eosinofílica y alérgica también se caracteriza por una cascada de eventos inflamatorios mediados por procesos de linfocitos T helper tipo 2 (Th2). Las composiciones que reducen o inhiben los procesos de los linfocitos T helper tipo 2 (Th2) pueden ser útiles para tratar o prevenir el asma eosinofílica y alérgica.</span>In certain embodiments, the asthma is eosinophilic or allergic asthma. Eosinophilic and allergic asthma is characterized by increased numbers of eosinophils in peripheral blood and airway secretions and is associated pathologically with thickening of the basement membrane zone and pharmacologically by response to corticosteroids [26] . Compositions that reduce or inhibit eosinophil recruitment or activation may be useful in treating or preventing eosinophilic and allergic asthma. Eosinophilic and allergic asthma is also characterized by a cascade of inflammatory events mediated by T helper type 2 (Th2) lymphocyte processes. Compositions that reduce or inhibit T helper type 2 (Th2) cell processes may be useful in treating or preventing eosinophilic and allergic asthma.</span>
  </p>
  <p id="p0213" num="0213" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones adicionales, las composiciones de la invención se utilizan para uso en el tratamiento o prevención del asma neutrofílica (o asma no eosinofílica). Un número elevado de neutrófilos se asocia con un asma grave que puede ser insensible al tratamiento con corticosteroides. Las composiciones que reducen o inhiben el reclutamiento o activación de neutrófilos pueden ser útiles para tratar o prevenir el asma neutrofílica.</span>In further embodiments, the compositions of the invention are for use in the treatment or prevention of neutrophilic asthma (or non-eosinophilic asthma). An elevated number of neutrophils is associated with severe asthma that may be unresponsive to corticosteroid treatment. Compositions that reduce or inhibit neutrophil recruitment or activation may be useful in treating or preventing neutrophilic asthma.</span>
  </p>
  <p id="p0214" num="0214" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El asma eosinofílica (también denominada asma Th2-alta) y el asma neutrofílica (también denominada asma Th2-baja o no Th2) tienen diferentes mecanismos fisiopatológicos subyacentes y presentan diferentes características clínicas. Por ejemplo, el asma con niveles altos de Th2 generalmente presenta un inicio temprano y presenta variaciones estacionales de los síntomas, mientras que el asma con niveles bajos de Th2 tiene un inicio mucho más tardío, generalmente alrededor de los 40 años o más tarde. El asma con niveles elevados de Th2 también se caracteriza por un aumento de los niveles sanguíneos de inmunoglobulina E (IgE), mientras que esta característica está ausente en el asma con niveles bajos de Th2. El asma alta Th2 también se caracteriza por niveles elevados de eosinófilos en el esputo. Por el contrario, el asma con niveles bajos de Th2 puede caracterizarse por niveles elevados de neutrófilos en el esputo. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento del asma con niveles bajos de Th2 o sin Th2. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento del asma con niveles altos de Th2.</span>Eosinophilic asthma (also called Th2-high asthma) and neutrophilic asthma (also called Th2-low or non-Th2 asthma) have different underlying pathophysiological mechanisms and present different clinical features. For example, high Th2 asthma typically has an early onset and seasonal variations in symptoms, whereas low Th2 asthma has a much later onset, usually around age 40 or later. Th2-elevated asthma is also characterized by increased blood levels of immunoglobulin E (IgE), whereas this feature is absent in Th2-low asthma. Th2 high asthma is also characterized by elevated levels of sputum eosinophils. In contrast, asthma with low Th2 levels may be characterized by elevated levels of neutrophils in the sputum. In certain embodiments, the compositions of the invention are for use in the treatment of asthma with low levels of Th2 or without Th2. In certain embodiments, the compositions of the invention are for use in the treatment of asthma with high Th2 levels.</span>
  </p>
  <p id="p0215" num="0215" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El asma eosinofílica y neutrofílica no son afecciones mutuamente excluyentes y los tratamientos que ayudan a abordar las respuestas de eosinófilos y neutrófilos pueden ser útiles para tratar el asma en general.</span>Eosinophilic and neutrophilic asthma are not mutually exclusive conditions, and treatments that help address eosinophil and neutrophil responses may be helpful in treating asthma in general.</span>
  </p>
  <p id="p0216" num="0216" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las composiciones de la invención son para uso en métodos que reducen una respuesta inflamatoria eosinofílica en el tratamiento o prevención del asma, o para uso en métodos de reducción de una respuesta inflamatoria neutrofílica en el tratamiento o prevención del asma. Como se señaló anteriormente, los niveles altos de eosinófilos en el asma se asocian patológicamente con el engrosamiento de la zona de la membrana basal, por lo que la reducción de la respuesta inflamatoria eosinofílica en el tratamiento o la prevención del asma puede abordar específicamente esta característica de la enfermedad. Además, los neutrófilos elevados, ya sea en combinación con eosinófilos elevados o en su ausencia, se asocian con asma grave y estrechamiento crónico de las vías respiratorias. Por lo tanto, la reducción de la respuesta inflamatoria neutrofílica puede ser particularmente útil para tratar el asma grave. 
</span>In certain embodiments, the compositions of the invention are for use in methods of reducing an eosinophilic inflammatory response in the treatment or prevention of asthma, or for use in methods of reducing a neutrophilic inflammatory response in the treatment or prevention of asthma. As noted above, high levels of eosinophils in asthma are pathologically associated with thickening of the basement membrane zone, so reducing the eosinophilic inflammatory response in the treatment or prevention of asthma may specifically address this feature. of the illness. Furthermore, elevated neutrophils, either in combination with elevated eosinophils or in their absence, are associated with severe asthma and chronic narrowing of the airways. Therefore, reducing the neutrophilic inflammatory response may be particularly useful in treating severe asthma. </span>
  </p>
  <p id="p0217" num="0217" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las composiciones reducen la infiltración peribronquiolar en el asma alérgica o son para uso para reducir la infiltración peribronquiolar en el tratamiento del asma alérgica. En determinadas realizaciones, las composiciones reducen la infiltración peribronquiolar y/o perivascular en el asma neutrofílica, o se usan para reducir la infiltración peribronquiolar y/o perivascular en el tratamiento del asma alérgica neutrofílica. En determinadas realizaciones, el tratamiento con composiciones de la invención proporciona una reducción o previene una elevación de los niveles de TNFa.</span>In certain embodiments, the compositions reduce peribronchiolar infiltration in allergic asthma or are for use in reducing peribronchiolar infiltration in the treatment of allergic asthma. In certain embodiments, the compositions reduce peribronchiolar and/or perivascular infiltration in neutrophilic asthma, or are used to reduce peribronchiolar and/or perivascular infiltration in the treatment of allergic neutrophilic asthma. In certain embodiments, treatment with compositions of the invention provides a reduction or prevents an elevation of TNFa levels.</span>
  </p>
  <p id="p0218" num="0218" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las composiciones de la invención son para uso en un método de tratamiento del asma que da como resultado una reducción de la respuesta inflamatoria eosinofílica y/o neutrofílica. En determinadas realizaciones, el paciente que se va a tratar tiene, o se ha identificado previamente que tiene, niveles elevados de neutrófilos o eosinófilos, por ejemplo, según se identifica mediante muestreo de sangre o análisis de esputo. Las composiciones de la invención pueden ser útiles para prevenir el desarrollo de asma en un recién nacido cuando se administran a un recién nacido o a una mujer embarazada. Las composiciones pueden ser útiles para prevenir el desarrollo de asma en niños. Las composiciones de la invención pueden ser útiles para tratar o prevenir el asma de inicio en la edad adulta. Las composiciones de la invención pueden ser útiles para manejar o aliviar el asma. Las composiciones de la invención pueden ser particularmente útiles para reducir los síntomas asociados con el asma agravada por alérgenos, tales como los ácaros del polvo doméstico.</span>In certain embodiments, the compositions of the invention are for use in a method of treating asthma that results in a reduction of the eosinophilic and/or neutrophilic inflammatory response. In certain embodiments, the patient to be treated has, or has been previously identified as having, elevated levels of neutrophils or eosinophils, eg, as identified by blood sampling or sputum analysis. The compositions of the invention may be useful in preventing the development of asthma in a newborn when administered to a newborn or pregnant woman. The compositions may be useful in preventing the development of asthma in children. The compositions of the invention may be useful for treating or preventing adult-onset asthma. The compositions of the invention may be useful for managing or alleviating asthma. The compositions of the invention may be particularly useful in reducing symptoms associated with asthma aggravated by allergens, such as house dust mites.</span>
  </p>
  <p id="p0219" num="0219" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El tratamiento o la prevención del asma puede referirse, por ejemplo, a un alivio de la gravedad de los síntomas o una reducción de la frecuencia de las exacerbaciones o del rango de desencadenantes que son un problema para el paciente.</span>Treatment or prevention of asthma may refer, for example, to alleviating the severity of symptoms or reducing the frequency of exacerbations or the range of triggers that are a problem for the patient.</span>
  </p>
  <p id="p0220" num="0220" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- Psoriasis</span>- psoriasis</span>
    </b>
  </p>
  <p id="p0221" num="0221" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La psoriasis es una enfermedad inflamatoria crónica de la piel. Se ha informado de sobreexpresión de HDAC1 en biopsias de piel de pacientes psoriásicos (Tovar-Castillo et al., 2007, Int J Dermatol, 46, 239-46) y se ha mostrado que un inhibidor de HDAC bloquea la conversión de Foxp3  Tregs en Foxp3-RORYt  IL-17/Tregs (un cambio asociado con la progresión de la psoriasis) (Bovenschen et al., 2011, J Invest Dermatol, 131, 1853-60). Por tanto, las composiciones de la invención pueden ser útiles para tratar o prevenir la psoriasis en un sujeto.</span>Psoriasis is a chronic inflammatory disease of the skin. Overexpression of HDAC1 has been reported in skin biopsies from psoriatic patients (Tovar-Castillo et al., 2007, Int J Dermatol, 46, 239-46) and an HDAC inhibitor has been shown to block the conversion of Foxp3 Tregs into Foxp3-RORYt IL-17/Tregs (a change associated with psoriasis progression) (Bovenschen et al., 2011, J Invest Dermatol, 131, 1853-60). Thus, the compositions of the invention may be useful for treating or preventing psoriasis in a subject.</span>
  </p>
  <p id="p0222" num="0222" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, las composiciones de la invención son para uso en el tratamiento o prevención de la psoriasis. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento o prevención de la psoriasis, en donde dicho tratamiento o prevención se logra reduciendo o previniendo la activación de HDAC. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento de un paciente con psoriasis, en donde el paciente tiene niveles o actividad de HDAC elevada.</span>In preferred embodiments, the compositions of the invention are for use in the treatment or prevention of psoriasis. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of psoriasis, wherein said treatment or prevention is achieved by reducing or preventing HDAC activation. In certain embodiments, the compositions of the invention are for use in treating a patient with psoriasis, where the patient has elevated HDAC levels or activity.</span>
  </p>
  <p id="p0223" num="0223" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- Lupus eritematoso sistémico</span>- Systemic lupus erythematosus</span>
    </b>
  </p>
  <p id="p0224" num="0224" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El lupus eritematoso sistémico (SLE) es una enfermedad autoinmune. Se cree que la inhibición de HDAC es un enfoque terapéutico prometedor para tratar el SLE basado en estudios en cultivos celulares y modelos de ratón de SLE (Reilly et al., 2011, Mol Med, 17 (5-6), 417-425) . Por tanto, las composiciones de la invención pueden ser útiles para tratar o prevenir el lupus eritematoso sistémico en un sujeto.</span>Systemic lupus erythematosus (SLE) is an autoimmune disease. HDAC inhibition is believed to be a promising therapeutic approach to treat SLE based on studies in cell culture and mouse models of SLE (Reilly et al., 2011, Mol Med, 17(5-6), 417-425) . Thus, the compositions of the invention may be useful for treating or preventing systemic lupus erythematosus in a subject.</span>
  </p>
  <p id="p0225" num="0225" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, las composiciones de la invención son para uso en el tratamiento o prevención del SLE. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento o prevención del SLE, en donde dicho tratamiento o prevención se logra reduciendo o previniendo la activación de HDAC. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento de un paciente con SLE, en donde el paciente tiene niveles o actividad de HDAC elevada.</span>In preferred embodiments, the compositions of the invention are for use in the treatment or prevention of SLE. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of SLE, wherein said treatment or prevention is achieved by reducing or preventing HDAC activation. In certain embodiments, the compositions of the invention are for use in treating a patient with SLE, where the patient has elevated HDAC levels or activity.</span>
  </p>
  <p id="p0226" num="0226" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- Rechazo de aloinjertos</span>- Allograft rejection</span>
    </b>
  </p>
  <p id="p0227" num="0227" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El rechazo del aloinjerto ocurre cuando los tejidos trasplantados son rechazados por el sistema inmunológico del receptor. Los estudios sobre trasplantes cardíacos murinos han demostrado que la inhibición de HDAC aumenta la acetilación de la histona 3 intra-injerto y está asociada con un aumento de los niveles intra-injerto de la proteína Foxp3 (un miembro de la familia de la transcripción en forkhead involucrado en el control de las respuestas inmunes), el mantenimiento de la arquitectura del tejido y la falta de los estigmas del rechazo crónico en relación con los controles (Wang et al., Immunol Cell Biol, 1-8). Por tanto, las composiciones de la invención pueden ser útiles para tratar o prevenir el rechazo al aloinjerto en un sujeto.</span>Allograft rejection occurs when the transplanted tissues are rejected by the recipient's immune system. Studies on murine heart transplants have shown that HDAC inhibition increases intra-graft histone 3 acetylation and is associated with increased intra-graft levels of the Foxp3 protein (a member of the forkhead transcription family). involved in the control of immune responses), maintenance of tissue architecture, and lack of chronic rejection stigmata relative to controls (Wang et al., Immunol Cell Biol, 1-8). Thus, the compositions of the invention may be useful for treating or preventing allograft rejection in a subject.</span>
  </p>
  <p id="p0228" num="0228" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, las composiciones de la invención son para uso en el tratamiento o prevención del rechazo del aloinjerto. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento o prevención del rechazo del aloinjerto, en donde dicho tratamiento o prevención se logra reduciendo o previniendo la activación de HDAC. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento de un paciente con rechazo del aloinjerto, en donde el paciente tiene niveles o actividad de HDAC elevada. 
</span>In preferred embodiments, the compositions of the invention are for use in the treatment or prevention of allograft rejection. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of allograft rejection, wherein said treatment or prevention is achieved by reducing or preventing HDAC activation. In certain embodiments, the compositions of the invention are for use in treating a patient with allograft rejection, where the patient has elevated HDAC levels or activity. </span>
  </p>
  <p id="p0229" num="0229" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- Diabetes</span>-Diabetes</span>
    </b>
  </p>
  <p id="p0231" num="0231" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La diabetes mellitus es un grupo de enfermedades en las que los niveles bajos de resistencia a la insulina y/o resistencia a la insulina periférica produce hiperglicermia. Se ha propuesto la inhibición de HDAC para tratar la diabetes mediante una variedad de mecanismos, incluida la des-represión de <i class="style-scope patent-text">Pdx1 </i>(Park et al., 2008, J Clin Invest, 118, 2316-24), mejorando la expresión del factor de transcripción <i class="style-scope patent-text">Ngn3 </i>para aumentar el conjunto de células progenitoras endocrinas (Haumaitre et al., 2008, Mol Cell Biol, 28, 6373-83) y mejorar la expresión de insulina (Molsey et al., 2003, J Biol Chem, 278, 19660-6) entre otros. La inhibición de H<sup class="style-scope patent-text">d</sup>A<sup class="style-scope patent-text">c </sup>también es un tratamiento prometedor para las complicaciones diabéticas tardías, como la nefropatía diabética y la isquemia retiniana (Christensen et al., 2011, Mol Med, 17 (5-6), 370-390). Por tanto, las composiciones de la invención pueden ser útiles para tratar o prevenir la diabetes en un sujeto.</span>Diabetes mellitus is a group of diseases in which low levels of insulin resistance and/or peripheral insulin resistance lead to hyperglycermia. Inhibition of HDAC has been proposed to treat diabetes through a variety of mechanisms, including de-repression of <i class="style-scope patent-text">Pdx1</i> (Park et al., 2008, J Clin Invest, 118, 2316-24), enhancing transcription factor expression <i class="style-scope patent-text">Ngn3</i> to increase endocrine progenitor cell pool (Haumaitre et al., 2008, Mol Cell Biol, 28, 6373-83) and enhance insulin expression (Molsey et al., 2003, J Biol Chem, 278, 19660-6 ) among others. H <sup class="style-scope patent-text">d</sup> A <sup class="style-scope patent-text">c</sup> inhibition is also a promising treatment for late diabetic complications such as diabetic nephropathy and retinal ischemia (Christensen et al., 2011, Mol Med, 17(5-6), 370-390). Thus, the compositions of the invention may be useful for treating or preventing diabetes in a subject.</span>
  </p>
  <p id="p0233" num="0233" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, las composiciones de la invención son para uso en el tratamiento o prevención de la diabetes. En realizaciones preferidas, las composiciones de la invención son para uso en el tratamiento o prevención de la diabetes de tipo I En realizaciones preferidas, las composiciones de la invención son para uso en el tratamiento o prevención de la diabetes de tipo II. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento o prevención de la diabetes, en donde dicho tratamiento o prevención se logra reduciendo o previniendo la activación de HDAC. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento de un paciente con diabetes, en donde el paciente tiene niveles o actividad de HDAC elevada. </span>In preferred embodiments, the compositions of the invention are for use in the treatment or prevention of diabetes. In preferred embodiments, the compositions of the invention are for use in the treatment or prevention of type I diabetes. In preferred embodiments, the compositions of the invention are for use in the treatment or prevention of type II diabetes. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of diabetes, wherein said treatment or prevention is achieved by reducing or preventing HDAC activation. In certain embodiments, the compositions of the invention are for use in treating a patient with diabetes, where the patient has elevated HDAC levels or activity.</span>
  </p>
  <p id="p0234" num="0234" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- Enfermedad de injerto contra huésped (GVHD)</span>- Graft versus host disease (GVHD)</span>
    </b>
  </p>
  <p id="p0236" num="0236" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las composiciones de la invención pueden usarse en el tratamiento o prevención de la enfermedad de injerto contra huésped (GVHD). La GVHD es una complicación médica posterior al trasplante de tejido alogénico en un sujeto. La GVHD ocurre comúnmente después de un trasplante de células madre o de médula ósea o de un órgano sólido, particularmente cuando el trasfondo genético del injerto (es decir, el donante) y el huésped (es decir, el receptor) son distintos.</span>The compositions of the invention can be used in the treatment or prevention of graft versus host disease (GVHD). GVHD is a medical complication following allogeneic tissue transplantation in a subject. GVHD commonly occurs after stem cell, bone marrow, or solid organ transplantation, particularly when the genetic background of the graft (ie, donor) and host (ie, recipient) are different.</span>
  </p>
  <p id="p0238" num="0238" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La fisiopatología de la GVHD comprende tres fases distintas. En primer lugar, las células presentadoras de antígenos (APC) del huésped, como las células dendríticas (DC), se activan tras el reconocimiento del tejido trasplantado como una sustancia extraña. La activación de APC precede al reclutamiento y activación de células inmunes efectoras, como las células T citotóxicas convencionales, lo que conduce a la destrucción o rechazo del tejido extraño.</span>The pathophysiology of GVHD comprises three distinct phases. First, host antigen-presenting cells (APCs), such as dendritic cells (DCs), are activated upon recognition of the transplanted tissue as a foreign substance. APC activation precedes the recruitment and activation of effector immune cells, such as conventional cytotoxic T cells, leading to destruction or rejection of foreign tissue.</span>
  </p>
  <p id="p0240" num="0240" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se ha demostrado que la inhibición de HDAC media en potentes efectos antiinflamatorios pleiotrópicos útiles en el tratamiento o prevención de la GVHD. La inhibición de HDAC puede inhibir en múltiples puntos de la cascada fisiopatológica de la GVHD. Por ejemplo, la inhibición de HDAC previene la activación de células presentadoras de antígenos y de células dendríticas contra tejidos alogénicos <i class="style-scope patent-text">in vivo </i>al mejorar la expresión de indoleamina 2,3-dioxigenasa de una manera dependiente de STAT-3 [27]. También se ha demostrado que la inhibición de la actividad de STAT-1 por HDAC es beneficiosa en el tratamiento o la prevención de la GVHD [28]. En determinadas realizaciones, la composición de la invención puede usarse en el tratamiento o prevención de la GVHD inhibiendo la activación de APC.</span>Inhibition of HDAC has been shown to mediate potent pleiotropic anti-inflammatory effects useful in the treatment or prevention of GVHD. HDAC inhibition can inhibit at multiple points in the pathophysiologic cascade of GVHD. For example, HDAC inhibition prevents activation of antigen-presenting cells and dendritic cells against allogeneic tissues <i class="style-scope patent-text">in vivo</i> by enhancing indoleamine 2,3-dioxygenase expression in a STAT-3-dependent manner [27]. Inhibition of STAT-1 activity by HDAC has also been shown to be beneficial in the treatment or prevention of GVHD [28]. In certain embodiments, the composition of the invention can be used in the treatment or prevention of GVHD by inhibiting APC activation.</span>
  </p>
  <p id="p0242" num="0242" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">También se ha mostrado que la inhibición de HDAC expande las poblaciones de células Treg y la actividad in vivo [29]. Se ha mostrado que la regulación positiva de la actividad de las células Treg mediada por la inhibición de HDAC suprime la actividad de las células T citotóxicas convencionales, que puede ser útil en el tratamiento o la prevención de la GVHD suprimiendo la 2a fase de la cascada patofisiológica de la GVHD. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento o la prevención de la GVHD reduciendo la actividad de las células T citotóxicas convencionales. En determinadas realizaciones, las composiciones de la invención pueden usarse para reducir la actividad de las células T citotóxicas convencionales. En determinadas realizaciones, la composición de la invención puede ser para uso en el tratamiento o la prevención de la GVHD mediante la regulación positiva de la actividad de las células Treg.</span>Inhibition of HDAC has also been shown to expand Treg cell populations and activity in vivo [29]. Upregulation of Treg cell activity mediated by HDAC inhibition has been shown to suppress conventional cytotoxic T cell activity, which may be useful in the treatment or prevention of GVHD by suppressing the 2nd phase of the cascade. pathophysiology of GVHD. In certain embodiments, the compositions of the invention are for use in treating or preventing GVHD by reducing the activity of conventional cytotoxic T cells. In certain embodiments, the compositions of the invention can be used to reduce the activity of conventional cytotoxic T cells. In certain embodiments, the composition of the invention may be for use in treating or preventing GVHD by upregulating Treg cell activity.</span>
  </p>
  <p id="p0244" num="0244" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se ha demostrado que las células NK de los donantes reducen la GVHD al eliminar las APC del huésped. Se ha mostrado que la inhibición de HDAC aumenta la actividad de las células NK. Por lo tanto, las composiciones de la invención pueden ser para uso para aumentar la actividad de las células NK, lo que puede ser útil en el tratamiento o prevención de GVHD al aumentar la eliminación de APC. En determinadas realizaciones, las composiciones de la invención pueden ser para uso en el tratamiento o la prevención de la GVHD mejorando la eliminación de las APC del huésped. En determinadas realizaciones, las composiciones de la invención pueden ser para uso en el tratamiento o la prevención de la GVHD mediante la potenciación de la actividad de las células NK. En determinadas realizaciones, las composiciones de la invención pueden ser para uso en el tratamiento o la prevención de la GVHD mejorando la eliminación mediada por la actividad de células NK de APC del huésped.</span>Donor NK cells have been shown to reduce GVHD by eliminating host APCs. Inhibition of HDAC has been shown to increase NK cell activity. Therefore, the compositions of the invention may be of use in increasing NK cell activity, which may be useful in the treatment or prevention of GVHD by increasing APC clearance. In certain embodiments, the compositions of the invention may be for use in treating or preventing GVHD by enhancing clearance of APCs from the host. In certain embodiments, the compositions of the invention may be for use in treating or preventing GVHD by enhancing NK cell activity. In certain embodiments, the compositions of the invention may be for use in treating or preventing GVHD by enhancing NK cell activity-mediated clearance of host APCs.</span>
  </p>
  <p id="p0246" num="0246" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las composiciones de la invención se pueden administrar después de que el huésped haya recibido el trasplante. En determinadas realizaciones, las composiciones de la invención se pueden administrar al huésped antes de que el sujeto haya recibido el trasplante. La administración de las composiciones de la invención antes de que se haya recibido el trasplante puede ser útil para estimular el sistema inmunológico del 
sujeto para que no provoque una respuesta inflamatoria o autoinmunitaria contra el tejido trasplantado. En determinadas realizaciones, las composiciones de la invención pueden usarse para prevenir o prevenir la aparición de GVHD. En determinadas realizaciones, la composición de la invención puede ser para uso en el tratamiento o prevención de la GVHD de forma profiláctica. En determinadas realizaciones, las composiciones de la invención pueden usarse en la profilaxis de la GVHD. En determinadas realizaciones, las composiciones de la invención pueden ser para uso en un método para prevenir el rechazo de tejido trasplantado en un sujeto.</span>In certain embodiments, the compositions of the invention can be administered after the host has received the transplant. In certain embodiments, the compositions of the invention may be administered to the host before the subject has received the transplant. The administration of the compositions of the invention before the transplant has been received can be useful to stimulate the immune system of the  subject so that it does not provoke an inflammatory or autoimmune response against the transplanted tissue. In certain embodiments, the compositions of the invention can be used to prevent or prevent the occurrence of GVHD. In certain embodiments, the composition of the invention may be for use in the treatment or prevention of GVHD in a prophylactic manner. In certain embodiments, the compositions of the invention can be used in the prophylaxis of GVHD. In certain embodiments, the compositions of the invention may be for use in a method of preventing rejection of transplanted tissue in a subject.</span>
  </p>
  <p id="p0248" num="0248" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las composiciones de la invención pueden ser útiles para tratar, retrasar, prevenir o prevenir la aparición de la GVHD aguda. Los síntomas de la GVHD aguda se manifiestan típicamente dentro de los primeros 100 días después del trasplante. El retraso, el tratamiento o la prevención de la GVHD aguda pueden ser particularmente beneficiosos para ayudar a la recuperación de los sujetos inmediatamente después de la cirugía de trasplante. En determinadas realizaciones, las composiciones pueden tratar, retrasar la aparición, prevenir o prevenir la aparición de GVHD aguda mediante la inhibición de la actividad de HDAC. En determinadas realizaciones, la composición de la invención puede tratar, retrasar la aparición, prevenir o prevenir la aparición de la GVHD mediante la regulación positiva de la actividad de las células Treg. Las composiciones pueden tratar, retrasar la aparición, prevenir o prevenir la aparición de GVHD aguda inhibiendo la actividad de las células T citotóxicas convencionales. Las composiciones de la invención pueden tratar, retrasar la aparición, prevenir o prevenir la aparición de GVHD aguda mejorando la actividad de las células NK. Las composiciones de la invención pueden tratar, retrasar la aparición, prevenir o prevenir la aparición de GVHD aguda inhibiendo la activación de APC.</span>In certain embodiments, the compositions of the invention may be useful in treating, delaying, preventing, or preventing the onset of acute GVHD. Symptoms of acute GVHD typically manifest within the first 100 days after transplant. Delaying, treating, or preventing acute GVHD may be particularly beneficial in helping subjects recover immediately after transplant surgery. In certain embodiments, the compositions can treat, delay onset, prevent, or prevent onset of acute GVHD by inhibiting HDAC activity. In certain embodiments, the composition of the invention can treat, delay onset, prevent, or prevent onset of GVHD by upregulating Treg cell activity. The compositions can treat, delay the onset, prevent or prevent the onset of acute GVHD by inhibiting the activity of conventional cytotoxic T cells. The compositions of the invention can treat, delay the onset, prevent or prevent the onset of acute GVHD by enhancing NK cell activity. Compositions of the invention can treat, delay onset, prevent or prevent onset of acute GVHD by inhibiting APC activation.</span>
  </p>
  <p id="p0250" num="0250" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las composiciones de la invención pueden tratar, retrasar la aparición, prevenir o prevenir la aparición de GVHD aguda cuando se administran a un sujeto dentro de los 100 días posteriores al trasplante. En determinadas realizaciones, las composiciones de la invención pueden tratar, retrasar la aparición, prevenir o prevenir la aparición de GVHD aguda cuando se administran a un sujeto de forma profiláctica, por ejemplo, cuando la composición se administra al sujeto antes del trasplante. En determinadas realizaciones, las composiciones de la invención pueden tratar, retrasar la aparición, prevenir o prevenir la aparición de GVHD aguda persistente, de aparición tardía o recurrente, como la GVHd aguda que se produce o reaparece más de 100 días después del trasplante.</span>In certain embodiments, the compositions of the invention can treat, delay the onset of, prevent, or prevent the onset of acute GVHD when administered to a subject within 100 days of transplantation. In certain embodiments, the compositions of the invention can treat, delay the onset of, prevent, or prevent the onset of acute GVHD when administered to a subject prophylactically, for example, when the composition is administered to the subject prior to transplantation. In certain embodiments, the compositions of the invention can treat, delay the onset, prevent, or prevent the onset of persistent, late-onset, or recurrent acute GVHD, such as acute GVHD that occurs or recurs more than 100 days after transplantation.</span>
  </p>
  <p id="p0252" num="0252" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, la composición de la invención puede tratar, retrasar la aparición de, o prevenir, o prevenir la aparición de uno o más síntomas de GVHD aguda seleccionados de la lista que consiste en sarpullido en la piel macropaular, náuseas, anorexia, diarrea, dolor abdominal grave, hiperbilirubinemia colestática e ilea.</span>In certain embodiments, the composition of the invention can treat, delay the onset of, or prevent, or prevent the onset of one or more symptoms of acute GVHD selected from the list consisting of macropaular skin rash, nausea, anorexia, diarrhea , severe abdominal pain, cholestatic hyperbilirubinemia, and ileus.</span>
  </p>
  <p id="p0254" num="0254" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las composiciones de la invención pueden ser útiles para tratar, retrasar, prevenir o prevenir la aparición de la GVHD aguda. La GVHD crónica es un trastorno multisistémico complejo que puede afectar a cualquier órgano y se caracteriza típicamente por fibrosis. La GVHD crónica puede evolucionar de GVHD aguda o puede surgir después de un período de inactividad después de la GVHD aguda, o puede surgir de novo. Los síntomas de la GVHD crónica pueden surgir en cualquier momento después del trasplante. En determinadas realizaciones, las composiciones pueden ser útiles para tratar, prevenir, prevenir la aparición o retrasar la aparición de la GVHD crónica al inhibir la actividad de HDAC. Las composiciones pueden tratar, retrasar la aparición, prevenir o prevenir la aparición de GVHD crónica regulando positivamente la actividad de las células Treg. Las composiciones pueden tratar, retrasar la aparición, prevenir o prevenir la aparición de GVHD crónica inhibiendo la actividad de las células T citotóxicas convencionales. Las composiciones de la invención pueden tratar, retrasar la aparición, prevenir o prevenir la aparición de GVHD crónica mejorando la actividad de las células NK. Las composiciones de la invención pueden tratar, retrasar la aparición, prevenir o prevenir la aparición de GVHD crónica inhibiendo la activación de APC DC.</span>In certain embodiments, the compositions of the invention may be useful in treating, delaying, preventing, or preventing the onset of acute GVHD. Chronic GVHD is a complex multisystem disorder that can affect any organ and is typically characterized by fibrosis. Chronic GVHD may evolve from acute GVHD or may arise after a period of inactivity after acute GVHD, or may arise de novo. Symptoms of chronic GVHD can appear at any time after transplant. In certain embodiments, the compositions may be useful for treating, preventing, preventing the onset of, or delaying the onset of chronic GVHD by inhibiting HDAC activity. The compositions can treat, delay onset, prevent or prevent onset of chronic GVHD by upregulating Treg cell activity. The compositions can treat, delay the onset, prevent or prevent the onset of chronic GVHD by inhibiting the activity of conventional cytotoxic T cells. The compositions of the invention can treat, delay the onset, prevent or prevent the onset of chronic GVHD by enhancing NK cell activity. The compositions of the invention can treat, delay the onset, prevent or prevent the onset of chronic GVHD by inhibiting the activation of APC DC.</span>
  </p>
  <p id="p0256" num="0256" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las composiciones de la invención son para la administración a un paciente que se ha sometido recientemente a un trasplante de células madre, médula ósea u órgano sólido. En determinadas realizaciones, las composiciones de la invención son para la administración a un paciente que necesita un trasplante de células madre, médula ósea o órgano sólido.</span>In certain embodiments, the compositions of the invention are for administration to a patient who has recently undergone a stem cell, bone marrow, or solid organ transplant. In certain embodiments, the compositions of the invention are for administration to a patient in need of a stem cell, bone marrow, or solid organ transplant.</span>
  </p>
  <p id="p0258" num="0258" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, la composición de la invención puede tratar, retrasar la aparición, prevenir o prevenir la aparición de uno o más síntomas de GVHD crónica seleccionados de la lista que consiste en: despigmentación, alopecia de nueva aparición, poiquilodermia, erupciones similares al liquen plano o características escleróticas, distrofia o pérdida de uñas, xerostomía, úlceras bucales (como estomatitis aftosa), características de tipo liquen en la boca (como liquen esclerosis), queratoconjuntivitis seca, síndrome de sicca, conjuntivitis cicatricial, fascititis, miositis, rigidez de las articulaciones, esclerosis vaginal, ulceraciones, anorexia, pérdida de peso, tejido esofágico, ictericia, transaminitis, derrames pleurales, bronquiolitis obliterante, síndrome nefrótico, pericarditis, trombocitopenia, anemia y neutropenia.</span>In certain embodiments, the composition of the invention can treat, delay the onset, prevent, or prevent the onset of one or more symptoms of chronic GVHD selected from the list consisting of: depigmentation, new-onset alopecia, poikiloderma, lichen-like rashes planus or sclerotic features, nail dystrophy or loss, xerostomia, mouth ulcers (such as aphthous stomatitis), lichen-like features of the mouth (such as lichen sclerosis), keratoconjunctivitis sicca, sicca syndrome, cicatricial conjunctivitis, fasciitis, myositis, joints, vaginal sclerosis, ulcerations, anorexia, weight loss, esophageal tissue, jaundice, transaminitis, pleural effusions, bronchiolitis obliterans, nephrotic syndrome, pericarditis, thrombocytopenia, anemia, and neutropenia.</span>
  </p>
  <p id="p0260" num="0260" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los inventores también han mostrado que las composiciones de la invención pueden reducir la colitis asociada con la GVHD. La colitis es un efecto secundario inflamatorio observado en pacientes con GVHD. Las composiciones de la invención también pueden ser útiles para tratar la inflamación del colon en un sujeto con GVHD. Por tanto, en algunas realizaciones, las composiciones de la invención son para uso en el tratamiento de la colitis en un sujeto con GVHD. En algunas realizaciones, las composiciones de la invención son para uso en la reducción de la gravedad de la colitis en un sujeto con GVHD. En algunas realizaciones, las composiciones de la invención son para uso en la 
reducción de la severidad de la colitis en el tratamiento de la GVHD. En algunas realizaciones, las composiciones de la invención son para uso en el tratamiento de la inflamación del colon en un sujeto con GVHD. En algunas realizaciones, las composiciones de la invención son para uso en la reducción de la gravedad de la inflamación del colon en un sujeto con GVHD. En algunas realizaciones, las composiciones de la invención son para uso en la reducción de la inflamación del colon en el tratamiento de la GVHD.</span>The inventors have also shown that the compositions of the invention can reduce colitis associated with GVHD. Colitis is an inflammatory side effect seen in patients with GVHD. Compositions of the invention may also be useful for treating inflammation of the colon in a subject with GVHD. Thus, in some embodiments, the compositions of the invention are for use in treating colitis in a subject with GVHD. In some embodiments, the compositions of the invention are for use in reducing the severity of colitis in a subject with GVHD. In some embodiments, the compositions of the invention are for use in the  reducing the severity of colitis in the treatment of GVHD. In some embodiments, the compositions of the invention are for use in treating inflammation of the colon in a subject with GVHD. In some embodiments, the compositions of the invention are for use in reducing the severity of inflammation of the colon in a subject with GVHD. In some embodiments, the compositions of the invention are for use in reducing inflammation of the colon in the treatment of GVHD.</span>
  </p>
  <p id="p0261" num="0261" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los inventores también han encontrado que las composiciones de la invención son útiles para mantener la función de barrera intestinal en sujetos con GVHD. Mantener la función de la barrera intestinal reduce la translocación de ciOCDinas inflamatorias a través de la barrera intestinal, lo que agrava la toxicidad en la GVHD [30]. En determinadas realizaciones, las composiciones de la invención se utilizan para mantener la función de barrera intestinal en el tratamiento de la GVHD. En algunas realizaciones, las composiciones de la invención se utilizan para reducir la translocación de ciOCDinas inflamatorias a través de la barrera intestinal en el tratamiento de la GVHD. En determinadas realizaciones, las composiciones de la invención pueden ser para uso en combinación con uno o más agentes farmacológicos para el tratamiento o la prevención de la GVHD. En determinadas realizaciones, el uno o más agentes farmacológicos son para la prevención o el tratamiento farmacológico de la GVHD. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento o la prevención de la GVHD en un sujeto que está recibiendo, ha recibido o está a punto de recibir uno o más de dichos agentes farmacológicos. En determinadas realizaciones, el uno o más agentes farmacológicos se seleccionan de la lista que consiste en: suberoilanilida, vorisnostat, ciclosporina ITF2357, ciclosporina, sirolimus, pentostatina, rituximab, imatinib, micofenolato de mofetilo, tacrolimús, prednisona, metotrexato, remestencel-L y proquimal, en donde el agente farmacológico se administra en una cantidad terapéuticamente eficaz para el tratamiento o la prevención de la GVHD. En algunas realizaciones, las composiciones de la invención son para uso en el tratamiento de la GVHD en un sujeto que ha recibido, está recibiendo o está a punto de recibir fotoforesis extracorpóreas.</span>The inventors have also found that the compositions of the invention are useful for maintaining intestinal barrier function in subjects with GVHD. Maintaining intestinal barrier function reduces translocation of inflammatory cyOCDins across the intestinal barrier, exacerbating toxicity in GVHD [30]. In certain embodiments, the compositions of the invention are used to maintain intestinal barrier function in the treatment of GVHD. In some embodiments, the compositions of the invention are used to reduce the translocation of inflammatory cyOCDins across the intestinal barrier in the treatment of GVHD. In certain embodiments, the compositions of the invention may be for use in combination with one or more pharmacological agents for the treatment or prevention of GVHD. In certain embodiments, the one or more pharmacological agents are for the prevention or pharmacological treatment of GVHD. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of GVHD in a subject who is receiving, has received, or is about to receive one or more such pharmacological agents. In certain embodiments, the one or more pharmacological agents are selected from the list consisting of: suberoylanilide, vorisnostat, cyclosporine ITF2357, cyclosporine, sirolimus, pentostatin, rituximab, imatinib, mycophenolate mofetil, tacrolimus, prednisone, methotrexate, remestencel-L, and prochimal, wherein the pharmacological agent is administered in a therapeutically effective amount for the treatment or prevention of GVHD. In some embodiments, the compositions of the invention are for use in the treatment of GVHD in a subject who has received, is receiving, or is about to receive extracorporeal photophoresis.</span>
  </p>
  <p id="p0262" num="0262" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Trastornos psiquiátricos y del comportamiento</span>Psychiatric and behavioral disorders</span>
      </i>
    </b>
  </p>
  <p id="p0263" num="0263" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos muestran que las composiciones de la invención reducen la hiperactividad en modelos de ratones de enfermedad neurológica. Por tanto, las composiciones de la invención pueden ser útiles para reducir la hiperactividad en un sujeto. La hiperactividad es un síntoma de trastornos del comportamiento y psiquiátricos, como el trastorno por déficit de atención e hiperactividad (ADHD), el trastorno de estrés postraumático, los trastornos de ansiedad, el trastorno afectivo bipolar y el trastorno obsesivo compulsivo. La hiperactividad puede ser síntoma de trastornos hormonales, como hipertiroidismo, hipercinética y resistencia a la hormona tiroidea. La hiperactividad también puede ser un síntoma de trastornos neuronales, como la adrenoleucodistrofia. La hiperactividad también puede ser un síntoma de trastorno hipercinético, esquizofrenia catatónica, anorexia nerviosa, síndrome de X frágil (FXS), fenilcetonuria (PKU), síndrome de alcoholismo fetal (FAS), ansiedad, depresión y síndrome de Tourette. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento o prevención de trastornos del comportamiento. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento o prevención de trastornos psiquiátricos. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento de trastornos emocionales y del comportamiento.</span>The Examples show that the compositions of the invention reduce hyperactivity in mouse models of neurological disease. Thus, the compositions of the invention may be useful in reducing hyperactivity in a subject. Hyperactivity is a symptom of behavioral and psychiatric disorders, such as attention deficit hyperactivity disorder (ADHD), post-traumatic stress disorder, anxiety disorders, bipolar affective disorder, and obsessive-compulsive disorder. Hyperactivity can be a symptom of hormonal disorders, such as hyperthyroidism, hyperkinetics, and thyroid hormone resistance. Hyperactivity can also be a symptom of neural disorders, such as adrenoleukodystrophy. Hyperactivity can also be a symptom of hyperkinetic disorder, catatonic schizophrenia, anorexia nervosa, fragile X syndrome (FXS), phenylketonuria (PKU), fetal alcohol syndrome (FAS), anxiety, depression, and Tourette syndrome. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of behavioral disorders. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of psychiatric disorders. In certain embodiments, the compositions of the invention are for use in the treatment of emotional and behavioral disorders.</span>
  </p>
  <p id="p0264" num="0264" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las composiciones son para uso en la reducción de la hiperactividad en el tratamiento del hipertiroidismo o la resistencia a la hormona tiroidea. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento de la hiperactividad en un paciente diagnosticado con hipertiroidismo o resistencia a la hormona tiroidea.</span>In certain embodiments, the compositions are for use in reducing hyperactivity in the treatment of hyperthyroidism or thyroid hormone resistance. In certain embodiments, the compositions of the invention are for use in treating hyperactivity in a patient diagnosed with hyperthyroidism or thyroid hormone resistance.</span>
  </p>
  <p id="p0265" num="0265" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las composiciones son para uso en la reducción de la hiperactividad en el tratamiento de la adrenoleucodistrofia. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento de la hiperactividad en un paciente diagnosticado con adrenoleucodistrofia.</span>In certain embodiments, the compositions are for use in reducing hyperactivity in the treatment of adrenoleukodystrophy. In certain embodiments, the compositions of the invention are for use in treating hyperactivity in a patient diagnosed with adrenoleukodystrophy.</span>
  </p>
  <p id="p0266" num="0266" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las composiciones son para uso en la reducción de la hiperactividad en el tratamiento de la esquizofrenia catatónica. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento de la hiperactividad en un paciente diagnosticado con esquizofrenia catatónica.</span>In certain embodiments, the compositions are for use in reducing hyperactivity in the treatment of catatonic schizophrenia. In certain embodiments, the compositions of the invention are for use in treating hyperactivity in a patient diagnosed with catatonic schizophrenia.</span>
  </p>
  <p id="p0267" num="0267" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las composiciones son para uso en la reducción de la hiperactividad en el tratamiento de la anorexia nerviosa. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento de la hiperactividad en un paciente diagnosticado con anorexia nerviosa.</span>In certain embodiments, the compositions are for use in reducing hyperactivity in the treatment of anorexia nervosa. In certain embodiments, the compositions of the invention are for use in treating hyperactivity in a patient diagnosed with anorexia nervosa.</span>
  </p>
  <p id="p0268" num="0268" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las composiciones son para uso en la reducción de la hiperactividad en el tratamiento del síndrome del X frágil. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento de la hiperactividad en un paciente diagnosticado con síndrome del X frágil (FXS).</span>In certain embodiments, the compositions are for use in reducing hyperactivity in the treatment of fragile X syndrome. In certain embodiments, the compositions of the invention are for use in treating hyperactivity in a patient diagnosed with fragile X syndrome (FXS).</span>
  </p>
  <p id="p0269" num="0269" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las composiciones son para uso en la reducción de la hiperactividad en el tratamiento de la fenilcetonuria. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento de la hiperactividad en un paciente diagnosticado con fenilcetonuria. 
</span>In certain embodiments, the compositions are for use in reducing hyperactivity in the treatment of phenylketonuria. In certain embodiments, the compositions of the invention are for use in treating hyperactivity in a patient diagnosed with phenylketonuria. </span>
  </p>
  <p id="p0270" num="0270" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las composiciones son para uso en la reducción de la hiperactividad en el tratamiento del síndrome de alcoholismo fetal. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento de la hiperactividad en un paciente diagnosticado con síndrome de alcoholismo fetal. En determinadas realizaciones, las composiciones son para uso en la reducción de la hiperactividad en el tratamiento de la ansiedad. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento de la hiperactividad en un paciente diagnosticado con ansiedad.</span>In certain embodiments, the compositions are for use in reducing hyperactivity in the treatment of fetal alcohol syndrome. In certain embodiments, the compositions of the invention are for use in treating hyperactivity in a patient diagnosed with fetal alcohol syndrome. In certain embodiments, the compositions are for use in reducing hyperactivity in the treatment of anxiety. In certain embodiments, the compositions of the invention are for use in treating hyperactivity in a patient diagnosed with anxiety.</span>
  </p>
  <p id="p0271" num="0271" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las composiciones son para uso en la reducción de la hiperactividad en el tratamiento de la depresión. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento de la hiperactividad en un paciente diagnosticado con depresión.</span>In certain embodiments, the compositions are for use in reducing hyperactivity in the treatment of depression. In certain embodiments, the compositions of the invention are for use in treating hyperactivity in a patient diagnosed with depression.</span>
  </p>
  <p id="p0272" num="0272" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las composiciones son para uso en la reducción de la hiperactividad en el tratamiento del síndrome de Tourette. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento de la hiperactividad en un paciente diagnosticado con síndrome de Tourette.</span>In certain embodiments, the compositions are for use in reducing hyperactivity in the treatment of Tourette's syndrome. In certain embodiments, the compositions of the invention are for use in treating hyperactivity in a patient diagnosed with Tourette's syndrome.</span>
  </p>
  <p id="p0273" num="0273" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- ADHD</span>- ADHD</span>
    </b>
  </p>
  <p id="p0274" num="0274" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, la composición de la invención es para uso en el tratamiento o prevención del ADHD. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento o prevención de la hiperactividad en sujetos con trastornos del comportamiento. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento o prevención de la hiperactividad en sujetos con ADHD. El ADHD puede manifestarse tanto en niños como en adultos. En algunas realizaciones, las composiciones de la invención son para uso en el tratamiento o prevención del ADHD en adultos. En algunas realizaciones, las composiciones son para uso en el tratamiento o la prevención del ADHD en niños.</span>In certain embodiments, the composition of the invention is for use in the treatment or prevention of ADHD. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of hyperactivity in subjects with behavioral disorders. In certain embodiments, the compositions of the invention are for use in treating or preventing hyperactivity in subjects with ADHD. ADHD can manifest in both children and adults. In some embodiments, the compositions of the invention are for use in the treatment or prevention of ADHD in adults. In some embodiments, the compositions are for use in treating or preventing ADHD in children.</span>
  </p>
  <p id="p0275" num="0275" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En algunas realizaciones, las composiciones son para uso en sujetos diagnosticados con ADHD. El diagnóstico de ADHD es un procedimiento complejo que a menudo implica la evaluación psicológica de un sujeto que muestra síntomas de ADHD, junto con un examen físico y posiblemente la detección de marcadores biológicos asociados con el ADHD, como la expresión de monoamino oxidasa plaquetaria, norepinefrina urinaria, MHPG urinario y niveles de fenetilamina urinaria.</span>In some embodiments, the compositions are for use in subjects diagnosed with ADHD. Diagnosis of ADHD is a complex procedure that often involves psychological evaluation of an individual exhibiting symptoms of ADHD, along with physical examination and possibly detection of biological markers associated with ADHD, such as expression of platelet monoamine oxidase, norepinephrine urine, urinary MHPG and urinary phenethylamine levels.</span>
  </p>
  <p id="p0276" num="0276" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El diagnóstico formal generalmente lo realiza un profesional de la salud psiquiátrica. Los diferentes países utilizan diferentes métricas para el diagnóstico y la clasificación del ADHD. En algunos países, el diagnóstico y la clasificación se realizan de acuerdo con los criterios definidos por la Asociación Americana de Psiquiatría en el Manual de Diagnóstico y Estadístico de los Trastornos Mentales (DSM). El DSM clasifica el ADHD en diferentes subtipos según la variedad de síntomas que presenta el sujeto. El ADHD puede diagnosticarse como ADHD de tipo predominantemente desatento (ADHD-pi). En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento o prevención del ADHD-pi. En determinadas realizaciones, las composiciones de la invención son para uso en un sujeto diagnosticado con ADHD-pi. En determinadas realizaciones, las composiciones de la invención son para uso en un método de tratamiento de un sujeto diagnosticado con ADHD-pi. El ADHD también se puede diagnosticar como ADHD de tipo predominantemente hiperactivo-impulsivo. En algunas realizaciones, las composiciones son para uso en el tratamiento o la prevención del tipo predominantemente hiperactivo-impulsivo de ADHD. En algunas realizaciones, las composiciones de la invención son para uso en un sujeto diagnosticado con ADHD de tipo predominantemente hiperactivo-impulsivo. En algunas realizaciones, las composiciones de la invención son para uso en un método de tratamiento de un sujeto diagnosticado con ADHD de tipo predominantemente hiperactivo-impulsivo.</span>The formal diagnosis is usually made by a psychiatric health professional. Different countries use different metrics for the diagnosis and classification of ADHD. In some countries, diagnosis and classification are made according to the criteria defined by the American Psychiatric Association in the Diagnostic and Statistical Manual of Mental Disorders (DSM). The DSM classifies ADHD into different subtypes depending on the variety of symptoms that the subject presents. ADHD can be diagnosed as ADHD predominantly inattentive type (ADHD-pi). In certain embodiments, the compositions of the invention are for use in the treatment or prevention of ADHD-pi. In certain embodiments, the compositions of the invention are for use in a subject diagnosed with ADHD-pi. In certain embodiments, the compositions of the invention are for use in a method of treating a subject diagnosed with ADHD-pi. ADHD can also be diagnosed as predominantly hyperactive-impulsive type ADHD. In some embodiments, the compositions are for use in treating or preventing the predominantly hyperactive-impulsive type of ADHD. In some embodiments, the compositions of the invention are for use in a subject diagnosed with ADHD of the predominantly hyperactive-impulsive type. In some embodiments, the compositions of the invention are for use in a method of treating a subject diagnosed with ADHD of the predominantly hyperactive-impulsive type.</span>
  </p>
  <p id="p0277" num="0277" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los síntomas del ADHD incluyen distracción fácil, olvido, soñar despierto, desorganización, falta de concentración y dificultad para completar tareas, con excesiva intranquilidad y desasosiego, hiperactividad, dificultad para esperar y permanecer sentado, comportamiento inmaduro. También pueden presentarse comportamientos destructivos. Para que los síntomas se asocien con el ADHD, deben estar presentes durante más de seis meses y deben aparecer en más de un entorno (como en el hogar, la escuela o el trabajo). En determinadas realizaciones, las composiciones son para uso en el tratamiento o prevención de uno o más síntomas del ADHD. En determinadas realizaciones, las composiciones son para uso en el tratamiento o la prevención de un sujeto que presenta uno o más síntomas de ADHD. En algunas realizaciones, las composiciones de la invención son para uso en el tratamiento o la prevención de la hiperactividad. En algunas realizaciones, las composiciones son para uso en un método para reducir la hiperactividad en un sujeto. En algunas realizaciones, las composiciones de la invención son para uso como medicamentos antihiperactividad.</span>ADHD symptoms include easily distractible, forgetfulness, daydreaming, disorganization, lack of concentration and difficulty completing tasks, with excessive restlessness and restlessness, hyperactivity, difficulty waiting and sitting still, immature behavior. Destructive behaviors may also occur. For symptoms to be associated with ADHD, they must be present for more than six months and appear in more than one setting (such as home, school, or work). In certain embodiments, the compositions are for use in treating or preventing one or more symptoms of ADHD. In certain embodiments, the compositions are for use in treating or preventing a subject exhibiting one or more symptoms of ADHD. In some embodiments, the compositions of the invention are for use in the treatment or prevention of hyperactivity. In some embodiments, the compositions are for use in a method of reducing hyperactivity in a subject. In some embodiments, the compositions of the invention are for use as antihyperactivity medications.</span>
  </p>
  <p id="p0278" num="0278" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Otros métodos de tratamiento del ADHD incluyen terapia psicológica, terapia conductual, terapia cognitivoconductual, psicoterapia interpersonal, medicamentos estimulantes, como metilfenidato, medicamentos no estimulantes, como atomoxetina, bupropión, guanfacina y clonidina. En determinadas realizaciones, las composiciones de la invención se utilizan en combinación con un método adicional de tratamiento del ADHD. 
</span>Other ADHD treatment methods include psychological therapy, behavioral therapy, cognitive behavioral therapy, interpersonal psychotherapy, stimulant medications, such as methylphenidate, non-stimulant medications, such as atomoxetine, bupropion, guanfacine, and clonidine. In certain embodiments, the compositions of the invention are used in combination with an additional method of treating ADHD. </span>
  </p>
  <p id="p0279" num="0279" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Trastorno obsesivo compulsivo (OCD)</span>Obsessive Compulsive Disorder (OCD)</span>
    </b>
  </p>
  <p id="p0280" num="0280" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento o prevención del OCD. En determinadas realizaciones, las composiciones son para uso en la reducción de la hiperactividad en el tratamiento de OCD. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento de la hiperactividad en un paciente diagnosticado con OCD.</span>In certain embodiments, the compositions of the invention are for use in the treatment or prevention of OCD. In certain embodiments, the compositions are for use in reducing hyperactivity in the treatment of OCD. In certain embodiments, the compositions of the invention are for use in treating hyperactivity in a patient diagnosed with OCD.</span>
  </p>
  <p id="p0281" num="0281" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El OCD es un trastorno heterogéneo, crónico e incapacitante que pertenece a los trastornos de ansiedad. Según la definición del DSM-IV, las características esenciales del OCD son las obsesiones y/o compulsiones recurrentes (criterio A) que son graves y consumen tiempo (más de una hora al día) o causan angustia marcada o interfieren significativamente con la rutina normal del sujeto, el funcionamiento ocupacional, las actividades sociales habituales o las relaciones (criterio C). Como en algún momento durante el curso del trastorno, la persona ha reconocido que las obsesiones o compulsiones son excesivas o irrazonables (criterio B).</span>OCD is a heterogeneous, chronic, and disabling disorder that belongs to the anxiety disorders. According to the DSM-IV definition, the essential features of OCD are recurrent obsessions and/or compulsions (criterion A) that are severe and time-consuming (more than one hour a day) or cause marked distress or significantly interfere with normal routine of the subject, occupational functioning, habitual social activities or relationships (criterion C). As at some point during the course of the disorder, the person has recognized that the obsessions or compulsions are excessive or unreasonable (Criterion B).</span>
  </p>
  <p id="p0282" num="0282" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las obsesiones se definen como pensamientos, impulsos o imágenes recurrentes y persistentes que se experimentan como intrusivos e inapropiados y causan ansiedad o angustia marcada. Los pensamientos, impulsos o imágenes no son simplemente preocupaciones excesivas sobre problemas de la vida real, son reconocidos por el paciente como producto de su propia mente (p. ej., miedo a la contaminación, obsesión por la simetría). La persona intenta ignorar, reprimir o neutralizar las obsesiones con otros pensamientos o acciones.</span>Obsessions are defined as recurrent and persistent thoughts, urges, or images that are experienced as intrusive and inappropriate and cause marked anxiety or distress. The thoughts, impulses, or images are not simply excessive worries about real-life problems, they are recognized by the patient as a product of their own mind (eg, fear of contamination, obsession with symmetry). The person tries to ignore, repress, or neutralize the obsessions with other thoughts or actions.</span>
  </p>
  <p id="p0283" num="0283" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las compulsiones se definen como comportamientos repetitivos (p. ej., lavarse las manos, ordenar, acumular, controlar) o actos mentales (p. ej., rezar, contar, repetir palabras en silencio) que la persona se siente impulsada a realizar en respuesta a una obsesión o de acuerdo con reglas que deben aplicarse rígidamente.</span>Compulsions are defined as repetitive behaviors (eg, washing hands, tidying, hoarding, controlling) or mental acts (eg, praying, counting, repeating words silently) that the person feels compelled to perform in response to an obsession or according to rules that must be rigidly applied.</span>
  </p>
  <p id="p0284" num="0284" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El OCD a menudo se asocia con tasas de comorbilidad de otras enfermedades psiquiátricas, incluido el trastorno depresivo mayor, otros trastornos de ansiedad (trastorno de ansiedad generalizada, trastorno de ansiedad social, trastorno de pánico), abuso de sustancias y trastornos de la alimentación (anorexia y bulimia).</span>OCD is often associated with comorbid rates of other psychiatric illnesses, including major depressive disorder, other anxiety disorders (generalized anxiety disorder, social anxiety disorder, panic disorder), substance abuse, and eating disorders ( anorexia and bulimia).</span>
  </p>
  <p id="p0285" num="0285" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El OCD es un trastorno psiquiátrico que puede desarrollarse o persistir debido a una disfunción del eje microbiotaintestino-cerebro. Por consiguiente, en realizaciones preferidas, las composiciones de la invención son para uso en el tratamiento o prevención del OCD en un sujeto.</span>OCD is a psychiatric disorder that can develop or persist due to dysfunction of the gut-microbiota-brain axis. Accordingly, in preferred embodiments, the compositions of the invention are for use in the treatment or prevention of OCD in a subject.</span>
  </p>
  <p id="p0286" num="0286" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las composiciones de la invención previenen, reducen o alivian las características sintomáticas esenciales del OCD. En determinadas realizaciones, las composiciones de la invención previenen, reducen o alivian las obsesiones y/o compulsiones recurrentes en un tema. En determinadas realizaciones, las obsesiones son pensamientos, impulsos o imágenes recurrentes o persistentes que son experiencias tan intrusivas e inapropiadas y que provocan una ansiedad o angustia marcada. En ciertas realizaciones, las compulsiones son comportamientos repetitivos que el sujeto se siente impulsado a realizar en respuesta a una obsesión o de acuerdo con reglas que deben aplicarse rígidamente.</span>In certain embodiments, the compositions of the invention prevent, reduce, or alleviate essential symptomatic features of OCD. In certain embodiments, the compositions of the invention prevent, reduce, or alleviate recurring obsessions and/or compulsions in a subject. In certain embodiments, obsessions are recurrent or persistent thoughts, urges, or images that are experiences that are so intrusive and inappropriate that they cause marked anxiety or distress. In certain embodiments, the compulsions are repetitive behaviors that the subject feels driven to perform in response to an obsession or in accordance with rules that must be rigidly enforced.</span>
  </p>
  <p id="p0287" num="0287" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las composiciones de la invención mejoran los síntomas del OCD en un sujeto de acuerdo con el diagnóstico de Y-BOCS y/o NIMH-OC y/o escalas sintomáticas. En algunas realizaciones, la escala Y-BOCS se usa para controlar la mejora de los puntos finales primarios. En algunas realizaciones, la escala NIMH-OC se usa para controlar la mejora de los parámetros secundarios.</span>In certain embodiments, compositions of the invention ameliorate OCD symptoms in a subject according to the Y-BOCS and/or NIMH-OC diagnosis and/or symptom scales. In some embodiments, the Y-BOCS scale is used to control the improvement of the primary endpoints. In some embodiments, the NIMH-OC scale is used to control the enhancement of secondary parameters.</span>
  </p>
  <p id="p0288" num="0288" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En algunas realizaciones, las composiciones de la invención mejoran la escala de Impresión Clínica Global - Mejora Global (CGI-I) para evaluar trastornos psiquiátricos y neurológicos. En algunas realizaciones, las composiciones de la invención muestran un efecto positivo sobre el funcionamiento social global (relaciones, trabajo, <i class="style-scope patent-text">etc.) </i>del sujeto con ASD. En algunas realizaciones, la escala global es la escala de discapacidad de Sheehan.</span>In some embodiments, compositions of the invention improve the Clinical Global Impression - Global Improvement (CGI-I) scale for evaluating psychiatric and neurological disorders. In some embodiments, the compositions of the invention show a positive effect on the global social functioning (relationships, work, <i class="style-scope patent-text">etc.)</i> of the ASD subject. In some embodiments, the global scale is the Sheehan disability scale.</span>
  </p>
  <p id="p0289" num="0289" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, las composiciones de la invención previenen, reducen o alivian al menos una comorbilidad del OCD. Las comorbilidades del OCD incluyen trastorno depresivo mayor, otros trastornos de ansiedad (trastorno de ansiedad generalizada, trastorno de ansiedad social, trastorno de pánico), abuso de sustancias y trastornos de la alimentación (anorexia y bulimia), síndrome de Gilles de la Tourette, ADHD (trastorno de déficit de atención/hiperactividad) y trastornos del desarrollo.</span>In preferred embodiments, the compositions of the invention prevent, reduce, or alleviate at least one comorbidity of OCD. OCD comorbidities include major depressive disorder, other anxiety disorders (generalized anxiety disorder, social anxiety disorder, panic disorder), substance abuse and eating disorders (anorexia and bulimia), Gilles de la Tourette syndrome, ADHD (attention deficit/hyperactivity disorder) and developmental disorders.</span>
  </p>
  <p id="p0290" num="0290" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En algunas realizaciones, las composiciones de la invención son particularmente efectivas para prevenir, reducir o aliviar el OCD cuando se usan en combinación con otra terapia para tratar el OCD. Tales terapias incluyen inhibidores de la recaptación de serotonina y dopamina; clomipramina y antipsicóticos.</span>In some embodiments, the compositions of the invention are particularly effective in preventing, reducing, or alleviating OCD when used in combination with other therapy to treat OCD. Such therapies include serotonin and dopamine reuptake inhibitors; clomipramine and antipsychotics.</span>
  </p>
  <p id="p0291" num="0291" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- Trastornos de ansiedad</span>- Anxiety disorders</span>
    </b>
  </p>
  <p id="p0292" num="0292" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento o prevención de trastornos de la ansiedad. En determinadas realizaciones, las composiciones son para uso en la reducción de la hiperactividad en el tratamiento del trastorno de la ansiedad. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento de la hiperactividad en un paciente diagnosticado un trastorno de la ansiedad. 
</span>In certain embodiments, the compositions of the invention are for use in the treatment or prevention of anxiety disorders. In certain embodiments, the compositions are for use in reducing hyperactivity in the treatment of anxiety disorder. In certain embodiments, the compositions of the invention are for use in treating hyperactivity in a patient diagnosed with an anxiety disorder. </span>
  </p>
  <p id="p0293" num="0293" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los trastornos de ansiedad son un grupo de trastornos mentales caracterizados por sentimientos de ansiedad y miedo. Hay una serie de trastornos de ansiedad que incluyen el trastorno de ansiedad generalizada (GAD); fobia específica; trastorno de ansiedad social; trastorno de ansiedad por separación; agrorafobia; trastorno de pánico y mutismo selectivo.</span>Anxiety disorders are a group of mental disorders characterized by feelings of anxiety and fear. There are a number of anxiety disorders including generalized anxiety disorder (GAD); specific phobia; social anxiety disorder; separation anxiety disorder; agroraphobia; panic disorder and selective mutism.</span>
  </p>
  <p id="p0294" num="0294" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El GAD se diagnostica de acuerdo con DMS-5 en seis criterios. El primer criterio es demasiada ansiedad o preocupación durante más de seis meses en los que la ansiedad o preocupación está presente la mayor parte del tiempo con respecto a muchas actividades. El segundo criterio es que el sujeto es incapaz de manejar los síntomas del primer criterio. El tercer criterio es que ocurren al menos tres (uno en niños) de los siguientes: inquietud; se cansa fácilmente; problemas para concentrarse; irritabilidad; tensión muscular y problemas para dormir. Los tres últimos criterios son que los síntomas provoquen un deterioro social, ocupacional y funcional significativo; los síntomas no se deben a medicamentos, drogas u otros problemas de salud física; y los síntomas no encajan mejor con otro problema psiquiátrico como el trastorno de pánico. Todos los demás trastornos de ansiedad pueden considerarse diagnósticos diferenciales de GAD.</span>GAD is diagnosed according to DMS-5 on six criteria. The first criterion is excessive anxiety or worry for more than six months in which the anxiety or worry is present most of the time regarding many activities. The second criterion is that the subject is unable to manage the symptoms of the first criterion. The third criterion is that at least three (one in children) of the following occur: restlessness; tires easily; trouble concentrating; irritability; muscle tension and trouble sleeping. The last three criteria are that the symptoms cause significant social, occupational, and functional impairment; the symptoms are not due to medications, drugs, or other physical health problems; and the symptoms do not fit better with another psychiatric problem such as panic disorder. All other anxiety disorders can be considered differential diagnoses of GAD.</span>
  </p>
  <p id="p0295" num="0295" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El GAD se asocia con frecuencia con un amplio espectro de otros trastornos mentales como comorbilidades, incluida la depresión; trastornos por uso de sustancias; estrés; IBS; insomnio; dolores de cabeza dolor; eventos cardíacos; problemas interpersonales y ADHD.</span>GAD is frequently associated with a wide spectrum of other mental disorders as comorbidities, including depression; substance use disorders; stress; IBS; insomnia; pain headaches; cardiac events; interpersonal problems and ADHD.</span>
  </p>
  <p id="p0296" num="0296" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los trastornos de ansiedad son trastornos psiquiátricos que pueden desarrollarse o persistir debido a una disfunción del eje microbiota-intestino-cerebro. Por consiguiente, en realizaciones preferidas, las composiciones de la invención son para uso en el tratamiento o prevención de trastornos de ansiedad en un sujeto. En determinadas realizaciones, el trastorno de ansiedad es un trastorno de ansiedad generalizada (GAD); fobia específica; trastorno de ansiedad social; trastorno de ansiedad por separación; agorafobia; trastorno de pánico y mutismo selectivo.</span>Anxiety disorders are psychiatric disorders that may develop or persist due to dysfunction of the microbiota-gut-brain axis. Accordingly, in preferred embodiments, the compositions of the invention are for use in the treatment or prevention of anxiety disorders in a subject. In certain embodiments, the anxiety disorder is a generalized anxiety disorder (GAD); specific phobia; social anxiety disorder; separation anxiety disorder; agoraphobia; panic disorder and selective mutism.</span>
  </p>
  <p id="p0297" num="0297" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las composiciones de la invención previenen, reducen o alivian uno o más de los síntomas del GAD en un sujeto según la clasificación de los criterios de DMS-5 enumerados en el presente documento. Según DMS-5, los mismos síntomas se asocian con otros trastornos de ansiedad. Por tanto, en determinadas realizaciones, las composiciones de la invención previenen, reducen o alivian uno o más de los síntomas de los trastornos de ansiedad en un sujeto. En realizaciones preferidas, las composiciones de la invención previenen, reducen o alivian la ansiedad o preocupación del sujeto. En determinadas realizaciones, las composiciones de la invención reducen la aparición de síntomas en un período de seis meses. En determinadas realizaciones, la composición de la invención previene, reduce o alivia la inquietud; fatiga; pérdida de concentración; irritabilidad; tensión muscular; y/o problemas con el sueño. En algunas realizaciones, las composiciones de la invención previenen, reducen o alivian el deterioro social, ocupacional y funcional asociado con los trastornos de ansiedad.</span>In certain embodiments, the compositions of the invention prevent, reduce, or alleviate one or more of the symptoms of GAD in a subject as classified by the DMS-5 criteria listed herein. According to DMS-5, the same symptoms are associated with other anxiety disorders. Thus, in certain embodiments, the compositions of the invention prevent, reduce, or alleviate one or more symptoms of anxiety disorders in a subject. In preferred embodiments, the compositions of the invention prevent, reduce, or alleviate the anxiety or worry of the subject. In certain embodiments, the compositions of the invention reduce the onset of symptoms over a six month period. In certain embodiments, the composition of the invention prevents, reduces, or alleviates restlessness; fatigue; loss of concentration; irritability; muscle tension; and/or sleep problems. In some embodiments, the compositions of the invention prevent, reduce, or alleviate the social, occupational, and functional impairment associated with anxiety disorders.</span>
  </p>
  <p id="p0298" num="0298" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En algunas realizaciones, las composiciones de la invención mejoran los síntomas de los trastornos de ansiedad según una escala sintomática o diagnóstica. En ciertas realizaciones, la escala para evaluar la mejoría sintomática incluye la Escala de Calificación de Ansiedad de Hamilton (HAM-A). En algunas realizaciones, la escala tota1HAM-A se usa para evaluar el punto final primario. En otras realizaciones, el factor de ansiedad psíquica HAM-A puede ser útil como punto final secundario.</span>In some embodiments, compositions of the invention ameliorate symptoms of anxiety disorders on a symptom or diagnostic scale. In certain embodiments, the scale for evaluating symptomatic improvement includes the Hamilton Anxiety Rating Scale (HAM-A). In some embodiments, the total HAM-A scale is used to assess the primary endpoint. In other embodiments, the psychic anxiety factor HAM-A may be useful as a secondary endpoint.</span>
  </p>
  <p id="p0299" num="0299" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En algunas realizaciones, las composiciones de la invención mejoran la escala de Impresión Clínica Global - Mejora Global (CGI-I) para evaluar trastornos psiquiátricos y neurológicos. En algunas realizaciones, las composiciones de la invención muestran un efecto positivo sobre el deterioro social, ocupacional y funcional global del sujeto con trastorno de ansiedad. En algunas realizaciones, la escala global es la escala de discapacidad de Sheehan.</span>In some embodiments, compositions of the invention improve the Clinical Global Impression - Global Improvement (CGI-I) scale for evaluating psychiatric and neurological disorders. In some embodiments, the compositions of the invention show a positive effect on the overall social, occupational and functional impairment of the subject with anxiety disorder. In some embodiments, the global scale is the Sheehan disability scale.</span>
  </p>
  <p id="p0300" num="0300" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, las composiciones de la invención previenen, reducen o alivian al menos una comorbilidad del GAD y trastornos de ansiedad. Las comorbilidades del GAD incluyen depresión; trastornos por uso de sustancias; estrés; IBS; insomnio; dolores de cabeza; dolor; eventos cardíacos; problemas interpersonales y ADHD.</span>In preferred embodiments, the compositions of the invention prevent, reduce, or alleviate at least one comorbidity of GAD and anxiety disorders. GAD comorbidities include depression; substance use disorders; stress; IBS; insomnia; Headaches; pain; cardiac events; interpersonal problems and ADHD.</span>
  </p>
  <p id="p0301" num="0301" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En algunas realizaciones, las composiciones de la invención son particularmente efectivas para prevenir, reducir o aliviar los trastornos de ansiedad cuando se usan en combinación con otra terapia para tratar los trastornos de ansiedad. Tales terapias incluyen inhibidores selectivos de la recaptación de serotonina (venlafaxina, duloxetina, escitalopram y paroxetina); benzodiazepinas (alprazolam, lorazepam y clonazepam); pregabalina (Lyrica®) y gabapentina (Neurontin®); agonistas parciales del receptor de serotonina (buspirona y tandospirona); antidepresivos serotoninérgicos atípicos (como imipramina y clomipramina); inhibidores de la monoaminooxidasa (MAOI) (como moclobemida y fenelzina); hidroxizina; propranolol; clonidina; guanfacina y prazosina.</span>In some embodiments, the compositions of the invention are particularly effective in preventing, reducing, or alleviating anxiety disorders when used in combination with other therapy to treat anxiety disorders. Such therapies include selective serotonin reuptake inhibitors (venlafaxine, duloxetine, escitalopram, and paroxetine); benzodiazepines (alprazolam, lorazepam, and clonazepam); pregabalin (Lyrica®) and gabapentin (Neurontin®); serotonin receptor partial agonists (buspirone and tandospirone); atypical serotonergic antidepressants (such as imipramine and clomipramine); monoamine oxidase inhibitors (MAOIs) (such as moclobemide and phenelzine); hydroxyzine; propranolol; clonidine; guanfacine and prazosin.</span>
  </p>
  <p id="p0302" num="0302" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- Trastorno de estrés postraumático (PTSD)</span>- Post Traumatic Stress Disorder (PTSD)</span>
    </b>
  </p>
  <p id="p0303" num="0303" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento o prevención del PTSD. En determinadas realizaciones, las composiciones son para uso en la reducción de la hiperactividad en el tratamiento de PTSD. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento de la hiperactividad en un paciente diagnosticado con PTSD. 
</span>In certain embodiments, the compositions of the invention are for use in the treatment or prevention of PTSD. In certain embodiments, the compositions are for use in reducing hyperactivity in the treatment of PTSD. In certain embodiments, the compositions of the invention are for use in treating hyperactivity in a patient diagnosed with PTSD. </span>
  </p>
  <p id="p0304" num="0304" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El PTSD es un trastorno grave e incapacitante, una característica esencial del cual es la inclusión de un evento traumático como factor desencadenante de este trastorno.</span>PTSD is a serious and disabling disorder, an essential feature of which is the inclusion of a traumatic event as a triggering factor for this disorder.</span>
  </p>
  <p id="p0305" num="0305" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los síntomas de PTSD se agrupan en cuatro grupos principales de acuerdo con los criterios de DMS-V: (i) intrusión: los ejemplos incluyen pesadillas, pensamientos no deseados de los eventos traumáticos, flashbacks y reaccionar a recordatorios traumáticos con angustia emocional o reactividad fisiológica; (ii) evitación: los ejemplos incluyen evitar los desencadenantes de recuerdos traumáticos, incluidos lugares, conversaciones u otros recordatorios; (iii) alteraciones negativas en las cogniciones y el estado de ánimo: los ejemplos incluyen culpa distorsionada de sí mismo o de otros por el evento traumático, creencias negativas sobre uno mismo o el mundo, emociones negativas persistentes (por ejemplo, miedo, culpa, vergüenza), sentirse alienado y afecto restringido (p. ej., incapacidad para experimentar emociones positivas); (iv) alteraciones en la excitación y la reactividad: los ejemplos incluyen comportamiento enojado, imprudente o autodestructivo, problemas de sueño, problemas de concentración, mayor respuesta de sobresalto e hipervigilancia.</span>PTSD symptoms are grouped into four main groups according to the WMD-V criteria: (i) intrusive: examples include nightmares, unwanted thoughts of traumatic events, flashbacks, and reacting to traumatic reminders with emotional distress or physiological reactivity ; (ii) avoidance: examples include avoiding triggers of traumatic memories, including places, conversations, or other reminders; (iii) negative alterations in cognitions and mood: examples include distorted guilt of self or others for the traumatic event, negative beliefs about oneself or the world, persistent negative emotions (for example, fear, guilt, shame), feeling alienated, and restricted affect (eg, inability to experience positive emotions); (iv) disturbances in arousal and reactivity: Examples include angry, reckless, or self-destructive behavior, sleep problems, concentration problems, increased startle response, and hypervigilance.</span>
  </p>
  <p id="p0306" num="0306" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los síntomas que se resuelven dentro de las 4 semanas posteriores al evento traumático cumplen los criterios de un trastorno de estrés agudo. El DSM distingue entre agudo (duración de los síntomas de menos de tres meses) y PTSD crónico (duración de los síntomas de más de 3 meses). Si los síntomas comienzan más de 6 meses después del factor estresante, el trastorno se define como PTSD de aparición tardía.</span>Symptoms that resolve within 4 weeks of the traumatic event meet the criteria for an acute stress disorder. The DSM distinguishes between acute (symptom duration less than three months) and chronic PTSD (symptom duration greater than 3 months). If symptoms begin more than 6 months after the stressor, the disorder is defined as late-onset PTSD.</span>
  </p>
  <p id="p0307" num="0307" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El trastorno de estrés postraumático conlleva altas comorbilidades con trastorno depresivo mayor y trastornos por uso de sustancias.</span>Post-traumatic stress disorder carries high comorbidities with major depressive disorder and substance use disorders.</span>
  </p>
  <p id="p0308" num="0308" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El PTSD es un trastorno psiquiátrico que puede desarrollarse o persistir debido a una disfunción del eje microbiotaintestino-cerebro. Por consiguiente, en realizaciones preferidas, las composiciones de la invención son para uso en el tratamiento o prevención de PTSD en un sujeto. Según una patogénesis similar, en determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento o prevención de trastornos por estrés. En determinadas realizaciones, las composiciones de la invención tratan el trastorno de estrés agudo. En algunas realizaciones, las composiciones de la invención tratan PTSD agudo y/o crónico. En algunas realizaciones, las composiciones de la invención tratan el PTSD de aparición retardada.</span>PTSD is a psychiatric disorder that can develop or persist due to dysfunction of the gut-microbiota-brain axis. Accordingly, in preferred embodiments, the compositions of the invention are for use in the treatment or prevention of PTSD in a subject. According to a similar pathogenesis, in certain embodiments, the compositions of the invention are for use in the treatment or prevention of stress disorders. In certain embodiments, the compositions of the invention treat acute stress disorder. In some embodiments, the compositions of the invention treat acute and/or chronic PTSD. In some embodiments, the compositions of the invention treat delayed onset PTSD.</span>
  </p>
  <p id="p0309" num="0309" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las composiciones de la invención previenen, reducen o alivian uno o más de los síntomas del PTSD (o trastorno por estrés) en un sujeto según la clasificación de los criterios de DMS-5 enumerados en el presente documento. En realizaciones preferidas, las composiciones de la invención previenen, reducen o alivian los pensamientos intrusivos en un sujeto con PTSD. En realizaciones preferidas, las composiciones de la invención previenen, reducen o alivian el comportamiento de evitación en un sujeto con PTSD. En realizaciones preferidas, las composiciones de la invención previenen, reducen o alivian las alteraciones negativas en las cogniciones y el estado de ánimo en un sujeto con PTSD. En realizaciones preferidas, las composiciones de la invención previenen alteraciones en la excitación y reactividad en un sujeto con PTSD.</span>In certain embodiments, the compositions of the invention prevent, reduce, or alleviate one or more of the symptoms of PTSD (or stress disorder) in a subject as classified by the DMS-5 criteria listed herein. In preferred embodiments, the compositions of the invention prevent, reduce, or alleviate intrusive thoughts in a subject with PTSD. In preferred embodiments, the compositions of the invention prevent, reduce, or alleviate avoidance behavior in a subject with PTSD. In preferred embodiments, the compositions of the invention prevent, reduce, or alleviate negative alterations in cognitions and mood in a subject with PTSD. In preferred embodiments, the compositions of the invention prevent alterations in arousal and reactivity in a subject with PTSD.</span>
  </p>
  <p id="p0310" num="0310" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En algunas realizaciones, las composiciones de la invención mejoran los síntomas del PTSD y trastornos por estrés según una escala sintomática o diagnóstica. En determinadas realizaciones, la escala para evaluar la mejoría sintomática es la escala de PTSD administrado clínicamente (CAPS).</span>In some embodiments, the compositions of the invention ameliorate the symptoms of PTSD and stress disorders on a symptomatic or diagnostic scale. In certain embodiments, the scale for evaluating symptomatic improvement is the Clinically Managed PTSD Scale (CAPS).</span>
  </p>
  <p id="p0311" num="0311" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En algunas realizaciones, las composiciones de la invención mejoran la escala de Impresión Clínica Global - Mejora Global (CGI-I) para evaluar trastornos psiquiátricos y neurológicos. En algunas realizaciones, las composiciones de la invención muestran un efecto positivo sobre el deterioro social, ocupacional y funcional global del sujeto con PTSD y trastornos por estrés. En algunas realizaciones, la escala global es la escala de discapacidad de Sheehan. En realizaciones preferidas, las composiciones de la invención previenen, reducen o alivian al menos una comorbilidad del PTSD y trastornos de ansiedad. Las comorbilidades del PTSD y los trastornos por estrés incluyen MDD, trastornos por uso de sustancias; estrés y ansiedad.</span>In some embodiments, compositions of the invention improve the Clinical Global Impression - Global Improvement (CGI-I) scale for evaluating psychiatric and neurological disorders. In some embodiments, the compositions of the invention show a positive effect on the overall social, occupational, and functional impairment of the subject with PTSD and stress disorders. In some embodiments, the global scale is the Sheehan disability scale. In preferred embodiments, the compositions of the invention prevent, reduce, or alleviate at least one comorbidity of PTSD and anxiety disorders. Comorbidities of PTSD and stress disorders include MDD, substance use disorders; stress and anxiety.</span>
  </p>
  <p id="p0312" num="0312" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En algunas realizaciones, las composiciones de la invención son particularmente efectivas para prevenir, reducir o aliviar el PTSD y trastornos por estrés cuando se usan en combinación con otra terapia para tratar el PTSD y los trastornos por estrés. Tales terapias incluyen agentes serotoninérgicos, antidepresivos tricíclicos, estabilizadores del estado de ánimo, agentes inhibidores adrenérgicos, antipsicóticos, benzodiazepinas, sertralina (Zoloft®), fluoxetina (Prozac®) y/o paroxetina (Paxil®).</span>In some embodiments, the compositions of the invention are particularly effective in preventing, reducing, or alleviating PTSD and stress disorders when used in combination with other therapy to treat PTSD and stress disorders. Such therapies include serotonergic agents, tricyclic antidepressants, mood stabilizers, adrenergic inhibitory agents, antipsychotics, benzodiazepines, sertraline (Zoloft®), fluoxetine (Prozac®), and/or paroxetine (Paxil®).</span>
  </p>
  <p id="p0313" num="0313" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- Trastorno bipolar</span>- Bipolar disorder</span>
    </b>
  </p>
  <p id="p0314" num="0314" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento o prevención del trastorno bipolar. En determinadas realizaciones, las composiciones son para uso en la reducción de la hiperactividad en el tratamiento del trastorno bipolar. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento de la hiperactividad en un paciente diagnosticado con un trastorno bipolar. El trastorno bipolar en general es una enfermedad crónica. La manía es el síntoma cardinal del trastorno bipolar. Hay varios tipos de trastorno bipolar según la duración y el patrón específicos de los episodios maníacos y 
depresivos. En DMS-5, se hace una distinción entre trastorno bipolar I, trastorno bipolar II, trastorno ciclotímico, trastorno bipolar de ciclo rápido y trastorno bipolar NOS.</span>In certain embodiments, the compositions of the invention are for use in the treatment or prevention of bipolar disorder. In certain embodiments, the compositions are for use in reducing hyperactivity in the treatment of bipolar disorder. In certain embodiments, the compositions of the invention are for use in treating hyperactivity in a patient diagnosed with bipolar disorder. Bipolar disorder in general is a chronic illness. Mania is the cardinal symptom of bipolar disorder. There are several types of bipolar disorder based on the specific duration and pattern of manic episodes and  depressives In WMD-5, a distinction is made between Bipolar I Disorder, Bipolar II Disorder, Cyclothymic Disorder, Rapid Cycling Bipolar Disorder, and Bipolar Disorder NOS.</span>
  </p>
  <p id="p0315" num="0315" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Según el DSM, la manía es un período distinto de estado de ánimo anormal y persistentemente elevado, expansivo o irritable. El episodio debe durar una semana y el estado de ánimo debe tener al menos tres de los siguientes síntomas: alta autoestima; reducción de la necesidad de dormir; aumentar la velocidad del habla; salto rápido de ideas; distraído fácilmente; un mayor interés en metas o actividades; agitación psicomotora; mayor seguimiento de actividades con alto riesgo de peligro.</span>According to the DSM, mania is a distinct period of abnormally and persistently elevated, expansive, or irritable mood. The episode must last one week and the mood must have at least three of the following symptoms: high self-esteem; reduced need for sleep; increase the rate of speech; quick jump of ideas; easily distracted; an increased interest in goals or activities; psychomotor agitation; greater monitoring of activities with a high risk of danger.</span>
  </p>
  <p id="p0316" num="0316" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El trastorno bipolar I implica uno o más episodios maníacos o mixtos (manía y depresión) y al menos un episodio depresivo mayor (consulte los síntomas de los episodios de MDD más arriba). El trastorno bipolar II tiene uno o más episodios depresivos mayores acompañados de al menos un episodio hipomaníaco. No hay episodios maníacos o mixtos. La hipomanía es una forma menor de manía. Los síntomas son responsables de importantes deterioros sociales, ocupacionales y funcionales. La ciclotimia se caracteriza por cambios en la depresión de bajo nivel junto con períodos de hipomanía. Los síntomas deben estar presentes durante al menos dos años en adultos o un año en niños antes de que se pueda hacer un diagnóstico. Los períodos libres de síntomas en adultos y niños no duran más de dos meses o un mes, respectivamente. El trastorno bipolar de ciclo rápido es una forma grave de trastorno bipolar. Ocurre cuando una persona tiene al menos cuatro episodios de depresión mayor, manía, hipomanía o estados mixtos en un año. El trastorno bipolar no especificado (NOS) clasifica los síntomas bipolares que no encajan claramente en otros tipos. La NOS se diagnostica cuando hay múltiples síntomas bipolares, pero no lo suficiente para cumplir con la etiqueta de cualquiera de los otros subtipos.</span>Bipolar I disorder involves one or more manic or mixed episodes (mania and depression) and at least one major depressive episode (see MDD episode symptoms above). Bipolar II disorder has one or more major depressive episodes accompanied by at least one hypomanic episode. There are no manic or mixed episodes. Hypomania is a lesser form of mania. The symptoms are responsible for significant social, occupational, and functional impairments. Cyclothymia is characterized by changes in low-level depression along with periods of hypomania. Symptoms must be present for at least two years in adults or one year in children before a diagnosis can be made. Symptom-free periods in adults and children last no more than two months or one month, respectively. Rapid cycling bipolar disorder is a severe form of bipolar disorder. It occurs when a person has at least four episodes of major depression, mania, hypomania, or mixed states in a year. Bipolar Disorder Not Otherwise Specified (NOS) classifies bipolar symptoms that do not fit neatly into other types. NOS is diagnosed when there are multiple bipolar symptoms, but not enough to meet the label of any of the other subtypes.</span>
  </p>
  <p id="p0317" num="0317" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El trastorno bipolar se asocia con las siguientes comorbilidades: ADHD; trastornos de ansiedad; trastornos de sustancias; obesidad y síndrome metabólico.</span>Bipolar disorder is associated with the following comorbidities: ADHD; anxiety disorders; substance disorders; obesity and metabolic syndrome.</span>
  </p>
  <p id="p0318" num="0318" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El trastorno bipolar es un trastorno psiquiátrico que puede desarrollarse o persistir debido a una disfunción del eje microbiota-intestino-cerebro. Por tanto, en realizaciones preferidas, las composiciones de la invención son para uso para tratar o prevenir el trastorno bipolar en un sujeto. En determinadas realizaciones, el trastorno bipolar es el trastorno bipolar I. En determinadas realizaciones, el trastorno bipolar es el trastorno bipolar II. En determinadas realizaciones, el trastorno bipolar es un trastorno ciclotímico. En determinadas realizaciones, el trastorno bipolar es el trastorno bipolar de ciclo rápido. En determinadas realizaciones, el trastorno bipolar es el trastorno bipolar NOS. En realizaciones preferidas, las composiciones de la invención previenen, reducen o alivian uno o más de los síntomas del trastorno bipolar en un sujeto. En determinadas realizaciones, las composiciones de la invención previenen, reducen o alivian la aparición de episodios maníacos en un sujeto. En determinadas realizaciones, las composiciones de la invención previenen, reducen o alivian la aparición de un estado de ánimo anormal y persistentemente elevado, expansivo o irritable. En determinadas realizaciones, las composiciones de la invención previenen, reducen o alivian uno o más de los siguientes síntomas: alta autoestima; reducción de la necesidad de dormir; aumentar la velocidad del habla; salto rápido de ideas; distraído fácilmente; un mayor interés en metas o actividades; agitación psicomotora; mayor seguimiento de actividades con alto riesgo de peligro. En determinadas realizaciones, las composiciones de la invención previenen, reducen o alivian la aparición de uno o más episodios maníacos o mixtos en un sujeto. En determinadas realizaciones, las composiciones de la invención reducen la aparición de al menos un episodio depresivo mayor en un sujeto. En determinadas realizaciones, las composiciones de la invención previenen, reducen o alivian la aparición de al menos un episodio depresivo mayor acompañado de al menos un episodio hipomaníaco.</span>Bipolar disorder is a psychiatric disorder that can develop or persist due to dysfunction of the microbiota-gut-brain axis. Therefore, in preferred embodiments, the compositions of the invention are for use in treating or preventing bipolar disorder in a subject. In certain embodiments, the bipolar disorder is bipolar I disorder. In certain embodiments, the bipolar disorder is bipolar II disorder. In certain embodiments, the bipolar disorder is a cyclothymic disorder. In certain embodiments, the bipolar disorder is rapid cycling bipolar disorder. In certain embodiments, the bipolar disorder is bipolar disorder NOS. In preferred embodiments, the compositions of the invention prevent, reduce, or alleviate one or more of the symptoms of bipolar disorder in a subject. In certain embodiments, the compositions of the invention prevent, reduce, or alleviate the occurrence of manic episodes in a subject. In certain embodiments, the compositions of the invention prevent, reduce, or alleviate the occurrence of abnormally and persistently elevated, expansive, or irritable mood. In certain embodiments, the compositions of the invention prevent, reduce, or alleviate one or more of the following symptoms: high self-esteem; reduced need for sleep; increase the rate of speech; quick jump of ideas; easily distracted; an increased interest in goals or activities; psychomotor agitation; greater monitoring of activities with a high risk of danger. In certain embodiments, the compositions of the invention prevent, reduce, or alleviate the occurrence of one or more manic or mixed episodes in a subject. In certain embodiments, the compositions of the invention reduce the occurrence of at least one major depressive episode in a subject. In certain embodiments, the compositions of the invention prevent, reduce, or alleviate the occurrence of at least one major depressive episode accompanied by at least one hypomanic episode.</span>
  </p>
  <p id="p0319" num="0319" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, las composiciones de la invención tratan la fase aguda del trastorno bipolar y/o previenen la aparición de nuevos episodios. En determinadas realizaciones, las composiciones de la invención tratan la fase aguda de episodios maníacos/depresivos en un sujeto con trastorno bipolar y prevenir la aparición de más episodios maníacos/depresivos.</span>In preferred embodiments, the compositions of the invention treat the acute phase of bipolar disorder and/or prevent the appearance of new episodes. In certain embodiments, compositions of the invention treat the acute phase of manic/depressive episodes in a subject with bipolar disorder and prevent the occurrence of further manic/depressive episodes.</span>
  </p>
  <p id="p0320" num="0320" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En algunas realizaciones, las composiciones de la invención mejoran los síntomas del trastorno bipolar según una escala sintomática o diagnóstica. En determinadas realizaciones, la escala para evaluar la mejoría sintomática de los episodios maníacos es la Escala de calificación del estado maníaco y la Escala de calificación de la manía joven. En determinadas realizaciones, la escala es la escala de manía de Bech-Rafaelsen (BRMAS). En determinadas realizaciones, las escalas para evaluar la mejora sintomática del cambio de episodios maníacos a depresivos incluyen la Escala de valoración de depresión de Hamilton, la Escala de valoración de Montgomery-Asberg y la Escala de depresión de Bech-Rafaelsen.</span>In some embodiments, the compositions of the invention ameliorate the symptoms of bipolar disorder on a symptom or diagnostic scale. In certain embodiments, the scale for evaluating symptomatic improvement of manic episodes is the Manic State Rating Scale and the Young Mania Rating Scale. In certain embodiments, the scale is the Bech-Rafaelsen Manic Scale (BRMAS). In certain embodiments, scales for assessing symptomatic improvement of the switch from manic to depressive episodes include the Hamilton Depression Rating Scale, the Montgomery-Asberg Rating Scale, and the Bech-Rafaelsen Depression Scale.</span>
  </p>
  <p id="p0321" num="0321" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En algunas realizaciones, las composiciones de la invención mejoran la escala de Impresión Clínica Global - Mejora Global (CGI-I) para evaluar trastornos psiquiátricos y neurológicos. En algunas realizaciones, las composiciones de la invención muestran un efecto positivo sobre el deterioro social, ocupacional y funcional global del sujeto con trastorno de ansiedad.</span>In some embodiments, compositions of the invention improve the Clinical Global Impression - Global Improvement (CGI-I) scale for evaluating psychiatric and neurological disorders. In some embodiments, the compositions of the invention show a positive effect on the overall social, occupational and functional impairment of the subject with anxiety disorder.</span>
  </p>
  <p id="p0322" num="0322" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, las composiciones de la invención previenen, reducen o alivian al menos una comorbilidad del trastorno bipolar. En determinadas realizaciones, la comorbilidad se selecciona entre ADHD, trastornos de ansiedad, trastornos por sustancias, obesidad y síndrome metabólico. 
</span>In preferred embodiments, the compositions of the invention prevent, reduce, or alleviate at least one comorbidity of bipolar disorder. In certain embodiments, the comorbidity is selected from ADHD, anxiety disorders, substance use disorders, obesity, and metabolic syndrome. </span>
  </p>
  <p id="p0323" num="0323" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento o prevención de enfermedades maniacodepresivas y trastorno bipolar que no responden al litio y al divalproex.</span>In certain embodiments, the compositions of the invention are for use in the treatment or prevention of manic-depressive illnesses and bipolar disorder that are unresponsive to lithium and divalproex.</span>
  </p>
  <p id="p0324" num="0324" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En algunas realizaciones, las composiciones de la invención son particularmente efectivas para prevenir, reducir o aliviar el trastorno bipolar cuando se usan en combinación con otra terapia para tratar el trastorno bipolar. En determinadas realizaciones, tales terapias incluyen carbonato de litio, fármacos anticonvulsivos (que incluyen valproato, divalproex, carbamazepina y lamotrigina) y fármacos antipsicóticos (que incluyen aripiprazol, olanzapina, quetiapina y risperidona).</span>In some embodiments, the compositions of the invention are particularly effective in preventing, reducing, or alleviating bipolar disorder when used in combination with other therapy to treat bipolar disorder. In certain embodiments, such therapies include lithium carbonate, anticonvulsant drugs (including valproate, divalproex, carbamazepine, and lamotrigine), and antipsychotic drugs (including aripiprazole, olanzapine, quetiapine, and risperidone).</span>
  </p>
  <p id="p0325" num="0325" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cáncer</span>Cancer</span>
      </i>
    </b>
  </p>
  <p id="p0326" num="0326" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La función y expresión de HDAC se altera en una variedad de cánceres y, a menudo, conduce a un mal pronóstico. La función de HDAC en el cáncer está asociada con la expresión o función aberrante de genes que promueven la proliferación celular y fenotipos tumorigénicos. En determinados cánceres, las HDAC regulan principalmente la aparición del cáncer y se describen como oncogenes. En otros cánceres, las proteínas de onco-fusión reclutan HDAC de clase I para reprimir la expresión de genes que regulan la diferenciación celular o el control del ciclo celular, lo que lleva a la transformación celular. Se ha mostrado que la desactivación o inhibición de la expresión de HDAC tiene múltiples efectos anticancerígenos, como la detención del ciclo celular y la inhibición de la proliferación, apoptosis, diferenciación y senescencia y alteración de la angiogénesis. Por tanto, las composiciones de la invención pueden ser útiles en el tratamiento de cánceres mediados por la actividad de HDAC, inhibiendo la actividad de HDAC.</span>HDAC function and expression is altered in a variety of cancers, often leading to a poor prognosis. HDAC function in cancer is associated with the aberrant expression or function of genes that promote cell proliferation and tumorigenic phenotypes. In certain cancers, HDACs primarily regulate cancer development and are described as oncogenes. In other cancers, onco-fusion proteins recruit class I HDACs to repress the expression of genes that regulate cell differentiation or cell cycle control, leading to cell transformation. Knockdown or inhibition of HDAC expression has been shown to have multiple anticancer effects, including cell cycle arrest and inhibition of proliferation, apoptosis, differentiation and senescence, and alteration of angiogenesis. Therefore, the compositions of the invention may be useful in the treatment of cancers mediated by HDAC activity, by inhibiting HDAC activity.</span>
  </p>
  <p id="p0327" num="0327" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento o prevención del cáncer. En determinadas realizaciones, la composición de la invención es para uso en el tratamiento o prevención de cánceres mediados por una actividad HDAC elevada. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento o prevención del cáncer colorrectal.</span>In certain embodiments, the compositions of the invention are for use in the treatment or prevention of cancer. In certain embodiments, the composition of the invention is for use in the treatment or prevention of cancers mediated by elevated HDAC activity. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of colorectal cancer.</span>
  </p>
  <p id="p0328" num="0328" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, el tratamiento con las composiciones de la invención da como resultado una reducción del tamaño del tumor o una reducción del crecimiento del tumor. En determinadas realizaciones, las composiciones de la invención son para uso en la reducción del tamaño del tumor o la reducción del crecimiento del tumor. Las composiciones de la invención pueden ser eficaces para reducir el tamaño o el crecimiento del tumor. En determinadas realizaciones, las composiciones de la invención son para uso en pacientes con tumores sólidos. En determinadas realizaciones, las composiciones de la invención son para uso en la reducción o prevención de la angiogénesis en el tratamiento del cáncer. Los genes regulados por HDAC tienen funciones centrales en la angiogénesis. En determinadas realizaciones, las composiciones de la invención son para uso en la prevención de la metástasis.</span>In certain embodiments, treatment with the compositions of the invention results in a reduction in tumor size or a reduction in tumor growth. In certain embodiments, the compositions of the invention are for use in reducing tumor size or reducing tumor growth. The compositions of the invention may be effective in reducing tumor size or growth. In certain embodiments, the compositions of the invention are for use in patients with solid tumors. In certain embodiments, the compositions of the invention are for use in reducing or preventing angiogenesis in the treatment of cancer. HDAC-regulated genes have central roles in angiogenesis. In certain embodiments, the compositions of the invention are for use in the prevention of metastasis.</span>
  </p>
  <p id="p0329" num="0329" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento o prevención del cáncer gástrico. Se ha demostrado que HDAC2 desempeña un papel funcional en el desarrollo de cánceres gástricos y tumorigénesis colorrectal [31,32]. En modelos de ratones de cáncer colorrectal, la inhibición de HDAC2 resultó en una reducción de las velocidades de desarrollo de tumores. En determinadas realizaciones, las composiciones de la invención que inhiben selectivamente HDAC2 son para uso en el tratamiento o prevención del cáncer colorrectal, en particular el cáncer colorrectal mediado por una actividad elevada de HDAC2.</span>In certain embodiments, the compositions of the invention are for use in the treatment or prevention of gastric cancer. HDAC2 has been shown to play a functional role in the development of gastric cancers and colorectal tumorigenesis [31,32]. In mouse models of colorectal cancer, inhibition of HDAC2 resulted in reduced rates of tumor development. In certain embodiments, compositions of the invention that selectively inhibit HDAC2 are for use in the treatment or prevention of colorectal cancer, in particular colorectal cancer mediated by elevated HDAC2 activity.</span>
  </p>
  <p id="p0330" num="0330" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento o prevención del cáncer de mama. Las composiciones de la invención pueden ser efectivas para tratar el cáncer de mama, y se ha demostrado que las HDAC están reguladas positivamente en el cáncer de mama [33]. En determinadas realizaciones, las composiciones de la invención son para uso en la reducción del tamaño del tumor, la reducción del crecimiento del tumor o la reducción de la angiogénesis en el tratamiento del cáncer de mama.</span>In certain embodiments, the compositions of the invention are for use in the treatment or prevention of breast cancer. Compositions of the invention may be effective in treating breast cancer, and HDACs have been shown to be upregulated in breast cancer [33]. In certain embodiments, the compositions of the invention are for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of breast cancer.</span>
  </p>
  <p id="p0331" num="0331" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento o prevención del cáncer de próstata. Las composiciones de la invención pueden ser efectivas para tratar el cáncer de próstata, ya que la actividad de HDAC juega un papel importante en el desarrollo del cáncer de próstata [34]. En determinadas realizaciones, las composiciones de la invención son para uso en la reducción del tamaño del tumor, la reducción del crecimiento del tumor o la reducción de la angiogénesis en el tratamiento del cáncer de próstata. En determinadas realizaciones, el cáncer es cáncer de próstata refractario a las hormonas.</span>In certain embodiments, the compositions of the invention are for use in the treatment or prevention of prostate cancer. The compositions of the invention may be effective in treating prostate cancer, since HDAC activity plays an important role in the development of prostate cancer [34]. In certain embodiments, the compositions of the invention are for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of prostate cancer. In certain embodiments, the cancer is hormone-refractory prostate cancer.</span>
  </p>
  <p id="p0332" num="0332" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento o prevención del cáncer de pulmón. Las composiciones de la invención pueden ser efectivas para tratar el cáncer de pulmón, y se ha demostrado que las HDAC están reguladas positivamente en el cáncer de pulmón [35]. En determinadas realizaciones, las composiciones de la invención son para uso en la reducción del tamaño del tumor, la reducción del crecimiento del tumor o la reducción de la angiogénesis en el tratamiento del cáncer de pulmón. En realizaciones preferidas, el cáncer es carcinoma de pulmón. En realizaciones preferidas, las composiciones son para uso en el tratamiento del cáncer de pulmón con altos niveles de expresión de HDAC2. Se ha demostrado que ciertos tejidos de cáncer de pulmón expresan abundantemente HDAC2. La inactivación de HDAC2 reprime el crecimiento de células de cáncer de pulmón. Se ha demostrado que los altos niveles de actividad de HDAC2 reprimen la actividad de p53 [36]. El p53 activo detiene la división celular y finalmente conduce al inicio de la apoptosis. En determinadas 
realizaciones, las composiciones de la invención que inhiben HDAC2 son para uso en el tratamiento de cánceres de pulmón con niveles elevados de actividad de HDAC2.</span>In certain embodiments, the compositions of the invention are for use in the treatment or prevention of lung cancer. Compositions of the invention may be effective in treating lung cancer, and HDACs have been shown to be upregulated in lung cancer [35]. In certain embodiments, the compositions of the invention are for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of lung cancer. In preferred embodiments, the cancer is lung carcinoma. In preferred embodiments, the compositions are for use in treating lung cancer with high levels of expression of HDAC2. Certain lung cancer tissues have been shown to abundantly express HDAC2. Inactivation of HDAC2 represses the growth of lung cancer cells. High levels of HDAC2 activity have been shown to repress p53 activity [36]. Active p53 stops cell division and ultimately leads to the initiation of apoptosis. in certain  In embodiments, compositions of the invention that inhibit HDAC2 are for use in treating lung cancers with high levels of HDAC2 activity.</span>
  </p>
  <p id="p0334" num="0334" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento o prevención del cáncer de hígado. Las composiciones de la invención pueden ser efectivas para tratar el cáncer de hígado, y se ha demostrado que las HDAC están reguladas positivamente en el cáncer de hígado [37]. En determinadas realizaciones, las composiciones de la invención son para uso en la reducción del tamaño del tumor, la reducción del crecimiento del tumor o la reducción de la angiogénesis en el tratamiento del cáncer de hígado. En realizaciones preferidas, el cáncer es hepatoma (carcinoma hepatocelular). En determinadas formas de realización, el cáncer es un tumor de grado bajo o en estadio temprano.</span>In certain embodiments, the compositions of the invention are for use in the treatment or prevention of liver cancer. Compositions of the invention may be effective in treating liver cancer, and HDACs have been shown to be upregulated in liver cancer [37]. In certain embodiments, the compositions of the invention are for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of liver cancer. In preferred embodiments, the cancer is hepatoma (hepatocellular carcinoma). In certain embodiments, the cancer is a low-grade or early-stage tumor.</span>
  </p>
  <p id="p0336" num="0336" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento o prevención del carcinoma. Las composiciones de la invención pueden ser particularmente efectivas para tratar el carcinoma. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento o prevención del cáncer no-inmunogénico. Las composiciones de la invención pueden ser efectivas para tratar cánceres no inmunogénicos.</span>In certain embodiments, the compositions of the invention are for use in the treatment or prevention of carcinoma. The compositions of the invention may be particularly effective in treating carcinoma. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of non-immunogenic cancer. The compositions of the invention may be effective in treating non-immunogenic cancers.</span>
  </p>
  <p id="p0338" num="0338" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones adicionales, las composiciones de la invención son para uso en el tratamiento o prevención de leucemia linfoblástica aguda (ALL), leucemia mieloide aguda, carcinoma adrenocortical, carcinoma de células basales, cáncer de vías biliares, cáncer de vejiga, tumor óseo, osteosarcoma/histiocitoma fibroso maligno, glioma del tronco encefálico, tumor cerebral, astrocitoma cerebeloso, glioma maligno/astrocitoma cerebral, ependimoma, meduloblastoma, tumores neuroectodérmicos primitivos supratentoriales, cáncer de mama, bronquios adenomas/carcinoides, Linfoma de Burkitt, tumor carcinoide, cáncer de cuello uterino, leucemia linfocítica crónica, leucemia mielógena crónica, trastornos mieloproliferativos crónicos, cáncer de colon, linfoma cutáneo de células T, cáncer de endometrio, ependimoma, cáncer de esófago, sarcoma de Ewing, melanoma intraocular, retinoblastoma, cáncer de vesícula biliar cáncer, tumor carcinoide gastrointestinal, tumor del estroma gastrointestinal (GIST), tumor de células germinales, glioma, vías visuales e hipotalámicas infantiles, linfoma de Hodgkin, melanoma, carcinoma de células de los islotes, sarcoma de Kaposi, cáncer de células renales, cáncer de laringe, leucemias, linfomas, mesotelioma, neuroblastoma, linfoma no Hodgkin, cáncer de orofaringe, osteosarcoma, cáncer de ovario, cáncer de páncreas, cáncer de paratiroides, cáncer de faringe, adenoma pituitario, neoplasia de células plasmáticas, cáncer de próstata, carcinoma de células renales, retinoblastoma, sarcoma, cáncer de testículo, cáncer de tiroides o uterino cáncer.</span>In additional embodiments, the compositions of the invention are for use in the treatment or prevention of acute lymphoblastic leukemia (ALL), acute myeloid leukemia, adrenocortical carcinoma, basal cell carcinoma, bile duct cancer, bladder cancer, bone tumor, osteosarcoma /malignant fibrous histiocytoma, brainstem glioma, brain tumor, cerebellar astrocytoma, malignant glioma/cerebellar astrocytoma, ependymoma, medulloblastoma, supratentorial primitive neuroectodermal tumors, breast cancer, bronchial adenomas/carcinoids, Burkitt's lymphoma, carcinoid tumor, neck cancer uterine, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myeloproliferative disorders, colon cancer, cutaneous T-cell lymphoma, endometrial cancer, ependymoma, esophageal cancer, Ewing's sarcoma, intraocular melanoma, retinoblastoma, gallbladder cancer cancer, tumor gastrointestinal carcinoid, gastrointestinal stromal tumor (GIST), tumor germ cell carcinoma, glioma, infantile visual and hypothalamic pathways, Hodgkin's lymphoma, melanoma, islet cell carcinoma, Kaposi's sarcoma, renal cell cancer, laryngeal cancer, leukemias, lymphomas, mesothelioma, neuroblastoma, non-Hodgkin's lymphoma, oropharyngeal cancer, osteosarcoma, ovarian cancer, pancreatic cancer, parathyroid cancer, pharyngeal cancer, pituitary adenoma, plasma cell neoplasm, prostate cancer, renal cell carcinoma, retinoblastoma, sarcoma, testicular cancer, thyroid cancer or uterine cancer.</span>
  </p>
  <p id="p0340" num="0340" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las composiciones de la invención pueden ser particularmente efectivas cuando se usan en combinación con otros agentes terapéuticos. Los efectos inhibidores de HDAC de las composiciones de la invención pueden ser eficaces cuando se combinan con agentes anticancerosos más directos. Por tanto, en determinadas realizaciones, la invención proporciona una composición que comprende una cepa bacteriana del género <i class="style-scope patent-text">Bariatricus </i>y un agente anticanceroso. En realizaciones preferidas, el agente anticanceroso es un inhibidor de puntos de control inmunológico, una inmunoterapia con anticuerpos dirigidos, una terapia con células CAR-T, un virus oncolítico o un fármaco citostático. En realizaciones preferidas, la composición comprende un agente anticancerígeno seleccionado del grupo que consiste en: Yervoy (ipilimumab, BMS); Keytruda (pembrolizumab, Merck); Opdivo (nivolumab, BMS); MEDI4736 (AZ/MedImmune); MPDL3280A (Roche/Genentech); Tremelimumab (AZ/MedImmune); CT-011 (pidilizumab, CureTech); BMS-986015 (lirilumab, BMS); MEDI0680 (AZ/MedImmune); MSB-0010718C (Merck); PF-05082566 (Pfizer); MEDI6469 (AZ/MedImmune); BMS-986016 (BMS); BMS-663513 (urelumab, BMS); IMP321 (Prima Biomed); LAG525 (Novartis); ARGX-110 (arGEN-X); PF-05082466 (Pfizer); CDX-1127 (varlilumab; CellDex Therapeutics); TRX-518 (GITR Inc.); MK-4166 (Merck); JTX-2011 (Jounce Therapeutics); ARGX-115 (arGEN-X); NLG-9189 (indoximod, NewLink Genetics); INCB024360 (Incyte); IPH2201 (Innate Immotherapeutics/AZ); NLG-919 (NewLink Genetics); anti-VISTA (JnJ); Epacadostat (INCB24360, Incyte); F001287 (Flexus/BMS); CP 870893 (Universidad de Pensilvania); MGA271 (Macrogenix); Emactuzumab (Roche/Genentech); Galunisertib (Eli Lilly); Ulocuplumab (BMS); BKT140/BL8040 (Biokine Therapeutics); Bavituximab (Peregrine Pharmaceuticals); C<sup class="style-scope patent-text">c </sup>90002 (Celgene); 852A (Pfizer); VTX-2337 (VentiRx Pharmaceuticals); IMO-2055 (Hybridon, Idera Pharmaceuticals); LY2157299 (Eli Lilly); EW-7197 (Universidad Ewha Women, Korea); Vemurafenib (Plexxikon); Dabrafenib (Genentech/GSK); Bm S-777607 (BmS); BLZ945 (Centro del Cáncer Memorial Sloan-Kettering); Unituxin (dinutuximab, United Therapeutics Corporation); Blincyto (blinatumomab, Amgen); Cyramza (ramucirumab, Eli Lilly); Gazyva (obinutuzumab, Roche/Biogen); Kadcyla (adotrastuzumab emtansine, Roche/Genentech); Perjeta (pertuzumab, Roche/Genentech); Adcetris (brentuximab vedotin, TakedalMillennium); Arzerra (ofatumumab, <sup class="style-scope patent-text">g </sup>S<sup class="style-scope patent-text">k </sup>); Vectibix (panitumumab, Amgen); Avastin (bevacizumab, Roche/Genentech); Erbitux (cetuximab, BMS/Merck); Bexxar (tositumomab-I131, GSK); Zevalin (ibritumomab tiuxetan, Biogen); Campath (alemtuzumab, Bayer); Mylotarg (gemtuzumab ozogamicin, Pfizer); Herceptin (trastuzumab, Roche/Genentech); Rituxan (rituximab, Genentech/Biogen); volociximab (Abbvie); Enavatuzumab (Abbvie); ABT-414 (Abbvie); Elotuzumab (Abbvie/BMS); ALX-0141 (Ablynx); Ozaralizumab (Ablynx); Actimab-C (Actinium); Actimab-P (Actinium); Milatuzumab-dox (Actinium); Emab-SN-38 (Actinium); Naptumonmab estafenatox (Active Biotech); AFM13 (Affimed); AFM11 (Affimed); AGS-16C3F (Agensys); AGS-16M8F (Agensys); AGS-22ME (Agensys); AGS-15ME (Agensys); GS-67E (Agensys); ALXN6000 (samalizumab, Alexion); ALT-836 (Altor Bioscience); ALT-801 (Altor Bioscience); ALT-803 (Altor Bioscience); AMG780 (Amgen); a Mg 228 (Amgen); AMG820 (Amgen); Am G172 (Amgen); AMG595 (Amgen); AMG110 (Amgen); AMG232 (adecatumumab, Amgen); AMG211 (Amgen/MedImmune); BAY20-10112 (Amgen/Bayer); Rilotumumab (Amgen); Denosumab (Amgen); AMP-514 (Amgen); MEDI575 (AZ/MedImmune); 
MEDI3617 (AZ/MedImmune); MEDI6383 (AZ/MedImmune); MEDI551 (AZ/MedImmune); Moxetumomab pasudotox (AZ/MedImmune); MEDI565 (AZ/MedImmune); MEDI0639 (AZ/MedImmune); MEDI0680 (AZ/MedImmune); MEDI562 (AZ/MedImmune); AV-380 (AVEO); AV203 (AVEO); AV299 (AVEO); BAY79-4620 (Bayer); Anetumab ravtansine (Bayer); vantictumab (Bayer); BAY94-9343 (Bayer); Sibrotuzumab (Boehringer Ingleheim); BI-836845 (Boehringer Ingleheim); B-701 (BioClin); BIIB015 (Biogen); Obinutuzumab (Biogen/Genentech); BI-505 (Bioinvent); BI-1206 (Bioinvent); TB-403 (Bioinvent); BT-062 (Biotest) BIL-010t (Biosceptre); MDX-1203 (BMS); MDX-1204 (BMS); Necitumumab (BMS); CAN-4 (Cantargia AB); CDX-011 (Celldex); CDX1401 (Celldex); CDX301 (Celldex); U3-1565 (Daiichi Sankyo); patritumab (Daiichi Sankyo); tigatuzumab (Daiichi Sankyo); nimotuzumab (Daiichi Sankyo); DS-8895 (Daiichi Sankyo); DS-8873 (Daiichi Sankyo); DS-5573 (Daiichi Sankyo); MORab-004 (Eisai); MORab-009 (Eisai); MORab-003 (Eisai); MORab-066 (Eisai); LY3012207 (Eli Lilly); LY2875358 (Eli Lilly); LY2812176 (Eli Lilly); LY3012217(Eli Lilly); LY2495655 (Eli Lilly); LY3012212 (Eli Lilly); LY3012211 (Eli Lilly); LY3009806 (Eli Lilly); cixutumumab (Eli Lilly); Flanvotumab (Eli Lilly); IMC-TR1 (Eli Lilly); Ramucirumab (Eli Lilly); Tabalumab (Eli Lilly); Zanolimumab (Emergent Biosolution); Fg -3019 (FibroGen); FPA008 (Five Prime Therapeutics); FP-1039 (Five Prime Therapeutics); FPA144 (Five Prime Therapeutics); catumaxomab (Fresenius Biotech); IMAB362 (Ganymed); IMAB027 (Ganymed); HuMax-CD74 (Genmab); HuMax-TFADC (Genmab); GS-5745 (Gilead); GS-6624 (Gilead); OMP-21M18 (demcizumab, GSK); mapatumumab (GSK); Im Gn289 (ImmunoGen); IMGN901 (ImmunoGen); IMGN853 (ImmunoGen); IMGN529 (ImmunoGen); I<sup class="style-scope patent-text">m </sup>M<sup class="style-scope patent-text">u </sup>-130 (Immunomedics); milatuzumab-dox (Immunomedics); IMMU-115 (Immunomedics); IMMU-132 (Immunomedics); IMMU-106 (Immunomedics); IMMU-102 (Immunomedics); Epratuzumab (Immunomedics); Clivatuzumab (Immunomedics); IPH41 (Innate Immunotherapeutics); Daratumumab (Janssen/Genmab); CNTO-95 (Intetumumab, Janssen); CNTO-328 (siltuximab, Janssen); KB004 (KaloBios); mogamulizumab (Kyowa Hakko Kirrin); KW-2871 (ecromeximab, Life Science); Sonepcizumab (Lpath); Margetuximab (Macrogenics); Enoblituzumab (Macrogenics); MGD006 (Macrogenics); MGF007 (Macrogenics); MK-0646 (dalotuzumab, Merck); MK-3475 (Merck); Sym004 (Symphogen/Merck Serono); DI17E6 (Merck Serono); MOR208 (Morphosys); Mo R202 (Morphosys); Xmab5574 (Morphosys); BPC-1C (ensituximab, Precision Biologics); TAS266 (Novartis); <sup class="style-scope patent-text">l</sup>F<sup class="style-scope patent-text">a </sup>102 (Novartis); BHQ880 (Novartis/Morphosys); QGE031 (Novartis); HCD122 (lucatumumab, Novartis); LJM716 (Novartis); <sup class="style-scope patent-text">a </sup>T355 (Novartis); OMP-21 M18 (Demcizumab, OncoMed); OMP52M51 (Oncomed/GSK); OMP-59R5 (Oncomed/GSK); vantictumab (Oncomed/Bayer); CMC-544 (inotuzumab ozogamicin, Pfizer); PF-03446962 (Pfizer); PF-04856884 (Pfizer); PSMA-ADC (Progenics); REGN1400 (Regeneron); REGN910 (nesvacumab, Regeneron/Sanofi); REGN421 (enoticumab, Regeneron/Sanofi); RG7221, RG7356, RG7155, RG7444, RG7116, RG7458, RG7598, RG7599, RG7600, RG7636, RG7450, RG7593, RG7596, DCDS3410A, RG7414 (parsatuzumab), RG7160 (imgatuzumab), RG7159 (obintuzumab), RG7686, RG3638 (onartuzumab), RG7597 (Roche/Genentech); SAR307746 (Sanofi); SAR566658 (Sanofi); SAR650984 (Sanofi); SAR153192 (Sanofi); SAR3419 (Sanofi); SAR256212 (Sanofi), SGN-LIV1A (lintuzumab, Seattle Genetics); SGN-CD33A (Seattle Genetics); Sg N-75 (vorsetuzumab mafodotin, Seattle Genetics); SGN-19A (Seattle Genetics) SGN-CD70A (Seattle Genetics); SEA-CD40 (Seattle Genetics); ibritumomab tiuxetan (Spectrum); MLN0264 (Takeda); ganitumab (Takeda/Amgen); CEP-37250 (Teva); TB-403 (Thrombogenic); VB4-845 (Viventia); Xmab2512 (Xencor); Xmab5574 (Xencor); nimotuzumab (YM Biosciences); Carlumab (Janssen); NY-ESO TCR (Adaptimmune); MAGE-A-10 TCR (Adaptimmune); CTL019 (Novartis); JcAr015 (Juno Therapeutics); KTE-C19 CAR (Kite Pharma); UCART19 (Cellectis); <sup class="style-scope patent-text">b </sup>P<sup class="style-scope patent-text">x </sup>-401 (Bellicum Pharmaceuticals); BPX-601 (Bellicum Pharmaceuticals); ATTCK20 (Unum Therapeutics); CAR-NKG2D (Celyad); Onyx-015 (Onyx Pharmaceuticals); H101 (Shanghai Sunwaybio); DnX-2401 (DNAtrix); v Cn-01 (VCN Biosciences); Colo-Adl (PsiOxus Therapeutics); ProstAtak (Advantagene); Oncos-102 (Oncos Therapeutics); CG0070 (Cold Genesys); Pexa-vac (JX-594, Jennerex Biotherapeutics); GL-ONC1 (Genelux); T-VEC (Amgen); G207 (Medigene); HF10 (Takara Bio); SEPREHVIR (HSV1716, Virttu Biologics); OrienX010 (OrienGene Biotechnology); Reolysin (Oncolytics Biotech); SW-001 (Neotropix); Cacatak (CVA21, Viralytics); Alimta (Eli Lilly), cisplatin, oxaliplatin, irinotecan, ácido folínico, methotrexate, cyclophosphamide, 5-fluorouracil, Zykadia (Novartis), Tafinlar (GSK), Xalkori (Pfizer), Iressa (AZ), Gilotrif (Boehringer Ingelheim), Tarceva (Astellas Pharma), Halaven (Eisai Pharma), Veliparib (Abbvie), AZD9291 (AZ), Alectinib (Chugai), LDK378 (Novartis), Genetespib (Synta Pharma), Tergenpumatucel-L (NewLink Genetics), GV1001 (Kael-GemVax), Tivantinib (ArQule); Cytoxan (BMS); Oncovin (Eli Lilly); Adriamycin (Pfizer); Gemzar (Eli Lilly); Xeloda (Roche); Ixempra (BMS); Abraxane (Celgene); Trelstar (Debiopharm); Taxotere (Sanofi); Nexavar (Bayer); IMMU-132 (Immunomedics); E7449 (Eisai); Thermodox (Celsion); Cometriq (Exellxis); Lonsurf (Taiho Pharmaceuticals); Camptosar (Pfizer); UFT (Taiho Pharmaceuticals); y TS-1 (Taiho Pharmaceuticals).</span>The compositions of the invention can be particularly effective when used in combination with other therapeutic agents. The HDAC inhibitory effects of the compositions of the invention can be effective when combined with more direct anticancer agents. Thus, in certain embodiments, the invention provides a composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Bariatricus</i> and an anticancer agent. In preferred embodiments, the anticancer agent is an immune checkpoint inhibitor, a targeted antibody immunotherapy, a CAR-T cell therapy, an oncolytic virus, or a cytostatic drug. In preferred embodiments, the composition comprises an anticancer agent selected from the group consisting of: Yervoy (ipilimumab, BMS); Keytruda (pembrolizumab, Merck); Opdivo (nivolumab, BMS); MEDI4736 (AZ/MedImmune); MPDL3280A (Roche/Genentech); Tremelimumab (AZ/MedImmune); CT-011 (pidilizumab, CureTech); BMS-986015 (lirilumab, BMS); MEDI0680 (AZ/MedImmune); MSB-0010718C (Merck); PF-05082566 (Pfizer); MEDI6469 (AZ/MedImmune); BMS-986016 (BMS); BMS-663513 (urelumab, BMS); IMP321 (Prime Biomed); LAG525 (Novartis); ARGX-110 (arGEN-X); PF-05082466 (Pfizer); CDX-1127 (varlilumab; CellDex Therapeutics); TRX-518 (GITR Inc.); MK-4166 (Merck); JTX-2011 (Jounce Therapeutics); ARGX-115 (arGEN-X); NLG-9189 (indoximod, NewLink Genetics); INCB024360 (Incyte); IPH2201 (Innate Immotherapeutics/AZ); NLG-919 (New Link Genetics); anti-VISTA (JnJ); Epacadostat (INCB24360, Incyte); F001287 (Flexus/BMS); CP 870893 (University of Pennsylvania); MGA271 (Macrogenix); Emactuzumab (Roche/Genentech); Galunisertib (Eli Lilly); Ulocuplumab (BMS); BKT140/BL8040 (Biokine Therapeutics); Bavituximab (Peregrine Pharmaceuticals); C <sup class="style-scope patent-text">c</sup> 90002 (Celgene); 852A (Pfizer); VTX-2337 (VentiRx Pharmaceuticals); IMO-2055 (Hybridon, Idera Pharmaceuticals); LY2157299 (Eli Lilly); EW-7197 (Ewha Women's University, Korea); Vemurafenib (Plexxikon); Dabrafenib (Genentech/GSK); BmS-777607 (BmS); BLZ945 (Memorial Sloan-Kettering Cancer Center); Unituxin (dinutuximab, United Therapeutics Corporation); Blincyto (blinatumomab, Amgen); Cyramza (ramucirumab, Eli Lilly); Gazyva (obinutuzumab, Roche/Biogen); Kadcyla (adotrastuzumab emtansine, Roche/Genentech); Perjeta (pertuzumab, Roche/Genentech); Adcetris (brentuximab vedotin, TakedalMillennium); Arzerra (ofatumumab, <sup class="style-scope patent-text">g</sup> S <sup class="style-scope patent-text">k</sup> ); Vectibix (panitumumab, Amgen); Avastin (bevacizumab, Roche/Genentech); Erbitux (cetuximab, BMS/Merck); Bexxar (tositumomab-I131, GSK); Zevalin (ibritumomab tiuxetan, Biogen); Campath (alemtuzumab, Bayer); Mylotarg (gemtuzumab ozogamicin, Pfizer); Herceptin (trastuzumab, Roche/Genentech); Rituxan (rituximab, Genentech/Biogen); volociximab (Abbvie); Enavatuzumab (Abbvie); ABT-414 (Abbvie); Elotuzumab (Abbvie/BMS); ALX-0141 (Ablynx); Ozaralizumab (Ablynx); Actimab-C (Actinium); Actimab-P (Actinium); Milatuzumab-dox (Actinium); Emab-SN-38 (Actinium); Naptumonmab stafenatox (Active Biotech); AFM13 (Affimed); AFM11 (Affimed); AGS-16C3F (Agensys); AGS-16M8F (Agensys); AGS-22ME (Agensys); AGS-15ME (Agensys); GS-67E (Agensys); ALXN6000 (samalizumab, Alexion); ALT-836 (Altor Bioscience); ALT-801 (Altor Bioscience); ALT-803 (Altor Bioscience); AMG780 (Amgen); to Mg 228 (Amgen); AMG820 (Amgen); AmG172 (Amgen); AMG595 (Amgen); AMG110 (Amgen); AMG232 (adecatumumab, Amgen); AMG211 (Amgen/MedImmune); BAY20-10112 (Amgen/Bayer); Rilotumumab (Amgen); Denosumab (Amgen); AMP-514 (Amgen); MEDI575 (AZ/MedImmune);  MEDI3617 (AZ/MedImmune); MEDI6383 (AZ/MedImmune); MEDI551 (AZ/MedImmune); Moxetumomab pasudotox (AZ/MedImmune); MEDI565 (AZ/MedImmune); MEDI0639 (AZ/MedImmune); MEDI0680 (AZ/MedImmune); MEDI562 (AZ/MedImmune); AV-380 (AVEO); AV203 (AVEO); AV299 (AVEO); BAY79-4620 (Bayer); Anetumab ravtansine (Bayer); vantictumab (Bayer); BAY94-9343 (Bayer); Sibrotuzumab (Boehringer Ingleheim); BI-836845 (Boehringer Ingleheim); B-701 (BioClin); BIIB015 (Biogen); Obinutuzumab (Biogen/Genentech); BI-505 (Bioinvent); BI-1206 (Bioinvent); TB-403 (Bioinvent); BT-062 (Biotest) BIL-010t (Biosceptre); MDX-1203 (BMS); MDX-1204 (BMS); Necitumumab (BMS); CAN-4 (Cantargia AB); CDX-011 (Celldex); CDX1401 (Celldex); CDX301 (Celldex); U3-1565 (Daiichi Sankyo); patritumab (Daiichi Sankyo); tigatuzumab (Daiichi Sankyo); nimotuzumab (Daiichi Sankyo); DS-8895 (Daiichi Sankyo); DS-8873 (Daiichi Sankyo); DS-5573 (Daiichi Sankyo); MORab-004 (Eisai); MORab-009 (Eisai); MORab-003 (Eisai); MORab-066 (Eisai); LY3012207 (Eli Lilly); LY2875358 (Eli Lilly); LY2812176 (Eli Lilly); LY3012217(Eli Lilly); LY2495655 (Eli Lilly); LY3012212 (Eli Lilly); LY3012211 (Eli Lilly); LY3009806 (Eli Lilly); cixutumumab (Eli Lilly); Flanvotumab (Eli Lilly); IMC-TR1 (Eli Lilly); Ramucirumab (Eli Lilly); Tabalumab (Eli Lilly); Zanolimumab (Emergent Biosolution); Fg-3019 (FibroGen); FPA008 (Five Prime Therapeutics); FP-1039 (Five Prime Therapeutics); FPA144 (Five Prime Therapeutics); catumaxomab (Fresenius Biotech); IMAB362 (Ganymed); IMAB027 (Ganymed); HuMax-CD74 (Genmab); HuMax-TFADC (Genmab); GS-5745 (Gilead); GS-6624 (Gilead); OMP-21M18 (demcizumab, GSK); mapatumumab (GSK); ImGn289 (ImmunoGen); IMGN901 (ImmunoGen); IMGN853 (ImmunoGen); IMGN529 (ImmunoGen); I <sup class="style-scope patent-text">m</sup> M <sup class="style-scope patent-text">u</sup> -130 (Immunomedics); milatuzumab-dox (Immunomedics); IMMU-115 (Immunomedics); IMMU-132 (Immunomedics); IMMU-106 (Immunomedics); IMMU-102 (Immunomedics); Epratuzumab (Immunomedics); Clivatuzumab (Immunomedics); IPH41 (Innate Immunotherapeutics); Daratumumab (Janssen/Genmab); CNTO-95 (Intetumumab, Janssen); CNTO-328 (siltuximab, Janssen); KB004 (KaloBios); mogamulizumab (Kyowa Hakko Kirrin); KW-2871 (ecromeximab, Life Science); Sonepcizumab (Lpath); Margetuximab (Macrogenics); Enoblituzumab (Macrogenics); MGD006 (Macrogenics); MGF007 (Macrogenics); MK-0646 (dalotuzumab, Merck); MK-3475 (Merck); Sym004 (Symphogen/Merck Serono); DI17E6 (Merck Serono); MOR208 (Morphosys); MoR202 (Morphosys); Xmab5574 (Morphosys); PCB-1C (ensituximab, Precision Biologics); TAS266 (Novartis); <sup class="style-scope patent-text">l</sup> F <sup class="style-scope patent-text">at</sup> 102 (Novartis); BHQ880 (Novartis/Morphosys); QGE031 (Novartis); HCD122 (lucatumumab, Novartis); LJM716 (Novartis); <sup class="style-scope patent-text">to</sup> T355 (Novartis); OMP-21 M18 (Demcizumab, OncoMed); OMP52M51 (Oncomed/GSK); OMP-59R5 (Oncomed/GSK); vantictumab (Oncomed/Bayer); CMC-544 (inotuzumab ozogamicin, Pfizer); PF-03446962 (Pfizer); PF-04856884 (Pfizer); PSMA-ADC (Progenics); REGN1400 (Regeneron); REGN910 (nesvacumab, Regeneron/Sanofi); REGN421 (enoticumab, Regeneron/Sanofi); RG7221, RG7356, RG7155, RG7444, RG7116, RG7458, RG7598, RG7599, RG7600, RG7636, RG7450, RG7593, RG7596, DCDS3410A, RG7414 (parsatuzumab), RG7160 (imgatuzumab), RG7159 (obintuzumab), RG7686, RG3638 (onartuzumab), RG7597 (Roche/Genentech); SAR307746 (Sanofi); SAR566658 (Sanofi); SAR650984 (Sanofi); SAR153192 (Sanofi); SAR3419 (Sanofi); SAR256212 (Sanofi), SGN-LIV1A (lintuzumab, Seattle Genetics); SGN-CD33A (Seattle Genetics); Sg N-75 (vorsetuzumab mafodotin, Seattle Genetics); SGN-19A (Seattle Genetics) SGN-CD70A (Seattle Genetics); SEA-CD40 (Seattle Genetics); ibritumomab tiuxetan (Spectrum); MLN0264 (Takeda); ganitumab (Takeda/Amgen); CEP-37250 (Teva); TB-403 (Thrombogenic); VB4-845 (Viventia); Xmab2512 (Xencor); Xmab5574 (Xencor); nimotuzumab (YM Biosciences); Carlumab (Janssen); NY-ESO TCR (Adaptimmune); MAGE-A-10 TCR (Adaptimmune); CTL019 (Novartis); JcAr015 (Juno Therapeutics); KTE-C19 CAR (Kite Pharma); UCART19 (Cellectis); <sup class="style-scope patent-text">b</sup> P <sup class="style-scope patent-text">x</sup> -401 (Bellicum Pharmaceuticals); BPX-601 (Bellicum Pharmaceuticals); ATTCK20 (Unum Therapeutics); CAR-NKG2D (Celyad); Onyx-015 (Onyx Pharmaceuticals); H101 (Shanghai Sunway bio); DnX-2401 (DNAtrix); vCn-01 (VCN Biosciences); Colo-Adl (PsiOxus Therapeutics); Prostak (Advantagene); Oncos-102 (Oncos Therapeutics); CG0070 (Cold Genesys); Pexa-vac (JX-594, Jennerex Biotherapeutics); GL-ONC1 (Genelux); T-VEC (Amgen); G207 (Medigene); HF10 (Takara Bio); SEPREHVIR (HSV1716, Virttu Biologics); OrienX010 (OrienGene Biotechnology); Reolysin (Oncolytics Biotech); SW-001 (Neotropix); Cacatak (CVA21, Viralytics); Alimta (Eli Lilly), cisplatin, oxaliplatin, irinotecan, folinic acid, methotrexate, cyclophosphamide, 5-fluorouracil, Zykadia (Novartis), Tafinlar (GSK), Xalkori (Pfizer), Iressa (AZ), Gilotrif (Boehringer Ingelheim), Tarceva (Astellas Pharma), Halaven (Eisai Pharma), Veliparib (Abbvie), AZD9291 (AZ), Alectinib (Chugai), LDK378 (Novartis), Genetespib (Synta Pharma), Tergenpumatucel-L (NewLink Genetics), GV1001 (Kael-GemVax ), Tivantinib (ArQule); Cytoxane (BMS); Oncovin (Eli Lilly); Adriamycin (Pfizer); Gemzar (Eli Lilly); Xeloda (Roche); Ixempra (BMS); Abraxane (Celgene); Trelstar (Debiopharm); Taxotere (Sanofi); Nexavar (Bayer); IMMU-132 (Immunomedics); E7449 (Eisai); Thermodox (Celsion); Cometriq (Exellxis); Lonsurf (Taiho Pharmaceuticals); Camptosar (Pfizer); UFT (Taiho Pharmaceuticals); and TS-1 (Taiho Pharmaceuticals).</span>
  </p>
  <p id="p0342" num="0342" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Enfermedades neurodegenerativas</span>Neurodegenerative diseases</span>
      </i>
    </b>
  </p>
  <p id="p0344" num="0344" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- </span>-</span>
    </i>
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Enfermedad de Alzheimer y demencia.</span>Alzheimer's disease and dementia.</span>
    </b>
  </p>
  <p id="p0346" num="0346" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La acumulación aberrante de tau hiperfosforilada es una característica de las tauopatías neurodegenerativas como la enfermedad de Alzheimer. La reducción de la actividad de HDAC puede reducir los niveles de tau hiperfosforilada y aliviar los síntomas de los trastornos neurológicos provocados por la tau [38]. Por tanto, en determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento o prevención de tauopatías neurodegenerativas. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento de la enfermedad de Alzheimer.</span>Aberrant accumulation of hyperphosphorylated tau is a hallmark of neurodegenerative tauopathies such as Alzheimer's disease. Reducing HDAC activity can reduce levels of hyperphosphorylated tau and alleviate symptoms of tau-induced neurological disorders [38]. Thus, in certain embodiments, the compositions of the invention are for use in the treatment or prevention of neurodegenerative tauopathies. In certain embodiments, the compositions of the invention are for use in the treatment of Alzheimer's disease.</span>
  </p>
  <p id="p0348" num="0348" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En el DSM-5, el término demencia fue reemplazado por los términos trastorno neurocognitivo mayor y trastorno neurocognitivo leve. El trastorno neurocognitivo es una clase heterogénea de enfermedades psiquiátricas. El trastorno neurocognitivo más común es la enfermedad de Alzheimer, seguida de demencias vasculares o formas 
mixtas de las dos. Otras formas de trastornos neurodegenerativos (p. ej., enfermedad de cuerpos de Lewy, demencia frontotemporal, demencia de Parkinson, enfermedad de Creutzfeldt-Jakob, enfermedad de Huntington y síndrome de Wernicke-Korsakoff) se acompañan de demencia.</span>In DSM-5, the term dementia was replaced by the terms major neurocognitive disorder and mild neurocognitive disorder. Neurocognitive disorder is a heterogeneous class of psychiatric illnesses. The most common neurocognitive disorder is Alzheimer's disease, followed by vascular dementias or forms  mixed of the two. Other forms of neurodegenerative disorders (eg, Lewy body disease, frontotemporal dementia, Parkinson's dementia, Creutzfeldt-Jakob disease, Huntington disease, and Wernicke-Korsakoff syndrome) are associated with dementia.</span>
  </p>
  <p id="p0349" num="0349" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La enfermedad de Alzheimer y la demencia también se caracterizan por la pérdida neuronal, por lo que los efectos neuroprotectores y neuroproliferativos mostrados en los ejemplos de las composiciones de la invención indican que pueden ser útiles para tratar o prevenir estas afecciones.</span>Alzheimer's disease and dementia are also characterized by neuronal loss, therefore the neuroprotective and neuroproliferative effects shown in the examples of the compositions of the invention indicate that they may be useful in treating or preventing these conditions.</span>
  </p>
  <p id="p0350" num="0350" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los criterios sintomáticos para la demencia según el DSM-5 son evidencia de un deterioro cognitivo significativo de un nivel previo de desempeño en uno o más dominios cognitivos seleccionados de: aprendizaje y memoria; idioma; función ejecutiva; atención compleja; cognición perceptivo-motora y social. Los déficits cognitivos deben interferir con la independencia en las actividades cotidianas. Además, los déficits cognitivos no ocurren exclusivamente en el contexto de un delirio y no se explican mejor por otro trastorno mental (por ejemplo, MDD o esquizofrenia).</span>Symptom criteria for dementia according to DSM-5 are evidence of significant cognitive impairment from a previous level of performance in one or more cognitive domains selected from: learning and memory; idiom; executive function; complex care; perceptual-motor and social cognition. Cognitive deficits must interfere with independence in daily activities. Furthermore, cognitive deficits do not occur exclusively in the context of a delusion and are not better explained by another mental disorder (eg, MDD or schizophrenia).</span>
  </p>
  <p id="p0351" num="0351" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Además del síntoma principal, los sujetos con trastornos neurodegenerativos muestran síntomas conductuales y psiquiátricos que incluyen agitación, agresión, depresión, ansiedad, apatía, psicosis y alteraciones del ciclo de sueño-vigilia.</span>In addition to the primary symptom, individuals with neurodegenerative disorders display behavioral and psychiatric symptoms including agitation, aggression, depression, anxiety, apathy, psychosis, and sleep-wake cycle disturbances.</span>
  </p>
  <p id="p0352" num="0352" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los trastornos neurodegenerativos pueden desarrollarse o persistir debido a la disfunción del eje microbiotaintestino-cerebro. Por tanto, en realizaciones preferidas, las composiciones de la invención son para uso en el tratamiento o prevención de trastornos neurodegenerativos en un sujeto. En realizaciones preferidas, el trastorno neurodegenerativo es enfermedad de Alzheimer. En otras realizaciones, el trastorno neurodegenerativo se selecciona de demencias vasculares; enfermedad de Alzheimer de forma mixta y demencia vascular; enfermedad con cuerpos de Lewy; demencia frontotemporal; demencia de Parkinson; enfermedad de Creutzfeldt-Jakob; enfermedad de Huntington; y síndrome de Wernicke-Korsakoff.</span>Neurodegenerative disorders may develop or persist due to dysfunction of the gut-brain microbiota axis. Therefore, in preferred embodiments, the compositions of the invention are for use in the treatment or prevention of neurodegenerative disorders in a subject. In preferred embodiments, the neurodegenerative disorder is Alzheimer's disease. In other embodiments, the neurodegenerative disorder is selected from vascular dementias; mixed form Alzheimer's disease and vascular dementia; Lewy body disease; frontotemporal dementia; Parkinson's dementia; Creutzfeldt-Jakob disease; Huntington's disease; and Wernicke-Korsakoff syndrome.</span>
  </p>
  <p id="p0353" num="0353" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, las composiciones de la invención previenen, reducen o alivian uno o más de los síntomas de trastornos neurodegenerativos en un sujeto. En determinadas realizaciones, las composiciones de la invención previenen, reducen o alivian la aparición del deterioro cognitivo en un sujeto. En determinadas realizaciones, las composiciones de la invención mejoran el nivel de rendimiento de un sujeto con trastornos neurodegenerativos en uno o más dominios cognitivos seleccionados entre: aprendizaje y memoria; idioma; función ejecutiva; atención compleja; cognición perceptivo-motora y social. En algunas realizaciones, las composiciones de la invención previenen, reducen o alivian la aparición de uno o más síntomas conductuales y psiquiátricos asociados con trastornos neurodegenerativos seleccionados entre agitación, agresión, depresión, ansiedad, apatía, psicosis y alteraciones del ciclo sueño-vigilia.</span>In preferred embodiments, the compositions of the invention prevent, reduce, or alleviate one or more symptoms of neurodegenerative disorders in a subject. In certain embodiments, the compositions of the invention prevent, reduce, or alleviate the occurrence of cognitive impairment in a subject. In certain embodiments, the compositions of the invention improve the performance level of a subject with neurodegenerative disorders in one or more cognitive domains selected from: learning and memory; idiom; executive function; complex care; perceptual-motor and social cognition. In some embodiments, the compositions of the invention prevent, reduce, or alleviate the occurrence of one or more behavioral and psychiatric symptoms associated with neurodegenerative disorders selected from agitation, aggression, depression, anxiety, apathy, psychosis, and sleep-wake cycle disturbances.</span>
  </p>
  <p id="p0354" num="0354" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las composiciones de la invención previenen, reducen o alivian la enfermedad sintomática mediante la intervención en mecanismos patogénicos sospechosos en una etapa preclínica. En determinadas realizaciones, las composiciones de la invención mejoran la modificación de la enfermedad, con ralentización o detención de la progresión de los síntomas. En algunas realizaciones, la ralentización o la detención de la progresión de los síntomas se correlaciona con la evidencia del retraso del proceso neuropatológico subyacente. En realizaciones preferidas, las composiciones de la invención mejoran los síntomas de los trastornos neurodegenerativos que comprenden una mejora cognitiva y funcional mejorada. En realizaciones preferidas, las composiciones de la invención mejoran los síntomas conductuales y psiquiátricos de la demencia (BPSD). En realizaciones preferidas, las composiciones de la invención mejoran la capacidad de un sujeto con trastorno neurodegenerativo para realizar actividades cotidianas.</span>In certain embodiments, the compositions of the invention prevent, reduce, or alleviate symptomatic disease by intervening in suspected pathogenic mechanisms at a preclinical stage. In certain embodiments, the compositions of the invention improve disease modification, slowing or stopping the progression of symptoms. In some embodiments, slowing or stopping the progression of symptoms correlates with evidence of retardation of the underlying neuropathological process. In preferred embodiments, the compositions of the invention improve the symptoms of neurodegenerative disorders comprising improved cognitive and functional improvement. In preferred embodiments, the compositions of the invention improve behavioral and psychiatric symptoms of dementia (BPSD). In preferred embodiments, the compositions of the invention improve the ability of a subject with a neurodegenerative disorder to perform daily activities.</span>
  </p>
  <p id="p0355" num="0355" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, las composiciones de la invención mejoran tanto la cognición como el funcionamiento en un sujeto con enfermedad de Alzheimer. En algunas realizaciones, la composición de la invención mejora el criterio de valoración cognitivo en un sujeto con enfermedad de Alzheimer. En algunas realizaciones, las composiciones de la invención mejoran el criterio de valoración funcional en un sujeto con enfermedad de Alzheimer. En realizaciones preferidas, las composiciones de la invención mejoran el criterio de valoración cognitivo y funcional en un sujeto con enfermedad de Alzheimer. En aún otras realizaciones preferidas, las composiciones de la invención mejoran la respuesta clínica global (el criterio de valoración global) en un sujeto con enfermedad de Alzheimer.</span>In preferred embodiments, the compositions of the invention improve both cognition and functioning in a subject with Alzheimer's disease. In some embodiments, the composition of the invention improves cognitive endpoint in a subject with Alzheimer's disease. In some embodiments, the compositions of the invention improve functional endpoints in a subject with Alzheimer's disease. In preferred embodiments, the compositions of the invention improve cognitive and functional endpoints in a subject with Alzheimer's disease. In still other preferred embodiments, the compositions of the invention improve the overall clinical response (the global endpoint) in a subject with Alzheimer's disease.</span>
  </p>
  <p id="p0356" num="0356" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En algunas realizaciones, las composiciones de la invención mejoran los síntomas de los trastornos neurodegenerativos según una prueba sintomática o de diagnóstico. En ciertas realizaciones, las pruebas para evaluar la mejoría sintomática de la enfermedad de Alzheimer (y otros trastornos neurodegenerativos) se seleccionan de cognitivas objetivas, actividades de la vida diaria, evaluación global del cambio, pruebas de calidad de vida relacionadas con la salud y pruebas que evalúan síntomas conductuales y psiquiátricos de trastornos neurodegenerativos.</span>In some embodiments, the compositions of the invention ameliorate the symptoms of neurodegenerative disorders according to a symptomatic or diagnostic test. In certain embodiments, tests to assess symptomatic improvement in Alzheimer's disease (and other neurodegenerative disorders) are selected from objective cognitive, activities of daily living, global assessment of change, health-related quality of life tests, and that assess behavioral and psychiatric symptoms of neurodegenerative disorders.</span>
  </p>
  <p id="p0357" num="0357" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las pruebas cognitivas objetivas para la evaluación de la mejoría sintomática utilizan la subescala cognitiva de la Escala de evaluación de la enfermedad de Alzheimer (ADAS-cog) y la escala ADAS clásica. En determinadas realizaciones, la mejora sintomática de la cognición se evalúa utilizando la batería de pruebas neurofisiológicas para su uso en la enfermedad de Alzheimer (NTB). 
</span>In certain embodiments, objective cognitive tests for assessment of symptomatic improvement utilize the Alzheimer's Disease Assessment Scale cognitive subscale (ADAS-cog) and the classic ADAS scale. In certain embodiments, symptomatic improvement in cognition is assessed using the Neurophysiological Test Battery for Use in Alzheimer's Disease (NTB). </span>
  </p>
  <p id="p0358" num="0358" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En algunas realizaciones, la prueba de evaluación global del cambio utiliza la escala de Impresión Clínica Global -Mejora Global (CGI-I) para evaluar los trastornos psiquiátricos y neurológicos. En algunas realizaciones, la escala global es la Impresión de cambio más basada en entrevistas del médico (CIBIC-plus). En algunas realizaciones, la escala global es la Impresión Global del Cambio del Médico de la Unidad de Estudio Cooperativo de la Enfermedad de Alzheimer (ADCS-Cg IC).</span>In some embodiments, the global assessment of change test uses the Clinical Global Impression-Global Improvement (CGI-I) scale to assess psychiatric and neurological disorders. In some embodiments, the global scale is Physician Interview-Based Impression of Change plus (CIBIC-plus). In some embodiments, the global scale is the Alzheimer's Disease Cooperative Study Unit Physician Global Impression of Change (ADCS-Cg IC).</span>
  </p>
  <p id="p0359" num="0359" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las medidas de calidad de vida relacionadas con la salud son la QOL relacionada con la enfermedad de Alzheimer (ADRQL) y la QOL-enfermedad de Alzheimer (QOL-AD).</span>In certain embodiments, the health-related quality of life measures are Alzheimer's disease-related QOL (ADRQL) and Alzheimer's disease-QOL (AD-QOL).</span>
  </p>
  <p id="p0360" num="0360" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las pruebas que evalúan síntomas conductuales y psiquiátricos de trastornos neurodegenerativos se seleccionan de la Escala de Valoración de Patología Conductual en la enfermedad de Alzheimer (BEHAVE-AD); la Escala de Calificación Conductual para la Demencia (BRSD); el Inventario Neuropsiquiátrico (NPI); y el Inventario de Agitación de Cohen-Mansfield (CMAI).</span>In certain embodiments, tests that assess behavioral and psychiatric symptoms of neurodegenerative disorders are selected from the Alzheimer's Disease Behavioral Pathology Rating Scale (BEHAVE-AD); the Behavioral Rating Scale for Dementia (BRSD); the Neuropsychiatric Inventory (NPI); and the Cohen-Mansfield Agitation Inventory (CMAI).</span>
  </p>
  <p id="p0361" num="0361" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En algunas realizaciones, las composiciones de la invención son particularmente efectivas para prevenir, reducir o aliviar los trastornos de ansiedad cuando se usan en combinación con otra terapia para tratar los trastornos neurodegenerativos. En determinadas realizaciones, tales terapias incluyen inhibidores de acetilcolinesterasa que incluyen donepezil (Aricept®), galantamina (Razadyne®) y rivastigmina (Exelon®) y memantina.</span>In some embodiments, the compositions of the invention are particularly effective in preventing, reducing, or alleviating anxiety disorders when used in combination with other therapy to treat neurodegenerative disorders. In certain embodiments, such therapies include acetylcholinesterase inhibitors including donepezil (Aricept®), galantamine (Razadyne®), and rivastigmine (Exelon®), and memantine.</span>
  </p>
  <p id="p0362" num="0362" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- Enfermedad de Parkinson</span>- Parkinson's disease</span>
    </b>
  </p>
  <p id="p0363" num="0363" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La enfermedad de Parkinson es una enfermedad neurodegenerativa común caracterizada neuropatológicamente por la degeneración de poblaciones heterogéneas de células neurales (células productoras de dopamina). El diagnóstico clínico de la enfermedad de Parkinson requiere bradicinesia y al menos uno de los siguientes síntomas centrales: temblor en reposo; rigidez muscular y deterioro de los reflejos posturales. Otros signos y síntomas que pueden estar presentes o desarrollarse durante la progresión de la enfermedad son alteraciones autonómicas (sialorrea, seborrea, estreñimiento, alteraciones de la micción, funcionamiento sexual, hipotensión ortostática, hiperhidrosis), alteraciones del sueño y alteraciones en el sentido del olfato o del sentido de la temperatura. La enfermedad de Parkinson es una enfermedad neurodegenerativa que puede desarrollarse o persistir debido a la actividad de HDAC. Por ejemplo, se ha demostrado que la actividad de HDAC regula la agregación y el depósito de filamentos proteicos intracelulares tóxicos que son un sello distintivo de enfermedades neurodegenerativas como la enfermedad de Parkinson [39]. Se ha mostrado que la inhibición de la actividad de HDAC reduce los eventos de plegamiento de proteínas tóxicas en modelos de enfermedad de Parkinson. Por tanto, en realizaciones preferidas, las composiciones de la invención son para uso para tratar o prevenir la enfermedad de Parkinson en un sujeto.</span>Parkinson's disease is a common neurodegenerative disease characterized neuropathologically by the degeneration of heterogeneous populations of neural cells (dopamine-producing cells). The clinical diagnosis of Parkinson's disease requires bradykinesia and at least one of the following core symptoms: tremor at rest; muscle stiffness and impaired postural reflexes. Other signs and symptoms that may be present or develop during disease progression include autonomic disturbances (sialorrhea, seborrhea, constipation, micturition disturbances, sexual functioning, orthostatic hypotension, hyperhidrosis), sleep disturbances, and olfactory disturbances. or the sense of temperature. Parkinson's disease is a neurodegenerative disease that can develop or persist due to HDAC activity. For example, HDAC activity has been shown to regulate the aggregation and deposition of toxic intracellular protein filaments that are a hallmark of neurodegenerative diseases such as Parkinson's disease [39]. Inhibition of HDAC activity has been shown to reduce toxic protein folding events in models of Parkinson's disease. Therefore, in preferred embodiments, the compositions of the invention are for use in treating or preventing Parkinson's disease in a subject.</span>
  </p>
  <p id="p0364" num="0364" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas adicionales, las composiciones de la invención son para uso en método para tratar o prevenir la enfermedad de Parkinson. Las composiciones de la invención pueden mejorar las funciones motoras y cognitivas en modelos de la enfermedad de Parkinson. El tratamiento con las composiciones puede modular la señalización en los sistemas nerviosos central, autónomo y entérico; puede modular la actividad de la vía del eje HPA; puede modular neuroendocrino y/o vías neuroinmunes; y puede modular los niveles de metabolitos comensales, marcadores inflamatorios y/o permeabilidad gastrointestinal de un sujeto, todos los cuales están implicados en la neuropatología de la enfermedad de Parkinson. En realizaciones preferidas, la invención proporciona una composición que comprende una cepa bacteriana de la especie <i class="style-scope patent-text">Bariatricus massiliensis </i>para su uso en un método de tratamiento o prevención de la enfermedad de Parkinson. Las composiciones que usan <i class="style-scope patent-text">Bariatricus </i>pueden ser particularmente efectivas para tratar la enfermedad de Parkinson. La composición puede comprender además un ácido orgánico.</span>In further preferred embodiments, the compositions of the invention are for use in a method of treating or preventing Parkinson's disease. The compositions of the invention can improve motor and cognitive functions in models of Parkinson's disease. Treatment with the compositions can modulate signaling in the central, autonomic, and enteric nervous systems; can modulate HPA axis pathway activity; can modulate neuroendocrine and/or neuroimmune pathways; and can modulate a subject's levels of commensal metabolites, inflammatory markers, and/or gastrointestinal permeability, all of which are implicated in the neuropathology of Parkinson's disease. In preferred embodiments, the invention provides a composition comprising a bacterial strain of the species <i class="style-scope patent-text">Bariatricus massiliensis</i> for use in a method of treating or preventing Parkinson's disease. Compositions using <i class="style-scope patent-text">Bariatricus</i> may be particularly effective in treating Parkinson's disease. The composition may further comprise an organic acid.</span>
  </p>
  <p id="p0365" num="0365" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, las composiciones de la invención previenen, reducen o alivian uno o más de los síntomas de la enfermedad de Parkinson. En realizaciones preferidas, las composiciones de la invención previenen, reducen o alivian uno o más de los síntomas de la enfermedad de Parkinson en un sujeto. En determinadas realizaciones, las composiciones de la invención previenen, reducen o alivian la bradicinesia en un sujeto. En determinadas realizaciones, las composiciones de la invención previenen, reducen o alivian el temblor en reposo; rigidez muscular y/o deterioro del reflejo postural en un sujeto. En determinadas realizaciones, las composiciones de la invención previenen, reducen o alivian uno o más síntomas asociados con la progresión de la enfermedad de Parkinson seleccionados entre alteraciones autonómicas (sialorrea, seborrea, estreñimiento, alteraciones de la micción, funcionamiento sexual, hipotensión ortostática, hiperhidrosis), alteraciones del sueño y alteraciones en el sentido del olfato o el sentido de la temperatura.</span>In preferred embodiments, the compositions of the invention prevent, reduce, or alleviate one or more of the symptoms of Parkinson's disease. In preferred embodiments, the compositions of the invention prevent, reduce, or alleviate one or more of the symptoms of Parkinson's disease in a subject. In certain embodiments, the compositions of the invention prevent, reduce, or alleviate bradykinesia in a subject. In certain embodiments, the compositions of the invention prevent, reduce, or alleviate tremor at rest; muscle stiffness and/or postural reflex impairment in a subject. In certain embodiments, the compositions of the invention prevent, reduce or alleviate one or more symptoms associated with the progression of Parkinson's disease selected from among autonomic alterations (sialorrhea, seborrhea, constipation, urination alterations, sexual functioning, orthostatic hypotension, hyperhidrosis ), sleep disturbances, and disturbances in the sense of smell or the sense of temperature.</span>
  </p>
  <p id="p0366" num="0366" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, las composiciones de la invención previenen, reducen o alivian los síntomas depresivos comórbidos con la enfermedad de Parkinson. En determinadas realizaciones, las composiciones de la invención mejoran la memoria verbal y/o funciones ejecutivas. En determinadas realizaciones, las composiciones de la invención mejoran la atención, la memoria de trabajo, la fluidez verbal y/o la ansiedad.</span>In preferred embodiments, the compositions of the invention prevent, reduce, or alleviate depressive symptoms comorbid with Parkinson's disease. In certain embodiments, the compositions of the invention improve verbal memory and/or executive functions. In certain embodiments, the compositions of the invention improve attention, working memory, verbal fluency, and/or anxiety.</span>
  </p>
  <p id="p0367" num="0367" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En otras realizaciones preferidas, las composiciones de la invención previenen, reducen o alivian las disfunciones cognitivas comórbidas con la enfermedad de Parkinson.</span>In other preferred embodiments, the compositions of the invention prevent, reduce or alleviate cognitive dysfunctions comorbid with Parkinson's disease.</span>
  </p>
  <p id="p0368" num="0368" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las composiciones de la invención previenen, reducen o alivian la hiperactividad o el comportamiento similar a la ansiedad comórbido con la enfermedad de Parkinson. Se ha mostrado que los modelos 
de ratones de la enfermedad de Parkinson exhiben hiperactividad. Ciertos modelos han indicado que la hiperactividad puede ser consecuencia de niveles desequilibrados de neurotransmisores en el cerebro o cambios funcionales en otras estructuras dentro del cerebro que preceden a la degeneración de las neuronas dopaminérgicas. Por tanto, las alteraciones del comportamiento, como la hiperactividad, pueden ser síntomas de la enfermedad de Parkinson que preceden a la aparición de las alteraciones motoras. Se ha mostrado que las composiciones de la invención reducen la hiperactividad en modelos de ratones de la enfermedad de Parkinson. Por tanto, en determinadas realizaciones, las composiciones de la invención pueden ser para uso en la prevención de alteraciones motoras en la enfermedad de Parkinson. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento o la prevención de alteraciones del comportamiento asociadas con la enfermedad de Parkinson.</span>In certain embodiments, the compositions of the invention prevent, reduce, or alleviate hyperactivity or anxiety-like behavior comorbid with Parkinson's disease. It has been shown that the models  of Parkinson's disease mice exhibit hyperactivity. Some models have indicated that hyperactivity may be a consequence of unbalanced levels of neurotransmitters in the brain or functional changes in other structures within the brain that precede the degeneration of dopaminergic neurons. Therefore, behavioral disturbances, such as hyperactivity, may be symptoms of Parkinson's disease that precede the onset of motor disturbances. Compositions of the invention have been shown to reduce hyperactivity in mouse models of Parkinson's disease. Thus, in certain embodiments, the compositions of the invention may be for use in preventing motor disturbances in Parkinson's disease. In certain embodiments, the compositions of the invention are for use in treating or preventing behavioral disturbances associated with Parkinson's disease.</span>
  </p>
  <p id="p0369" num="0369" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las composiciones de la invención previenen, reducen o alivian la progresión de la enfermedad de Parkinson. En determinadas realizaciones, las composiciones de la invención previenen, reducen o alivian las complicaciones motoras posteriores. En determinadas realizaciones, las composiciones de la invención previenen, reducen o alivian las fluctuaciones motoras tardías. En determinadas realizaciones, las composiciones de la invención previenen, reducen o alivian la pérdida neuronal. En determinadas realizaciones, las composiciones de la invención mejoran los síntomas de la demencia de la enfermedad de Parkinson (PDD). En determinadas realizaciones, las composiciones de la invención previenen, reducen o alivian el deterioro de la función ejecutiva, atención y/o memoria de trabajo. En determinadas realizaciones, las composiciones de la invención mejoran la neurotransmisión dopaminérgica. En determinadas realizaciones, las composiciones de la invención previenen, reducen o alivian la neurotransmisión dopaminérgica alterada.</span>In certain embodiments, the compositions of the invention prevent, reduce, or ameliorate the progression of Parkinson's disease. In certain embodiments, the compositions of the invention prevent, reduce, or alleviate posterior motor complications. In certain embodiments, the compositions of the invention prevent, reduce, or alleviate late motor fluctuations. In certain embodiments, the compositions of the invention prevent, reduce, or alleviate neuronal loss. In certain embodiments, the compositions of the invention improve the symptoms of Parkinson's disease dementia (PDD). In certain embodiments, the compositions of the invention prevent, reduce, or alleviate impairment of executive function, attention, and/or working memory. In certain embodiments, the compositions of the invention enhance dopaminergic neurotransmission. In certain embodiments, the compositions of the invention prevent, reduce, or alleviate impaired dopaminergic neurotransmission.</span>
  </p>
  <p id="p0370" num="0370" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En algunas realizaciones, las composiciones de la invención mejoran los síntomas de la enfermedad de Parkinson según una escala sintomática o diagnóstica. En determinadas realizaciones, las pruebas para evaluar la mejora sintomática de la función motora en la enfermedad de Parkinson es la Escala Unificada de Valoración de la Enfermedad de Parkinson. En particular, UPDRS II considera la actividad de la vida diaria y UPDRS III considera el examen motor.</span>In some embodiments, the compositions of the invention ameliorate the symptoms of Parkinson's disease on a symptomatic or diagnostic scale. In certain embodiments, the test for evaluating symptomatic improvement of motor function in Parkinson's disease is the Unified Parkinson's Disease Rating Scale. In particular, UPDRS II considers the activity of daily living and UPDRS III considers the motor exam.</span>
  </p>
  <p id="p0371" num="0371" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En algunas realizaciones, las composiciones de la invención mejoran los síntomas asociados con el PDD según una prueba y/o escala sintomática o de diagnóstico. En determinadas realizaciones, la prueba o escala se selecciona de la Prueba de aprendizaje verbal de Hopkins - Revisada (HVLT-R); la prueba de interferencia de palabras y colores del sistema de funciones ejecutivas Delis-Kaplan (D-KEFS); la Escala de Calificación de Depresión de Hamilton (HAM-D 17; depresión); la Escala de Calificación de Ansiedad de Hamilton (HAM-A; ansiedad) y la Escala de Calificación de la Enfermedad de Parkinson Unificada (UPDRS; severidad de los síntomas de la PD).</span>In some embodiments, compositions of the invention ameliorate symptoms associated with PDD according to a symptom or diagnostic test and/or scale. In certain embodiments, the test or scale is selected from the Hopkins Verbal Learning Test - Revised (HVLT-R); the Delis-Kaplan Executive Function System (D-KEFS) color-word interference test; the Hamilton Depression Rating Scale (HAM-D 17; depression); the Hamilton Anxiety Rating Scale (HAM-A; anxiety) and the Unified Parkinson's Disease Rating Scale (UPDRS; PD symptom severity).</span>
  </p>
  <p id="p0372" num="0372" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En algunas realizaciones, las composiciones de la invención mejoran la escala de Impresión Clínica Global - Mejora Global (CGI-I) para evaluar trastornos psiquiátricos y neurológicos. En algunas realizaciones, las composiciones de la invención muestran un efecto positivo sobre el deterioro social y ocupacional global del sujeto con la enfermedad de Parkinson.</span>In some embodiments, compositions of the invention improve the Clinical Global Impression - Global Improvement (CGI-I) scale for evaluating psychiatric and neurological disorders. In some embodiments, the compositions of the invention show a positive effect on the overall social and occupational impairment of the subject with Parkinson's disease.</span>
  </p>
  <p id="p0373" num="0373" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento de prevención de los trastornos neurológicos como la enfermedad de Parkinson en un sujeto en el que dicho uso implica reducir o prevenir la pérdida de células dopaminérgicas en la sustancia nigra. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento de prevención de los trastornos neurológicos como la enfermedad de Parkinson en un sujeto en el que dicho uso implica reducir o prevenir la degeneración de neuronas dopaminérgicas en la sustancia nigra pars compacta. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento de prevención de los trastornos neurológicos como la enfermedad de Parkinson en un sujeto en el que dicho uso implica reducir o prevenir la degeneración de neuronas dopaminérgicas en la sustancia nigra pars compacta y la pérdida consecuente de sus fibras nerviosas de proyección en el cuerpo estriado. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento de prevención de trastornos neurológicos como la enfermedad de Parkinson en un sujeto en el que dicho uso implica reducir o prevenir la pérdida de neuronas dopaminérgicas nigroestriatales.</span>In certain embodiments, the compositions of the invention are for use in the treatment of prevention of neurological disorders such as Parkinson's disease in a subject where said use involves reducing or preventing the loss of dopaminergic cells in the substantia nigra. In certain embodiments, the compositions of the invention are for use in the treatment of prevention of neurological disorders such as Parkinson's disease in a subject where said use involves reducing or preventing the degeneration of dopaminergic neurons in the substantia nigra pars compacta. In certain embodiments, the compositions of the invention are for use in the treatment of prevention of neurological disorders such as Parkinson's disease in a subject where said use involves reducing or preventing the degeneration of dopaminergic neurons in the substantia nigra pars compacta and the consequent loss of its projection nerve fibers in the striatum. In certain embodiments, the compositions of the invention are for use in the treatment of prevention of neurological disorders such as Parkinson's disease in a subject where said use involves reducing or preventing the loss of nigrostriatal dopaminergic neurons.</span>
  </p>
  <p id="p0374" num="0374" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las composiciones de la invención se utilizan para tratar o prevenir trastornos neurológicos como la enfermedad de Parkinson en un sujeto en el que dicho uso implica aumentar los niveles de dopamina. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento de prevención de trastornos neurológicos como la enfermedad de Parkinson en un sujeto en el que dicho uso implica aumentar los niveles de DOPAC. En determinadas realizaciones, las composiciones de la invención son para uso en el tratamiento de prevención de trastornos neurológicos como la enfermedad de Parkinson en un sujeto en el que dicho uso implica aumentar los niveles de dopamina y DOPAC. En determinadas formas de realización, la dopamina y/o los niveles de DOPAC aumentan en el cuerpo estriado.</span>In certain embodiments, the compositions of the invention are used to treat or prevent neurological disorders such as Parkinson's disease in a subject where said use involves increasing dopamine levels. In certain embodiments, the compositions of the invention are for use in the prevention treatment of neurological disorders such as Parkinson's disease in a subject where said use involves increasing DOPAC levels. In certain embodiments, the compositions of the invention are for use in the prevention treatment of neurological disorders such as Parkinson's disease in a subject where said use involves increasing dopamine and DOPAC levels. In certain embodiments, dopamine and/or DOPAC levels are increased in the striatum.</span>
  </p>
  <p id="p0375" num="0375" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los ejemplos demuestran que las composiciones de la invención activan la activación de MAP2 (proteína 2 asociada a microtúbulos). MAP2 es un gen asociado con la diferenciación neuronal de MAP2 y se cree que es esencial para la formación de microtúbulos en neuritogénesis, por lo que las composiciones de la invención pueden ser particularmente útiles para tratar enfermedades neurodegenerativas. En algunas realizaciones, las composiciones de la invención son para uso en el tratamiento de una enfermedad neurodegenerativa, como la enfermedad de 
Alzheimer o la enfermedad de Parkinson, activando o aumentando los niveles de MAP2. Además, como MAP2 promueve el crecimiento de neuritas, que desempeñan un papel importante en la redistribución de neuronas dañadas y la sinaptogénesis, la expresión de MAP2 podría ir más allá de ser un marcador de diferenciación neuronal e indicar un "recableado neuronal" asociado con el resultado terapéutico de la enfermedad neuropatológica [22]. Los ejemplos demuestran que las composiciones de la invención modulan la expresión de varias proteínas en el cerebro. En particular, las composiciones de la invención aumentan la expresión de BDNF en el hipocampo y la corteza prefrontal. El BDNF es esencial para la plasticidad sináptica del adulto y la formación de recuerdos y se observa una disminución en los niveles de BDNF en pacientes con Alzheimer y Huntington. Por tanto, las composiciones de la invención son particularmente útiles para el tratamiento de la enfermedad de Alzheimer y Huntington. En determinadas realizaciones, las composiciones de la invención aumentan la expresión de BDNF en el cerebro.</span>The examples demonstrate that the compositions of the invention promote the activation of MAP2 (microtubule-associated protein 2). MAP2 is a gene associated with MAP2 neuronal differentiation and is believed to be essential for microtubule formation in neuritogenesis, thus compositions of the invention may be particularly useful for treating neurodegenerative diseases. In some embodiments, the compositions of the invention are for use in the treatment of a neurodegenerative disease, such as Alzheimer's disease.  Alzheimer's or Parkinson's disease, by activating or increasing the levels of MAP2. Furthermore, as MAP2 promotes the growth of neurites, which play an important role in the redistribution of damaged neurons and synaptogenesis, the expression of MAP2 could go beyond being a marker of neuronal differentiation and indicate "neuronal rewiring" associated with the therapeutic outcome of neuropathological disease [22]. The examples demonstrate that the compositions of the invention modulate the expression of various proteins in the brain. In particular, the compositions of the invention increase the expression of BDNF in the hippocampus and prefrontal cortex. BDNF is essential for adult synaptic plasticity and memory formation and decreased levels of BDNF are observed in Alzheimer's and Huntington's patients. Therefore, the compositions of the invention are particularly useful for the treatment of Alzheimer's and Huntington's disease. In certain embodiments, the compositions of the invention increase the expression of BDNF in the brain.</span>
  </p>
  <p id="p0376" num="0376" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Modos de administración</span>Administration modes</span>
      </i>
    </b>
  </p>
  <p id="p0377" num="0377" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Preferiblemente, las composiciones de la invención deben administrarse al tracto gastrointestinal para permitir el suministro a y/o colonización parcial o total del intestino con la cepa bacteriana de la invención. Generalmente, las composiciones de la invención se administran por vía oral, pero pueden administrarse por vía rectal, intranasal o por vía bucal o sublingual.</span>Preferably, the compositions of the invention should be administered to the gastrointestinal tract to allow delivery to and/or partial or total colonization of the intestine with the bacterial strain of the invention. Generally, the compositions of the invention are administered orally, but may be administered rectally, intranasally, or buccally or sublingually.</span>
  </p>
  <p id="p0378" num="0378" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las composiciones de la invención se pueden administrar como espuma, spray o gel. En determinadas realizaciones, las composiciones de la invención se pueden administrar como un supositorio, como un supositorio rectal, por ejemplo, en forma de aceite de teobroma (manteca de cacao), grasa dura sintética (p. ej., suppocire, witepsol), glicerogelatina, polietilenglicol o composición de glicerina de jabón.</span>In certain embodiments, the compositions of the invention can be administered as a foam, spray, or gel. In certain embodiments, compositions of the invention may be administered as a suppository, such as a rectal suppository, for example, in the form of theobroma (cocoa butter) oil, synthetic hard fat (eg, suppocire, witepsol), glycerogelatin, polyethylene glycol or glycerin composition of soap.</span>
  </p>
  <p id="p0379" num="0379" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, la composición de la invención se administra al tracto gastrointestinal a través de un tubo, tal como un tubo nasogástrico, tubo orogástrico, tubo gástrico, tubo de yeyunostomía (tubo en J), gastrostomía endoscópica percutánea (PEG), o un puerto, tal como un puerto de la pared torácica que proporciona acceso al estómago, yeyuno y otros puertos de acceso adecuados.</span>In certain embodiments, the composition of the invention is administered to the gastrointestinal tract through a tube, such as a nasogastric tube, orogastric tube, gastric tube, jejunostomy tube (J-tube), percutaneous endoscopic gastrostomy (PEG), or a port, such as a chest wall port that provides access to the stomach, jejunum, and other suitable access ports.</span>
  </p>
  <p id="p0380" num="0380" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las composiciones de la invención pueden administrarse una vez o pueden administrarse secuencialmente como parte de un régimen de tratamiento. En determinadas realizaciones, las composiciones de la invención deben administrarse diariamente.</span>The compositions of the invention may be administered once or may be administered sequentially as part of a treatment regimen. In certain embodiments, the compositions of the invention must be administered daily.</span>
  </p>
  <p id="p0381" num="0381" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones de la invención, el tratamiento según la invención se acompaña de la evaluación de la microbiota intestinal del paciente. El tratamiento puede repetirse si se administra y/o la colonización parcial o total con la cepa de la invención no se logra de manera que no se observe eficacia, o el tratamiento puede interrumpirse si el suministro y/o la colonización parcial o total tiene éxito y se observa eficacia.</span>In certain embodiments of the invention, treatment according to the invention is accompanied by assessment of the patient's gut microbiota. Treatment may be repeated if administration and/or partial or total colonization with the strain of the invention is not achieved such that no efficacy is observed, or treatment may be discontinued if administration and/or partial or total colonization is successful. and efficacy is observed.</span>
  </p>
  <p id="p0382" num="0382" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, la composición de la invención se puede administrar a un animal preñado, por ejemplo, un mamífero como un ser humano para prevenir el desarrollo de una enfermedad inflamatoria o autoinmune en su hijo en el útero y/o después de que nazca.</span>In certain embodiments, the composition of the invention may be administered to a pregnant animal, eg, a mammal such as a human, to prevent the development of an inflammatory or autoimmune disease in her child in utero and/or after it is born.</span>
  </p>
  <p id="p0383" num="0383" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las composiciones de la invención pueden administrarse a un paciente que ha sido diagnosticado con una enfermedad o afección mediada por una actividad histona desacetilasa elevada, o que se ha identificado como en riesgo de una enfermedad o afección mediada por una actividad histona desacetilasa elevada. Las composiciones también se pueden administrar como medida profiláctica para prevenir el desarrollo de enfermedades o afecciones mediadas por una actividad elevada de histona desacetilasa en un paciente sano.</span>The compositions of the invention may be administered to a patient who has been diagnosed with a disease or condition mediated by elevated histone deacetylase activity, or who has been identified as being at risk for a disease or condition mediated by elevated histone deacetylase activity. The compositions can also be administered as a prophylactic measure to prevent the development of diseases or conditions mediated by elevated histone deacetylase activity in a healthy patient.</span>
  </p>
  <p id="p0384" num="0384" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las composiciones de la invención se pueden administrar a un paciente que se ha identificado que tiene una microbiota intestinal anormal. Por ejemplo, el paciente puede tener una colonización reducida o ausente por <i class="style-scope patent-text">Bariatricus, </i>y en particular por <i class="style-scope patent-text">Bariatricus massiliensis.</i> </span>The compositions of the invention can be administered to a patient who has been identified as having an abnormal gut microbiota. For example, the patient may have reduced or absent colonization by <i class="style-scope patent-text">Bariatricus,</i> and in particular by <i class="style-scope patent-text">Bariatricus massiliensis.</i> </span>
  </p>
  <p id="p0385" num="0385" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las composiciones de la invención se pueden administrar como un producto alimenticio, tal como un suplemento nutricional.</span>The compositions of the invention can be administered as a food product, such as a nutritional supplement.</span>
  </p>
  <p id="p0386" num="0386" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Generalmente, las composiciones de la invención son para el tratamiento de seres humanos, aunque pueden usarse para tratar animales, incluidos mamíferos monogástricos como aves de corral, cerdos, gatos, perros, caballos o conejos. Las composiciones de la invención pueden ser útiles para mejorar el crecimiento y el rendimiento de los animales. Si se administra a animales, se puede usar sonda oral.</span>Generally, the compositions of the invention are for the treatment of humans, although they can be used to treat animals, including monogastric mammals such as poultry, pigs, cats, dogs, horses or rabbits. The compositions of the invention may be useful for improving the growth and performance of animals. If administered to animals, oral gavage may be used.</span>
  </p>
  <p id="p0387" num="0387" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Composiciones</span>compositions</span>
      </i>
    </b>
  </p>
  <p id="p0388" num="0388" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La composición de la invención comprende bacterias. En realizaciones preferidas de la invención, la composición se formula en forma liofilizada. Por ejemplo, la composición de la invención puede comprender gránulos o cápsulas de gelatina, por ejemplo cápsulas de gelatina dura, que comprenden una cepa bacteriana de la invención. 
</span>The composition of the invention comprises bacteria. In preferred embodiments of the invention, the composition is formulated in lyophilized form. For example, the composition of the invention may comprise gelatin capsules or granules, eg hard gelatin capsules, comprising a bacterial strain of the invention. </span>
  </p>
  <p id="p0389" num="0389" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Preferiblemente, la composición de la invención comprende bacterias liofilizadas. La liofilización de bacterias es un procedimiento bien establecido y la orientación pertinente está disponible, por ejemplo, en las referencias [40,,42]. Alternativamente, la composición de la invención puede comprender un cultivo bacteriano activo vivo.</span>Preferably, the composition of the invention comprises freeze-dried bacteria. Lyophilization of bacteria is a well-established procedure and relevant guidance is available, for example, in references [40, 42]. Alternatively, the composition of the invention may comprise a live active bacterial culture.</span>
  </p>
  <p id="p0390" num="0390" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, la composición de la invención se encapsula para permitir el suministro de la cepa bacteriana al intestino. La encapsulación protege la composición de la degradación hasta el suministro en la ubicación objetivo mediante, por ejemplo, la ruptura con estímulos químicos o físicos como presión, actividad enzimática o desintegración física, que pueden desencadenarse por cambios en el pH. Puede usarse cualquier método de encapsulación apropiado. Las técnicas de encapsulación ejemplares incluyen atrapamiento dentro de una matriz porosa, unión o adsorción sobre superficies sólidas del portador, autoagregación por floculación o con agentes reticulantes y contención mecánica detrás de una membrana microporosa o microcápsula. Orientación sobre encapsulación que puede ser útil para preparar composiciones de la invención está disponible en, por ejemplo, referencias [43] y [44].</span>In preferred embodiments, the composition of the invention is encapsulated to allow delivery of the bacterial strain to the intestine. Encapsulation protects the composition from degradation until delivery to the target location by, for example, breaking down with chemical or physical stimuli such as pressure, enzymatic activity, or physical disintegration, which can be triggered by changes in pH. Any suitable encapsulation method can be used. Exemplary encapsulation techniques include entrapment within a porous matrix, binding or adsorption onto solid carrier surfaces, self-aggregation by flocculation or with cross-linking agents, and mechanical containment behind a microporous membrane or microcapsule. Guidance on encapsulation that may be useful in preparing compositions of the invention is available in, for example, references [43] and [44].</span>
  </p>
  <p id="p0391" num="0391" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La composición se puede administrar por vía oral y puede estar en forma de comprimido, cápsula o polvo. Se prefieren los productos encapsulados porque los <i class="style-scope patent-text">Bariatricus </i>son anaerobios. Se pueden incluir otros ingredientes (como la vitamina C, por ejemplo) como captadores de oxígeno y sustratos prebióticos para mejorar la administración y/o colonización y supervivencia parcial o total <i class="style-scope patent-text">in vivo. </i>Alternativamente, la composición probiótica de la invención puede administrarse por vía oral como alimento o producto nutricional, tal como leche o producto lácteo fermentado a base de suero, o como producto farmacéutico.</span>The composition can be administered orally and can be in the form of a tablet, capsule or powder. Encapsulated products are preferred because <i class="style-scope patent-text">Bariatricus</i> are anaerobes. Other ingredients (such as vitamin C, for example) may be included as oxygen scavengers and prebiotic substrates to improve delivery and/or colonization and partial or total survival <i class="style-scope patent-text">in vivo.</i> Alternatively, the probiotic composition of the invention may be administered orally as a food or nutritional product, such as milk or whey-based fermented milk product, or as a pharmaceutical.</span>
  </p>
  <p id="p0392" num="0392" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La composición se puede formular como probiótico.</span>The composition can be formulated as a probiotic.</span>
  </p>
  <p id="p0393" num="0393" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Una composición de la invención incluye una cantidad terapéuticamente eficaz de una cepa bacteriana de la invención. Una cantidad terapéuticamente eficaz de una cepa bacteriana es suficiente para ejercer un efecto beneficioso sobre un paciente. Una cantidad terapéuticamente eficaz de una cepa bacteriana puede ser suficiente para dar como resultado el suministro a y/o colonización parcial o total del intestino del paciente.</span>A composition of the invention includes a therapeutically effective amount of a bacterial strain of the invention. A therapeutically effective amount of a bacterial strain is sufficient to exert a beneficial effect on a patient. A therapeutically effective amount of a bacterial strain may be sufficient to result in delivery to and/or partial or total colonization of the patient's intestine.</span>
  </p>
  <p id="p0394" num="0394" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Una dosis diaria adecuada de la bacteria, por ejemplo para un ser humano adulto, puede ser de aproximadamente 1 x 103 a aproximadamente 1 x 1011 unidades formadoras de colonias (UFC); por ejemplo, de aproximadamente 1 x 107 a aproximadamente 1 x 1010 UFC; en otro ejemplo, de aproximadamente 1 x 106 a aproximadamente 1 x 1010 UFC; en otro ejemplo, de aproximadamente 1 x 107 a aproximadamente 1 x 1011 UFC; en otro ejemplo, de aproximadamente 1 x 108 a aproximadamente 1 x 1010 UFC; en otro ejemplo, de aproximadamente 1 x 108 a aproximadamente 1 x 1011 UFC.</span>A suitable daily dose of the bacterium, for example for an adult human, may be from about 1 x 103 to about 1 x 1011 colony-forming units (CFUs); for example, from about 1 x 107 to about 1 x 1010 CFU; in another example, from about 1 x 106 to about 1 x 1010 CFU; in another example, from about 1 x 107 to about 1 x 1011 CFU; in another example, from about 1 x 108 to about 1 x 1010 CFU; in another example, from about 1 x 108 to about 1 x 1011 CFU.</span>
  </p>
  <p id="p0395" num="0395" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, la dosis de bacterias es de al menos 109 células por día, tal como al menos 1010, al menos 1011 o al menos 1012 células por día.</span>In certain embodiments, the dose of bacteria is at least 109 cells per day, such as at least 1010, at least 1011, or at least 1012 cells per day.</span>
  </p>
  <p id="p0396" num="0396" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, la composición contiene la cepa bacteriana en una cantidad de aproximadamente 1 x 106 a aproximadamente 1 x 1011 UFC/g, con respecto al peso de la composición; por ejemplo, de aproximadamente 1 x 108 a aproximadamente 1 x 1010 UFC/g. La dosis puede ser, por ejemplo, 1 g, 3 g, 5 g y 10 g. En determinadas realizaciones, la invención proporciona la composición farmacéutica anterior, en la que la cantidad de cepa bacteriana es de aproximadamente 1 x 103 a aproximadamente 1 x 1011 unidades formadoras de colonias por gramo con respecto al peso de la composición.</span>In certain embodiments, the composition contains the bacterial strain in an amount of from about 1 x 106 to about 1 x 1011 CFU/g, based on the weight of the composition; for example, from about 1 x 108 to about 1 x 1010 CFU/g. The dose can be, for example, 1 g, 3 g, 5 g and 10 g. In certain embodiments, the invention provides the above pharmaceutical composition, wherein the amount of bacterial strain is from about 1 x 103 to about 1 x 1011 colony-forming units per gram based on the weight of the composition.</span>
  </p>
  <p id="p0397" num="0397" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, la invención proporciona la composición farmacéutica anterior, en la que la composición se administra a una dosis de entre 500 mg y 1000 mg, entre 600 mg y 900 mg, entre 700 mg y 800 mg, entre 500 mg y 750 mg o entre 750 mg y 1000 mg. En determinadas realizaciones, la invención proporciona la composición farmacéutica anterior, en la que la bacteria liofilizada en la composición farmacéutica se administra a una dosis de entre 500 mg y 1000 mg, entre 600 mg y 900 mg, entre 700 mg y 800 mg, entre 500 mg y 750 mg o entre 750 mg y 1000 mg.</span>In certain embodiments, the invention provides the above pharmaceutical composition, wherein the composition is administered at a dose of between 500 mg and 1000 mg, between 600 mg and 900 mg, between 700 mg and 800 mg, between 500 mg and 750 mg or between 750 mg and 1000 mg. In certain embodiments, the invention provides the above pharmaceutical composition, wherein the lyophilized bacteria in the pharmaceutical composition is administered at a dose of between 500 mg and 1000 mg, between 600 mg and 900 mg, between 700 mg and 800 mg, between 500 mg and 750 mg or between 750 mg and 1000 mg.</span>
  </p>
  <p id="p0398" num="0398" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Normalmente, un probiótico, como la composición de la invención, se combina opcionalmente con al menos un compuesto prebiótico adecuado. Un compuesto prebiótico suele ser un carbohidrato no digerible, como un oligo o polisacárido, o un alcohol de azúcar, que no se degrada ni se absorbe en el tracto digestivo superior. Los prebióticos conocidos incluyen productos comerciales tales como inulina y transgalactooligosacáridos.</span>Typically, a probiotic, such as the composition of the invention, is optionally combined with at least one suitable prebiotic compound. A prebiotic compound is usually an indigestible carbohydrate, such as an oligo or polysaccharide, or a sugar alcohol, that is not broken down or absorbed in the upper digestive tract. Known prebiotics include commercial products such as inulin and transgalactooligosaccharides.</span>
  </p>
  <p id="p0399" num="0399" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, la composición probiótica de la presente invención incluye un compuesto prebiótico en una cantidad de aproximadamente 1 a aproximadamente 30% en peso, con respecto al peso total de la composición (p. ej., de 5 a 20% en peso). Los carbohidratos se pueden seleccionar del grupo que consiste en: fructo-oligosacáridos (o FOS), fructo-oligosacáridos de cadena corta, inulina, isomalt-oligosacáridos, pectinas, xilooligosacáridos (o XOS), quitosano-oligosacáridos (o COS), beta -glucanos, almidones resistentes y modificados con goma de cultivo, polidextrosa, D-tagatosa, fibras de acacia, algarroba, avena y fibras de cítricos. En un aspecto, los prebióticos son los fructooligosacáridos de cadena corta (por simplicidad mostrados a continuación en el presente documento como FOSs-cc); dichos FOSs-cc no son carbohidratos digeribles, generalmente obtenidos por 
conversión del azúcar de remolacha y que incluyen una molécula de sacarosa a la que se unen tres moléculas de glucosa.</span>In certain embodiments, the probiotic composition of the present invention includes a prebiotic compound in an amount of from about 1 to about 30% by weight, based on the total weight of the composition (eg, from 5 to 20% by weight). . Carbohydrates may be selected from the group consisting of: fructo-oligosaccharides (or FOS), short-chain fructo-oligosaccharides, inulin, isomalt-oligosaccharides, pectins, xylooligosaccharides (or XOS), chitosan-oligosaccharides (or COS), beta- glucans, resistant and modified starches with crop gum, polydextrose, D-tagatose, fibers from acacia, carob, oats and citrus fibers. In one aspect, the prebiotics are short-chain fructooligosaccharides (for simplicity shown hereinafter as FOSs-cc); said FOSs-cc are not digestible carbohydrates, generally obtained by  conversion of beet sugar and that include a sucrose molecule to which three glucose molecules are attached.</span>
  </p>
  <p id="p0401" num="0401" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las composiciones de la invención pueden comprender excipientes o vehículos farmacéuticamente aceptables. Se pueden encontrar ejemplos de tales excipientes adecuados en la referencia [45]. Se conocen en la técnica farmacéutica portadores o diluyentes aceptables para uso terapéutico y se describen, por ejemplo, en la referencia [46]. Ejemplos de portadores adecuados incluyen lactosa, almidón, glucosa, metilcelulosa, estearato de magnesio, manitol, sorbitol y similares. Ejemplos de diluyentes adecuados incluyen etanol, glicerol y agua. El diluyente, excipiente o portador farmacéutico se puede seleccionar conforme a la vía de administración deseada y la práctica farmacéutica estándar. Las composiciones farmacéuticas pueden comprender como, o además de, el vehículo, excipiente o diluyente cualquier aglutinante(s), lubricante(s), agente(s) de suspensión, agente(s) de revestimiento, agente(s) solubilizantes adecuados. Ejemplos de aglutinantes adecuados incluyen almidón, gelatina, azúcares naturales tales como glucosa, lactosa anhidra, lactosa en flujo libre, beta-lactosa, endulzantes de maíz, gomas naturales y sintéticas, tales como acacia, tragacanto o alginato de sodio, carboximetilcelulosa y polietilenglicol. Ejemplos de lubricantes adecuados incluyen oleato de sodio, estearato de sodio, estearato de magnesio, benzoato de sodio, acetato de sodio, cloruro de sodio y similares. En la composición farmacéutica se pueden proporcionar conservantes, estabilizadores, colorantes e incluso agentes aromatizantes. Ejemplos de conservantes incluyen benzoato de sodio, ácido sórbico y ésteres de ácido p-hidroxibenzoico. También se pueden usar antioxidantes y agentes de suspensión.</span>The compositions of the invention may comprise pharmaceutically acceptable carriers or excipients. Examples of such suitable excipients can be found in reference [45]. Acceptable carriers or diluents for therapeutic use are known in the pharmaceutical art and are described, for example, in reference [46]. Examples of suitable carriers include lactose, starch, glucose, methylcellulose, magnesium stearate, mannitol, sorbitol, and the like. Examples of suitable diluents include ethanol, glycerol, and water. The pharmaceutical diluent, excipient or carrier may be selected according to the desired route of administration and standard pharmaceutical practice. The pharmaceutical compositions may comprise as, or in addition to, the carrier, excipient or diluent any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), solubilizing agent(s). Examples of suitable binders include starch, gelatin, natural sugars such as glucose, anhydrous lactose, free flowing lactose, beta-lactose, corn sweeteners, natural and synthetic gums, such as acacia, tragacanth or sodium alginate, carboxymethylcellulose and polyethylene glycol. Examples of suitable lubricants include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like. Preservatives, stabilizers, colorants and even flavoring agents can be provided in the pharmaceutical composition. Examples of preservatives include sodium benzoate, sorbic acid, and esters of p-hydroxybenzoic acid. Antioxidants and suspending agents can also be used.</span>
  </p>
  <p id="p0403" num="0403" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las composiciones de la invención se pueden formular como un producto alimenticio. Por ejemplo, un producto alimenticio puede proporcionar un beneficio nutricional además del efecto terapéutico de la invención, como en un suplemento nutricional. De manera similar, se puede formular un producto alimenticio para mejorar el sabor de la composición de la invención o para hacer que la composición sea más atractiva para consumir al ser más similar a un artículo alimenticio común, en lugar de a una composición farmacéutica. En determinadas realizaciones, la composición de la invención se formula como un producto a base de leche. El término "producto a base de leche" significa cualquier producto a base de leche o suero líquido o semisólido que tenga un contenido de grasa variable. El producto a base de leche puede ser, p. ej., leche de vaca, leche de cabra, leche de oveja, leche desnatada, leche entera, leche recombinada de leche en polvo y suero sin ningún procesamiento, o un producto procesado, como yogur, leche cuajada, cuajada, leche agria, leche entera agria, leche de mantequilla y otros productos lácteos agrios. Otro grupo importante incluye las bebidas lácteas, como las bebidas de suero, leches fermentadas, leches condensadas, leches para lactantes o bebés; leches aromatizadas, helados; alimentos que contienen leche, como dulces.</span>The compositions of the invention can be formulated as a food product. For example, a food product may provide a nutritional benefit in addition to the therapeutic effect of the invention, as in a nutritional supplement. Similarly, a food product may be formulated to enhance the taste of the composition of the invention or to make the composition more attractive to consume by being more similar to a common food item, rather than a pharmaceutical composition. In certain embodiments, the composition of the invention is formulated as a milk-based product. The term "milk-based product" means any liquid or semi-solid milk or whey-based product having variable fat content. The milk-based product can be e.g. cow's milk, goat's milk, sheep's milk, skim milk, whole milk, milk recombined from milk powder and whey without any processing, or a processed product, such as yogurt, curdled milk, curd, sour milk, milk whole sour, buttermilk and other sour milk products. Another important group includes milk drinks, such as whey drinks, fermented milks, condensed milks, milks for infants or babies; flavored milks, ice creams; foods that contain milk, such as sweets.</span>
  </p>
  <p id="p0405" num="0405" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, las composiciones de la invención contienen una única cepa o especie bacteriana y no contienen ninguna otra cepa o especie bacteriana. Tales composiciones pueden comprender sólo cantidades <i class="style-scope patent-text">mínimas </i>o biológicamente irrelevantes de otras cepas o especies bacterianas. Tales composiciones pueden ser un cultivo sustancialmente exento de otras especies de organismos. En determinadas realizaciones, las composiciones de la invención consisten en 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 o 16 cepas o especies bacterianas. En determinadas realizaciones, las composiciones consisten en 1 a 10, preferiblemente de 1 a 5 cepas o especies bacterianas.</span>In certain embodiments, compositions of the invention contain a single bacterial strain or species and do not contain any other bacterial strain or species. Such compositions may comprise only <i class="style-scope patent-text">minute</i> or biologically irrelevant amounts of other bacterial strains or species. Such compositions may be a culture substantially free of other species of organisms. In certain embodiments, compositions of the invention consist of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 bacterial strains or species. In certain embodiments, the compositions consist of 1 to 10, preferably 1 to 5 bacterial strains or species.</span>
  </p>
  <p id="p0407" num="0407" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las composiciones para su uso de acuerdo con la invención pueden requerir o no aprobación de comercialización. </span>Compositions for use in accordance with the invention may or may not require marketing approval.</span>
  </p>
  <p id="p0408" num="0408" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En algunos casos, la cepa bacteriana liofilizada se reconstituye antes de la administración. En algunos casos, la reconstitución se realiza mediante el uso de un diluyente descrito en el presente documento.</span>In some cases, the lyophilized bacterial strain is reconstituted prior to administration. In some cases, reconstitution is accomplished through the use of a diluent described herein.</span>
  </p>
  <p id="p0410" num="0410" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las composiciones de la invención pueden comprender excipientes, diluyentes o vehículos farmacéuticamente aceptables.</span>The compositions of the invention may comprise pharmaceutically acceptable excipients, diluents or carriers.</span>
  </p>
  <p id="p0412" num="0412" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, la invención proporciona una composición farmacéutica que comprende: una cepa bacteriana de la invención; y un excipiente, vehículo o diluyente farmacéuticamente aceptable; en el que la cepa bacteriana está en una cantidad suficiente para tratar un trastorno cuando se administra a un sujeto que lo necesita; y en el que el trastorno se selecciona del grupo que consiste en enfermedades neurodegenerativas, como la enfermedad de Alzheimer, la enfermedad de Huntington o la enfermedad de Parkinson, lesión cerebral, como accidente cerebrovascular, trastornos del comportamiento, como el trastorno por déficit de atención con hiperactividad, enfermedades inflamatorias del intestino, como la enfermedad de Crohn, cáncer, como cáncer de próstata, cáncer colorrectal, cáncer de mama, cáncer de pulmón, cáncer de hígado o cáncer gástrico.</span>In certain embodiments, the invention provides a pharmaceutical composition comprising: a bacterial strain of the invention; and a pharmaceutically acceptable excipient, carrier, or diluent; wherein the bacterial strain is in an amount sufficient to treat a disorder when administered to a subject in need thereof; and wherein the disorder is selected from the group consisting of neurodegenerative diseases, such as Alzheimer's disease, Huntington's disease, or Parkinson's disease, brain injury, such as stroke, behavioral disorders, such as attention deficit disorder with hyperactivity, inflammatory bowel diseases, such as Crohn's disease, cancer, such as prostate cancer, colorectal cancer, breast cancer, lung cancer, liver cancer, or gastric cancer.</span>
  </p>
  <p id="p0414" num="0414" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, la invención proporciona una composición farmacéutica que comprende: una cepa bacteriana de la invención; y un excipiente, vehículo o diluyente farmacéuticamente aceptable; en el que la cepa bacteriana está en una cantidad suficiente para tratar o prevenir una enfermedad o afección mediada por una actividad HDAC elevada. En realizaciones preferidas, dicha enfermedad o afección se selecciona del grupo que consiste en enfermedades neurodegenerativas, como la enfermedad de Alzheimer, la enfermedad de Huntington o la enfermedad de Parkinson, lesión cerebral, como accidente cerebrovascular, trastornos del comportamiento, como el trastorno por déficit de atención e hiperactividad, enfermedades inflamatorias del intestino, como la enfermedad de 
Crohn, cáncer, como cáncer de próstata, cáncer colorrectal, cáncer de mama, cáncer de pulmón, cáncer de hígado o cáncer gástrico.</span>In certain embodiments, the invention provides a pharmaceutical composition comprising: a bacterial strain of the invention; and a pharmaceutically acceptable excipient, carrier, or diluent; wherein the bacterial strain is in an amount sufficient to treat or prevent a disease or condition mediated by elevated HDAC activity. In preferred embodiments, said disease or condition is selected from the group consisting of neurodegenerative diseases, such as Alzheimer's disease, Huntington's disease or Parkinson's disease, brain injury, such as stroke, behavioral disorders, such as deficit disorder attention and hyperactivity disorder, inflammatory bowel diseases, such as  Crohn's, cancer, such as prostate cancer, colorectal cancer, breast cancer, lung cancer, liver cancer, or gastric cancer.</span>
  </p>
  <p id="p0415" num="0415" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, la invención proporciona la composición farmacéutica anterior, en la que la cantidad de cepa bacteriana es de aproximadamente 1 x 103 a aproximadamente 1 x 1011 unidades formadoras de colonias por gramo con respecto al peso de la composición.</span>In certain embodiments, the invention provides the above pharmaceutical composition, wherein the amount of bacterial strain is from about 1 x 103 to about 1 x 1011 colony-forming units per gram based on the weight of the composition.</span>
  </p>
  <p id="p0416" num="0416" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, la invención proporciona la composición farmacéutica anterior, en la que la composición se administra en una dosis de 1 g, 3 g, 5 g o 10 g.</span>In certain embodiments, the invention provides the above pharmaceutical composition, wherein the composition is administered in a 1 g, 3 g, 5 g, or 10 g dose.</span>
  </p>
  <p id="p0417" num="0417" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, la invención proporciona la composición farmacéutica anterior, en la que la composición se administra mediante un método seleccionado del grupo que consiste en oral, rectal, subcutáneo, nasal, bucal y sublingual.</span>In certain embodiments, the invention provides the above pharmaceutical composition, wherein the composition is administered by a method selected from the group consisting of oral, rectal, subcutaneous, nasal, buccal, and sublingual.</span>
  </p>
  <p id="p0418" num="0418" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, la invención proporciona la composición farmacéutica anterior, que comprende un vehículo seleccionado del grupo que consiste en lactosa, almidón, glucosa, metilcelulosa, estearato de magnesio, manitol y sorbitol.</span>In certain embodiments, the invention provides the above pharmaceutical composition, comprising a carrier selected from the group consisting of lactose, starch, glucose, methylcellulose, magnesium stearate, mannitol, and sorbitol.</span>
  </p>
  <p id="p0419" num="0419" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la invención proporciona la composición farmacéutica anterior, que comprende un diluyente seleccionado del grupo que consiste en etanol, glicerol y agua.</span>In certain embodiments, the invention provides the above pharmaceutical composition, comprising a diluent selected from the group consisting of ethanol, glycerol, and water.</span>
  </p>
  <p id="p0420" num="0420" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la invención proporciona la composición farmacéutica anterior, que comprende un excipiente seleccionado del grupo que consiste en almidón, gelatina, glucosa, lactosa anhidra, lactosa de flujo libre, beta-lactosa, edulcorante de maíz, goma arábiga, tragacanto, alginato de sodio, carboximetil celulosa, polietilenglicol, oleato de sodio, estearato de sodio, estearato de magnesio, benzoato de sodio, acetato de sodio y cloruro de sodio.</span>In certain embodiments, the invention provides the above pharmaceutical composition, comprising an excipient selected from the group consisting of starch, gelatin, glucose, anhydrous lactose, free-flow lactose, beta-lactose, corn sweetener, gum arabic, tragacanth, alginate sodium, carboxymethyl cellulose, polyethylene glycol, sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate and sodium chloride.</span>
  </p>
  <p id="p0421" num="0421" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, la invención proporciona la composición farmacéutica anterior, que comprende además al menos uno de entre un conservante, un antioxidante y un estabilizador.</span>In certain embodiments, the invention provides the above pharmaceutical composition, further comprising at least one of a preservative, an antioxidant, and a stabilizer.</span>
  </p>
  <p id="p0422" num="0422" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, la invención proporciona la composición farmacéutica anterior, que comprende un conservante seleccionado del grupo que consiste en benzoato de sodio, ácido sórbico y ésteres de ácido phidroxibenzoico.</span>In certain embodiments, the invention provides the above pharmaceutical composition, comprising a preservative selected from the group consisting of sodium benzoate, sorbic acid, and esters of p-hydroxybenzoic acid.</span>
  </p>
  <p id="p0423" num="0423" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En determinadas realizaciones, la invención proporciona la composición farmacéutica anterior, en la que dicha cepa bacteriana está liofilizada.</span>In certain embodiments, the invention provides the above pharmaceutical composition, wherein said bacterial strain is lyophilized.</span>
  </p>
  <p id="p0424" num="0424" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la invención proporciona la composición farmacéutica anterior, en la que cuando la composición se almacena en un recipiente sellado a aproximadamente 4 °C o aproximadamente 25 °C y el recipiente se coloca en una atmósfera que tiene 50% de humedad relativa, al menos 80% de la cepa bacteriana medida en unidades formadoras de colonias, permanece después de un período de al menos aproximadamente: 1 mes, 3 meses, 6 meses, 1 año, 1,5 años, 2 años, 2,5 años o 3 años.</span>In certain embodiments, the invention provides the above pharmaceutical composition, wherein when the composition is stored in a sealed container at about 4°C or about 25°C and the container is placed in an atmosphere having 50% relative humidity, at least 80% of the bacterial strain measured in colony forming units, remains after a period of at least about: 1 month, 3 months, 6 months, 1 year, 1.5 years, 2 years, 2.5 years or 3 years.</span>
  </p>
  <p id="p0425" num="0425" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Métodos de cultivo</span>cultivation methods</span>
      </i>
    </b>
  </p>
  <p id="p0426" num="0426" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las cepas bacterianas para su uso en la presente invención se pueden cultivar usando técnicas de microbiología estándar como se detalla, por ejemplo, en las referencias <b class="style-scope patent-text">[47,,49].</b> </span>Bacterial strains for use in the present invention can be cultured using standard microbiology techniques as detailed, for example, in references <b class="style-scope patent-text">[47, 49].</b> </span>
  </p>
  <p id="p0427" num="0427" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El medio sólido o líquido usado para el cultivo puede ser agar YCFA o medio YCFA. El medio YCFA puede incluir (por 100 ml, valores aproximados): Casitone (1,0 g), extracto de levadura (0,25 g), NaHCO3 (0,4 g), cisteína (0,1 g), K2HPO4 (0,045 g), KH2PO4 (0,045 g), NaCl (0,09 g), (NH4)2SO4 (0,09 g), MgSO4 • 7H2O (0,009 g), CaCl2 (0,009 g), resazurina (0,1 mg), hemina (1 mg), biotina (1 pg), cobalamina (1 pg), <i class="style-scope patent-text">ácido </i>p-aminobenzoico (3 pg), ácido fólico (5 pg) y piridoxamina (15 pg).</span>The solid or liquid medium used for the culture may be YCFA agar or YCFA medium. YCFA medium may include (per 100 mL, approximate values): Casitone (1.0 g), yeast extract (0.25 g), NaHCO3 (0.4 g), cysteine (0.1 g), K2HPO4 ( 0.045 g), KH2PO4 (0.045 g), NaCl (0.09 g), (NH4)2SO4 (0.09 g), MgSO4 • 7H2O (0.009 g), CaCl2 (0.009 g), Resazurin (0.1 mg) , hemin (1 mg), biotin (1 pg), cobalamin (1 pg), p-aminobenzoic <i class="style-scope patent-text">acid</i> (3 pg), folic acid (5 pg) and pyridoxamine (15 pg).</span>
  </p>
  <p id="p0428" num="0428" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cepas bacterianas para su uso en composiciones de vacunas</span>Bacterial strains for use in vaccine compositions</span>
      </i>
    </b>
  </p>
  <p id="p0429" num="0429" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los inventores han identificado que las cepas bacterianas de la invención son útiles para tratar o prevenir enfermedades o afecciones mediadas por HDAC. Es probable que esto sea el resultado del efecto que las cepas bacterianas de la invención tienen sobre el sistema inmunológico del huésped. Por lo tanto, las composiciones de la invención también pueden ser útiles para prevenir enfermedades o afecciones mediadas por HDAC, cuando se administran como composiciones de vacuna. En ciertas de tales realizaciones, las cepas bacterianas de la invención se pueden matar, inactivar o atenuar. En ciertas de tales realizaciones, las composiciones pueden comprender un adyuvante de vacuna. En determinadas realizaciones, las composiciones son para administración mediante inyección, tal como mediante inyección subcutánea. 
</span>The inventors have identified that the bacterial strains of the invention are useful for treating or preventing diseases or conditions mediated by HDACs. This is likely to be the result of the effect that the bacterial strains of the invention have on the host's immune system. Therefore, the compositions of the invention may also be useful for preventing HDAC-mediated diseases or conditions, when administered as vaccine compositions. In certain such embodiments, the bacterial strains of the invention can be killed, inactivated, or attenuated. In certain such embodiments, the compositions may comprise a vaccine adjuvant. In certain embodiments, the compositions are for administration by injection, such as by subcutaneous injection. </span>
  </p>
  <p id="p0430" num="0430" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">General</span>general</span>
      </i>
    </b>
  </p>
  <p id="p0431" num="0431" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La práctica de la presente invención empleará, a menos que se indique lo contrario, métodos convencionales de química, bioquímica, biología molecular, inmunología y farmacología, dentro de la técnica. Tales técnicas se explican completamente en la bibliografía. Ver, <i class="style-scope patent-text">p. ej., </i>referencias [50] y [51,57], <i class="style-scope patent-text">etc.</i> </span>The practice of the present invention will employ, unless otherwise indicated, conventional methods of chemistry, biochemistry, molecular biology, immunology, and pharmacology, within the art. Such techniques are fully explained in the literature. See, <i class="style-scope patent-text">p. g.,</i> references [50] and [51,57], <i class="style-scope patent-text">etc.</i> </span>
  </p>
  <p id="p0432" num="0432" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El término "que comprende" abarca "que incluye" así como "que consiste", p. ej., una composición "que comprende" X puede consistir exclusivamente en X o puede incluir algo adicional, p. ej,. X <b class="style-scope patent-text">+ Y.</b> </span>The term "comprising" encompasses "including" as well as "consisting", e.g. e.g., a composition "comprising" X may consist exclusively of X or may include something additional, e.g. eg. x <b class="style-scope patent-text">+ y</b> </span>
  </p>
  <p id="p0433" num="0433" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El término "aproximadamente" en relación con un valor numérico <b class="style-scope patent-text">x </b>es opcional y significa, por ejemplo, x+10%. La palabra "sustancialmente" no excluye "completamente", p. ej., una composición que está "sustancialmente libre" de Y puede estar completamente libre de Y. Cuando sea necesario, la palabra "sustancialmente" puede omitirse de la definición de la invención.</span>The term "approximately" in relation to a numerical value <b class="style-scope patent-text">x</b> is optional and means, for example, x+10%. The word "substantially" does not exclude "completely", e.g. eg, a composition that is "substantially free" of Y may be completely free of Y. When necessary, the word "substantially" may be omitted from the definition of the invention.</span>
  </p>
  <p id="p0434" num="0434" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las referencias a un porcentaje de identidad de secuencia entre dos secuencias de nucleótidos significan que, cuando se alinean, ese porcentaje de nucleótidos es el mismo al comparar las dos secuencias. Este alineamiento y el porcentaje de homología o identidad de secuencia se pueden determinar usando programas de software conocidos en la técnica, por ejemplo los descritos en la sección 7.7.18 de la ref. [58]. Una alineación preferida se determina mediante el algoritmo de búsqueda de homología de Smith-Waterman usando una búsqueda de huecos afines con una penalización por apertura de huecos de 12 y una penalización por extensión de huecos de 2, matriz BLOSUM de 62. El algoritmo de búsqueda de homología de Smith-Waterman se describe en la ref. [59].</span>References to a percentage of sequence identity between two nucleotide sequences mean that, when aligned, that percentage of nucleotides is the same when comparing the two sequences. This alignment and percent sequence homology or identity can be determined using software programs known in the art, for example those described in section 7.7.18 of ref. [58]. A preferred alignment is determined by the Smith-Waterman homology search algorithm using an affine gap search with a gap opening penalty of 12 and a gap extension penalty of 2, BLOSUM matrix of 62. The search algorithm of Smith-Waterman homology is described in ref. [59].</span>
  </p>
  <p id="p0435" num="0435" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">A menos que se indique específicamente, un proceso o método que comprende numerosos pasos puede comprender pasos adicionales al principio o al final del método, o puede comprender etapas intermedias adicionales. Además, las etapas se pueden combinar, omitir o realizar en un orden alternativo, si es apropiado.</span>Unless specifically stated, a process or method comprising numerous steps may comprise additional steps at the beginning or end of the method, or may comprise additional intermediate steps. Additionally, the steps may be combined, omitted, or performed in an alternate order, if appropriate.</span>
  </p>
  <p id="p0436" num="0436" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se describen en el presente las realizaciones preferidas de la invención. Se apreciará que las características especificadas en cada realización pueden combinarse con otras características especificadas, para proporcionar realizaciones adicionales. En particular, las realizaciones destacadas en el presente documento como adecuadas, típicas o preferidas pueden combinarse entre sí (excepto cuando son mutuamente excluyentes).</span>Preferred embodiments of the invention are described herein. It will be appreciated that features specified in each embodiment may be combined with other features specified, to provide additional embodiments. In particular, embodiments highlighted herein as suitable, typical, or preferred may be combined with one another (except where mutually exclusive).</span>
  </p>
  <p id="p0437" num="0437" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">MODO(S) DE LLEVAR A CABO LA INVENCIÓN</span>MODE(S) OF CARRYING OUT THE INVENTION</span>
    </b>
  </p>
  <p id="p0438" num="0438" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 1 - Eficacia de las bacterias sobre la actividad de la histona desacetilasa</span>Example 1 - Efficacy of bacteria on histone deacetylase activity</span>
      </i>
    </b>
  </p>
  <p id="p0439" num="0439" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Introducción</span>Introduction</span>
      </i>
    </b>
  </p>
  <p id="p0440" num="0440" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los inventores buscaron investigar la eficacia de la cepa 43042 de <i class="style-scope patent-text">Bariatricus massiliensis </i>y sus metabolitos sobre la inhibición de HDAC.</span>The inventors sought to investigate the efficacy of <i class="style-scope patent-text">Bariatricus massiliensis</i> strain 43042 and its metabolites on HDAC inhibition.</span>
  </p>
  <p id="p0441" num="0441" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Materiales y métodos</span>Materials and methods</span>
      </i>
    </b>
  </p>
  <p id="p0442" num="0442" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Recolección de sobrenadante libre de células y cultivo bacteriano</span>Collection of cell-free supernatant and bacterial culture</span>
      </i>
    </b>
  </p>
  <p id="p0443" num="0443" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se cultivaron anaeróbicamente cultivos puros de bacterias 43042 en caldo YCFA hasta que alcanzaron su fase de crecimiento estacionario. Los cultivos se centrifugaron a 5.000 x g durante 5 minutos y el sobrenadante libre de células (CFS) se filtró usando un filtro de 0,2 pM (Millipore, UK). Alícuotas de 1 mL del CFS se almacenaron a -80 °C hasta uso. Se obtuvieron butirato de sodio, ácido hexanoico y valérico de Sigma Aldrich (Reino Unido) y se prepararon suspensiones en caldo YCFA.</span>Pure cultures of 43042 bacteria were grown anaerobically in YCFA broth until they reached their stationary growth phase. Cultures were centrifuged at 5,000 x g for 5 minutes and cell free supernatant (CFS) was filtered using a 0.2 pM filter (Millipore, UK). Aliquots of 1 mL of the CFS were stored at -80 °C until use. Sodium butyrate, hexanoic and valeric acid were obtained from Sigma Aldrich (UK) and suspensions were prepared in YCFA broth.</span>
  </p>
  <p id="p0444" num="0444" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cuantificación de SCFA y MCFA de sobrenadantes bacterianos</span>SCFA and MCFA quantification of bacterial supernatants</span>
      </i>
    </b>
  </p>
  <p id="p0445" num="0445" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los ácidos grasos de cadena corta (SCFA) y los ácidos grasos de cadena media (MCFA) de los sobrenadantes bacterianos se analizaron y cuantificaron mediante MS Omics APS de la siguiente manera. Las muestras se acidificaron usando ácido clorhídrico y se añadieron patrones internos marcados con deuterio. Todas las muestras se analizaron en orden aleatorio. El análisis se realizó usando una columna de alta polaridad (Zebron™ ZB-FFAP, GC Cap. Columna de 30 mx 0,25 mm x 0,25 pm) instalada en un GC (7890B, Agilent) acoplado con un detector de cuatro polos (59977B, Agilent). El sistema fue controlado por ChemStation (Agilent). Los datos sin procesar se convirtieron al formato netCDF usando Chemstation (Agilent), antes de que los datos fueran importados y procesados en Matlab R2014b (Mathworks, Inc.) usando el software PARADlSe descrito por Johnsen, 2017, J Chromatogr A, 1503, 57-64.</span>Short chain fatty acids (SCFA) and medium chain fatty acids (MCFA) of bacterial supernatants were analyzed and quantified by MS Omics APS as follows. Samples were acidified using hydrochloric acid and deuterium-labeled internal standards were added. All samples were analyzed in random order. Analysis was performed using a high polarity column (Zebron™ ZB-FFAP, GC Cap. 30 m x 0.25 mm x 0.25 pm column) installed on a GC (7890B, Agilent) coupled with a four-pole detector. (59977B, Agilent). The system was controlled by ChemStation (Agilent). Raw data was converted to netCDF format using Chemstation (Agilent), before data was imported and processed in Matlab R2014b (Mathworks, Inc.) using PARADlSe software described by Johnsen, 2017, J Chromatogr A, 1503, 57 -64.</span>
  </p>
  <p id="p0446" num="0446" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Análisis de actividad global de HDAC</span>Global HDAC activity analysis</span>
      </i>
    </b>
  </p>
  <p id="p0447" num="0447" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se aislaron células enteras y sobrenadantes libres de células de cultivos de fase estacionaria 43042 mediante centrifugación y filtración en un filtro de 0,22 uM. Las células HT-29 se utilizaron 3 días después de la confluencia y se redujeron en 1 ml de DTS 24 horas antes del comienzo del experimento. Las células HT-29 se desafiaron con 10 % sobrenadante libre de células se diluyó en DTS y se dejó incubar durante 48 horas. A continuación, se extrajeron 
las proteínas nucleasa utilizando el kit de extracción Sigma Aldrich Nuclease y las muestras se congelaron rápidamente antes de la medición de la actividad HDAC. El kit de actividad HDAC se evaluó fluorométricamente utilizando el kit Sigma Aldrich (Reino Unido).</span>Whole cells and cell-free supernatants from 43042 stationary phase cultures were isolated by centrifugation and filtration on a 0.22 uM filter. HT-29 cells were used 3 days after confluency and reduced in 1 ml DTS 24 hours before the start of the experiment. HT-29 cells were challenged with 10% cell-free supernatant diluted in DTS and allowed to incubate for 48 hours. They were then extracted  nuclease proteins using the Sigma Aldrich Nuclease Extraction Kit and samples were snap frozen prior to measurement of HDAC activity. The HDAC activity kit was assessed fluorometrically using the Sigma Aldrich kit (UK).</span>
  </p>
  <p id="p0448" num="0448" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">A nális is de activ idad específica de H D A C</span>H D A C specific activity assays</span>
      </i>
    </b>
  </p>
  <p id="p0449" num="0449" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se analizó la actividad de inhibición de HDAC específica para HDAC1, 2, 3, 4, 5, 6, 9 utilizando kits de ensayo fluorogénicos para cada tipo de HDAC (BPS Bioscience, CA). Los ensayos se realizaron de acuerdo con las instrucciones del fabricante y cada muestra se realizó en réplicas. Los sobrenadantes libres de células se diluyeron 1 en 10 y se expusieron a proteínas HDAC específicas proporcionadas en el kit para mantener la coherencia entre los métodos.</span>Specific HDAC inhibition activity was assayed for HDAC1, 2, 3, 4, 5, 6, 9 using fluorogenic assay kits for each type of HDAC (BPS Bioscience, CA). Assays were performed according to the manufacturer's instructions and each sample was run in replicates. Cell-free supernatants were diluted 1 in 10 and challenged with specific HDAC proteins provided in the kit to maintain consistency between methods.</span>
  </p>
  <p id="p0450" num="0450" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">R esultados</span>Results</span>
      </i>
    </b>
  </p>
  <p id="p0451" num="0451" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Células enteras 43042 y sobrenadantes libres de células reducen la actividad global de HDAC</span>Whole 43042 cells and cell-free supernatants reduce overall HDAC activity</span>
    </i>
  </p>
  <p id="p0452" num="0452" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los resultados mostrados en la Figura 1 muestran que células completas 43042 y CFS reducen la actividad global de HDAC en una cantidad estadísticamente significativa.</span>The results shown in Figure 1 show that whole 43042 and CFS cells reduce overall HDAC activity by a statistically significant amount.</span>
  </p>
  <p id="p0453" num="0453" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">43042 produce el butirato del metabolito inhibidor de HDAC</span>43042 produces the HDAC inhibitory metabolite butyrate</span>
    </i>
  </p>
  <p id="p0454" num="0454" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El sobrenadante 43042 mostró una fuerte inhibición de HDAC y se encontró que producía cantidades significativas de butirato (Figura 2A).</span>Supernatant 43042 showed strong HDAC inhibition and was found to produce significant amounts of butyrate (Figure 2A).</span>
  </p>
  <p id="p0455" num="0455" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para investigar qué metabolitos eran responsables de la inhibición de HDAC inducida por la cepa, se midieron diferentes concentraciones de ácido hexanoico, ácido valérico y butirato de sodio para determinar su inhibición de HDAC en células HT-29 completas y en lisado de células HT-29. Los resultados en la Fig. 2B muestran significante (P &lt; 0,05) inhibición de la actividad de HDAC por butirato de sodio en células completas así como en el lisado celular, mientras que el ácido hexanoico mostró una actividad inhibidora significativa. El ácido valérico inhibió la actividad total de HDAC (* (p &lt; 0,05), ** (p &lt; 0,005), *** (P &lt; 0,001), ****(p &lt; 0,0001)).</span>To investigate which metabolites were responsible for strain-induced HDAC inhibition, different concentrations of hexanoic acid, valeric acid, and sodium butyrate were measured for their HDAC inhibition in whole HT-29 cells and in HT-29 cell lysate. . The results in Fig. 2B show significant (P &lt; 0.05) inhibition of HDAC activity by sodium butyrate in whole cells as well as in cell lysate, while hexanoic acid showed significant inhibitory activity. Valeric acid inhibited total HDAC activity (* (p &lt; 0.05), ** (p &lt; 0.005), *** (p &lt; 0.001), **** (p &lt; 0.0001)).</span>
  </p>
  <p id="p0456" num="0456" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los inhibidores de HDAC totales potentes investigaron las IHDAC de clase diana.</span>Potent total HDAC inhibitors investigated target class IHDACs.</span>
    </i>
  </p>
  <p id="p0457" num="0457" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se investigó el perfil de inhibición de HDAC específico de la cepa de bacterias de prueba. Se llevaron a cabo ensayos de inhibición de HDAC específicos (BPS Bioscience, CA) para las HDAC de Clase I. Se analizó la capacidad de la cepa bacteriana para inhibir las enzimas HDAC. Los resultados (Figura 3) demuestran que 43042 es un potente inhibidor de las enzimas HDAC de clase 1 (HDAC1, 2 y 3), en particular HDAC2.</span>The specific HDAC inhibition profile of the test bacteria strain was investigated. Specific HDAC inhibition assays (BPS Bioscience, CA) were performed for Class I HDACs. The ability of the bacterial strain to inhibit HDAC enzymes was tested. The results (Figure 3) demonstrate that 43042 is a potent inhibitor of HDAC class 1 enzymes (HDAC1, 2 and 3), in particular HDAC2.</span>
  </p>
  <p id="p0458" num="0458" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Discusión</span>Discussion</span>
      </i>
    </b>
  </p>
  <p id="p0459" num="0459" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Curiosamente, los resultados de la actividad específica de HDAC muestran que la cepa probada es un potente inhibidor de las HDAC de clase I, y en particular de las HDAC2 (Figura 3). Las HDAC de clase I (HDAC1, 2, 3 y 8) residen en el núcleo y se expresan de forma ubicua en varios tipos de células humanas. Las HDAC 1-3 comparten más del 50% de homología, pero tienen estructuras y funciones celulares distintas [60]. Están involucrados principalmente en la supervivencia, proliferación y diferenciación celular y, por lo tanto, la inhibición puede ser útil en una amplia gama de enfermedades. [61,62,63,64,65]. Estos datos muestran que las composiciones de la invención pueden ser útiles para tratar enfermedades mediadas por HDAC.</span>Interestingly, the HDAC specific activity results show that the tested strain is a potent inhibitor of class I HDACs, and in particular HDAC2 (Figure 3). Class I HDACs (HDAC1, 2, 3, and 8) reside in the nucleus and are ubiquitously expressed in various human cell types. HDACs 1-3 share more than 50% homology, but have distinct cellular structures and functions [60]. They are primarily involved in cell survival, proliferation, and differentiation, and therefore inhibition may be useful in a wide range of diseases. [61,62,63,64,65]. These data show that the compositions of the invention may be useful for treating HDAC-mediated diseases.</span>
  </p>
  <p id="p0460" num="0460" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">E jem plo 2: eficacia de las bacterias sobre la h iperactiv idad</span>E xam ple 2: Efficacy of bacteria on hyperactivity</span>
      </i>
    </b>
  </p>
  <p id="p0462" num="0462" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Introducción</span>Introduction</span>
      </i>
    </b>
  </p>
  <p id="p0463" num="0463" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El objetivo de este estudio fue evaluar los efectos de las bacterias anaeróbicas utilizando ratones lesionados por MPTP. Un número de 72 ratones fueron lesionados con MPTP (6 grupos con n=12 animales cada uno) se trataron diariamente durante 18 días mediante sonda oral con 43042, vehículo o compuesto de referencia, comenzando 14 días antes de la inducción de la enfermedad. Un grupo de n=12 los animales sirvieron como control de lesión simulada y se trataron con vehículo.</span>The aim of this study was to evaluate the effects of anaerobic bacteria using MPTP-injured mice. A number of 72 MPTP-lesioned mice (6 groups with n=12 animals each) were treated daily for 18 days by oral gavage with 43042, vehicle or reference compound, beginning 14 days prior to disease induction. A group of n=12 animals served as sham-injury controls and were treated with vehicle.</span>
  </p>
  <p id="p0464" num="0464" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">M ateriales y m étodos</span>Materials and methods</span>
      </i>
    </b>
  </p>
  <p id="p0466" num="0466" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">A nim ales</span>Animals</span>
      </i>
    </b>
  </p>
  <p id="p0467" num="0467" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Todos los animales fueron alojados en jaulas ventiladas individuales (IVC) y estaban libres de patógenos pero no se mantuvieron bajo SPF. Además, las jaulas se abrieron bajo un flujo de aire laminar.</span>All animals were housed in individual ventilated cages (IVC) and were pathogen free but not maintained under SPF. Furthermore, the cages were opened under a laminar air flow.</span>
  </p>
  <p id="p0468" num="0468" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los ratones se alojaron en jaulas ventiladas individuales de dos proveedores diferentes y en tres tamaños diferentes: jaulas de policarbonato de la empresa Ehret de tipo 1 largo: 426 cm 2 o tipo 2 largo: 530 cm 2 o jaulas de polisulfona de Tecniplast "greenline": 500 cm2. Ambos sistemas de ventilación de aire incluían sistemas de filtro HEPA (clase HEPA 14), que cumplen con la norma actual. 
</span>The mice were housed in individual ventilated cages from two different suppliers and in three different sizes: polycarbonate cages from the Ehret company of type 1 length: 426 cm 2 or type 2 length: 530 cm 2 or polysulfone cages from Tecniplast "greenline" : 500 cm2. Both air ventilation systems included HEPA filter systems (HEPA class 14), which comply with the current standard. </span>
  </p>
  <p id="p0469" num="0469" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para evaluar el estado de salud de los animales se utilizan animales centinela.</span>Sentinel animals are used to assess the health status of the animals.</span>
  </p>
  <p id="p0470" num="0470" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se utilizaron ratones CD1 adultos (al menos 8 semanas), hembras (para evitar agresiones entre machos) como centinelas. Los centinelas se alojaron en parejas por jaula.</span>Adult CD1 mice (at least 8 weeks old), female (to avoid male-male aggression) were used as sentinels. Sentinels were housed in pairs per cage.</span>
  </p>
  <p id="p0471" num="0471" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se mantuvieron los siguientes parámetros para el alojamiento de los animales:</span>The following parameters were maintained for the accommodation of the animals:</span>
  </p>
  <p id="p0472" num="0472" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- Ciclo de 12 horas luz-oscuridad (horario de verano: luces encendidas de 6 a.m. a 6 p.m., luces apagadas de 6 p.m. a 6 a.m.; horario de invierno: luces encendidas de 5 a.m. a 5 p.m., luces apagadas de 5 p.m. a 5 a.m.)</span>- 12-hour light-dark cycle (summer time: lights on from 6 a.m. to 6 p.m., lights off from 6 p.m. to 6 a.m.; winter time: lights on from 5 a.m. to 5 p.m., lights off from 5 p.m. to 5 am)</span>
  </p>
  <p id="p0473" num="0473" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- Intensidad de luz: valor crítico: ratón [&lt;400 Lux]</span>- Light intensity: critical value: mouse [&lt;400 Lux]</span>
  </p>
  <p id="p0474" num="0474" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- Volumen: valor crítico: [&lt;60 dB]</span>- Volume: critical value: [&lt;60 dB]</span>
  </p>
  <p id="p0475" num="0475" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- Ruido de fondo continuo a bajo volumen (p. ej., Radio encendida durante la fase de luz)</span>- Continuous background noise at low volume (eg Radio on during light phase)</span>
  </p>
  <p id="p0476" num="0476" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- Temperatura ambiente: 20-24°C</span>- Room temperature: 20-24°C</span>
  </p>
  <p id="p0477" num="0477" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- Humedad: 30-70%</span>- Humidity: 30-70%</span>
  </p>
  <p id="p0478" num="0478" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- La humedad y la temperatura ambiente se controlaron de forma centralizada mediante un sistema de alarma.</span>- Humidity and room temperature were centrally controlled by an alarm system.</span>
  </p>
  <p id="p0479" num="0479" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- Como material de lecho se utilizó material granulado de madera que posee una alta propiedad de succión y mostró una porción de material fino bajo (p. ej., Lignocel)</span>- Wood grain material was used as bedding material which has high suction property and showed low fine material portion (e.g. Lignocel)</span>
  </p>
  <p id="p0480" num="0480" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- Como material de anidación de enriquecimiento se utilizaron "Nestlets"</span>- Nestlets were used as enrichment nesting material.</span>
  </p>
  <p id="p0481" num="0481" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- Se utilizaron alimentos de mantenimiento estándar para ratones y ratas o alimentos de cría para animales reproductores (p. ej., Altromin)</span>- Standard maintenance feeds for mice and rats or rearing feeds for breeder animals (e.g. Altromin) were used</span>
  </p>
  <p id="p0482" num="0482" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- Se utilizó agua del grifo normal como suministro de agua.</span>- Normal tap water was used as the water supply.</span>
  </p>
  <p id="p0483" num="0483" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se utilizó el menor número de animales cumpliendo con la normativa vigente y la integridad científica. El bienestar de los animales se tuvo en cuenta en términos de número y extensión de los procedimientos a realizar.</span>The smallest number of animals was used, complying with current regulations and scientific integrity. The welfare of the animals was taken into account in terms of the number and extent of the procedures to be performed.</span>
  </p>
  <p id="p0484" num="0484" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se aplicaron al estudio las precauciones de seguridad que operan dentro de la instalación de prueba.</span>Safety precautions operating within the test facility were applied to the study.</span>
  </p>
  <p id="p0485" num="0485" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Detalles de los animales utilizados</span>Details of the animals used</span>
      </i>
    </b>
  </p>
  <p id="p0486" num="0486" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Línea de ratón: C57BL/6J (Cepa de ratones JAX™) Número de almacenamiento de ratones JAX™ 000664</span>Mouse Line: C57BL/6J (JAX™ Mice Strain) JAX™ Mice Stock Number 000664</span>
  </p>
  <p id="p0487" num="0487" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Proveedor: Laboratorios Charles River</span>Provider: Charles River Laboratories</span>
  </p>
  <p id="p0488" num="0488" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Edad al inicio: ~10 semanas</span>Age at onset: ~10 weeks</span>
  </p>
  <p id="p0489" num="0489" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Alojamiento de animales</span>animal housing</span>
      </i>
    </b>
  </p>
  <p id="p0490" num="0490" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tan pronto como los animales llegaron a QPS Austria, fueron llevados a la sala de animales asignada, se desempacaron y se verificó su estado de salud. Se cotejó la información sobre el sistema de transporte y los datos proporcionados por Charles River Laboratories (CRL) de antemano. Se generó una lista de animales que incluía el IRN, la edad al momento del parto y el sexo. Los animales se habituaron durante al menos una semana antes del inicio del estudio.</span>As soon as the animals arrived at QPS Austria, they were taken to the assigned animal room, unpacked and their health status checked. Information about the transportation system and data provided by Charles River Laboratories (CRL) were collated beforehand. A list of animals was generated that included IRN, age at calving, and sex. The animals were habituated for at least one week before the start of the study.</span>
  </p>
  <p id="p0491" num="0491" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Alojamiento</span>accommodation</span>
      </i>
    </b>
  </p>
  <p id="p0492" num="0492" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los animales se alojaron en grupos de dos. La temperatura ambiente se mantuvo aproximadamente a 20-24 ° C y la humedad relativa entre 30 y 70%. Los animales se alojaron bajo un ciclo de luz constante (12 horas luz/oscuridad; (horario de verano: luces encendidas de 6 a.m. a 6 p.m., luces apagadas de 6 p.m. a 6 a.m.; horario de invierno: luces encendidas de 5 a.m. a 5 p.m., luces apagadas de 5 p.m. a 5 a.m.). Los animales disponían ad libitum de pienso estándar para roedores seco y granulado (Altromin), así como agua corriente normal.</span>The animals were housed in groups of two. Room temperature was kept at approximately 20-24 °C and relative humidity between 30 and 70%. The animals were housed under a constant light cycle (12 hours light/dark; (summer hours: lights on from 6 am to 6 pm, lights off from 6 pm to 6 am; winter hours: lights on from 5 am to 6 pm). 5 pm, lights off 5 pm to 5 am) Animals were provided ad libitum with standard dry pelleted rodent chow (Altromin), as well as normal tap water.</span>
  </p>
  <p id="p0493" num="0493" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Identificación</span>ID</span>
      </i>
    </b>
  </p>
  <p id="p0494" num="0494" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los animales se numeraron consecutivamente mediante la asignación clásica, si no estaban ya presentes a la llegada. 
</span>Animals were consecutively numbered by classical assignment, if not already present on arrival. </span>
  </p>
  <p id="p0495" num="0495" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cada jaula se identificó mediante una tarjeta de color que indicaba el número de estudio, el sexo, los números de registro individual (IRN) de los animales, la edad en el momento del parto y la asignación del grupo de tratamiento.</span>Each cage was identified by a colored card indicating study number, sex, individual animal registration numbers (IRNs), age at calving, and treatment group assignment.</span>
  </p>
  <p id="p0496" num="0496" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Asignación de grupo</span>group assignment</span>
      </i>
    </b>
  </p>
  <p id="p0497" num="0497" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Sólo se incluyeron en el estudio animales que aparentemente se encontraban en buenas condiciones de salud. Los animales se asignaron a los grupos de tratamiento con respecto al peso corporal, los resultados de la prueba IRWIN de referencia y, respectivamente, la composición en las jaulas.</span>Only animals that appeared to be in good health were included in the study. Animals were assigned to treatment groups with respect to body weight, baseline IRWIN test results, and cage composition, respectively.</span>
  </p>
  <p id="p0498" num="0498" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los detalles de los métodos que no se especificaron en las secciones posteriores de este plan de estudio se encuentran en los procedimientos operativos estándar apropiados.</span>Details of methods not specified in later sections of this syllabus can be found in the appropriate standard operating procedures.</span>
  </p>
  <p id="p0499" num="0499" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Manejo específico de animales y aleatorización</span>Specific animal management and randomization</span>
      </i>
    </b>
  </p>
  <p id="p0500" num="0500" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los guantes debían cambiarse entre cada grupo de tratamiento y rociarse con una disolución de etanol al 70% entre cada jaula del mismo grupo para minimizar el riesgo de contaminación cuando se manipulaban animales (p. ej.,: tratamiento, pruebas de comportamiento, limpieza y muestreo de tejidos).</span>Gloves were to be changed between each treatment group and sprayed with a 70% ethanol solution between each cage in the same group to minimize the risk of contamination when handling animals (eg, treatment, behavioral testing, cleaning and tissue sampling).</span>
  </p>
  <p id="p0501" num="0501" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El tratamiento tenía que ser aleatorio y alternado diariamente para evitar que los mismos grupos fueran tratados a la misma hora cada día. Además, las pruebas de comportamiento debían realizarse en un orden pseudoaleatorio, alternando cada día, para evitar que se manipularan los mismos animales en los mismos momentos. Los animales también se asignaron al azar por jaula en el muestreo de tejido.</span>Treatment had to be randomized and alternated daily to avoid the same groups being treated at the same time each day. In addition, behavioral tests had to be performed in a pseudorandom order, alternating each day, to avoid handling the same animals at the same times. Animals were also randomized by cage for tissue sampling.</span>
  </p>
  <p id="p0502" num="0502" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Asignación del grupo de tratamiento, tratamiento</span>Treatment group assignment, treatment</span>
      </i>
    </b>
  </p>
  <p id="p0503" num="0503" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se asignaron 72 ratones macho a 5 grupos de tratamiento diferentes. Los grupos se trataron diariamente durante 18 días mediante sonda oral con 43042 (Grupo C), o vehículo (PBS) (Grupos A, B y E) o vehículo (PBS anaeróbico -Grupo D). El tratamiento oral se inició 14 días antes de la lesión por MPTP. Los animales del Grupo E recibieron un tratamiento con vehículo diario (PBS) p.o. y se inyectaron i.p. (intraperitoneal) con el fármaco de referencia 30 minutos antes y 90 minutos después del primer MPTP el Día 0. El volumen de aplicación para el tratamiento p.o. con vehículo fue de 200 pl por ratón. 43042 eran de reservas de glicerol (gly). Para el tratamiento oral, las sondas nasogástricas para aplicaciones se almacenaron en viales que contenían etanol al 70% y se lavaron antes y después de cada uso con agua destilada. Cada grupo de tratamiento tenía su propio vial de etanol y sonda nasogástrica y un vial de agua destilada. Inmediatamente antes del tratamiento, se lavó cada jeringa con N2.</span>72 male mice were assigned to 5 different treatment groups. Groups were treated daily for 18 days by oral gavage with 43042 (Group C), or vehicle (PBS) (Groups A, B, and E) or vehicle (PBS anaerobic-Group D). Oral treatment was started 14 days before MPTP injury. Group E animals received daily vehicle treatment (PBS) p.o. and injected i.p. (intraperitoneal) with the reference drug 30 minutes before and 90 minutes after the first MPTP on Day 0. The application volume for treatment p.o. with vehicle was 200 pl per mouse. 43,042 were from glycerol (gly) pools. For oral treatment, nasogastric tubes for applications were stored in vials containing 70% ethanol and washed before and after each use with distilled water. Each treatment group had its own vial of ethanol and nasogastric tube and one vial of distilled water. Immediately before treatment, each syringe was flushed with N2.</span>
  </p>
  <p id="p0504" num="0504" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El día 0 MPTP (20 mg/kg b.w. 4 veces, intervalo entre tratamientos de 2 h) se inyectó i.p. en animales de los Grupos B, C, D y E. Un grupo de animales (A) se lesionó de forma simulada mediante la administración i.p. del vehículo de MPTP (disolución salina al 0,9%). El volumen de aplicación fue de 10 pl por g de peso corporal. El pesaje de los animales se realizó antes del tratamiento con MPTP para dosificar a los animales de acuerdo con su peso corporal real. Posteriormente, los animales recibieron el tratamiento diario p.o..</span>On day 0 MPTP (20 mg/kg b.w. 4 times, 2 h interval between treatments) was injected i.p. in animals of Groups B, C, D and E. One group of animals (A) was sham-injured by i.p. of the MPTP vehicle (0.9% saline). The application volume was 10 pl per g of body weight. Weighing of the animals was performed prior to MPTP treatment to dose the animals according to their actual body weight. Subsequently, the animals received daily treatment p.o.</span>
  </p>
  <p id="p0505" num="0505" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Prueba de Campo Abierto</span>Open Field Test</span>
      </i>
    </b>
  </p>
  <p id="p0506" num="0506" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La prueba de campo abierto se realizó el Día 2.</span>The open field test was performed on Day 2.</span>
  </p>
  <p id="p0507" num="0507" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La actividad espontánea y la ansiedad se evaluaron en Campo Abierto mediante la evaluación de los siguientes parámetros: hiperactividad[es], actividad[es]. Para ello se utilizó un Campo Abierto Plexiglas (48x48 cm; TSE-System®). Los rayos foto infrarrojos se colocaron a una distancia de 1,4 cm alrededor de la caja. Para detectar la cría (de pie sobre las patas traseras), se montó otra fila de haces foto 4 cm por encima de la primera. Cada sesión de prueba tuvo una duración de 5 minutos para verificar el comportamiento de los ratones en el nuevo entorno, ya que los primeros minutos de la prueba de campo abierto fueron los más adecuados para mostrar el comportamiento de exploración de los animales. A partir de entonces se contó el número de bolos fecales, como medida de emocionalidad. El Campo Abierto se limpió con etanol al 70% después de cada ratón para eliminar los rastros de olor. Las pruebas se realizaron en condiciones de iluminación ambiental estándar durante la fase de luz del ciclo circadiano.</span>Spontaneous activity and anxiety were evaluated in the Open Field by evaluating the following parameters: hyperactivity[s], activity[s]. For this, a Plexiglas Open Field (48x48 cm; TSE-System®) was used. The photoinfrared rays were placed at a distance of 1.4 cm around the box. To detect the pup (standing on its hind legs), another row of photo beams was mounted 4 cm above the first. Each test session lasted 5 minutes to verify the behavior of the mice in the new environment, since the first minutes of the open field test were the most suitable to show the exploration behavior of the animals. Thereafter, the number of fecal boluses was counted as a measure of emotionality. The Open Field was cleaned with 70% ethanol after each mouse to remove odor traces. The tests were performed under standard ambient lighting conditions during the light phase of the circadian cycle.</span>
  </p>
  <p id="p0508" num="0508" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Estadísticas</span>statistics</span>
    </b>
  </p>
  <p id="p0509" num="0509" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se realizó un análisis estadístico básico, por lo que se probó la normalidad de los datos brutos mediante la prueba de Kolmogorow-Smirnow. Si se confirmó la distribución normal, las diferencias entre dos grupos se probaron con la prueba T o entre más de dos grupos con el análisis de varianza unidireccional. Si los datos no estaban distribuidos normalmente, las diferencias entre dos grupos se probaron con la prueba de Mann-Whitney o entre más de dos grupos con la prueba de Kruskal-Wallis. La prueba posterior de Bonferroni se utilizó como prueba post hoc para el análisis de varianza unidireccional y la prueba de Dunn se utilizó como prueba post hoc para la prueba de Kruskal-Wallis. Las diferencias de grupo a lo largo del tiempo se probaron mediante el análisis de varianza bidireccional seguido de la prueba posterior de Bonferroni. Si era apropiado, los datos se presentaron como media ± o  error estándar de la media (SEM). 
</span>A basic statistical analysis was performed, so the normality of the raw data was tested using the Kolmogorow-Smirnow test. If normal distribution was confirmed, differences between two groups were tested with the t-test or between more than two groups with one-way analysis of variance. If data were not normally distributed, differences between two groups were tested with the Mann-Whitney test or between more than two groups with the Kruskal-Wallis test. Bonferroni's posterior test was used as a post hoc test for the one-way analysis of variance and Dunn's test was used as a post hoc test for the Kruskal-Wallis test. Group differences over time were tested using two-way analysis of variance followed by Bonferroni post-test. If appropriate, data were presented as mean ± or standard error of the mean (SEM). </span>
  </p>
  <p id="p0510" num="0510" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los análisis estadísticos se realizaron comparando todos los grupos con A (control positivo), B (control negativo), E (elemento de referencia) y C con D (vehículo para el Grupo C).</span>Statistical analyzes were performed comparing all groups with A (positive control), B (negative control), E (control element) and C with D (vehicle for Group C).</span>
  </p>
  <p id="p0512" num="0512" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultados</span>Results</span>
      </i>
    </b>
  </p>
  <p id="p0514" num="0514" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Observaciones generales y estado de salud</span>General observations and health status</span>
      </i>
    </b>
  </p>
  <p id="p0516" num="0516" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los animales toleraron bien la administración de cepas de bacterias. El día de la lesión de MPTP y, si era necesario, al día siguiente, se utilizó una luz roja para calentar a los animales. Si los animales se encontraban en condiciones subóptimas (se sentían fríos, deshidratados, comportamiento anormal), se les suministraba alimento húmedo y tratamiento con disolución salina subcutánea si era necesario. Durante el estudio, los siguientes 6 animales murieron por razones desconocidas.</span>The animals tolerated the administration of bacterial strains well. On the day of MPTP injury and, if necessary, the following day, a red light was used to warm the animals. If animals were in suboptimal condition (feeling cold, dehydrated, abnormal behavior), they were given wet food and subcutaneous saline treatment if necessary. During the study, the following 6 animals died for unknown reasons.</span>
  </p>
  <p id="p0518" num="0518" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Pruebas de Campo Abierto</span>Open Field Tests</span>
      </i>
    </b>
  </p>
  <p id="p0520" num="0520" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El Día 2 del curso de estudio (2 días después de la lesión de MPTP) los animales fueron probados en la Prueba de Campo Abierto. La prueba mostró que la hiperactividad y la actividad se reducen significativamente en los animales del Grupo C (43042) y del grupo D (Vehículo (PBS anaeróbico)) en comparación con los animales tratados con lesión simulada y con vehículo del Grupo A (Figura 84). También en comparación con el elemento de referencia del Grupo E (7-nitroindazol), los animales del Grupo G mostraron una hiperactividad significativamente reducida en las Pruebas de Campo Abierto.</span>On Day 2 of the study course (2 days after MPTP injury) the animals were tested in the Open Field Test. The test showed that hyperactivity and activity are significantly reduced in Group C (43042) and Group D (Vehicle (Anaerobic PBS)) animals compared to sham-injury and vehicle-treated animals from Group A (Figure 84). ). Also compared to the Group E reference (7-nitroindazole), Group G animals showed significantly reduced hyperactivity in the Open Field Tests.</span>
  </p>
  <p id="p0522" num="0522" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Discusión</span>Discussion</span>
      </i>
    </b>
  </p>
  <p id="p0524" num="0524" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La marcada reducción de la hiperactividad en ratones a los que se les administró 43042 7 en comparación con controles de solo vehículo destaca que 43042 puede ser útil en el tratamiento o prevención de afecciones o enfermedades asociadas con la hiperactividad, como trastornos del comportamiento, incluido el ADHD y la enfermedad de Parkinson. La hiperactividad se ha asociado con un aumento de la ansiedad en sujetos con enfermedad de Parkinson.</span>The marked reduction in hyperactivity in mice administered 43042 7 compared to vehicle-only controls highlights that 43042 may be useful in the treatment or prevention of conditions or diseases associated with hyperactivity, such as behavioral disorders, including ADHD and Parkinson's disease. Hyperactivity has been associated with increased anxiety in subjects with Parkinson's disease.</span>
  </p>
  <p id="p0526" num="0526" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 3 - Eficacia de la cepa 43171 de Bariatricus massiliensis para mejorar la supervivencia de la GVHD </span>Example 3 - Efficacy of Bariatricus massiliensis strain 43171 in improving GVHD survival</span>
      </i>
    </b>
  </p>
  <p id="p0527" num="0527" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Objetivo</span>Target</span>
      </i>
    </b>
  </p>
  <p id="p0529" num="0529" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los inventores buscaron determinar el efecto de la cepa 43171 de <i class="style-scope patent-text">Bariatricus massiliensis </i>sobre la enfermedad de injerto contra huésped (GVHD) inducida en ratones Balb/C.</span>The inventors sought to determine the effect of <i class="style-scope patent-text">Bariatricus massiliensis</i> strain 43171 on induced graft versus host disease (GVHD) in Balb/C mice.</span>
  </p>
  <p id="p0531" num="0531" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Material y métodos</span>Material and methods</span>
      </i>
    </b>
  </p>
  <p id="p0533" num="0533" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <i class="style-scope patent-text">- </i>Animales</span> <i class="style-scope patent-text">-</i> Animals</span>
    </b>
  </p>
  <p id="p0535" num="0535" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ratones macho Balb/C (BALB/cAnNCrl; 6-8 semanas de edad; n=125) con un peso corporal inicial promedio (± SEM) de 20,67 ± 0,11 g se obtuvieron de Charles River Laboratories (Wilmington, MA). n=75 macho C57B1/6 (C57B1/6NCrl; 6-8 semanas de edad) adicional se obtuvieron del mismo proveedor. Los animales se aclimataron antes del comienzo del estudio. Durante este período, los animales fueron observados diariamente con el fin de rechazar cualquiera que se presentara en mal estado.</span>Male Balb/C mice (BALB/cAnNCrl; 6-8 weeks of age; n=125) with a mean (±SEM) initial body weight of 20.67±0.11 g were obtained from Charles River Laboratories (Wilmington, MA). ). n=75 additional male C57B1/6 (C57B1/6NCrl; 6-8 weeks old) were obtained from the same supplier. The animals were acclimatized before the beginning of the study. During this period, the animals were observed daily in order to reject any that appeared in poor condition.</span>
  </p>
  <p id="p0537" num="0537" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- Alojamiento</span>- Accommodation</span>
    </b>
  </p>
  <p id="p0539" num="0539" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El estudio se realizó en salas para animales provistas de aire filtrado HEPA a una temperatura de 70 ± 5 °F y 50% ± 20% de humedad relativa. Los animales se alojaron en grupos de 4-6 por jaula. Específicamente, grupos con 8 animales/grupo estaban alojados en n=4/jaula; grupos con 10 animales/grupo estaban alojados en n=5/jaula; y grupos con 12 animales por grupo se alojaron en n=6/jaula. Los animales se alojaron en jaulas ventiladas individualmente y filtradas con HEPA. Las jaulas se separaron geográficamente en las rejillas para minimizar la contaminación cruzada entre los grupos. Los cuartos de los animales se establecieron para mantener un mínimo de 12 a 15 cambios de aire por hora. La habitación estaba en un temporizador automático durante un ciclo luz/oscuridad de 12 horas encendido y 12 horas apagado sin crepúsculo. Se utilizó ropa de cama Alpha-dri® (irradiada). Además de la ropa de cama, cada jaula se proporcionó con enviro-dri y una cabaña de pastor (enriquecimiento). El suelo se barrió a diario y se pasó la mopa un mínimo de dos veces por semana con un detergente comercial. Las paredes y las rejillas de las jaulas se limpiaron con una esponja como mínimo una vez al mes con una disolución diluida de lejía. Se utilizó una tarjeta o etiqueta de la jaula con la información apropiada necesaria para identificar el estudio, la dosis, el número de animal y el grupo de tratamiento para marcar todas las jaulas. La temperatura y la humedad relativa se registraron durante el estudio y se conservaron los registros. Todos los técnicos se pusieron el EPP (bata de laboratorio, guantes, gafas de seguridad) antes de ingresar al lab/vivarium y trabajar con animales. 
</span>The study was conducted in animal rooms provided with HEPA-filtered air at a temperature of 70 ± 5°F and 50% ± 20% relative humidity. Animals were housed in groups of 4-6 per cage. Specifically, groups with 8 animals/group were housed in n=4/cage; groups with 10 animals/group were housed in n=5/cage; and groups with 12 animals per group were housed in n=6/cage. Animals were housed in individually ventilated, HEPA-filtered cages. Cages were geographically separated on grids to minimize cross-contamination between groups. Animal rooms were set up to maintain a minimum of 12 to 15 air changes per hour. The room was on an automatic timer during a light/dark cycle of 12 hours on and 12 hours off with no twilight. Alpha-dri® (irradiated) bedding was used. In addition to bedding, each cage was provided with enviro-dri and a herder's hut (enrichment). The floor was swept daily and mopped a minimum of twice a week with a commercial detergent. Cage walls and grids were sponged at least once a month with a dilute bleach solution. A cage tag or card with the appropriate information necessary to identify the study, dose, animal number, and treatment group was used to mark all cages. Temperature and relative humidity were recorded during the study and the records were kept. All technicians put on PPE (lab coat, gloves, safety glasses) before entering the lab/vivarium and working with animals. </span>
  </p>
  <p id="p0540" num="0540" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- Dieta</span>- Diet</span>
    </b>
  </p>
  <p id="p0541" num="0541" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los animales fueron alimentados con alimento para roedores estéril (irradiado) LabDiet 5053 y se les proporcionó agua (ósmosis inversa) ad libitum. No se proporcionó ningún enriquecimiento a base de alimentos.</span>Animals were fed sterile (irradiated) LabDiet 5053 rodent chow and provided with water (reverse osmosis) ad libitum. No food-based enrichment was provided.</span>
  </p>
  <p id="p0542" num="0542" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- Asignaciones y aleatorización de animales</span>- Allocations and randomization of animals</span>
    </b>
  </p>
  <p id="p0543" num="0543" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los animales se asignaron al azar en 5 grupos al comienzo del estudio. Cada grupo comprendía entre 8 y 12 ratones. Cada grupo se subdividió en las cohortes A y B (n=4-6 ratones por grupo por cohorte); las cohortes habían escalonado las líneas de tiempo de la enfermedad.</span>Animals were randomized into 5 groups at the beginning of the study. Each group comprised between 8 and 12 mice. Each group was subdivided into cohorts A and B (n=4-6 mice per group per cohort); the cohorts had staggered disease timelines.</span>
  </p>
  <p id="p0544" num="0544" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- Análisis de la cinética de crecimiento de NCIMB 43171</span>- Analysis of the growth kinetics of NCIMB 43171</span>
    </b>
  </p>
  <p id="p0545" num="0545" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Antes de la administración de la curva/máximo de crecimiento de NCIMB 43171 se determinaron las OD y se determinó el recuento de colonias virtuales (VCC) a una OD600 máxima y después del lavado. El análisis de la curva/máximo de crecimiento se llevó a cabo el análisis de OD. A las 6 <sup class="style-scope patent-text">a </sup>M, se llevó un tubo de cada una de las reservas bacterianas congeladas a la cámara Coy. Los tubos se dejaron descongelar, se mezclaron cuidadosamente pipeteando hacia arriba y hacia abajo, y dos tubos (duplicados) que contenían 9,5 ml de caldo YCFA prerreducido y precalentado (37 °C) se inocularon con 500 pl de reserva de bacterias. Estos fueron los precultivos. Los precultivos se incubaron a 37 °C en la cámara Coy durante 24 horas. A las 6 AM del día siguiente (es decir, después de 24 horas de incubación), se extrajo una pequeña alícuota de cada cultivo de la cámara Coy y se determinó la OD600 mediante nanogota. Los tubos se mezclaron por inversión antes de retirar la alícuota para la medición de la OD600. El resto de los cultivos de 24 horas (usando el tubo con la OD600 más alta como se determinó anteriormente) se cultivaron por duplicado como sigue: se usaron 250 pL de cultivo de 24 horas NCIMB 43171 para inocular dos tubos que contenían 24,75 ml de caldo YCFA precalentado. Estos cultivos se incubaron a 37 °C en la cámara Coy durante 24 horas y se extrajo una pequeña alícuota de la cámara Coy para medir la OD600 cada dos horas durante 16 horas (es decir, a las 8 AM., 10 AM, 12 PM., 2 PM, 4 PM, 6 PM, 8 PM y 10 PM) y a las 24 horas (6 AM del día siguiente). Los tubos se mezclaron por inversión antes de retirar la alícuota para la medición de la OD600.</span>ODs were determined prior to administration of NCIMB 43171 growth curve/maximum and virtual colony count (VCC) was determined at maximum OD600 and after washing. Growth curve/maximum analysis was performed by OD analysis. At 6 <sup class="style-scope patent-text">to</sup> M, each tube of frozen bacterial stocks to Coy chamber took. The tubes were allowed to thaw, mixed gently by pipetting up and down, and two tubes (duplicates) containing 9.5 ml of pre-warmed (37°C) pre-reduced YCFA broth were inoculated with 500 μl of bacteria stock. These were the precultures. The precultures were incubated at 37 °C in the Coy chamber for 24 hours. At 6 AM the following day (ie, after 24 hours of incubation), a small aliquot of each culture was removed from the Coy chamber and the OD600 determined by nanodroplet. The tubes were mixed by inversion before removing the aliquot for OD600 measurement. The remaining 24-hour cultures (using the tube with the highest OD600 as determined above) were cultured in duplicate as follows: 250 pL of NCIMB 43171 24-hour culture was used to inoculate two tubes containing 24.75 mL of preheated YCFA broth. These cultures were incubated at 37°C in the Coy chamber for 24 hours and a small aliquot was removed from the Coy chamber for OD600 measurement every two hours for 16 hours (i.e., 8 AM, 10 AM, 12 PM). ., 2 PM, 4 PM, 6 PM, 8 PM and 10 PM) and 24 hours (6 AM the next day). The tubes were mixed by inversion before removing the aliquot for OD600 measurement.</span>
  </p>
  <p id="p0546" num="0546" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El análisis de VCC en la OD máxima se produjo de la siguiente manera: se llevó un tubo de reserva NCIMB 43171 a la cámara Coy. Se dejó que los tubos se descongelaran, después se mezclaron cuidadosamente pipeteándolos arriba y abajo y dos tubos (duplicados) que contenían 9,5 mL de caldo YCFA prerreducido, precalentado se inocularon con 500 pL de reserva de bacterias. Estos fueron los precultivos. Los precultivos se incubaron a 37 °C en la cámara Coy durante 24 horas. El día siguiente (es decir, después de 24 horas de incubación), se extrajo una pequeña alícuota de cada cultivo de la cámara Coy y se determinó la OD600 mediante nanogota. Los tubos se mezclaron por inversión antes de retirar la alícuota para la medición de la OD600. El resto de los cultivos de 24 horas (usando los tubos con la OD más alta) se cultivaron por duplicado como sigue: se usaron 250 pl para inocular dos tubos que contenían 24,75 ml de caldo YCFA precalentado. Estos fueron los principales cultivos. Se extrajo una pequeña alícuota del cultivo principal de la cámara Coy en el momento indicado y se determinó la OD600 mediante nanogota. Los tubos se mezclaron por inversión antes de retirar la alícuota para la medición de la OD600. El VCC de la reserva restante se determinó de la siguiente manera: una serie de diluciones individuales (sin diluir, 1:103, 1:104, 1:105, y 1:106) se preparó en PBS. El resto de cada cultivo se transfirió luego a un tubo cónico de 50 mL, y los tubos se sacaron de la cámara Coy y se centrifugaron (3500xg; 15 minutos). Una vez que se completó la centrifugación, los tubos se devolvieron a la cámara Coy, y se retiraron los sobrenadantes (con cuidado de no alterar los pélets) y se midieron. Los sedimentos se resuspendieron en volúmenes de PBS equivalentes a los de los sobrenadantes eliminados y se mezclaron cuidadosamente con una pipeta (sin agitación con vórtex). Una serie de diluciones individuales (sin diluir, 1:103, 1:104, 1:105, y 1:106) se preparó en PBS. Ambas series de diluciones (caldo y PBS suspendidas) se sembraron en placas puntuales (20 pl) por triplicado en un cuadrante de una placa de agar YCFA prerreducida. Las placas se incubaron a 37 °C en la cámara Coy durante 48 horas, y el VCC de cualquier dilución produjo manchas con 5-20 UFC/spot fue contado. Los valores de VCC de las tres manchas/mancha fueron promediados para determinar el VCC/mL de cultivos nocturnos en caldo y se centrifugaron/resuspendieron en PBS.</span>Analysis of VCC at maximum OD occurred as follows: An NCIMB 43171 stock tube was brought into the Coy chamber. The tubes were allowed to thaw, then mixed gently by pipetting up and down and two tubes (duplicates) containing 9.5 mL of pre-warmed, pre-reduced YCFA broth were inoculated with 500 pL of bacteria stock. These were the precultures. The precultures were incubated at 37 °C in the Coy chamber for 24 hours. The following day (ie, after 24 hours of incubation), a small aliquot of each culture was removed from the Coy chamber and the OD600 determined by nanodroplet. The tubes were mixed by inversion before removing the aliquot for OD600 measurement. The remainder of the 24 hour cultures (using the tubes with the highest OD) were grown in duplicate as follows: 250 μl was used to inoculate two tubes containing 24.75 ml of prewarmed YCFA broth. These were the main crops. A small aliquot of the main culture was removed from the Coy chamber at the indicated time and the OD600 was determined by nanodroplet. The tubes were mixed by inversion before removing the aliquot for OD600 measurement. The VCC of the remaining pool was determined as follows: A series of individual dilutions (undiluted, 1:103, 1:104, 1:105, and 1:106) was prepared in PBS. The remainder of each culture was then transferred to a 50 mL conical tube, and the tubes were removed from the Coy chamber and centrifuged (3500xg; 15 min). Once centrifugation was complete, the tubes were returned to the Coy chamber, and the supernatants were removed (being careful not to disturb the pellets) and measured. The pellets were resuspended in volumes of PBS equivalent to that of the removed supernatants and carefully mixed by pipette (no vortexing). A series of individual dilutions (undiluted, 1:103, 1:104, 1:105, and 1:106) was prepared in PBS. Both dilution series (suspended broth and PBS) were spot-plated (20 μl) in triplicate on one quadrant of a pre-reduced YCFA agar plate. Plates were incubated at 37°C in the Coy chamber for 48 hours, and VCC from any spotted dilution with 5-20 CFU/spot was counted. The VCC values of the three spots/spot were averaged to determine the VCC/mL of overnight cultures in broth and centrifuged/resuspended in PBS.</span>
  </p>
  <p id="p0547" num="0547" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- Preparación de dosificación NCIMB 43171</span>- NCIMB 43171 dosage preparation</span>
    </b>
  </p>
  <p id="p0548" num="0548" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Dos días antes de cada momento de dosificación, un tubo (1 mL/tubo) por cepa de reservas congeladas de NCIMB 43171 se introdujeron en la cámara Coy. Se dejó descongelar los tubos y se inocularon dos tubos de 15 ml, cada uno con 9,5 ml de caldo YCFA pre-reducido y precalentado, con 0,5 ml de cada reserva de bacterias. Estos fueron los precultivos (tubos 1 y 2). Los precultivos se incubaron a 37 °C en la cámara Coy durante 24 horas.</span>Two days prior to each dosing time, one tube (1 mL/tube) per strain of frozen stocks of NCIMB 43171 was introduced into the Coy chamber. The tubes were allowed to thaw and two 15 ml tubes, each containing 9.5 ml of pre-warmed, pre-reduced YCFA broth, were inoculated with 0.5 ml of each bacterial stock. These were the precultures (tubes 1 and 2). The precultures were incubated at 37 °C in the Coy chamber for 24 hours.</span>
  </p>
  <p id="p0549" num="0549" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Después de la incubación durante 24 horas, un día antes de cada momento de dosificación, los cultivos se mezclaron por inversión y se extrajo una pequeña alícuota (20 pL) de los cultivos de la cámara Coy para la determinación de la OD600 mediante nanogota. Cualquier tubo (1 o 2) por cepa que tuviera el valor de OD600 más alto se utilizó para el cultivo principal, por duplicado, de la siguiente manera: se usaron 250 pL del precultivo con la OD600 más alta para inocular 24,75 mL de caldo YCFA precalentado en una cónica de 50 mL (por duplicado; tubos A y B). Estos cultivos principales se incubaron en la cámara Coy (a 37 °) durante 14 horas.</span>After incubation for 24 hours, one day before each dosing time, the cultures were mixed by inversion and a small aliquot (20 pL) of the cultures was removed from the Coy chamber for OD600 determination by nanodroplet. Whichever tube (1 or 2) per strain had the highest OD600 value was used for the main culture, in duplicate, as follows: 250 pL of the preculture with the highest OD600 was used to inoculate 24.75 mL of prewarmed YCFA broth in a 50 mL conical (in duplicate; tubes A and B). These main cultures were incubated in the Coy chamber (at 37°) for 14 hours.</span>
  </p>
  <p id="p0550" num="0550" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En cada día de dosificación (después de las incubaciones de cultivos principales anteriores), los cultivos se mezclaron por inversión y se extrajo una pequeña alícuota (20 pL) de los cultivos de la cámara Coy para la 
determinación de la OD600 mediante nanogota. A continuación, se retiraron los tubos de la cámara Coy y se centrifugaron (3500 xg; 15 minutos). Una vez que se completó la centrifugación, los tubos se devolvieron a la cámara Coy, y se retiraron los sobrenadantes (con cuidado de no alterar los pélets) con pipeta. Los sedimentos se resuspendieron en 2,04 ml de PBS. Los gránulos se mezclaron cuidadosamente pipeteando (sin agitar con vórtex). Se pipeteó una alícuota (0,5 ml) de cada cepa en tubos Eppendorf y se retuvo en la cámara Coy. El resto de cada cepa se retiró de la cámara Coy y se usó para la dosificación (0,1 ml por animal), con cuidado de dosificar a los animales lo más rápido posible después de la resuspensión.</span>On each day of dosing (after the previous main culture incubations), the cultures were mixed by inversion and a small aliquot (20 pL) of the cultures was removed from the Coy chamber for analysis.  determination of OD600 by droplet. The tubes were then removed from the Coy chamber and centrifuged (3500 xg; 15 minutes). Once centrifugation was complete, the tubes were returned to the Coy chamber, and the supernatants (being careful not to disturb the pellets) were removed by pipetting. The pellets were resuspended in 2.04 ml PBS. The beads were carefully mixed by pipetting (without vortexing). An aliquot (0.5 ml) of each strain was pipetted into Eppendorf tubes and retained in the Coy chamber. The remainder of each strain was removed from the Coy chamber and used for dosing (0.1 ml per animal), with care to dose animals as quickly as possible after resuspension.</span>
  </p>
  <p id="p0552" num="0552" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La alícuota de 0,5 ml de cada cepa retenida en la cámara Coy se utilizó para la preparación de una serie de diluciones individuales en MRD prerreducida; la 1:107, 1:108, 1:109, y 1:1010 las diluciones se sembraron en placas puntuales (20 pl) por triplicado en un cuadrante de una placa de agar YCFA prerreducida. Las placas se incubaron a 37 °C en la cámara Coy durante 48 horas, y el VCC de cualquier dilución produjo manchas con un recuento de 5-20 UFC/mancha. Los valores VCC de tres manchas/mancha fueron promediados para determinar el VCC/mL del material de dosificación experimental.</span>The 0.5 ml aliquot of each strain retained in the Coy chamber was used for the preparation of a single dilution series in pre-reduced MRD; The 1:107, 1:108, 1:109, and 1:1010 dilutions were spot-plated (20 pl) in triplicate on one quadrant of a pre-reduced YCFA agar plate. Plates were incubated at 37°C in the Coy chamber for 48 hours, and VCC from any dilution produced spots with a count of 5-20 CFU/spot. The VCC values of three spots/spot were averaged to determine the VCC/mL of the experimental dosage material.</span>
  </p>
  <p id="p0554" num="0554" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- Fase de Pretratamiento</span>- Pretreatment phase</span>
    </b>
  </p>
  <p id="p0556" num="0556" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Todos los animales fueron pesados y asignados al azar por peso en grupos de tratamiento antes del inicio del estudio. Antes de la inducción de la GVHD en los días -1 y 0, todos los animales se pretrataron (PO) con PBS (Grupos 1-4), NCIMB 43171 (Grupo 5) o control de sal de butirato (Grupo 6) diariamente a partir del Día-14. El butirato se utilizó como control positivo ya que se ha identificado un déficit de butirato en el intestino de pacientes con GVHD. Los tratamientos se administraron a grupos al azar, y los tratamientos grupales se alternaron diariamente para evitar que los mismos grupos fueran tratados a la misma hora cada día. Una vez que comenzó la dosificación del artículo de prueba, se tuvo cuidado de minimizar la contaminación cruzada del grupo: el técnico cambió los guantes entre los grupos de tratamiento y se roció con alcohol isopropílico al 70% entre cada jaula del mismo grupo.</span>All animals were weighed and randomized by weight into treatment groups before the start of the study. Prior to induction of GVHD on days -1 and 0, all animals were pretreated (PO) with PBS (Groups 1-4), NCIMB 43171 (Group 5), or butyrate salt control (Group 6) daily at from Day-14. Butyrate was used as a positive control since butyrate deficiency has been identified in the intestine of GVHD patients. Treatments were given to groups at random, and group treatments were alternated daily to avoid the same groups being treated at the same time each day. Once test article dosing began, care was taken to minimize group cross-contamination: gloves were changed between treatment groups by the technician, and 70% isopropyl alcohol was sprayed between each cage in the same group.</span>
  </p>
  <p id="p0558" num="0558" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- Modelado de GVHD</span>- GVHD modeling</span>
    </b>
  </p>
  <p id="p0560" num="0560" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La GVHD se indujo en ratones usando una sola dosis aguda de 8 Gy de irradiación corporal total (TBI) el Día -1. El Día 0, a estos ratones receptores se les administró una inyección intravenosa de una combinación de células de la médula ósea empobrecidas en células T y células esplénicas del donante de ratones C57B1/6 en PBS. Las células de la médula ósea se aislaron usando prácticas de lavado estándar, y se agotaron las células T usando el antígeno de células T de la superficie celular c D3, con un kit de CD3-biotina (catálogo de Miltenyi Biotec 130-094-973). Los esplenocitos se aislaron usando disociadores Miltenyi GentleMACS. Los animales del Grupo 1 sirvieron como controles ingenuos y no recibieron TBI ni transferencia celular. Los animales del Grupo 2 sirvieron como controles de irradiación y recibieron los 8 Gy de TBI el Día -1, pero no recibieron una transferencia celular el Día 0. Los animales del Grupo 3 sirvieron como controles de transferencia adoptiva singénica; estos animales recibieron 8 Gy de TBI el Día -1 y una inyección intravenosa de una combinación de células de la médula ósea agotadas de células T y células esplénicas de ratones donantes Balb/C en PBS estéril.</span>GVHD was induced in mice using a single acute dose of 8 Gy total body irradiation (TBI) on Day -1. On Day 0, these recipient mice were given an intravenous injection of a combination of T cell-depleted bone marrow cells and donor spleen cells from C57B1/6 mice in PBS. Bone marrow cells were isolated using standard washing practices, and T cells were depleted using the cell surface T cell antigen cD3, with a CD3-biotin kit (Miltenyi Biotec catalog 130-094-973 ). Splenocytes were isolated using Miltenyi GentleMACS dissociators. Group 1 animals served as naive controls and received neither TBI nor cell transfer. Group 2 animals served as irradiation controls and received the 8 Gy TBI on Day -1, but did not receive a cell transfer on Day 0. Group 3 animals served as syngeneic adoptive transfer controls; these animals received 8 Gy of TBI on Day -1 and an intravenous injection of a combination of T cell-depleted bone marrow cells and spleen cells from Balb/C donor mice in sterile PBS.</span>
  </p>
  <p id="p0562" num="0562" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La dosificación diaria del artículo de prueba continuó durante la duración del estudio (días -14 a 30). La supervivencia de los animales se registró diariamente, como una indicación de la gravedad de la GVHD. Los animales también se pesaron, observaron y se les dio una puntuación clínica de GVHD diariamente durante la duración del estudio después de la inducción de GVHD. La puntuación de la GVHD se evaluó mediante un sistema de puntuación estándar basado en cinco criterios (Tabla 21): porcentaje de cambio de peso, postura (encorvado), actividad, textura del pelaje e integridad de la piel (puntuación máxima = 10).</span>Daily dosing of the test article continued for the duration of the study (days -14 to 30). Animal survival was recorded daily, as an indication of the severity of GVHD. Animals were also weighed, observed, and given a clinical GVHD score daily for the duration of the study after GVHD induction. The GVHD score was assessed using a standard scoring system based on five criteria (Table 21): percentage change in weight, posture (stooped), activity, coat texture, and skin integrity (maximum score = 10).</span>
  </p>
  <p id="p0564" num="0564" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tabla 1: Evaluación de la GVHD en ratones trasplantados (puntuación diaria)</span>Table 1: Evaluation of GVHD in transplanted mice (daily score)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text">
      <span class="google-src-text style-scope patent-text">
        </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/94/44/28/1f8ed2fd3858eb/imgf000043_0001.png" class="style-scope patent-text"><img img-content="table" inline="no" id="imgf000043_0001" he="227" wi="1860" file="imgf000043_0001.tif" img-format="tif" width="7440" height="908" alt="Figure imgf000043_0001" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/94/44/28/1f8ed2fd3858eb/imgf000043_0001.png"></a></div>
      
      <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/94/44/28/1f8ed2fd3858eb/imgf000043_0001.png" class="style-scope patent-text"><img img-content="table" inline="no" id="imgf000043_0001" he="227" wi="1860" file="imgf000043_0001.tif" img-format="tif" width="7440" height="908" alt="Figure imgf000043_0001" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/94/44/28/1f8ed2fd3858eb/imgf000043_0001.png"></a></div>
    
  <p class="style-scope patent-text"></p>
  <p id="p0569" num="0569" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">A los animales que perdieron el 20% de su peso corporal se les administraron líquidos subcutáneos (SID; disolución salina) y se les proporcionó alimento ablandado. Si algún animal individual del estudio requería alimento ablandado, 
todos los animales del estudio recibían alimento ablandado hasta que la pérdida de peso del animal individual hubiera sido rescatada. El tratamiento continuó hasta la eutanasia programada o la pérdida de peso corporal superior a 30%. Los animales que no podían enderezarse, estaban fríos al tacto o moribundos fueron sacrificados. El Día 29, todos los animales supervivientes se sometieron a una endoscopia para controlar la inflamación del colon. Se tomaron imágenes y se puntuó la gravedad de la colitis y la consistencia de las heces utilizando la escala de puntuación que se muestra en la Tabla 2.</span>Animals that lost 20% of their body weight were given subcutaneous fluids (SID; saline) and given softened feed. If any individual animal in the study required softened feed,  all study animals received softened feed until the individual animal's weight loss had been rescued. Treatment continued until scheduled euthanasia or body weight loss greater than 30%. Animals that could not straighten up, were cold to the touch, or dying were euthanized. On Day 29, all surviving animals underwent endoscopy to check for colonic inflammation. Images were taken and the severity of colitis and stool consistency were scored using the scoring scale shown in Table 2.</span>
  </p>
  <p id="p0571" num="0571" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tabla 2: Escala de puntuación de colitis por endoscopia</span>Table 2: Endoscopy Colitis Scoring Scale</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text">
      <span class="google-src-text style-scope patent-text">
        </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/7e/ac/5e/fa8dfb55983beb/imgf000044_0001.png" class="style-scope patent-text"><img img-content="table" inline="no" id="imgf000044_0001" he="227" wi="1620" file="imgf000044_0001.tif" img-format="tif" width="6480" height="908" alt="Figure imgf000044_0001" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/7e/ac/5e/fa8dfb55983beb/imgf000044_0001.png"></a></div>
      
      <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/7e/ac/5e/fa8dfb55983beb/imgf000044_0001.png" class="style-scope patent-text"><img img-content="table" inline="no" id="imgf000044_0001" he="227" wi="1620" file="imgf000044_0001.tif" img-format="tif" width="6480" height="908" alt="Figure imgf000044_0001" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/7e/ac/5e/fa8dfb55983beb/imgf000044_0001.png"></a></div>
    
  <p class="style-scope patent-text"></p>
  <p id="p0576" num="0576" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El Día 30, se recogió sangre mediante sangrado por RO; Se recogió sangre (aproximadamente 150 - 300 pL) en dos tubos; aproximadamente dos tercios de la sangre se recogió en tubos K2EDTA y el tercio restante se recogió en tubos de heparina-litio. Ambas muestras se centrifugaron y procesaron para plasma, y los tubos de plasma se etiquetaron claramente para indicar el anticoagulante utilizado. Para la muestra de K2EDTA, el plasma se dividió en alícuotas de la siguiente manera: 25 pL (para usar en el ensayo de citrulina posterior) y el resto. Todo el plasma se congeló a -80 °C. Todas las muestras de K2EDTA fueron evaluadas para citrulina mediante ELISA al finalizar el estudio.</span>On Day 30, blood was collected by RO bleeding; Blood (approximately 150-300 pL) was collected in two tubes; approximately two-thirds of the blood was collected in K2EDTA tubes and the remaining third was collected in lithium-heparin tubes. Both samples were centrifuged and processed for plasma, and the plasma tubes were clearly labeled to indicate the anticoagulant used. For the K2EDTA sample, the plasma was aliquoted as follows: 25 pL (for use in the subsequent citrulline assay) and the remainder. All plasma was frozen at -80°C. All K2EDTA samples were evaluated for citrulline by ELISA at the end of the study.</span>
  </p>
  <p id="p0578" num="0578" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La eutanasia se realizó mediante inhalación de CO2 y dislocación cervical, sin recolección de órganos para animales sacrificados fuera de horario durante la fase de TBI del estudio. La eutanasia se realizó mediante dislocación cervical únicamente, con recolección de órganos, para los animales sacrificados fuera de horario durante la fase de GVHD del estudio. Las recolecciones de terminales ocurrieron en la mesa. La mesa se limpió con alcohol isopropílico al 70% y un desinfectante comercial antes de comenzar. Los instrumentos se limpiaron con alcohol isopropílico al 70% entre animales y con un desinfectante comercial entre grupos.</span>Euthanasia was performed by CO2 inhalation and cervical dislocation, without organ harvesting for animals sacrificed after hours during the TBI phase of the study. Euthanasia was performed by cervical dislocation only, with organ harvesting, for animals sacrificed after hours during the GVHD phase of the study. Terminal pickups occurred at the table. The table was cleaned with 70% isopropyl alcohol and a commercial disinfectant before starting. Instruments were cleaned with 70% isopropyl alcohol between animals and with a commercial disinfectant between groups.</span>
  </p>
  <p id="p0580" num="0580" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- Análisis estadísticos</span>- Statistical analysis</span>
    </b>
  </p>
  <p id="p0582" num="0582" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los datos paramétricos se analizaron mediante ANOVA de una vía con la prueba de comparaciones múltiples de Tukey para comparar todos los grupos entre sí. Los datos no paramétricos se analizaron mediante la prueba de Kruskal-Wallis con la prueba de comparaciones múltiples de Dunn para comparar todos los grupos entre sí. Se llevó a cabo análisis estadísticos usando el software GraphPad Prism 7 (La Jolla, CA).</span>Parametric data were analyzed by one-way ANOVA with Tukey's multiple comparisons test to compare all groups with each other. Nonparametric data were analyzed using the Kruskal-Wallis test with Dunn's multiple comparisons test to compare all groups with each other. Statistical analyzes were performed using GraphPad Prism 7 software (La Jolla, CA).</span>
  </p>
  <p id="p0584" num="0584" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultados y discusión</span>Results and Discussion</span>
      </i>
    </b>
  </p>
  <p id="p0586" num="0586" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- Peso corporal</span>- Body weight</span>
    </b>
  </p>
  <p id="p0588" num="0588" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los animales se pesaron diariamente durante la duración del estudio, y el peso corporal medio de todos los grupos durante el transcurso del estudio se muestra en la Figura 5. Se calculó el cambio de peso corporal en relación con el Día - 14 (Figura 6) o el Día 0 (Figura 7). Con el fin de determinar diferencias estadísticamente significativas entre los grupos en el peso corporal medio o en el cambio de peso corporal medio en relación con el Día -14 o el Día 0, se calculó el área bajo la curva (AUC) utilizando la regla de transformación trapezoidal y se muestra en los recuadros de las Figuras 5, 6 y 7. Para tener en cuenta la deserción del grupo, el cambio de peso corporal en relación con el Día 0 mostrado con el peso corporal con el que murió un animal se trasladó durante la duración del estudio para los animales encontrados muertos o sacrificados (para todos los grupos con la excepción del Grupo 2) se muestra en la Figura 8, con el recuadro AUC.</span>Animals were weighed daily for the duration of the study, and the mean body weight of all groups over the course of the study is shown in Figure 5. Body weight change relative to Day - 14 was calculated (Figure 6). or Day 0 (Figure 7). In order to determine statistically significant differences between groups in mean body weight or mean body weight change relative to Day -14 or Day 0, the area under the curve (AUC) was calculated using the rule of thumb. trapezoidal transformation and is shown in the insets of Figures 5, 6 and 7. To account for group dropout, the change in body weight relative to Day 0 shown with the body weight at which an animal died was moved over the duration of the study for animals found dead or euthanized (for all groups except Group 2) is shown in Figure 8, inset AUC.</span>
  </p>
  <p id="p0590" num="0590" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">No se observaron diferencias importantes en el peso corporal medio (Figura 5) para ningún grupo durante el período de pretratamiento. Todos los grupos expuestos a TBI demostraron una pérdida de peso corporal de los días 0 a 3. El peso corporal medio de los animales del Grupo 3 (PBS - TBI  transferencia singénica) se recuperó desde este punto en adelante y finalmente regresó a la línea de base. El peso corporal medio de los animales del Grupo 2 (solo PBS - TBI) no se recuperó antes de la muerte de todos los animales del grupo. Para todos los demás grupos de estudio, el peso corporal medio continuó disminuyendo hasta el Día 7, aumentó hasta el Día 14 y, posteriormente, disminuyó durante la duración del estudio. El peso corporal medio en los Grupos 2, 5 y 6 se redujo significativamente 
durante el transcurso del estudio en comparación con el Grupo 1 (PBS - sin tratamiento previo). Por el contrario, el peso corporal medio en los Grupos 3-6 aumentó significativamente durante el transcurso del estudio en comparación con el Grupo 2. Finalmente, el peso corporal medio en los Grupos 5 y 6 se redujo significativamente durante el transcurso del estudio en comparación con el Grupo 3. No se observaron diferencias significativas en el peso corporal medio durante el transcurso del estudio al comparar los grupos de tratamiento (Grupos 5 y 6) con el Grupo 4 (PBS - TBI+transferencia alogeneica). Esta misma tendencia se observó cuando a los ratones se les administró el inmunosupresor tacrolimus, una terapia conocida de la GVHD (Figura 9).</span>No significant differences in mean body weight (FIG. 5) were observed for any group during the pretreatment period. All groups exposed to TBI demonstrated a loss in body weight from days 0 to 3. The mean body weight of animals in Group 3 (PBS - TBI syngeneic transfer) recovered from this point onward and eventually returned to baseline. base. The mean body weight of the animals in Group 2 (PBS-TBI only) did not recover before the death of all the animals in the group. For all other study groups, mean body weight continued to decrease through Day 7, increased through Day 14, and then decreased for the duration of the study. The mean body weight in Groups 2, 5 and 6 was significantly reduced  during the course of the study compared to Group 1 (PBS - naïve). In contrast, mean body weight in Groups 3-6 increased significantly over the course of the study compared to Group 2. Finally, mean body weight in Groups 5 and 6 significantly decreased over the course of the study compared with Group 3. No significant differences in mean body weight were observed over the course of the study when comparing the treatment groups (Groups 5 and 6) with Group 4 (PBS-TBI+allogeneic transfer). This same trend was observed when mice were administered the immunosuppressant tacrolimus, a known therapy for GVHD (FIG. 9).</span>
  </p>
  <p id="p0592" num="0592" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El cambio de peso corporal medio en relación con el Día -14 (Figura 6) aumentó para todos los grupos durante el período de pretratamiento, y la cinética del cambio de peso corporal en relación con el Día -14 desde el Día 0 en adelante fue similar a la observada para la media peso corporal. Los animales de los Grupos 2 y 4-6 demostraron una pérdida de peso corporal significativamente mayor durante el transcurso del estudio en comparación con el Grupo 1 y el Grupo 3.</span>Mean body weight change relative to Day -14 (Figure 6) increased for all groups during the pretreatment period, and the kinetics of body weight change relative to Day -14 from Day 0 onward were similar to that observed for mean body weight. Animals in Groups 2 and 4-6 demonstrated significantly greater body weight loss over the course of the study compared to Group 1 and Group 3.</span>
  </p>
  <p id="p0594" num="0594" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El cambio de peso corporal medio en relación con el Día 0 (Figuras 7 y 8) disminuyó para todos los grupos expuestos a TBI de los días 0 a 3, momento en el que comenzó el aumento de peso corporal para los animales del Grupo 3; la pérdida de peso corporal continuó para todos los demás grupos hasta el Día 4. El cambio de peso corporal en relación con el Día 0 aumentó del Día 7 al Día 14, y se observó una pérdida de peso corporal media para los Grupos 4-6 desde el Día 14 hasta el final del estudio el Día 30. Si bien el patrón general en el cambio de peso corporal en relación con el Día 0 fue similar independientemente de si el peso corporal se llevó adelante para los animales fallecidos, las diferencias estadísticamente significativas entre los grupos difirieron. Se observó una pérdida de peso corporal significativamente mayor en comparación con los Grupos 1, 2 y 3 para los Grupos 4-6 con y sin peso corporal para los animales muertos trasladados, nuevamente, lo cual es similar a la tendencia observada en ratones a los que se les administró la terapia conocida de GVHD tacrolimus (Figura 9).</span>Mean body weight change relative to Day 0 (Figures 7 and 8) decreased for all TBI-exposed groups from days 0 to 3, at which time body weight gain began for Group 3 animals; body weight loss continued for all other groups through Day 4. Body weight change relative to Day 0 increased from Day 7 to Day 14, and mean body weight loss was observed for Groups 4-6 from Day 14 to the end of the study on Day 30. While the overall pattern in body weight change relative to Day 0 was similar regardless of whether body weight was carried forward for deceased animals, statistically significant differences between groups differed. Significantly greater body weight loss compared to Groups 1, 2, and 3 was observed for Groups 4-6 with and without body weight for the transferred dead animals, again, which is similar to the trend observed in mice at the who were administered the known GVHD therapy tacrolimus (Figure 9).</span>
  </p>
  <p id="p0596" num="0596" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- Supervivencia</span>- survival</span>
    </b>
  </p>
  <p id="p0598" num="0598" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los animales se evaluaron diariamente para determinar su supervivencia o moribundidad, y en la Figura 10 se muestra una curva de Kaplan-Meier que muestra la supervivencia durante la duración del estudio. La supervivencia fue del 100% en los Grupos 1 y 3, 0% en el Grupo 2 y el 75% en el Grupo 5. La supervivencia observada en el Grupo 5 mejoró notablemente en comparación con los Grupos 4 y 6. Esto es significativo, ya que se ha propuesto el butirato como tratamiento para la GVHD [66]. Las tasas de supervivencia fueron comparables a las de los ratones controles a los que se les administró el conocido tratamiento de GVHD tacrolimus (FK506 - Figura 11)</span>Animals were assessed daily for survival or moribundity, and a Kaplan-Meier curve showing survival over the duration of the study is shown in Figure 10. Survival was 100% in Groups 1 and 3, 0% in Group 2 and 75% in Group 5. Survival observed in Group 5 was markedly improved compared to Groups 4 and 6. This is significant, since butyrate has been proposed as a treatment for GVHD [66]. Survival rates were comparable to control mice given the known GVHD treatment tacrolimus (FK506 - Figure 11)</span>
  </p>
  <p id="p0600" num="0600" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- Puntuaciones de GVHD</span>- GVHD scores</span>
    </b>
  </p>
  <p id="p0602" num="0602" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se evaluaron las puntuaciones de la GVHD (según la puntuación de múltiples parámetros que se muestra en la Tabla 2) en todos los animales desde el Día 0 hasta el final del estudio el Día 30. Las puntuaciones medias de GVHD para todos los grupos se muestran en la Figura 12, y estos mismos datos presentados con la puntuación de GVHD con la que un animal murió se muestran en la Figura 13. El AUC se calculó utilizando la regla de transformación trapezoidal para determinar diferencias estadísticamente significativas en las puntuaciones generales de GVHD entre los grupos, y esto se muestra en los recuadros de las Figuras 12 y 13. La puntuación clínica de la GVHD asignada a cada animal es una combinación que consta de postura (figura 14A), actividad (figura 14B), textura del pelaje (figura 14C), integridad de la piel (figura 14D) y pérdida de peso (figura 14E).</span>GVHD scores (according to the multiparameter score shown in Table 2) were evaluated in all animals from Day 0 to the end of the study on Day 30. Mean GVHD scores for all groups are shown. in Figure 12, and these same data presented with the GVHD score at which one animal died are shown in Figure 13. AUC was calculated using the trapezoidal transformation rule to determine statistically significant differences in overall GVHD scores between groups, and this is shown in the boxes in Figures 12 and 13. The clinical GVHD score assigned to each animal is a composite consisting of posture (figure 14A), activity (figure 14B), coat texture (figure 14C), skin integrity (FIG. 14D), and weight loss (FIG. 14E).</span>
  </p>
  <p id="p0604" num="0604" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La inyección intravenosa de esplenocitos alogénicos y células de la médula ósea indujo GVHD en todos los grupos que comenzó alrededor del Día 19 y aumentó progresivamente en gravedad hasta la conclusión del estudio. Hubo una puntuación inicial de GVHD aumentada entre los Días 0-7, presumiblemente debido a un TBI y al injerto; La supervivencia de los animales más allá de este punto verifica el injerto exitoso de las células trasplantadas. Si bien la cinética de la puntuación de la GVHD fue similar independientemente de si la puntuación de la GVHD se llevó adelante para los animales fallecidos, las diferencias estadísticamente significativas entre los grupos difirieron. Los animales de los Grupos 3-6 demostraron puntuaciones medias de GVHD significativamente aumentadas en comparación con los Grupos 1 y 2 con y sin puntuaciones de GVHD para los animales muertos transferidos; asimismo, los animales de los Grupos 4-6 demostraron un aumento significativo de las puntuaciones medias de GVHD en comparación con el Grupo 3 en ambos casos. Esta tendencia también se observó en modelos de ratones de GVHD a los que se les administró el inmunosupresor tacrolimus, que es una terapia conocida de GVHD (Figura 15).</span>Intravenous injection of allogeneic splenocytes and bone marrow cells induced GVHD in all groups beginning around Day 19 and progressively increasing in severity until the conclusion of the study. There was an increased baseline GVHD score between Days 0-7, presumably due to TBI and grafting; Survival of the animals beyond this point verifies successful engraftment of the transplanted cells. Although the kinetics of the GVHD score were similar regardless of whether the GVHD score was carried out for deceased animals, the statistically significant differences between groups differed. Animals from Groups 3-6 demonstrated significantly increased mean GVHD scores compared to Groups 1 and 2 with and without GVHD scores for dead transferred animals; likewise, animals from Groups 4-6 demonstrated a significant increase in mean GVHD scores compared to Group 3 in both cases. This trend was also observed in mouse models of GVHD administered the immunosuppressant tacrolimus, which is a known therapy of GVHD (Figure 15).</span>
  </p>
  <p id="p0606" num="0606" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- Endoscopia</span>- Endoscopy</span>
    </b>
  </p>
  <p id="p0608" num="0608" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los animales se sometieron a una endoscopia el Día 29 para evaluar la inflamación del colon. La colitis se puntuó visualmente en una escala de cinco puntos que va de 0 para normal a 4 para ulceración grave (Tabla 3). La gravedad media de la colitis se muestra en la Figura 16.</span>Animals underwent endoscopy on Day 29 to assess for colonic inflammation. Colitis was scored visually on a five-point scale ranging from 0 for normal to 4 for severe ulceration (Table 3). The mean severity of colitis is shown in Figure 16.</span>
  </p>
  <p id="p0610" num="0610" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las puntuaciones medias de gravedad de la colitis aumentaron para los animales tratados con la cepa 43171 y los tratados con butirato en comparación con los ratones sin tratamiento previo (Grupo 1). Sin embargo, la colitis fue significativamente menor en los ratones tratados con la cepa 43171 en comparación con los ratones tratados con 
butirato. Esto es significativo, ya que se ha sugerido la corrección del déficit de butirato como tratamiento para la colitis [67]. Las imágenes de endoscopia representativas se muestran en la Figura 17.</span>Mean colitis severity scores were increased for animals treated with strain 43171 and those treated with butyrate compared to naïve mice (Group 1). However, colitis was significantly less in mice treated with strain 43171 compared to mice treated with  butyrate. This is significant, as correction of butyrate deficiency has been suggested as a treatment for colitis [67]. Representative endoscopy images are shown in Figure 17.</span>
  </p>
  <p id="p0612" num="0612" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">- Citrulina plasmática</span>- Plasma citrulline</span>
    </b>
  </p>
  <p id="p0614" num="0614" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se extrajo sangre antes de la eutanasia de todos los animales supervivientes y se procesó para obtener plasma. La citrulina plasmática se evaluó como marcador de permeabilidad intestinal por duplicado mediante ELISA. Una reducción de los niveles plasmáticos de citrulina corresponde a una pérdida de masa de células epiteliales que indica un aumento de la permeabilidad de la barrera intestinal. El mantenimiento de la función de barrera intestinal (es decir, el mantenimiento de la impermeabilidad intestinal) es importante para el tratamiento de la GVHD [68]. Los resultados se muestran en la Figura 18. Los ratones a los que se les administró la cepa 43171 mantuvieron mayores niveles de citrulina en plasma en comparación con los ratones a los que se les administró sales de butirato (Grupo 6), lo cual es significativo considerando el papel del butirato en el mantenimiento de la función de barrera correcta.</span>Blood was collected prior to euthanasia from all surviving animals and processed to obtain plasma. Plasma citrulline was evaluated as a marker of intestinal permeability in duplicate by ELISA. A reduction in plasma citrulline levels corresponds to a loss of epithelial cell mass indicating increased permeability of the intestinal barrier. Maintenance of intestinal barrier function (ie, maintenance of intestinal impermeability) is important for the treatment of GVHD [68]. The results are shown in Figure 18. Mice administered strain 43171 maintained higher plasma citrulline levels compared to mice administered butyrate salts (Group 6), which is significant. considering the role of butyrate in maintaining the correct barrier function.</span>
  </p>
  <p id="p0616" num="0616" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">E jem plo 3: Prueba de estabilidad</span>Example 3: Stability test</span>
      </i>
    </b>
  </p>
  <p id="p0618" num="0618" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Una composición descrita en este documento que contiene al menos una cepa bacteriana descrita en este documento se almacena en un recipiente sellado a 25 °C o 4 °C y el recipiente se coloca en una atmósfera que tenga 30%, 40%, 50%, 60%, 70%, 75%, 80%, 90% o 95% de humedad relativa. Después de 1 mes, 2 meses, 3 meses, 6 meses, 1 año, 1,5 años, 2 años, 2,5 años o 3 años, al menos 50%, 60%, 70%, el 80% o el 90% de la cepa bacteriana permanecerá medido en unidades formadoras de colonias determinadas por protocolos estándar.</span>A composition described herein containing at least one bacterial strain described herein is stored in a sealed container at 25°C or 4°C and the container is placed in an atmosphere having 30%, 40%, 50%, 60%, 70%, 75%, 80%, 90% or 95% relative humidity. After 1 month, 2 months, 3 months, 6 months, 1 year, 1.5 years, 2 years, 2.5 years or 3 years, at least 50%, 60%, 70%, 80% or 90 % of the bacterial strain will remain measured in colony forming units determined by standard protocols.</span>
  </p>
  <p id="p0620" num="0620" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">E jem plo 4: E ficacia de los inóculos bacterianos p ara red u cir la secreción de IL -6</span>Example 4: Efficacy of Bacterial Inoculums in Reducing IL-6 Secretion</span>
      </i>
    </b>
  </p>
  <p id="p0622" num="0622" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Introducción</span>Introduction</span>
      </i>
    </b>
  </p>
  <p id="p0624" num="0624" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La activación de ciOCDinas proinflamatorias se ha asociado con daño en la enfermedad inflamatoria. El lipopolisacárido (LPS) es un estimulador conocido de la citoquina proinflamatoria IL-6. Las células U373 se trataron con composiciones que comprenden la cepa 43042 de la invención en combinación con LPS para observar su capacidad para modular los niveles de IL-6.</span>Activation of proinflammatory cyOCDins has been associated with damage in inflammatory disease. Lipopolysaccharide (LPS) is a known stimulator of the proinflammatory cytokine IL-6. U373 cells were treated with compositions comprising the 43042 strain of the invention in combination with LPS to observe their ability to modulate IL-6 levels.</span>
  </p>
  <p id="p0626" num="0626" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">M étodos</span>M ethods</span>
      </i>
    </b>
  </p>
  <p id="p0628" num="0628" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">U373 es una línea celular de astrocitoma de glioblastoma humano. Las células (utilizadas entre el pase 20 y el pase 37) se mantuvieron en 25 ml de MEME 4,5 g/L D-glucosa suplementada con FBS inactivado por calor al 10%, L-glutamina 4 mM, 100 U/ml penicilina, 100 pg/ml estreptomicina y 5 pg/ml plasmocina, 1% aminoácidos no esenciales, 1% piruvato de sodio (denominado en todo momento medio de crecimiento completo).</span>U373 is a human glioblastoma astrocytoma cell line. Cells (used between passage 20 and passage 37) were maintained in 25 ml MEME 4.5 g/L D-glucose supplemented with 10% heat-inactivated FBS, 4 mM L-glutamine, 100 U/ml penicillin. , 100 pg/ml streptomycin and 5 pg/ml plasmocin, 1% non-essential amino acids, 1% sodium pyruvate (referred to as complete growth medium throughout).</span>
  </p>
  <p id="p0630" num="0630" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las células se colocaron en placas en placas de 24 pocillos a una densidad de 100.000 células/pocillo en 1ml de medio de crecimiento completo y se dejó permanecer a 37°C/5% CO2 durante 72h. El día del tratamiento, se retiró el medio de cada pocillo, las células se enjuagaron con 0,5 ml de medio de lavado (MEME sin suero), 0,9 ml de medio de estimulación (medio MEME que contiene 2% FBS) que contiene 1 pg/ml Se añadió LPS a los pocillos apropiados y se incubó a 37 °C y 5% CO2. Después de 1 hora de preincubación, las células se retiraron de la incubadora de CO2 y se trataron con 100 pl de sobrenadante bacteriano derivado de la cepa 43042. El control de medios se utilizó como control. Las células después se incubaron durante otras 24h a 37 °C/5% CO2, después de los cual los sobrenadantes libres de células se recogieron y se desespumaron a 10.000g a 4°C durante 3 min. Se extrajeron alícuotas de las muestras en microtubos de 1,5 ml y se almacenaron a -80°C para ELISA hIL-6 y hIL-8. </span>Cells were plated in 24-well plates at a density of 100,000 cells/well in 1ml complete growth medium and allowed to stand at 37°C/5% CO2 for 72h. On the day of treatment, the medium was removed from each well, the cells were rinsed with 0.5 ml wash medium (MEME without serum), 0.9 ml stimulation medium (MEME medium containing 2% FBS) containing contains 1 pg/ml LPS was added to the appropriate wells and incubated at 37°C and 5% CO2. After 1 hour of preincubation, cells were removed from the CO 2 incubator and treated with 100 μl of bacterial supernatant derived from strain 43042. Media control was used as control. Cells were then incubated for a further 24h at 37°C/5% CO2, after which cell-free supernatants were collected and skimmed at 10,000g at 4°C for 3 min. Samples were aliquoted into 1.5 ml microtubes and stored at -80°C for hIL-6 and hIL-8 ELISA.</span>
  </p>
  <p id="p0631" num="0631" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">R esultados</span>Results</span>
      </i>
    </b>
  </p>
  <p id="p0633" num="0633" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los resultados de los experimentos se muestran en la Figura 19. El tratamiento de las células con LPS y la cepa de bacterias condujo a una disminución del nivel de IL-6 secretado.</span>The results of the experiments are shown in Figure 19. Treatment of the cells with LPS and the bacteria strain led to a decrease in the level of secreted IL-6.</span>
  </p>
  <p id="p0635" num="0635" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">E jem plo 5: A ctivación de M AP2</span>E xam ple 5: Activation of MAP2</span>
      </i>
    </b>
  </p>
  <p id="p0637" num="0637" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se investigó el efecto de la cepa 43042 sobre la expresión de un gen asociado con la diferenciación neuronal: la proteína 2 asociada a microtúbulos (MAP2). El análisis de qPCR reveló que la transcripción de MAP2 estaba regulada al alza por 43042 por encima de las muestras de control de medios en células de neuroblastoma SH-SY5Y (ver Figura 20).</span>The effect of strain 43042 on the expression of a gene associated with neuronal differentiation: microtubule-associated protein 2 (MAP2) was investigated. qPCR analysis revealed that MAP2 transcription was upregulated by 43042 above media control samples in SH-SY5Y neuroblastoma cells (see Figure 20).</span>
  </p>
  <p id="p0639" num="0639" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las células SH-SY5Y son una línea celular de neuroblastoma. Las células se cultivaron en medio Ham F-12 de mezcla de nutrientes al 50% y MEM al 50% suplementado con L-glutamina 2 mM, FBS inactivado por calor al 10%, 100 U/ml penicilina y 100 pg/ml estreptomicina. Las células SH-SY5Y se sembraron en placas de 6 pocillos a una densidad de 0,5 x 106 células. Después de 24 h, las células se trataron en medio de diferenciación (medio de crecimiento que contenía 1% FBS sin RA) con sobrenadantes bacterianos al 10% o YCFA  o RA 10uM durante 24 h. Se recogieron las células y se aisló el ARN total de acuerdo con el proOCDolo del mini kit RNeasy (Qiagen). El ADNc se preparó utilizando el kit de transcripción inversa de ADNc de alta capacidad (Applied Biosystems). La expresión génica se midió mediante qPCR. Se utilizó GAPDH como control interno. Se calcularon los cambios múltiplos utilizando el método 2A(-AACt). 
</span>SH-SY5Y cells are a neuroblastoma cell line. Cells were grown in Ham F-12 medium of 50% nutrient mix and 50% MEM supplemented with 2 mM L-glutamine, 10% heat inactivated FBS, 100 U/ml penicillin and 100 pg/ml streptomycin. SH-SY5Y cells were seeded in 6-well plates at a density of 0.5 x 10 6 cells. After 24 h, cells were treated in differentiation medium (growth medium containing 1% FBS without RA) with 10% bacterial supernatants or YCFA or 10 uM RA for 24 h. Cells were harvested and total RNA was isolated according to the RNeasy mini kit proOCDolo (Qiagen). cDNA was prepared using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Gene expression was measured by qPCR. GAPDH was used as internal control. Multiple changes were calculated using the 2A(-AACt) method. </span>
  </p>
  <p id="p0640" num="0640" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Lista de cebadores utilizados para el análisis de expresión génica <i class="style-scope patent-text">in vitro </i>mediante qPCR.</span>List of primers used for <i class="style-scope patent-text">in vitro</i> gene expression analysis by qPCR.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text">
      <span class="google-src-text style-scope patent-text">
        </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/eb/11/e7/18da7aa751bf65/imgf000047_0001.png" class="style-scope patent-text"><img img-content="table" inline="no" id="imgf000047_0001" he="151" wi="1720" file="imgf000047_0001.tif" img-format="tif" width="6880" height="604" alt="Figure imgf000047_0001" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/eb/11/e7/18da7aa751bf65/imgf000047_0001.png"></a></div>
      
      <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/eb/11/e7/18da7aa751bf65/imgf000047_0001.png" class="style-scope patent-text"><img img-content="table" inline="no" id="imgf000047_0001" he="151" wi="1720" file="imgf000047_0001.tif" img-format="tif" width="6880" height="604" alt="Figure imgf000047_0001" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/eb/11/e7/18da7aa751bf65/imgf000047_0001.png"></a></div>
    
  <p class="style-scope patent-text"></p>
  <p id="p0645" num="0645" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">E jem plo 6: Efecto sobre la expresión de m arcadores funcionales en e l intestino</span>Example 6: Effect on the expression of functional markers in the intestine</span>
      </i>
    </b>
  </p>
  <p id="p0647" num="0647" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resum en</span>Summary</span>
      </i>
    </b>
  </p>
  <p id="p0649" num="0649" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Este estudio investigó el efecto de la cepa 43042 de <i class="style-scope patent-text">Bariatricus massiliensis </i>sobre la expresión de proteínas de unión estrecha y marcadores funcionales en el intestino. La indolamina 2,3 dioxigenasa-1 (IDO1) es una enzima que inicia el catabolismo del triptófano a lo largo de una vía que genera varios metabolitos bioactivos basados en quinurenina. La triptófano hidroxilasa-1 (TPH-1) cataliza la formación de 5-hidroxi-L-triptófano (5-HTP) a partir de L-triptófano, el primer paso limitante en la biosíntesis de 5-HT.</span>This study investigated the effect of <i class="style-scope patent-text">Bariatricus massiliensis</i> strain 43042 on the expression of tight junction proteins and functional markers in the intestine. Indoleamine 2,3 dioxygenase-1 (IDO1) is an enzyme that initiates the catabolism of tryptophan along a pathway that generates several bioactive metabolites based on kynurenine. Tryptophan hydroxylase-1 (TPH-1) catalyzes the formation of 5-hydroxy-L-tryptophan (5-HTP) from L-tryptophan, the first rate-limiting step in 5-HT biosynthesis.</span>
  </p>
  <p id="p0651" num="0651" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">M étodo</span>M ethod</span>
      </i>
    </b>
  </p>
  <p id="p0653" num="0653" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ratones BALB/c machos recibieron alimentación por sonda oral (volumen de 200 pl) de 1 x 109 UFC de la cepa bacteriana durante 6 días consecutivos. En el Día 7, los animales se sometieron a eutanasia. Se extirpó tejido intestinal (segmentos de 1 cm de íleon y colon). El ARN total se extrajo con el kit de aislamiento de miARN mirVana™ (tecnologías Ambion/Llife, Paisley, Reino Unido) y tratados con DNasa (tecnologías Turbo DNA-free, Ambion/life) de acuerdo con las recomendaciones del fabricante. El ARN se cuantificó usando un espectrofotómetro NanoDrop™ (Thermo Fisher Scientific Inc., Wilmington, Delaware, EE. UU.) De acuerdo con las instrucciones del fabricante. La calidad del ARN se evaluó utilizando el Agilent Bioanalyzer (Agilent, Stockport, Reino Unido) de acuerdo con el procedimiento del fabricante y se calculó un número de integridad del ARN (RIN). ARN con valor de RIN &gt;7 se utilizó para experimentos posteriores. El ARN se transcribió de forma inversa a ADNc usando el kit de ADNc de alta capacidad de Applied Biosystems (Applied Biosystems, Warrington, Reino Unido) de acuerdo con las instrucciones del fabricante. Brevemente, la transcriptasa inversa multiscribe (50 U/pL) se añadió como parte de la mezcla maestra de RT, se incubó a 25 °C durante 10 min, 37 °C durante 2 h, 85 °C durante 5 min y se almacenó a 4 °C. La PCR cuantitativa se llevó a cabo usando sondas (6 carboxifluoresceína - FAM) diseñadas por Applied Biosystems para genes diana específicos de ratón, mientras se usaba p-actina como control endógeno. Las reacciones de amplificación contenían 1 pl de ADNc, 5 pl de la mezcla maestra de PCR 2X (Roche) y 900 nM de cada cebador y se llevaron a un total de 10 pl mediante la adición de agua libre de RNasa. Todas las reacciones se realizaron por triplicado utilizando placas de 96 pocillos en el sistema LightCycler®480. Las condiciones de ciclo térmico fueron las recomendadas por el fabricante (Roche) durante 55 ciclos. Para comprobar la contaminación por amplicones, cada experimento no contenía controles de plantilla por triplicado para cada sonda utilizada. Se registraron los valores de umbral de ciclo (Ct). Los datos se normalizaron usando p-actina y se transformaron usando el método 2-AACT y se presentaron como un cambio de veces frente al grupo de control.</span>Male BALB/c mice received oral gavage (200 pl volume) of 1 x 10 9 CFU of the bacterial strain for 6 consecutive days. On Day 7, the animals were euthanized. Intestinal tissue (1 cm segments of ileum and colon) was removed. Total RNA was extracted with the mirVana™ miRNA isolation kit (Ambion/Llife technologies, Paisley, UK) and treated with DNase (Turbo DNA-free technologies, Ambion/life) according to the manufacturer's recommendations. RNA was quantified using a NanoDrop™ spectrophotometer (Thermo Fisher Scientific Inc., Wilmington, Delaware, USA) according to the manufacturer's instructions. RNA quality was assessed using the Agilent Bioanalyzer (Agilent, Stockport, UK) according to the manufacturer's procedure and an RNA integrity number (RIN) was calculated. RNA with RIN value &gt;7 was used for further experiments. RNA was reverse transcribed to cDNA using the Applied Biosystems High Throughput cDNA Kit (Applied Biosystems, Warrington, UK) according to the manufacturer's instructions. Briefly, multiscribe reverse transcriptase (50 U/pL) was added as part of the RT master mix, incubated at 25 °C for 10 min, 37 °C for 2 h, 85 °C for 5 min, and stored at 4°C Quantitative PCR was carried out using probes (6 carboxyfluorescein - FAM) designed by Applied Biosystems for mouse-specific target genes, while using p-actin as endogenous control. Amplification reactions contained 1 pl of cDNA, 5 pl of 2X PCR master mix (Roche) and 900 nM of each primer and were brought to a total of 10 pl by the addition of RNase-free water. All reactions were performed in triplicate using 96-well plates on the LightCycler®480 system. Thermal cycling conditions were those recommended by the manufacturer (Roche) for 55 cycles. To check for amplicon contamination, each experiment contained no template controls in triplicate for each probe used. Cycle threshold (Ct) values were recorded. Data was normalized using p-actin and transformed using the 2-AACT method and presented as fold change versus control group.</span>
  </p>
  <p id="p0655" num="0655" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">R esultados</span>Results</span>
      </i>
    </b>
  </p>
  <p id="p0657" num="0657" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">De los genes probados, la expresión de IDO1 fue diferente en los ratones que habían recibido la cepa bacteriana en comparación con los animales que recibieron el vehículo. Hubo un aumento significativo en el íleon (Fig. 21A) y una disminución significativa en el colon (Fig. 21B). La expresión de IDO1 en el colon se asocia con la mejora de la enfermedad en un modelo de colitis en ratón [69]. Por tanto, las cepas bacterianas del género <i class="style-scope patent-text">Bariatricus </i>pueden ser útiles en el tratamiento o prevención de enfermedades inflamatorias del intestino.</span>Of the genes tested, IDO1 expression was different in mice that had received the bacterial strain compared to animals that received vehicle. There was a significant increase in the ileum (FIG. 21A) and a significant decrease in the colon (FIG. 21B). IDO1 expression in the colon is associated with disease improvement in a mouse model of colitis [69]. Thus, bacterial strains of the <i class="style-scope patent-text">Bariatricus</i> genus may be useful in the treatment or prevention of inflammatory bowel diseases.</span>
  </p>
  <p id="p0659" num="0659" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">E jem plo 7: E fecto sobre la expresión génica en el cerebro</span>Example 7: Effect on gene expression in the brain</span>
      </i>
    </b>
  </p>
  <p id="p0661" num="0661" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resum en</span>Summary</span>
      </i>
    </b>
  </p>
  <p id="p0663" num="0663" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Este estudio investigó el efecto de la cepa 43042 de <i class="style-scope patent-text">Bariatricus massiliensis </i>sobre la expresión de ciertos genes de interés en el cerebro. Niveles de ARNm para marcadores del sistema oxiOCDinérgico (receptor de oxiOCDina y receptor de vasopresina), sistema endocrino (mineralocorticoide (Nr3cl); receptor de glucocorticoide (Nr3c2); factor de liberación de corticosterona (CRF) y receptores; factor neurotrófico derivado del cerebro (BDNF)), sistema inmunológico (11-6, TNF-a, TLR-4); y sistemas de neurotransmisores (receptor NMDA 2A (Grin2A); receptor NMDA 2B (Grin2B); subunidad A2 del receptor GABAA; subunidad B1 del receptor GABAB; serotonina 2C) se evaluaron en la amígdala, el hipocampo y la corteza prefrontal (PFC), que son regiones cerebrales clave del sistema límbico involucrado en la respuesta emocional. 
</span>This study investigated the effect of <i class="style-scope patent-text">Bariatricus massiliensis</i> strain 43042 on the expression of certain genes of interest in the brain. mRNA levels for markers of the oxyOCDinergic system (oxyOCDin receptor and vasopressin receptor), endocrine system (mineralocorticoid (Nr3cl); glucocorticoid receptor (Nr3c2); corticosterone releasing factor (CRF) and receptors; brain-derived neurotrophic factor ( BDNF)), immune system (11-6, TNF-a, TLR-4); and neurotransmitter systems (NMDA receptor 2A (Grin2A); NMDA receptor 2B (Grin2B); GABAA receptor A2 subunit; GABAB receptor B1 subunit; serotonin 2C) were assessed in the amygdala, hippocampus, and prefrontal cortex (PFC), which are key brain regions of the limbic system involved in emotional response. </span>
  </p>
  <p id="p0664" num="0664" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Materiales y Métodos</span>Materials and methods</span>
      </i>
    </b>
  </p>
  <p id="p0666" num="0666" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Método</span>Method</span>
      </i>
    </b>
  </p>
  <p id="p0668" num="0668" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ratones BALB/c machos recibieron alimentación por sonda oral (volumen de 200 pl) de 1 x 109 UFC de la cepa bacteriana durante 6 días consecutivos. En el Día 7, los animales se sometieron a eutanasia. El cerebro se extirpó rápidamente, se diseccionó y cada región del cerebro se congeló instantáneamente en hielo seco y se almacenó a -80 °C para análisis adicionales. La expresión de ARNm se cuantificó como se describe en el Ejemplo 6.</span>Male BALB/c mice received oral gavage (200 pl volume) of 1 x 10 9 CFU of the bacterial strain for 6 consecutive days. On Day 7, the animals were euthanized. The brain was rapidly excised, dissected, and each brain region snap-frozen on dry ice and stored at -80°C for further analysis. mRNA expression was quantified as described in Example 6.</span>
  </p>
  <p id="p0670" num="0670" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultados</span>Results</span>
      </i>
    </b>
  </p>
  <p id="p0672" num="0672" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Como se muestra en la Figura 22, a partir de los genes probados, un aumento significativo en la expresión del receptor de glucocorticoides (A), receptor de mineralocorticoides (B), BDNF (C), Grin 2B (D), CRH (E), CFR1 (F), se observó CD11b (G) y GABA A2 (H) en el hipocampo. Como se muestra en la Figura 23, el receptor de oxiOCDina (A), el receptor de glucocorticoides (B), el receptor de mineralocorticoides (C), Grin 2A (D) y Grin 2B (E) exhibieron una expresión significativamente mayor en la amígdala. En la corteza prefrontal, el BDNF (A), CRFR1 (B) y el receptor de mineralocorticoides (C) se regularon significativamente como resultado del tratamiento con la bacteria (Fig. 24).</span>As shown in Figure 22, from the genes tested, a significant increase in the expression of glucocorticoid receptor (A), mineralocorticoid receptor (B), BDNF (C), Grin 2B (D), CRH (E ), CFR1 (F), CD11b (G) and GABA A2 (H) were observed in the hippocampus. As shown in Figure 23, oxyOCDin receptor (A), glucocorticoid receptor (B), mineralocorticoid receptor (C), Grin 2A (D), and Grin 2B (E) exhibited significantly higher expression in the amygdala. In the prefrontal cortex, BDNF (A), CRFR1 (B), and the mineralocorticoid receptor (C) were significantly upregulated as a result of bacteria treatment (Fig. 24).</span>
  </p>
  <p id="p0674" num="0674" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Esto indica que <i class="style-scope patent-text">Bariatricus </i>puede ser útil en el tratamiento o prevención de trastornos o afecciones que pueden beneficiarse de la modulación de los niveles de expresión de estas proteínas en el cerebro, p. ej., enfermedades y trastornos del SNC. En particular, el BDNF y su receptor son esenciales para la plasticidad sináptica del adulto y la formación de recuerdos. [70]. Se observó una disminución en el ARNm de BDNF en el hipocampo de individuos con enfermedad de Alzheimer [71]. Los estudios de metanálisis también muestran que los pacientes con enfermedad de Alzheimer tienen un nivel reducido de BDNF sérico [72]. También se observó una disminución de la proteína BDNF en las regiones del cerebro caudado y putamen de pacientes que padecían la enfermedad de Huntington [73]. Por lo tanto, las cepas bacterianas de la invención pueden ser particularmente útiles en el tratamiento de enfermedades neurodegenerativas, p. ej., la enfermedad de Alzheimer y Huntington.</span>This indicates that <i class="style-scope patent-text">Bariatricus</i> may be useful in the treatment or prevention of disorders or conditions that may benefit from modulating the expression levels of these proteins in the brain, e.g. eg, diseases and disorders of the CNS. In particular, BDNF and its receptor are essential for adult synaptic plasticity and memory formation. [70]. A decrease in BDNF mRNA was observed in the hippocampus of individuals with Alzheimer's disease [71]. Meta-analysis studies also show that patients with Alzheimer's disease have a reduced level of serum BDNF [72]. A decrease in BDNF protein was also observed in the caudate and putamen brain regions of patients suffering from Huntington's disease [73]. Therefore, the bacterial strains of the invention may be particularly useful in the treatment of neurodegenerative diseases, e.g. eg, Alzheimer's and Huntington's disease.</span>
  </p>
  <p id="p0676" num="0676" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Secuencias</span>sequences</span>
    </b>
  </p>
  <p id="p0678" num="0678" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SEQ ID NO: 1- secuencia del gen de ARNr 16S 43042 (conseso 2 lecturas acopladas usando Geneious) </span>SEQ ID NO: 1- 16S rRNA gene sequence 43042 (consensus 2 coupled reads using Geneious)</span>
    </b>
  </p>
  <p id="p0679" num="0679" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AGCTCCCTCCTTTCGGTTGGGTCACTGACTTCGGGCGTTACTGACTCCCATGGTGTGACG GGCGGTGTGTACAAGACCCGGGAACGTATTCACCGCGACATTCTGATTCGCGATTACTA GCGATTCCAGCTTCATGTAGTCGAGTTGCAGACTACAATCCGAACTGAGACGTTATTTTT GGGATTTGCTCCGCCTCGCGGCCTCGCTTCCCTTTGTTTACGCCATTGTAGCACGTGTGT </span>AGCTCCCTCCTTTCGGTTGGGTCACTGACTTCGGGCGTTACTGACTCCCATGGTGTGACG GGCGGTGTGTACAAGACCCGGGAACGTATTCACCGCGACATTCTGATTCGCGATTACTA GCGATTCCAGCTTCATGTAGTCGAGTTGCAGACTACAATCCGAACTGAGACGTTATTTTT GGGATTTGCTCCGCCTCGCGGCCTCGTCCCTTTGTTTACGCCATTGTAGCACGTGTGT</span>
    </b>
  </p>
  <p id="p0680" num="0680" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AGCCCTGATCATAAGGGGCATGATGATTTGACGTCATCCCCACCTTCCTCCAGGTTATCC CT GGC AGT CTCTCT AGAGTGCCC ACCTT AA AT GCT GGCT ACT A AAGAT A AGGGTTGCGC TCGTTGCGGGACTTAACCCAACATCTCACGACACGAGCTGACGACAACCATGCACCACC </span>AGCCCTGATCATAAGGGGCATGATGATTTGACGTCATCCCCACCTTCCTCCAGGTTATCC CT GGC AGT CTCTCT AGAGTGCCC ACCTT AA AT GCT GGCT ACT A AAGAT A AGGGTTGCGC TCGTTGCGGGACTTAACCCAACATCTCACGACACGAGCTGACGACAACCATGCACCACC</span>
    </b>
    
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">TGTCTCCAGTGCCCCGAAGGGAAAGTACATTACATACTCTGTCACCGGGATGTCAAGAC CAGGTAAGGTTCTTCGCGTTGCTTCGAATTAAACCACATGCTCCACCGCTTGTGCGGGTC CCCGTCAATTCCTTTGAGTTTCATTCTTGCGAACGTACTCCCCAGGTGGAATACTTACTG CGTTTGCTGCGGCACCGAATGGCTTTGCCACCCGACACCTAGTATTCATCGTTTACGGCG TGGACTACCAGGGTATCTAATCCTGTTTGCTCCCCACGCTTTCGAGCATCAACGTCAGTC ATCGTCCAGTAAGCCGCCTTCGCCACTGGTGTTCCTCCCAATATCTACGCATTTCACCGC TACACTGGGAATTCCACTTACCTCTCCGACACTCTAGCTGCATAGTTTCCAAAGCAGTCC CGGGGTTGAGCCCCGGGCTTTCACTCCAGACTTACACAGCCGTCTACGCTCCCTTTACAC CCAGTAAATCCGGATAACGCTTGCACCATACGTATTACCGCGGCTGCTGGCACGTATTT AGCCGGTGCTTCTTAGTCAGGTACCGTCATTTTCTTCCCTGCTGATAGAGCTTTACATAC CGAAATACTTCTTCGCTCACGCGGCGTCGCTGCATCAGGGTTTCCCCCATTGTGCAATAT TCCCCACTGCTGCCTCCCGTAGGAGTTTGGGCCGTGTCTCAGTCCCAATGTGGCCGGTCA CCCTCTCAGGTCGGCTACTGATCGTCGCCTTGGTGGGCCGTTACCCCGCCAACCAGCTAA TCAGACGCGGGTCCATCTCATACCACCGGAGTTTTTACCACCGCACCATGCGGTGCTGTG GTCTTATACGGTATTAGCAGCCATTTCTAACTGTTATCCCCTTGTATGAGGCAGGTTACC CACGCGTTACTCACCCGTCCGCCACTCAGTCACGAAAACCTTCCTTCCGAAGAAATCGA GTTCTAAGTGCTTCGTCGACTGCA SEQ ID NO: 2- secuencia del gen de ARNr 16S cepa 43171 (conseso 2 lecturas acopladas usando Geneious) </span>TGTCTCCAGTGCCCCGAAGGGAAAGTACATTACATACTCTGTCACCGGGATGTCAAGAC CAGGTAAGGTTCTTCGCGTTGCTTCGAATTAAACCACATGCTCCACCGCTTGTGCGGGTC CCCGTCAATTCCTTTGAGTTTCATTCTTGCGAACGTACTCCCCAGGTGGAATACTTACTG CGTTTGCTGCGGCACCGAATGGCTTTGCCACCCGACACCTAGTATTCATCGTTTACGGCG TGGACTACCAGGGTATCTAATCCTGTTTGCTCCCCACGCTTTCGAGCATCAACGTCAGTC ATCGTCCAGTAAGCCGCCTTCGCCACTGGTGTTCCTCCCAATATCTACGCATTTCACCGC TACACTGGGAATTCCACTTACCTCTCCGACACTCTAGCTGCATAGTTTCCAAAGCAGTCC CGGGGTTGAGCCCCGGGCTTTCACTCCAGACTTACACAGCCGTCTACGCTCCCTTTACAC CCAGTAAATCCGGATAACGCTTGCACCATACGTATTACCGCGGCTGCTGGCACGTATTT AGCCGGTGCTTCTTAGTCAGGTACCGTCATTTTCTTCCCTGCTGATAGAGCTTTACATAC CGAAATACTTCTTCGCTCACGCGGCGTCGCTGCATCAGGGTTTCCCCCATTGTGCAATAT TCCCCACTGCTGCCTCCCGTAGGAGTTTGGGCCGTGTCTCAGTCCCAATGTGGCCGGTCA CCCTCTCAGGTCGGCTACTGATCGTCGCCTTGGTGGGCCGTTACCCCGCCAACCAGCTAA TCAGACGCGGGTCCATCTCATACCACCGGAGTTTTTACCACCGCACCATGCGGTGCTGTG GTCTTATACGGTATTAGCAGCCATTTCTAACTGTTATCCCCTTGTATGAGGCAGGTTACC CACGCGTTACTCACCCGTCCGCCACTCAGTCACGAAAACCTTCCTTCCGAAGAAATCGA GTTCTAAGTGCTTCGTCGACTGCA SE Q ID NO: 2- strain 43171 16S rRNA gene sequence (consensus 2 coupled reads using Geneious)</span>
    </b>
  </p>
  <p id="p0681" num="0681" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ACCCGGGAACGTATTCACCGCGACATTCTGATTCGCGATTACTAGCGATTCCAGCTTCAT GTAGTCGAGTTGCAGACTACAATCCGAACTGAGACGTTATTTTTGGGATTTGCTCCGCCT CGCGGCCTCGCTTCCCTTTGTTTACGCCATTGTAGCACGTGTGTAGCCCTGATCATAAGG GGCATGATGATTTGACGTCATCCCCACCTTCCTCCAGGTTATCCCTGGCAGTCTCTCTAG AGTGCCCACCTTAAATGCTGGCTACTAAAGATAAGGGTTGCGCTCGTTGCGGGACTTAA CCCAACATCTCACGACACGAGCTGACGACAACCATGCACCACCTGTCTCCAGTGCCCCG AAGGGAAAGTACATTACATACTCTGTCACCGGGATGTCAAGACCAGGTAAGGTTCTTCG CGTTGCTTCGAATTAAACCACATGCTCCACCGCTTGTGCGGGTCCCCGTCAATTCCTTTG AGTTTCATTCTTGCGAACGTACTCCCCAGGTGGAATACTTACTGCGTTTGCTGCGGCACC GAATGGCTTTGCCACCCGACACCTAGTATTCATCGTTTACGGCGTGGACTACCAGGGTAT CTAATCCTGTTTGCTCCCCACGCTTTCGAGCATCAACGTCAGTCATCGTCCAGTAAGCCG CCTTCGCCACTGGTGTTCCTCCCAATATCTACGCATTTCACCGCTACACTGGGAATTCCA CTTACCTCTCCGACACTCTAGCTGCATAGTTTCCAAAGCAGTCCCGGGGTTGAGCCCCGG GCTTTCACTCCAGACTTACACAGCCGTCTACGCTCCCTTTACACCCAGTAAATCCGGATA ACGCTTGCACCATACGTATTACCGCGGCTGCTGGCACGTATTTAGCCGGTGCTTCTTAGT CAGGTACCGTCATTTTCTTCCCTGCTGATAGAGCTTTACATACCGAAATACTTCTTCGCT CACGCGGCGTCGCTGCATCAGGGTTTCCCCCATTGTGCAATATTCCCCACTGCTGCCTCC CGTAGGAGTTTGGGCCGTGTCTCAGTCCCAATGTGGCCGGTCACCCTCTCAGGTCGGCTA CTGATCGTCGCCTTGGTGGGCCGTTACCCCGCCAACCAGCTAATCAGACGCGGGTCCAT</span>ACCCGGGAACGTATTCACCGCGACATTCTGATTCGCGATTACTAGCGATTCCAGCTTCAT GTAGTCGAGTTGCAGACTACAATCCGAACTGAGACGTTATTTTTGGGATTTGCTCCGCCT CGCGGCCTCGCTTCCCTTTGTTTACGCCATTGTAGCACGTGTGTAGCCCTGATCATAAGG GGCATGATGATTTGACGTCATCCCCACCTTCCTCCAGGTTATCCCTGGCAGTCTCTCTAG AGTGCCCACCTTAAATGCTGGCTACTAAAGATAAGGGTTGCGCTCGTTGCGGGACTTAA CCCAACATCTCACGACACGAGCTGACGACAACCATGCACCACCTGTCTCCAGTGCCCCG AAGGGAAAGTACATTACATACTCTGTCACCGGGATGTCAAGACCAGGTAAGGTTCTTCG CGTTGCTTCGAATTAAACCACATGCTCCACCGCTTGTGCGGGTCCCCGTCAATTCCTTTG AGTTTCATTCTTGCGAACGTACTCCCCAGGTGGAATACTTACTGCGTTTGCTGCGGCACC GAATGGCTTTGCCACCCGACACCTAGTATTCATCGTTTACGGCGTGGACTACCAGGGTAT CTAATCCTGTTTGCTCCCCACGCTTTCGAGCATCAACGTCAGTCATCGTCCAGTAAGCCG CCTTCGCCACTGGTGTTCCTCCCAATATCTACGCATTTCACCGCTACACTGGGAATTCCA CTTACCTCTCCGACACTCTAGCTGCATAGTTTCCAAAGCAGTCCCGGGGTTGAGCCCCGG GCTTTCACTCCAGACTTACACAGCCGTCTACGCTCCCTTTACACCCAGTAAATCCGGATA ACGCTTGCACCATACGTATTACCGCGGCTGCTGGCACGTATTTAGCCGGTGCTTCTTAGT CAGGTACCGTCATTTTCTTCCCTGCTGATAGAGCTTTACATACCGAAATACTTCTTCGCT CACGCGGCGTCGCTGCATCAGGGTTTC CCCCATTGTGCAATATTCCCCACTGCTGCCTCC CGTAGGAGTTGGGCCGTGTCTCAGTCCCAATGTGGCCGGTCACCCTCTCAGGTCGGCTA CTGATCGTCGCCTTGGTGGGCCGTTACCCCGCCAACCAGCTAATCAGACGCGGGTCCAT</span>
    </b>
  </p>
  <p id="p0683" num="0683" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">CTCATACCACCGGAGTTTTTACCACCGCACCATGCGGTGCTGTGGTCTTATACGGTATTA GCAGCCATTTCTAACTGTTATCCCCTTGTATGAGGCA </span>CTCATACCACCGGAGTTTTTACCACCGCACCATGCGGTGCTGTGGTCTTATACGGTATTA GCAGCCATTTCTAACTGTTATCCCCTTGTATGAGGGCA</span>
    </b>
    
  </p>
  <p id="p0684" num="0684" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">REFERENCIAS</span>REFERENCES</span>
    </b>
  </p>
  <p id="p0685" num="0685" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">1</b>] Spor et al. (<b class="style-scope patent-text">2011</b>) Nat Rev Microbio!. <b class="style-scope patent-text">9</b>(<b class="style-scope patent-text">4</b>):<b class="style-scope patent-text">279-90</b>.</span>[ <b class="style-scope patent-text">1</b> ] Spor et al. ( <b class="style-scope patent-text">2011</b> ) Nat Rev Microbe!. <b class="style-scope patent-text">9</b> ( <b class="style-scope patent-text">4</b> ): <b class="style-scope patent-text">279-90</b> .</span>
  </p>
  <p id="p0686" num="0686" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">2</b>] Eckburg et al. (<b class="style-scope patent-text">2005</b>) Science. <b class="style-scope patent-text">10</b>;<b class="style-scope patent-text">308</b>(<b class="style-scope patent-text">5728</b>):<b class="style-scope patent-text">1635-8</b>.</span>[ <b class="style-scope patent-text">2</b> ] Eckburg et al. ( <b class="style-scope patent-text">2005</b> ) Science. <b class="style-scope patent-text">10</b> ; <b class="style-scope patent-text">308</b> ( <b class="style-scope patent-text">5728</b> ): <b class="style-scope patent-text">1635-8</b> .</span>
  </p>
  <p id="p0687" num="0687" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">3</b>] Macpherson et al. (<b class="style-scope patent-text">2001</b>) Microbes Infect. <b class="style-scope patent-text">3</b>(<b class="style-scope patent-text">12</b>):<b class="style-scope patent-text">1021-35</b> </span>[ <b class="style-scope patent-text">3</b> ] Macpherson et al. ( <b class="style-scope patent-text">2001</b> ) Microbes Infect. <b class="style-scope patent-text">3</b> ( <b class="style-scope patent-text">12</b> ): <b class="style-scope patent-text">1021-35</b> </span>
  </p>
  <p id="p0688" num="0688" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">4</b>] Macpherson et al. (<b class="style-scope patent-text">2002</b>) Cell Mol Life Sci. <b class="style-scope patent-text">59</b>(<b class="style-scope patent-text">12</b>):<b class="style-scope patent-text">2088-96</b>.</span>[ <b class="style-scope patent-text">4</b> ] Macpherson et al. ( <b class="style-scope patent-text">2002</b> ) Cell Mol Life Sci. <b class="style-scope patent-text">59</b> ( <b class="style-scope patent-text">12</b> ): <b class="style-scope patent-text">2088-96</b> .</span>
  </p>
  <p id="p0689" num="0689" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">5</b>] Mazmanian et al. (<b class="style-scope patent-text">2005</b>) Cell <b class="style-scope patent-text">15</b>;<b class="style-scope patent-text">122</b>(<b class="style-scope patent-text">1</b>):<b class="style-scope patent-text">107-18</b>.</span>[ <b class="style-scope patent-text">5</b> ] Mazmanian et al. ( <b class="style-scope patent-text">2005</b> ) Cell <b class="style-scope patent-text">15</b> ; <b class="style-scope patent-text">122</b> ( <b class="style-scope patent-text">1</b> ): <b class="style-scope patent-text">107-18</b> .</span>
  </p>
  <p id="p0690" num="0690" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">6</b>] Frank et al. (<b class="style-scope patent-text">2007</b>) <b class="style-scope patent-text">PNAS 104</b>(<b class="style-scope patent-text">34</b>): <b class="style-scope patent-text">13780-5</b>.</span>[ <b class="style-scope patent-text">6</b> ] Frank et al. ( <b class="style-scope patent-text">2007</b> ) <b class="style-scope patent-text">PNAS 104</b> ( <b class="style-scope patent-text">34</b> ): <b class="style-scope patent-text">13780-5</b> .</span>
  </p>
  <p id="p0691" num="0691" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">7</b>] Scanlan et al. (<b class="style-scope patent-text">2006</b>) J Clin Microbiol. <b class="style-scope patent-text">44</b>(<b class="style-scope patent-text">11 </b>):<b class="style-scope patent-text">3980-8</b>.</span>[ <b class="style-scope patent-text">7</b> ] Scanlan et al. ( <b class="style-scope patent-text">2006</b> ) J Clin Microbiol. <b class="style-scope patent-text">44</b> ( <b class="style-scope patent-text">11</b> ): <b class="style-scope patent-text">3980-8</b> .</span>
  </p>
  <p id="p0692" num="0692" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">8</b>] Kang et al. (<b class="style-scope patent-text">2010</b>) Inflamm Bowel Dis. <b class="style-scope patent-text">16</b>(<b class="style-scope patent-text">12</b>):<b class="style-scope patent-text">2034-42</b>.</span>[ <b class="style-scope patent-text">8</b> ] Kang et al. ( <b class="style-scope patent-text">2010</b> ) Inflamm Bowel Dis. <b class="style-scope patent-text">16</b> ( <b class="style-scope patent-text">12</b> ): <b class="style-scope patent-text">2034-42</b> .</span>
  </p>
  <p id="p0693" num="0693" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">9</b>] Machiels et al. (<b class="style-scope patent-text">2013</b>) Gut. <b class="style-scope patent-text">63</b>(<b class="style-scope patent-text">8</b>): <b class="style-scope patent-text">1275-83</b>.</span>[ <b class="style-scope patent-text">9</b> ] Machiels et al. ( <b class="style-scope patent-text">2013</b> ) Gut. <b class="style-scope patent-text">63</b> ( <b class="style-scope patent-text">8</b> ): <b class="style-scope patent-text">1275-83</b> .</span>
  </p>
  <p id="p0694" num="0694" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">10</b>] <b class="style-scope patent-text">WO 2013/050792</b> </span>[ <b class="style-scope patent-text">10</b> ] <b class="style-scope patent-text">WO 2013/050792</b> </span>
  </p>
  <p id="p0695" num="0695" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">11</b>] <b class="style-scope patent-text">WO 03/046580</b> </span>[ <b class="style-scope patent-text">11</b> ] <b class="style-scope patent-text">WO 03/046580</b> </span>
  </p>
  <p id="p0696" num="0696" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">12</b>] <b class="style-scope patent-text">WO 2013/008039</b> </span>[ <b class="style-scope patent-text">12</b> ] <b class="style-scope patent-text">WO 2013/008039</b> </span>
  </p>
  <p id="p0697" num="0697" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">13</b>] <b class="style-scope patent-text">WO 2014/167338</b> </span>[ <b class="style-scope patent-text">13</b> ] <b class="style-scope patent-text">WO 2014/167338</b> </span>
  </p>
  <p id="p0698" num="0698" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">14</b>] Goldin and Gorbach (<b class="style-scope patent-text">2008</b>) Clin Infect Dis. <b class="style-scope patent-text">46 </b>Suppl <b class="style-scope patent-text">2</b>:<b class="style-scope patent-text">S96-100</b>.</span>[ <b class="style-scope patent-text">14</b> ] Goldin and Gorbach ( <b class="style-scope patent-text">2008</b> ) Clin Infect Dis. <b class="style-scope patent-text">46</b> Suppl <b class="style-scope patent-text">2</b> : <b class="style-scope patent-text">S96-100</b> .</span>
  </p>
  <p id="p0699" num="0699" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">15</b>] Azad et al. (<b class="style-scope patent-text">2013</b>) <b class="style-scope patent-text">BMJ.347</b>:<b class="style-scope patent-text">f6471</b>.</span>[ <b class="style-scope patent-text">15</b> ] Azad et al. ( <b class="style-scope patent-text">2013</b> ) <b class="style-scope patent-text">BMJ.347</b> : <b class="style-scope patent-text">f6471</b> .</span>
  </p>
  <p id="p0700" num="0700" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">16</b>] Masco et al. (<b class="style-scope patent-text">2003</b>) Systematic and Applied Microbiology, <b class="style-scope patent-text">26</b>:<b class="style-scope patent-text">557-563</b>.</span>[ <b class="style-scope patent-text">16</b> ] Masco et al. ( <b class="style-scope patent-text">2003</b> ) Systematic and Applied Microbiology, <b class="style-scope patent-text">26</b> : <b class="style-scope patent-text">557-563</b> .</span>
  </p>
  <p id="p0701" num="0701" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">17</b>] Srútková et al. (<b class="style-scope patent-text">2011</b>) J. Microbiol. Methods, <b class="style-scope patent-text">87</b>(<b class="style-scope patent-text">1</b>):<b class="style-scope patent-text">10-6</b>.</span>[ <b class="style-scope patent-text">17</b> ] Srútková et al. ( <b class="style-scope patent-text">2011</b> ) J. Microbiol. Methods, <b class="style-scope patent-text">87</b> ( <b class="style-scope patent-text">1</b> ): <b class="style-scope patent-text">10-6</b> .</span>
  </p>
  <p id="p0702" num="0702" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">18</b>] Tang, et al. (<b class="style-scope patent-text">2017</b>) J Am Heart Assoc, <b class="style-scope patent-text">6</b>(<b class="style-scope patent-text">10</b>).</span>[ <b class="style-scope patent-text">18</b> ] Tang et al. ( <b class="style-scope patent-text">2017</b> ) J Am Heart Assoc, <b class="style-scope patent-text">6</b> ( <b class="style-scope patent-text">10</b> ).</span>
  </p>
  <p id="p0703" num="0703" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">19</b>] Wang et al. (<b class="style-scope patent-text">2015</b>) <b class="style-scope patent-text">PNAS 112</b>(<b class="style-scope patent-text">9</b>):<b class="style-scope patent-text">2583-2858</b> </span>[ <b class="style-scope patent-text">19</b> ] Wang et al. ( <b class="style-scope patent-text">2015</b> ) <b class="style-scope patent-text">PNAS 112</b> ( <b class="style-scope patent-text">9</b> ): <b class="style-scope patent-text">2583-2858</b> </span>
  </p>
  <p id="p0704" num="0704" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">20</b>] Psaty et al. (<b class="style-scope patent-text">2003</b>) <b class="style-scope patent-text">JAMA, 289</b>(<b class="style-scope patent-text">19</b>):<b class="style-scope patent-text">2534-44</b> </span>[ <b class="style-scope patent-text">20</b> ] Psaty et al. ( <b class="style-scope patent-text">2003</b> ) <b class="style-scope patent-text">JAMA, 289</b> ( <b class="style-scope patent-text">19</b> ): <b class="style-scope patent-text">2534-44</b> </span>
  </p>
  <p id="p0705" num="0705" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">21</b>] Lancet. (<b class="style-scope patent-text">1995</b>) <b class="style-scope patent-text">346</b>(<b class="style-scope patent-text">8991-8992</b>): <b class="style-scope patent-text">1647-53</b> </span>[ <b class="style-scope patent-text">21</b> ] Lancet. ( <b class="style-scope patent-text">1995</b> ) <b class="style-scope patent-text">346</b> ( <b class="style-scope patent-text">8991-8992</b> ): <b class="style-scope patent-text">1647-53</b> </span>
  </p>
  <p id="p0706" num="0706" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">22</b>] Abdanipour, Schluesener, Tiraihi, &amp; Noori-Zadeh, <b class="style-scope patent-text">2015 </b>Neurol Res, <b class="style-scope patent-text">37</b>(<b class="style-scope patent-text">3</b>), <b class="style-scope patent-text">223-228</b>. doi: <b class="style-scope patent-text">10.1179/1743132814Y</b>.<b class="style-scope patent-text">0000000438</b> </span>[ <b class="style-scope patent-text">22</b> ] Abdanipour, Schluesener, Tiraihi, &amp; Noori-Zadeh, <b class="style-scope patent-text">2015</b> Neurol Res, <b class="style-scope patent-text">37</b> ( <b class="style-scope patent-text">3</b> ), <b class="style-scope patent-text">223-228</b> . doi: <b class="style-scope patent-text">10.1179/1743132814Y</b> . <b class="style-scope patent-text">0000000438</b> </span>
  </p>
  <p id="p0707" num="0707" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">23</b>] Leoni et al. (<b class="style-scope patent-text">2005</b>) Mol. Med., <b class="style-scope patent-text">11 </b>(<b class="style-scope patent-text">1-12</b>) <b class="style-scope patent-text">1-15</b>.</span>[ <b class="style-scope patent-text">23</b> ] Leoni et al. ( <b class="style-scope patent-text">2005</b> ) Mol. Med., <b class="style-scope patent-text">11</b> ( <b class="style-scope patent-text">1-12</b> ) <b class="style-scope patent-text">1-15</b> .</span>
  </p>
  <p id="p0708" num="0708" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">24</b>] Glauben, et al. (<b class="style-scope patent-text">2006</b>) Journal of Immunology, <b class="style-scope patent-text">176</b>(<b class="style-scope patent-text">8</b>): <b class="style-scope patent-text">5015-5022</b> </span>[ <b class="style-scope patent-text">24</b> ] Glauben et al. ( <b class="style-scope patent-text">2006</b> ) Journal of Immunology, <b class="style-scope patent-text">176</b> ( <b class="style-scope patent-text">8</b> ): <b class="style-scope patent-text">5015-5022</b> </span>
  </p>
  <p id="p0709" num="0709" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">25</b>] Gasche et al <b class="style-scope patent-text">200 </b>Inflammatory Bowel Diseases <b class="style-scope patent-text">6</b>: <b class="style-scope patent-text">8-15</b> </span>[ <b class="style-scope patent-text">25</b> ] Gasche et al <b class="style-scope patent-text">200</b> Inflammatory Bowel Diseases <b class="style-scope patent-text">6</b> : <b class="style-scope patent-text">8–15</b> </span>
  </p>
  <p id="p0710" num="0710" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">26</b>] Fahy (<b class="style-scope patent-text">2009</b>) ProcAm Thorac Soc <b class="style-scope patent-text">6.256-259</b> </span>[ <b class="style-scope patent-text">26</b> ] Fahy ( <b class="style-scope patent-text">2009</b> ) ProcAm Thorac Soc <b class="style-scope patent-text">6.256-259</b> </span>
  </p>
  <p id="p0711" num="0711" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">27</b>] Reddy et al (<b class="style-scope patent-text">2008</b>) J Clin. Invest. <b class="style-scope patent-text">118</b>:<b class="style-scope patent-text">2562-73</b> </span>[ <b class="style-scope patent-text">27</b> ] Reddy et al ( <b class="style-scope patent-text">2008</b> ) J Clin. Invest. <b class="style-scope patent-text">118</b> : <b class="style-scope patent-text">2562-73</b> </span>
  </p>
  <p id="p0712" num="0712" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">28</b>] Leng et al (<b class="style-scope patent-text">2006</b>) Exp. Hematol. <b class="style-scope patent-text">34</b>:<b class="style-scope patent-text">776-787</b> </span>[ <b class="style-scope patent-text">28</b> ] Leng et al ( <b class="style-scope patent-text">2006</b> ) Exp. Hematol. <b class="style-scope patent-text">34</b> : <b class="style-scope patent-text">776-787</b> </span>
  </p>
  <p id="p0713" num="0713" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">29</b>] Tao et al (<b class="style-scope patent-text">2007</b>) Nat. Med. <b class="style-scope patent-text">13</b>:<b class="style-scope patent-text">1299-1307</b> </span>[ <b class="style-scope patent-text">29</b> ] Tao et al ( <b class="style-scope patent-text">2007</b> ) Nat. Med. <b class="style-scope patent-text">13</b> : <b class="style-scope patent-text">1299-1307</b> </span>
  </p>
  <p id="p0714" num="0714" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">30</b>] Johansson and Ekman (<b class="style-scope patent-text">2004</b>) Blood <b class="style-scope patent-text">104</b>:<b class="style-scope patent-text">5075</b> </span>[ <b class="style-scope patent-text">30</b> ] Johansson and Ekman ( <b class="style-scope patent-text">2004</b> ) Blood <b class="style-scope patent-text">104</b> : <b class="style-scope patent-text">5075</b> </span>
  </p>
  <p id="p0715" num="0715" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">31</b>] Song et al (<b class="style-scope patent-text">2005</b>) <b class="style-scope patent-text">APMIS 113</b>: <b class="style-scope patent-text">264-268</b> </span>[ <b class="style-scope patent-text">31</b> ] Song et al ( <b class="style-scope patent-text">2005</b> ) <b class="style-scope patent-text">APMIS 113</b> : <b class="style-scope patent-text">264-268</b> </span>
  </p>
  <p id="p0716" num="0716" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">32</b>] Zimmerman et al (<b class="style-scope patent-text">2007</b>) Cancer Res <b class="style-scope patent-text">67</b>: <b class="style-scope patent-text">9074-54</b> </span>[ <b class="style-scope patent-text">32</b> ] Zimmerman et al ( <b class="style-scope patent-text">2007</b> ) Cancer Res <b class="style-scope patent-text">67</b> : <b class="style-scope patent-text">9074-54</b> </span>
  </p>
  <p id="p0717" num="0717" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">33</b>] Zhang et al (<b class="style-scope patent-text">2005</b>) Breast Cancer Res Treat <b class="style-scope patent-text">94</b>: <b class="style-scope patent-text">11-16</b> </span>[ <b class="style-scope patent-text">33</b> ] Zhang et al ( <b class="style-scope patent-text">2005</b> ) Breast Cancer Res Treat <b class="style-scope patent-text">94</b> : <b class="style-scope patent-text">11–16</b> </span>
  </p>
  <p id="p0718" num="0718" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">34</b>] Abbas and Gupta (<b class="style-scope patent-text">2008</b>) Epigenetics <b class="style-scope patent-text">3</b>: <b class="style-scope patent-text">300-309</b> </span>[ <b class="style-scope patent-text">34</b> ] Abbas and Gupta ( <b class="style-scope patent-text">2008</b> ) Epigenetics <b class="style-scope patent-text">3</b> : <b class="style-scope patent-text">300-309</b> </span>
  </p>
  <p id="p0719" num="0719" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">35</b>] Minamiya et al (<b class="style-scope patent-text">2011</b>) Lung Cancer <b class="style-scope patent-text">74</b>: <b class="style-scope patent-text">300-4 </b>
</span>[ <b class="style-scope patent-text">35</b> ] Minamiya et al ( <b class="style-scope patent-text">2011</b> ) Lung Cancer <b class="style-scope patent-text">74</b> : <b class="style-scope patent-text">300-4</b> </span>
  </p>
  <p id="p0720" num="0720" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">36</b>] Jung et al (<b class="style-scope patent-text">2012</b>) J Cell Biochem <b class="style-scope patent-text">113</b>: <b class="style-scope patent-text">2167-2177</b> </span>[ <b class="style-scope patent-text">36</b> ] Jung et al ( <b class="style-scope patent-text">2012</b> ) J Cell Biochem <b class="style-scope patent-text">113</b> : <b class="style-scope patent-text">2167–2177</b> </span>
  </p>
  <p id="p0721" num="0721" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">37</b>] Quint et al <b class="style-scope patent-text">2011 </b>Virchows Arch <b class="style-scope patent-text">459</b>: <b class="style-scope patent-text">129-139</b> </span>[ <b class="style-scope patent-text">37</b> ] Quint et al <b class="style-scope patent-text">2011</b> Virchows Arch <b class="style-scope patent-text">459</b> : <b class="style-scope patent-text">129-139</b> </span>
  </p>
  <p id="p0722" num="0722" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">38</b>] Cook et al (<b class="style-scope patent-text">2014</b>) Hum Mol Genet <b class="style-scope patent-text">23</b>:<b class="style-scope patent-text">104-106</b> </span>[ <b class="style-scope patent-text">38</b> ] Cook et al ( <b class="style-scope patent-text">2014</b> ) Hum Mol Genet <b class="style-scope patent-text">23</b> : <b class="style-scope patent-text">104-106</b> </span>
  </p>
  <p id="p0723" num="0723" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">39</b>] Simoes-Pires et al (<b class="style-scope patent-text">2013</b>) Mol Neurodegen <b class="style-scope patent-text">8</b>: <b class="style-scope patent-text">7</b> </span>[ <b class="style-scope patent-text">39</b> ] Simoes-Pires et al ( <b class="style-scope patent-text">2013</b> ) Mol Neurodegen <b class="style-scope patent-text">8</b> : <b class="style-scope patent-text">7</b> </span>
  </p>
  <p id="p0724" num="0724" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">40</b>] Miyamoto-Shinohara et al. (<b class="style-scope patent-text">2008</b>) J. Gen. Appl. Microbiol., <b class="style-scope patent-text">54</b>, <b class="style-scope patent-text">9-24</b>.</span>[ <b class="style-scope patent-text">40</b> ] Miyamoto-Shinohara et al. ( <b class="style-scope patent-text">2008</b> ) J. Gen. Appl. Microbiol., <b class="style-scope patent-text">54</b> , <b class="style-scope patent-text">9-24</b> .</span>
  </p>
  <p id="p0725" num="0725" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">41</b>] Cryopreservation and Freeze-Drying Protocols, ed. by Day and McLellan, Humana Press.</span>[ <b class="style-scope patent-text">41</b> ] Cryopreservation and Freeze-Drying Protocols, ed. by Day and McLellan, Humana Press.</span>
  </p>
  <p id="p0726" num="0726" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">42</b>] Leslie et al. (<b class="style-scope patent-text">1995</b>) Appl. Environ. Microbiol. <b class="style-scope patent-text">61</b>, <b class="style-scope patent-text">3592-3597</b>.</span>[ <b class="style-scope patent-text">42</b> ] Leslie et al. ( <b class="style-scope patent-text">1995</b> ) Appl. Environment. microbiol. <b class="style-scope patent-text">61</b> , <b class="style-scope patent-text">3592-3597</b> .</span>
  </p>
  <p id="p0727" num="0727" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">43</b>] Mitropoulou et al. (<b class="style-scope patent-text">2013</b>) J Nutr Metab. (<b class="style-scope patent-text">2013</b>) <b class="style-scope patent-text">716861</b>.</span>[ <b class="style-scope patent-text">43</b> ] Mitropoulou et al. ( <b class="style-scope patent-text">2013</b> ) J Nutr Metab. ( <b class="style-scope patent-text">2013</b> ) <b class="style-scope patent-text">716861</b> .</span>
  </p>
  <p id="p0728" num="0728" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">44</b>] Kailasapathy et al. (<b class="style-scope patent-text">2002</b>) Curr Issues Intest Microbiol. <b class="style-scope patent-text">3</b>(<b class="style-scope patent-text">2</b>):<b class="style-scope patent-text">39-48</b>.</span>[ <b class="style-scope patent-text">44</b> ] Kailasapathy et al. ( <b class="style-scope patent-text">2002</b> ) Curr Issues Intest Microbiol. <b class="style-scope patent-text">3</b> ( <b class="style-scope patent-text">2</b> ): <b class="style-scope patent-text">39-48</b> .</span>
  </p>
  <p id="p0729" num="0729" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">45</b>] Handbook of Pharmaceutical Excipients, <b class="style-scope patent-text">2nd </b>Edition, (<b class="style-scope patent-text">1994</b>), Edited by A Wade and PJ Weller</span>[ <b class="style-scope patent-text">45</b> ] Handbook of Pharmaceutical Excipients, <b class="style-scope patent-text">2nd</b> Edition, ( <b class="style-scope patent-text">1994</b> ), Edited by A Wade and PJ Weller</span>
  </p>
  <p id="p0730" num="0730" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">46</b>] Remington's Pharmaceutical Sciences, Mack Publishing Co. (<b class="style-scope patent-text">A</b>. <b class="style-scope patent-text">R</b>. Gennaro edit. <b class="style-scope patent-text">1985</b>)</span> <b class="style-scope patent-text">[46]</b> Remington's Pharmaceutical Sciences, Mack Publishing Co. <b class="style-scope patent-text">(A.</b> <b class="style-scope patent-text">R.</b> Gennaro edit. <b class="style-scope patent-text">1985)</b> </span>
  </p>
  <p id="p0731" num="0731" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">47</b>] Handbook of Microbiological Media, Fourth Edition (<b class="style-scope patent-text">2010</b>) Ronald Atlas, CRC Press.</span>[ <b class="style-scope patent-text">47</b> ] Handbook of Microbiological Media, Fourth Edition ( <b class="style-scope patent-text">2010</b> ) Ronald Atlas, CRC Press.</span>
  </p>
  <p id="p0732" num="0732" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">48</b>] Maintaining Cultures for Biotechnology and Industry (<b class="style-scope patent-text">1996</b>) Jennie C. Hunter-Cevera, Academic Press [<b class="style-scope patent-text">49</b>] Strobel (<b class="style-scope patent-text">2009</b>) Methods Mol Biol. <b class="style-scope patent-text">581</b>:<b class="style-scope patent-text">247-61</b>.</span>[ <b class="style-scope patent-text">48</b> ] Maintaining Cultures for Biotechnology and Industry ( <b class="style-scope patent-text">1996</b> ) Jennie C. Hunter-Cevera, Academic Press [ <b class="style-scope patent-text">49</b> ] Strobel ( <b class="style-scope patent-text">2009</b> ) Methods Mol Biol. <b class="style-scope patent-text">581</b> : <b class="style-scope patent-text">247-61</b> .</span>
  </p>
  <p id="p0733" num="0733" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">50</b>] Gennaro (<b class="style-scope patent-text">2000</b>) Remington: The Science and Practice of Pharmacy. <b class="style-scope patent-text">20th </b>edition, ISBN: <b class="style-scope patent-text">0683306472</b>.</span>[ <b class="style-scope patent-text">50</b> ] Gennaro ( <b class="style-scope patent-text">2000</b> ) Remington: The Science and Practice of Pharmacy. <b class="style-scope patent-text">20th</b> edition, ISBN: <b class="style-scope patent-text">0683306472</b> .</span>
  </p>
  <p id="p0734" num="0734" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">51</b>] Molecular Biology Techniques: An Intensive Laboratory Course, (Ream et al., eds., <b class="style-scope patent-text">1998</b>, Academic Press).</span>[ <b class="style-scope patent-text">51</b> ] Molecular Biology Techniques: An Intensive Laboratory Course, (Ream et al., eds., <b class="style-scope patent-text">1998</b> , Academic Press).</span>
  </p>
  <p id="p0735" num="0735" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">52</b>] Methods In Enzymology (S. Colowick and N. Kaplan, eds., Academic Press, Inc.)</span>[ <b class="style-scope patent-text">52</b> ] Methods In Enzymology (S. Colowick and N. Kaplan, eds., Academic Press, Inc.)</span>
  </p>
  <p id="p0736" num="0736" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">53</b>] Handbook of Experimental Immunology, Vols. I-IV (D.M. Weir and C.C. Blackwell, eds, <b class="style-scope patent-text">1986</b>, Blackwell Scientific Publications)</span>[ <b class="style-scope patent-text">53</b> ] Handbook of Experimental Immunology, Vols. I-IV (DM Weir and CC Blackwell, eds, <b class="style-scope patent-text">1986</b> , Blackwell Scientific Publications)</span>
  </p>
  <p id="p0737" num="0737" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">54</b>] Sambrook et al. (<b class="style-scope patent-text">2001</b>) Molecular Cloning: A Laboratory Manual, <b class="style-scope patent-text">3a </b>edition (Cold Spring Harbor Laboratory Press).</span>[ <b class="style-scope patent-text">54</b> ] Sambrook et al. ( <b class="style-scope patent-text">2001</b> ) Molecular Cloning: A Laboratory Manual, <b class="style-scope patent-text">3rd</b> edition (Cold Spring Harbor Laboratory Press).</span>
  </p>
  <p id="p0738" num="0738" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">55</b>] Handbook of Surface and Colloidal Chemistry (Birdi, <b class="style-scope patent-text">K.S</b>. ed., <b class="style-scope patent-text">CRC </b>Press, <b class="style-scope patent-text">1997</b>)</span>[ <b class="style-scope patent-text">55</b> ] Handbook of Surface and Colloidal Chemistry (Birdi, <b class="style-scope patent-text">KS</b> . ed., <b class="style-scope patent-text">CRC</b> Press, <b class="style-scope patent-text">1997</b> )</span>
  </p>
  <p id="p0739" num="0739" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">56</b>] Ausubel et al. (<b class="style-scope patent-text">eds</b>) (<b class="style-scope patent-text">2002</b>) Short protocols in molecular biology, <b class="style-scope patent-text">5th </b>edition (Current Protocols).</span>[ <b class="style-scope patent-text">56</b> ] Ausubel et al. ( <b class="style-scope patent-text">eds</b> ) ( <b class="style-scope patent-text">2002</b> ) Short protocols in molecular biology, <b class="style-scope patent-text">5th</b> edition (Current Protocols).</span>
  </p>
  <p id="p0740" num="0740" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">57</b>] PCR (Introduction to Biotechniques Series), <b class="style-scope patent-text">2a </b>ed. (Newton &amp; Graham eds., <b class="style-scope patent-text">1997</b>, Springer Verlag)</span>[ <b class="style-scope patent-text">57</b> ] PCR (Introduction to Biotechniques Series), <b class="style-scope patent-text">2nd</b> ed. (Newton &amp; Graham eds., <b class="style-scope patent-text">1997</b> , Springer Verlag)</span>
  </p>
  <p id="p0741" num="0741" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">58</b>] Current Protocols in Molecular Biology (<b class="style-scope patent-text">F.M</b>. Ausubel et al., eds., <b class="style-scope patent-text">1987</b>) Supplement <b class="style-scope patent-text">30</b> </span>[ <b class="style-scope patent-text">58</b> ] Current Protocols in Molecular Biology ( <b class="style-scope patent-text">FM</b> . Ausubel et al., eds., <b class="style-scope patent-text">1987</b> ) Supplement <b class="style-scope patent-text">30</b> </span>
  </p>
  <p id="p0742" num="0742" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">59</b>] Smith &amp; Waterman (<b class="style-scope patent-text">1981</b>) Adv. Appl. Math. <b class="style-scope patent-text">2</b>: <b class="style-scope patent-text">482-489</b> </span>[ <b class="style-scope patent-text">59</b> ] Smith &amp; Waterman ( <b class="style-scope patent-text">1981</b> ) Adv. App. Math. <b class="style-scope patent-text">2</b> : <b class="style-scope patent-text">482-489</b> </span>
  </p>
  <p id="p0743" num="0743" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">60</b>] West and Johnstone, (<b class="style-scope patent-text">2014</b>) J Clin Invest, <b class="style-scope patent-text">124</b>, <b class="style-scope patent-text">30-39</b> </span>[ <b class="style-scope patent-text">60</b> ] West and Johnstone, ( <b class="style-scope patent-text">2014</b> ) J Clin Invest, <b class="style-scope patent-text">124</b> , <b class="style-scope patent-text">30-39</b> </span>
  </p>
  <p id="p0744" num="0744" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">61</b>] Glauben et al (<b class="style-scope patent-text">2006</b>) J Immunol. <b class="style-scope patent-text">176</b>, <b class="style-scope patent-text">5015-5022</b> </span>[ <b class="style-scope patent-text">61</b> ] Glauben et al ( <b class="style-scope patent-text">2006</b> ) J Immunol. <b class="style-scope patent-text">176</b> , <b class="style-scope patent-text">5015-5022</b> </span>
  </p>
  <p id="p0745" num="0745" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">62</b>] Angiolilli et al. (<b class="style-scope patent-text">2017</b>) Ann Rheum Dis. <b class="style-scope patent-text">76</b>, <b class="style-scope patent-text">277-285</b> </span>[ <b class="style-scope patent-text">62</b> ] Angiolilli et al. ( <b class="style-scope patent-text">2017</b> ) Ann Rheum Dis. <b class="style-scope patent-text">76</b> , <b class="style-scope patent-text">277-285</b> </span>
  </p>
  <p id="p0746" num="0746" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">63</b>] Gonneaud et al (<b class="style-scope patent-text">2014</b>). J Inflamm. <b class="style-scope patent-text">11</b>: <b class="style-scope patent-text">43</b> </span>[ <b class="style-scope patent-text">63</b> ] Gonneaud et al ( <b class="style-scope patent-text">2014</b> ). J Inflamm. <b class="style-scope patent-text">11</b> : <b class="style-scope patent-text">43</b> </span>
  </p>
  <p id="p0747" num="0747" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">64</b>] Alenghat et al. (<b class="style-scope patent-text">2013</b>). Nature. <b class="style-scope patent-text">504</b>: <b class="style-scope patent-text">153-157</b> </span>[ <b class="style-scope patent-text">64</b> ] Alenghat et al. ( <b class="style-scope patent-text">2013</b> ). Nature. <b class="style-scope patent-text">504</b> : <b class="style-scope patent-text">153-157</b> </span>
  </p>
  <p id="p0748" num="0748" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">65</b>] Felice et al (<b class="style-scope patent-text">2015</b>). Ailment Pharmacol Ther. <b class="style-scope patent-text">41</b>: <b class="style-scope patent-text">26-38</b> </span>[ <b class="style-scope patent-text">65</b> ] Felice et al ( <b class="style-scope patent-text">2015</b> ). Ailment Pharmacol Ther. <b class="style-scope patent-text">41</b> : <b class="style-scope patent-text">26-38</b> </span>
  </p>
  <p id="p0749" num="0749" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">66</b>] Matthewson et al (<b class="style-scope patent-text">2016</b>) Nature Immunology <b class="style-scope patent-text">15</b>: <b class="style-scope patent-text">505-513</b> </span>[ <b class="style-scope patent-text">66</b> ] Matthewson et al ( <b class="style-scope patent-text">2016</b> ) Nature Immunology <b class="style-scope patent-text">15</b> : <b class="style-scope patent-text">505–513</b> </span>
  </p>
  <p id="p0750" num="0750" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">67</b>] Baas, T (<b class="style-scope patent-text">2013</b>) Sci<b class="style-scope patent-text">BX 6</b>: doi:<b class="style-scope patent-text">10.1038</b>/scibx.<b class="style-scope patent-text">2013.1310</b> </span>[ <b class="style-scope patent-text">67</b> ] Baas, T ( <b class="style-scope patent-text">2013</b> ) Sci <b class="style-scope patent-text">BX 6</b> : doi: <b class="style-scope patent-text">10.1038</b> /scibx. <b class="style-scope patent-text">2013.1310</b> </span>
  </p>
  <p id="p0751" num="0751" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">68</b>] Johansson and Ekman (<b class="style-scope patent-text">2004</b>) Blood <b class="style-scope patent-text">104</b>:<b class="style-scope patent-text">5075</b> </span>[ <b class="style-scope patent-text">68</b> ] Johansson and Ekman ( <b class="style-scope patent-text">2004</b> ) Blood <b class="style-scope patent-text">104</b> : <b class="style-scope patent-text">5075</b> </span>
  </p>
  <p id="p0752" num="0752" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">69</b>] Coquerelle et al. (<b class="style-scope patent-text">2009</b>) Gut. <b class="style-scope patent-text">58</b>: <b class="style-scope patent-text">1363-1373</b>.</span>[ <b class="style-scope patent-text">69</b> ] Coquerelle et al. ( <b class="style-scope patent-text">2009</b> ) Gut. <b class="style-scope patent-text">58</b> : <b class="style-scope patent-text">1363-1373</b> .</span>
  </p>
  <p id="p0753" num="0753" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[<b class="style-scope patent-text">70</b>] Andero et al. (<b class="style-scope patent-text">2014</b>) Prog Mol Biol Transl Sci. <b class="style-scope patent-text">122</b>:<b class="style-scope patent-text">169-92</b>. 
</span>[ <b class="style-scope patent-text">70</b> ] Andero et al. ( <b class="style-scope patent-text">2014</b> ) Prog Mol Biol Transl Sci. <b class="style-scope patent-text">122</b> : <b class="style-scope patent-text">169-92</b> .</span>
  </p>
</description>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
            </div>
            <div class="flex flex-width style-scope patent-result">
              <section id="claims" class="style-scope patent-result">
                <h3 class="style-scope patent-result">
                  <div class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result">Claims <span class="style-scope patent-result">(16)</span></div>
                    <div class="collapse style-scope patent-result">
                      Hide Dependent <iron-icon style="height: 15px; width: 15px;" icon="expand-less" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 8l-6 6 1.41 1.41L12 10.83l4.59 4.58L18 14z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon><template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </div>
                  </div>
                  <div class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result"></div>
                    <div class="righthead style-scope patent-result">translated from Spanish</div>
                  </div>
                </h3>
                <patent-text name="claims" enable-text-selection="" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><claims mxw-id="PCLM316182876" lang="EN" load-source="google" class="style-scope patent-text">
  <claim-statement class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">REIVINDICACIONES
  </span></span></claim-statement>
  <claim id="clm-0001" num="1" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">1. Una composición que comprende una cepa bacteriana del género <i class="style-scope patent-text">Bariatricus, </i>para uso en terapia.</span>1. A composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Bariatricus,</i> for use in therapy.</span>
    </claim-text>
  </claim>
  <claim id="clm-0002" num="2" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">2. La composición para su uso según la reivindicación 1, para su uso en el tratamiento o prevención de una enfermedad o afección mediada por una actividad elevada de histona desacetilasa (HDAC).</span>2. The composition for use according to claim 1, for use in the treatment or prevention of a disease or condition mediated by elevated histone deacetylase (HDAC) activity.</span>
    </claim-text>
  </claim>
  <claim id="clm-0003" num="3" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">3. La composición para su uso de acuerdo con cualquier reivindicación anterior, para su uso en el tratamiento o prevención de una enfermedad o afección mediada por una actividad elevada de HDAC de Clase I.</span>3. The composition for use according to any preceding claim, for use in the treatment or prevention of a disease or condition mediated by elevated Class I HDAC activity.</span>
    </claim-text>
  </claim>
  <claim id="clm-0004" num="4" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">4. La composición para su uso de acuerdo con cualquier reivindicación precedente, para su uso en un método de inhibición selectiva de la actividad de HDAC de Clase I en el tratamiento de una afección mediada por una actividad de HDAC de Clase I elevada.</span>4. The composition for use according to any preceding claim, for use in a method of selectively inhibiting Class I HDAC activity in the treatment of a condition mediated by elevated Class I HDAC activity.</span>
    </claim-text>
  </claim>
  <claim id="clm-0005" num="5" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5. La composición para su uso según cualquier reivindicación anterior, en la que la composición se utiliza para inhibir selectivamente HDAC1, HDAC2 o HDAC3 en una enfermedad o afección mediada por una actividad elevada de HDAC1, HDAC2 o HDAC3.</span>5. The composition for use according to any preceding claim, wherein the composition is used to selectively inhibit HDAC1, HDAC2 or HDAC3 in a disease or condition mediated by elevated HDAC1, HDAC2 or HDAC3 activity.</span>
    </claim-text>
  </claim>
  <claim id="clm-0006" num="6" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">6. La composición para su uso de acuerdo con cualquier reivindicación anterior, para su uso en un paciente con actividad HDAC elevada.</span>6. The composition for use according to any preceding claim, for use in a patient with elevated HDAC activity.</span>
    </claim-text>
  </claim>
  <claim id="clm-0007" num="7" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">7. La composición para uso según cualquier reivindicación anterior, para uso en el tratamiento o prevención de una enfermedad o afección seleccionada del grupo que consiste en: una enfermedad neurodegenerativa, como la enfermedad de Alzheimer, la enfermedad de Huntington o enfermedad de Parkinson; lesión cerebral, como accidente cerebrovascular; trastornos del comportamiento o psiquiátricos, tales como trastorno por déficit de atención e hiperactividad, trastorno obsesivo compulsivo, trastorno de ansiedad, trastorno bipolar o trastorno por estrés postraumático; una enfermedad inflamatoria o autoinmune, como asma, artritis, psoriasis, esclerosis múltiple, diabetes, rechazo de aloinjertos, enfermedad de injerto contra huésped o una enfermedad inflamatoria del intestino, como la enfermedad de Crohn; o cáncer, como cáncer de próstata, cáncer colorrectal, cáncer de mama, cáncer de pulmón, cáncer de hígado o cáncer gástrico.</span>7. The composition for use according to any preceding claim, for use in the treatment or prevention of a disease or condition selected from the group consisting of: a neurodegenerative disease, such as Alzheimer's disease, Huntington's disease or Parkinson's disease; brain injury, such as stroke; behavioral or psychiatric disorders, such as attention deficit hyperactivity disorder, obsessive-compulsive disorder, anxiety disorder, bipolar disorder, or post-traumatic stress disorder; an inflammatory or autoimmune disease, such as asthma, arthritis, psoriasis, multiple sclerosis, diabetes, allograft rejection, graft-versus-host disease, or an inflammatory bowel disease, such as Crohn's disease; or cancer, such as prostate cancer, colorectal cancer, breast cancer, lung cancer, liver cancer, or gastric cancer.</span>
    </claim-text>
  </claim>
  <claim id="clm-0008" num="8" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">8. Una composición que comprende una cepa bacteriana del género <i class="style-scope patent-text">Bariatricus, </i>para su uso en el tratamiento o prevención de una enfermedad o afección seleccionada de la lista que consiste en: una enfermedad neurodegenerativa, como la enfermedad de Alzheimer, la enfermedad de Huntington o la enfermedad de Parkinson, lesión cerebral, tales como apoplejía, una enfermedad inflamatoria o autoinmune, tal como asma, artritis, psoriasis, esclerosis múltiple, diabetes, rechazo de aloinjertos, enfermedad de injerto contra huésped o una enfermedad inflamatoria del intestino, tal como enfermedad de Crohn o colitis ulcerosa; o cáncer, como cáncer de próstata, cáncer colorrectal, cáncer de mama, cáncer de pulmón, cáncer de hígado o cáncer gástrico.</span>8. A composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Bariatricus,</i> for use in the treatment or prevention of a disease or condition selected from the list consisting of: a neurodegenerative disease, such as Alzheimer's disease, Huntington's disease or Parkinson's disease, brain injury, such as stroke, an inflammatory or autoimmune disease, such as asthma, arthritis, psoriasis, multiple sclerosis, diabetes, allograft rejection, graft-versus-host disease, or an inflammatory bowel disease, such as Parkinson's disease Crohn's or ulcerative colitis; or cancer, such as prostate cancer, colorectal cancer, breast cancer, lung cancer, liver cancer, or gastric cancer.</span>
    </claim-text>
  </claim>
  <claim id="clm-0009" num="9" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">9. La composición para su uso de cualquier reivindicación anterior, en la que la cepa bacteriana es de la especie <i class="style-scope patent-text">Bariatricus massiliensis.</i> </span>9. The composition for use of any preceding claim, wherein the bacterial strain is of the species <i class="style-scope patent-text">Bariatricus massiliensis.</i> </span>
    </claim-text>
  </claim>
  <claim id="clm-0010" num="10" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10. La composición para su uso de cualquier reivindicación anterior, en la que la cepa bacteriana tiene una secuencia del gen de ARNr 16s que es al menos 95%, 96%, 97%, 98%, 99%, 99,5% o 99,9% idéntico a SEQ ID NO:1 o SEQ ID NO:2, o en el que la cepa bacteriana tiene la secuencia del gen ARNr 16s representada por SEQ ID NO:1 o SEQ ID NO:2.</span>10. The composition for use of any preceding claim, wherein the bacterial strain has a 16s rRNA gene sequence that is at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to SEQ ID NO:1 or SEQ ID NO:2, or wherein the bacterial strain has the 16s rRNA gene sequence represented by SEQ ID NO:1 or SEQ ID NO:2.</span>
    </claim-text>
  </claim>
  <claim id="clm-0011" num="11" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">11. La composición para uso de cualquier reivindicación anterior, en la que la composición es para administración oral.</span>11. The composition for use of any preceding claim, wherein the composition is for oral administration.</span>
    </claim-text>
  </claim>
  <claim id="clm-0012" num="12" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">12. La composición para su uso de cualquier reivindicación precedente, en la que la cepa bacteriana está liofilizada.</span>12. The composition for use of any preceding claim, wherein the bacterial strain is lyophilized.</span>
    </claim-text>
  </claim>
  <claim id="clm-0013" num="13" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">13. Un producto alimenticio que comprende la composición de cualquier reivindicación anterior, para el uso de cualquier reivindicación anterior.</span>13. A food product comprising the composition of any preceding claim, for the use of any preceding claim.</span>
    </claim-text>
  </claim>
  <claim id="clm-0014" num="14" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">14. Una célula de la cepa <i class="style-scope patent-text">Bariatricus massiliensis </i>depositada con el número de acceso NCIMB 43042.</span>14. A cell of the <i class="style-scope patent-text">Bariatricus massiliensis</i> strain deposited under NCIMB accession number 43042.</span>
    </claim-text>
  </claim>
  <claim id="clm-0015" num="15" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15. Una célula de la <i class="style-scope patent-text">cepa de Bariatricus massiliensis </i>depositada con el número de acceso NCIMB 43042 para uso en terapia, preferiblemente para uso en el tratamiento o prevención de una enfermedad o afección como se define en una de las reivindicaciones 2-8.</span>15. A <i class="style-scope patent-text">Bariatricus massiliensis strain</i> cell deposited under accession number NCIMB 43042 for use in therapy, preferably for use in the treatment or prevention of a disease or condition as defined in one of claims 2-8.</span>
    </claim-text>
  </claim>
  <claim id="clm-0016" num="16" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">16. Una célula de la cepa de <i class="style-scope patent-text">Bariatricus massiliensis </i>depositada con el número de acceso NCIMB 43171 para uso en terapia, preferiblemente para uso en el tratamiento o prevención de una enfermedad o afección como se define en una de las reivindicaciones 2-8. 
</span>16. A <i class="style-scope patent-text">Bariatricus massiliensis</i> strain cell deposited under accession number NCIMB 43171 for use in therapy, preferably for use in the treatment or prevention of a disease or condition as defined in one of claims 2-8.</span>
    </claim-text>
  </claim>
</claims>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
            </div>
          </div>

          <div class="footer style-scope patent-result">

            
            <h3 id="patentCitations" class="scroll-target style-scope patent-result">
              Patent Citations (6)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication number</span>
                    <span class="th style-scope patent-result">Priority date</span>
                    <span class="th style-scope patent-result">Publication date</span>
                    <span class="th style-scope patent-result">Assignee</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                  <div class="tr style-scope patent-result">
                    <span class="td famheader style-scope patent-result">Family To Family Citations</span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                  </div>

                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB0127916D0/en"><a id="link" href="#" class="style-scope state-modifier">GB0127916D0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-11-21</span>
                    <span class="td style-scope patent-result">2002-01-16</span>
                    <span class="td style-scope patent-result">Rowett Res Inst</span>
                    <span class="td style-scope patent-result">Method 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB201112091D0/en"><a id="link" href="#" class="style-scope state-modifier">GB201112091D0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-07-14</span>
                    <span class="td style-scope patent-result">2011-08-31</span>
                    <span class="td style-scope patent-result">Gt Biolog Ltd</span>
                    <span class="td style-scope patent-result">Bacterial strains isolated from pigs 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB201117313D0/en"><a id="link" href="#" class="style-scope state-modifier">GB201117313D0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-10-07</span>
                    <span class="td style-scope patent-result">2011-11-16</span>
                    <span class="td style-scope patent-result">Gt Biolog Ltd</span>
                    <span class="td style-scope patent-result">Bacterium for use in medicine 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB201306536D0/en"><a id="link" href="#" class="style-scope state-modifier">GB201306536D0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-04-10</span>
                    <span class="td style-scope patent-result">2013-05-22</span>
                    <span class="td style-scope patent-result">Gt Biolog Ltd</span>
                    <span class="td style-scope patent-result">Polypeptide and immune modulation 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR20180083894A/en"><a id="link" href="#" class="style-scope state-modifier">KR20180083894A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2015-11-24</span>
                    <span class="td style-scope patent-result">2018-07-23</span>
                    <span class="td style-scope patent-result">세레스 테라퓨틱스, 인코포레이티드</span>
                    <span class="td style-scope patent-result">
  Designed bacterial composition
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AU2017234120A1/en"><a id="link" href="#" class="style-scope state-modifier">AU2017234120A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2016-03-14</span>
                    <span class="td style-scope patent-result">2018-09-20</span>
                    <span class="td style-scope patent-result">Holobiome, Inc.</span>
                    <span class="td style-scope patent-result">Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system 
     </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                </div>
              </div>
            </div>
            <div style="padding: 10px 12px; font-size: 11px;" class="style-scope patent-result">* Cited by examiner, † Cited by third party</div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="similarDocuments" class="scroll-target style-scope patent-result">
              Similar Documents
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication</span>
                    <span class="th style-scope patent-result">Publication Date</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP2020125351A/en"><a id="link" href="#" class="style-scope state-modifier">JP2020125351A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2020-08-20</span>
                    <span class="td style-scope patent-result">Compositions comprising bacterial strains 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP2021075556A/en"><a id="link" href="#" class="style-scope state-modifier">JP2021075556A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2021-05-20</span>
                    <span class="td style-scope patent-result">Compositions containing bacterial strains of genus megasphaera and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/TW201729822A/en"><a id="link" href="#" class="style-scope state-modifier">TW201729822A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2017-09-01</span>
                    <span class="td style-scope patent-result">Compositions comprising bacterial strains 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/TW201729820A/en"><a id="link" href="#" class="style-scope state-modifier">TW201729820A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2017-09-01</span>
                    <span class="td style-scope patent-result">Compositions comprising bacterial strains 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20220265733A1/en"><a id="link" href="#" class="style-scope state-modifier">US20220265733A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2022-08-25</span>
                    <span class="td style-scope patent-result">Compositions comprising bacterial strains 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/TWI787272B/en"><a id="link" href="#" class="style-scope state-modifier">TWI787272B</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2022-12-21</span>
                    <span class="td style-scope patent-result">Compositions comprising bacterial strains 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/TW201907927A/en"><a id="link" href="#" class="style-scope state-modifier">TW201907927A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2019-03-01</span>
                    <span class="td style-scope patent-result">
  Composition comprising a bacterial strain
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20210275606A1/en"><a id="link" href="#" class="style-scope state-modifier">US20210275606A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2021-09-09</span>
                    <span class="td style-scope patent-result">Compositions comprising bacterial strains 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ES2887903T3/en"><a id="link" href="#" class="style-scope state-modifier">ES2887903T3</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2021-12-28</span>
                    <span class="td style-scope patent-result">
  Compositions comprising bacterial strains
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/TW202128199A/en"><a id="link" href="#" class="style-scope state-modifier">TW202128199A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2021-08-01</span>
                    <span class="td style-scope patent-result">Compositions comprising bacterial strains 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/TW202135842A/en"><a id="link" href="#" class="style-scope state-modifier">TW202135842A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2021-10-01</span>
                    <span class="td style-scope patent-result">Compositions comprising bacterial strains 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2020079282A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2020079282A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2020-04-23</span>
                    <span class="td style-scope patent-result">Compositions comprising bacterial strains 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="relatedApplications" class="scroll-target style-scope patent-result">Priority And Related Applications</h3>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="appsClaimingPriority" class="scroll-target style-scope patent-result">
              Applications Claiming Priority (4)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Application</span>
                    <span class="th style-scope patent-result">Filing date</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        EP18179641<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2018-06-25</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB201814836D0/en"><a id="link" href="#" class="style-scope state-modifier">GBGB1814836.1A</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2018-09-12</span>
                    <span class="td style-scope patent-result">Compositions comprising bacterial strains 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB201905000D0/en"><a id="link" href="#" class="style-scope state-modifier">GBGB1905000.4A</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2019-04-09</span>
                    <span class="td style-scope patent-result">Compositions comprising bacterial strains 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2020002370A1/en"><a id="link" href="#" class="style-scope state-modifier">PCT/EP2019/066905</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2019-06-25</span>
                    <span class="td style-scope patent-result">Compositions comprising bacterial strains 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            <div id="notices" class="vertical layout center style-scope patent-result">
              
                <span class="style-scope patent-result">Data provided by IFI CLAIMS Patent Services</span>
              <template is="dom-if" class="style-scope patent-result"></template>
            </div>
          </div>
          <div class="bottombar style-scope patent-result">
            <bottom-bar class="style-scope patent-result"><template is="dom-if" class="style-scope bottom-bar"></template>
</bottom-bar>
          </div>
        </div>
      </div>
      <template is="dom-if" class="style-scope patent-result"></template>
    </div>
  </patent-result>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
  </result-container>
        </div>
      </div>
    
        </div>
      </div>
      <search-footer class="style-scope search-ui">
    
    

    <div id="footer" class="vertical layout center style-scope search-footer">
        <span class="links style-scope search-footer">
          <overlay-tooltip positioning-target="#footerAbout" direction="top" class="style-scope search-footer" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Learn more about data coverage, search syntax and other features.
    </div>
  </overlay-tooltip>
          <a id="footerAbout" data-proto="ABOUT" href="https://support.google.com/faqs/answer/6390996" target="_blank" class="style-scope search-footer">About</a>
          <overlay-tooltip positioning-target="#footerFeedback" direction="top" class="style-scope search-footer" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Send feedback about technical issues or feature requests for Google Patents.
    </div>
  </overlay-tooltip>
          <a id="footerFeedback" data-proto="SEND_FEEDBACK" href="#" onclick="sendFeedback();" class="style-scope search-footer">Send Feedback</a>
          <a data-proto="PUBLIC_DATASETS" href="https://console.cloud.google.com/marketplace/product/google_patents_public_datasets/google-patents-public-data" target="_blank" class="style-scope search-footer">Public Datasets</a>
          <a data-proto="TERMS" href="https://www.google.com/policies/terms/" target="_blank" class="style-scope search-footer">Terms</a>
          <a data-proto="PRIVACY_POLICY" href="https://www.google.com/privacy/privacy-policy.html" target="blank" class="style-scope search-footer">Privacy Policy</a>
          <a data-proto="SEARCH_HELP" href="https://support.google.com/websearch/" target="_blank" class="style-scope search-footer">Help</a>
        </span>
    </div>
  </search-footer>
    </div>

  </search-ui>
  </search-result>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <paper-toast id="toast" duration="3000" class="style-scope search-app x-scope paper-toast-0" aria-hidden="true" style="outline: none; display: none;">
    

    <span id="label" class="style-scope paper-toast"></span>
    
      <div id="noticeContent" class="style-scope search-app"></div>
    
  </paper-toast>
  </search-app>
    <script type="text/javascript" src="//www.gstatic.com/feedback/api.js"></script>
    <script type="text/javascript" src="//www.gstatic.com/feedback/js/help/prod/service/lazy.min.js"></script>
    <script type="text/javascript">
      if (window.help && window.help.service) {
        helpApi = window.help.service.Lazy.create(0, {apiKey: 'AIzaSyDTEI_0tLX4varJ7bwK8aT-eOI5qr3BmyI', locale: 'en-US'});
        window.requestedSurveys = new Set();
        window.requestSurvey = function(triggerId) {
          if (window.requestedSurveys.has(triggerId)) {
            return;
          }
          window.requestedSurveys.add(triggerId);
          helpApi.requestSurvey({
            triggerId: triggerId,
            enableTestingMode: false,
            callback: (requestSurveyCallbackParam) => {
              if (!requestSurveyCallbackParam.surveyData) {
                return;
              }
              helpApi.presentSurvey({
                productData: {
                  productVersion: window.version,
                  customData: {
                    "experiments": "",
                  },
                },
                surveyData: requestSurveyCallbackParam.surveyData,
                colorScheme: 1,
                customZIndex: 10000,
              });
            }
          });
        };

        window.requestSurvey('YXTwAsvoW0kedxbuTdH0RArc9VhT');
      }
    </script>
    <script src="/sw/null_loader.js"></script>
  

<iframe id="apiproxyddf475d63cd8173a637a287407211e3c7614fb050.2210653605" name="apiproxyddf475d63cd8173a637a287407211e3c7614fb050.2210653605" style="width: 1px; height: 1px; position: absolute; top: -100px; display: none;" src="https://scone-pa.clients6.google.com/static/proxy.html?usegapi=1&amp;jsh=m%3B%2F_%2Fscs%2Fabc-static%2F_%2Fjs%2Fk%3Dgapi.lb.en.IKZeRvoAYNY.O%2Fam%3DAAAQ%2Fd%3D1%2Frs%3DAHpOoo-SMWTzMRJrTty6iE5dL_aWGYOnuw%2Fm%3D__features__#parent=https%3A%2F%2Fpatents.google.com&amp;rpctoken=1833777124" tabindex="-1" aria-hidden="true"></iframe><iron-a11y-announcer>
    
    <div class="style-scope iron-a11y-announcer" aria-live="polite"></div>
  </iron-a11y-announcer></body></html>